https://www.medthority.com/journals/multiple-sclerosis/alemtuzumab-treatment-of-multiple-sclerosis-in-real-world-clinical-practice--a-report-from-a-single-italian-center-/2025-01-21T15:15:54+00:00weekly0.7https://www.medthority.com/journals/diabetes-mellitus-without-complication/sotagliflozin--the-first-dual-sglt-inhibitor--current-outlook-and-perspectives-/2021-09-24T07:22:49+00:00weekly0.7https://www.medthority.com/journals/leukaemia/brain-invasion-by-chronic-lymphocytic-leukemia-/2025-01-14T10:34:36+00:00weekly0.7https://www.medthority.com/journals/shock/fluid-management-in-sepsis--the-potential-beneficial-effects-of-albumin/2021-09-24T07:28:34+00:00weekly0.7https://www.medthority.com/journals/melanomas-of-skin/risk-of-cumulative-toxicity-after-complete-melanoma-response-with-pembrolizumab-/2025-01-14T11:08:21+00:00weekly0.7https://www.medthority.com/journals/other-lower-respiratory-disease/differences-in-tolerability-of-pirfenidone-between-elderly-and-younger-patients-with-idiopathic-pulmonary-fibrosis-/2022-11-01T11:08:05+00:00weekly0.7https://www.medthority.com/journals/other-lower-respiratory-disease/telomere-abnormalities-in-the-pathobiology-of-idiopathic-pulmonary-fibrosis-/2022-11-01T11:05:47+00:00weekly0.7https://www.medthority.com/journals/multiple-sclerosis/mechanisms-of-neurobehavioral-abnormalities-in-multiple-sclerosis--contributions-from-neural-and-immune-components-/2023-09-05T09:27:40+00:00weekly0.7https://www.medthority.com/journals/coagulation-and-haemorrhagic-disorders/genetics--diagnosis-and-clinical-features-of-congenital-hypodysfibrinogenemia--a-systematic-literature-review-and-report-of-a-novel-mutation-/2025-01-16T13:05:06+00:00weekly0.7https://www.medthority.com/journals/diabetes-mellitus-without-complication/oral-manifestations-in-patients-with-diabetes-mellitus-/2021-09-24T07:22:49+00:00weekly0.7https://www.medthority.com/journals/diabetes-mellitus-without-complication/water-soluble-vitamins-and-their-role-in-diabetes-and-its-complications-/2025-01-16T11:16:07+00:00weekly0.7https://www.medthority.com/journals/cystic-fibrosis/chloride-and-sodium-ion-concentrations-in-saliva-and-sweat-as-a-method-to-diagnose-cystic-fibrosis-/2022-12-06T08:43:28+00:00weekly0.7https://www.medthority.com/journals/headache/advanced-imaging-in-the-evaluation-of-migraine-headaches-/2023-05-22T14:05:24+00:00weekly0.7https://www.medthority.com/journals/sleep-apnea/pathophysiology-of-central-sleep-apneas-/2021-10-11T08:56:58+00:00weekly0.7https://www.medthority.com/journals/behavioural-disorders/why-is-there-selective-subcortical-vulnerability-in-adhd--clues-from-postmortem-brain-gene-expression-data-/2021-09-24T07:20:27+00:00weekly0.7https://www.medthority.com/journals/multiple-sclerosis/role-of-b-cells-and-antibodies-in-multiple-sclerosis-/2025-01-21T15:17:05+00:00weekly0.7https://www.medthority.com/journals/shock/effects-of-levosimendan-on-mortality-in-patients-with-septic-shock--systematic-review-with-meta-analysis-and-trial-sequential-analysis-/2022-11-09T15:22:24+00:00weekly0.7https://www.medthority.com/journals/asthma/primary-care-of-asthma--new-options-for-severe-eosinophilic-asthma-/2025-01-28T16:07:57+00:00weekly0.7https://www.medthority.com/journals/rheumatoid-arthritis/efficacy-and-safety-of-interleukin-1-antagonists-in-rheumatoid-arthritis--a-systematic-review-and-meta-analysis-/2022-11-09T11:08:20+00:00weekly0.7https://www.medthority.com/journals/allergic-reactions/dupilumab-progressively-improves-systemic-and-cutaneous-abnormalities-in-patients-with-atopic-dermatitis-/2025-01-23T10:56:18+00:00weekly0.7https://www.medthority.com/journals/parkinsons-disease/apomorphine-subcutaneous-infusion-in-patients-with-parkinson-s-disease-with-persistent-motor-fluctuations--toledo---a-multicentre--double-blind--randomised--placebo-controlled-trial-/2025-01-14T13:45:19+00:00weekly0.7https://www.medthority.com/journals/other-perinatal-conditions/neonatal-diabetes-mellitus--an-update-on-diagnosis-and-management-/2021-09-24T07:27:01+00:00weekly0.7https://www.medthority.com/journals/cardiac-dysrhythmias/the-4q25-variant-rs13143308t-links-risk-of-atrial-fibrillation-to-defective-calcium-homoeostasis-/2022-11-22T15:14:09+00:00weekly0.7https://www.medthority.com/journals/hepatitis/combined-gs-4774-and-tenofovir-therapy-can-improve-hbv-specific-t-cell-responses-in-patients-with-chronic-hepatitis-/2025-01-24T09:54:38+00:00weekly0.7https://www.medthority.com/journals/psoriasis/advances-in-understanding-the-immunological-pathways-in-psoriasis/2021-10-18T13:55:43+00:00weekly0.7https://www.medthority.com/journals/prostate-cancer/diet-and-lifestyle-considerations-for-patients-with-prostate-cancer-/2022-06-28T08:31:39+00:00weekly0.7https://www.medthority.com/journals/parkinsons-disease/csf-and-blood-biomarkers-for-parkinson-s-disease-/2025-01-24T09:47:49+00:00weekly0.7https://www.medthority.com/journals/asthma/global--regional--and-national-deaths--prevalence--disability-adjusted-life-years--and-years-lived-with-disability-for-chronic-obstructive-pulmonary-disease-and-asthma--1990-2015--a-systematic-analysis-for-the-global-burden-of-disease-study-2015-/2025-01-16T10:20:41+00:00weekly0.7https://www.medthority.com/journals/urticaria/how-does-omalizumab-affect-the-immunoinflammatory-response-in-patients-with-chronic-spontaneous-urticaria-/2025-01-23T10:18:04+00:00weekly0.7https://www.medthority.com/journals/other-lower-respiratory-disease/long-term-safety-and-tolerability-of-nintedanib-in-patients-with-idiopathic-pulmonary-fibrosis--results-from-the-open-label-extension-study--inpulsis-on-/2025-01-14T11:29:47+00:00weekly0.7https://www.medthority.com/journals/prostate-cancer/androgen-deprivation-therapy-in-nonmetastatic-prostate-cancer-patients--indications--treatment-effects--and-new-predictive-biomarkers-/2025-01-14T09:08:39+00:00weekly0.7https://www.medthority.com/journals/ovarian-cancer/parp-inhibitors--review-of-mechanisms-of-action-and-brca1-2-mutation-targeting-/2021-09-24T07:27:22+00:00weekly0.7https://www.medthority.com/journals/hiv-infection/efficacy--safety--and-tolerability-of-dolutegravir-rilpivirine-for-the-maintenance-of-virological-suppression-in-adults-with-hiv-1--phase-3--randomised--non-inferiority-sword-1-and-sword-2-studies-/2025-01-14T10:01:42+00:00weekly0.7https://www.medthority.com/journals/alzheimers-disease-and-dementia/apathy-and-anxiety-are-early-markers-of-alzheimer-s-disease-/2022-11-14T11:07:20+00:00weekly0.7https://www.medthority.com/journals/melanomas-of-skin/methods-of-melanoma-detection-/2022-10-21T08:32:23+00:00weekly0.7https://www.medthority.com/journals/allergic-reactions/mycophenolate-mofetil-and-atopic-dermatitis--systematic-review-and-meta-analysis-/2025-01-23T10:55:36+00:00weekly0.7https://www.medthority.com/journals/chronic-obstructive-pulmonary-disease-copd-and-bronchiectasis/blood-eosinophils-and-treatment-response-with-triple-and-dual-combination-therapy-in-chronic-obstructive-pulmonary-disease--analysis-of-the-impact-trial-/2025-01-16T11:06:57+00:00weekly0.7https://www.medthority.com/journals/leukaemia/chronic-lymphocytic-leukaemia--from-genetics-to-treatment-/2022-10-18T14:46:28+00:00weekly0.7https://www.medthority.com/journals/psoriatic-arthritis/role-of-methotrexate-in-the-management-of-psoriatic-arthritis/2021-11-08T13:47:33+00:00weekly0.7https://www.medthority.com/journals/other-lower-respiratory-disease/ultrasound-mapping-of-lung-changes-in-idiopathic-pulmonary-fibrosis-/2025-01-14T11:30:23+00:00weekly0.7https://www.medthority.com/journals/other-hereditary-or-degenerative-neurological-disorders/safety-and-efficacy-of-olesoxime-in-patients-with-type-2-or-non-ambulatory-type-3-spinal-muscular-atrophy--a-randomised--double-blind--placebo-controlled-phase-2-trial-/2021-09-24T07:26:33+00:00weekly0.7https://www.medthority.com/journals/sleep-apnea/prevalence-and-characteristics-of-positional-sleep-apnea-in-the-hypnolaus-population-based-cohort/2021-10-11T08:44:42+00:00weekly0.7https://www.medthority.com/journals/alzheimers-disease-and-dementia/the-alzheimer-s-disease-exposome-/2025-01-16T10:05:45+00:00weekly0.7https://www.medthority.com/journals/alzheimers-disease-and-dementia/nilvadipine-in-mild-to-moderate-alzheimer-disease--a-randomised-controlled-trial-/2022-11-14T11:05:33+00:00weekly0.7https://www.medthority.com/journals/melanomas-of-skin/the-safety-and-efficacy-of-dabrafenib-and-trametinib-for-the-treatment-of-melanoma-/2025-01-14T11:18:27+00:00weekly0.7https://www.medthority.com/journals/other-hereditary-or-degenerative-neurological-disorders/discovery-of-risdiplam--a-selective-survival-of-motor-neuron-2---smn2--gene-splicing-modifier-for-the-treatment-of-spinal-muscular-atrophy--sma--/2021-09-24T07:26:33+00:00weekly0.7https://www.medthority.com/journals/other-upper-respiratory-disease/anti-ige-treatment-in-allergic-rhinitis-/2022-11-01T13:00:06+00:00weekly0.7https://www.medthority.com/journals/complications-of-surgical-procedures-or-medical-care/comfort-and-patient-centred-care-without-excessive-sedation--the-ecash-concept/2021-09-24T07:21:45+00:00weekly0.7https://www.medthority.com/journals/cardiac-dysrhythmias/incidence-of-previously-undiagnosed-atrial-fibrillation-using-insertable-cardiac-monitors-in-a-high-risk-population--the-reveal-af-study-/2022-11-22T15:02:43+00:00weekly0.7https://www.medthority.com/journals/other-hereditary-or-degenerative-neurological-disorders/the-diagnosis-of-progressive-supranuclear-palsy--current-opinions-and-challenges-/2021-09-24T07:26:33+00:00weekly0.7https://www.medthority.com/journals/other-upper-respiratory-disease/new-drugs-in-early-stage-clinical-trials-for-allergic-rhinitis-/2025-01-13T15:23:14+00:00weekly0.7https://www.medthority.com/journals/parkinsons-disease/safinamide--a-review-in-parkinson-s-disease-/2021-09-24T07:27:28+00:00weekly0.7https://www.medthority.com/journals/other-lower-respiratory-disease/a-comprehensive-and-practical-approach-to-the-management-of-idiopathic-pulmonary-fibrosis-/2025-01-14T11:36:02+00:00weekly0.7https://www.medthority.com/journals/other-lower-respiratory-disease/overview-of-idiopathic-pulmonary-fibrosis--evidence-based-guidelines--and-recent-developments-in-the-treatment-landscape-/2022-11-01T10:51:56+00:00weekly0.7https://www.medthority.com/journals/leukaemia/prognostic-significance-of-cdkn2a-b-deletions-in-acute-lymphoblastic-leukaemia--a-meta-analysis-/2025-01-14T10:35:14+00:00weekly0.7https://www.medthority.com/journals/hepatitis/the-role-of-hepatitis-b-core-related-antigen-/2021-09-24T07:23:43+00:00weekly0.7https://www.medthority.com/journals/psoriasis/ixekizumab-treatment-for-psoriasis-integrated-efficacy-analysis-of-three-double-blinded-controlled-studies-uncover-1-uncover-2-uncover-3/2025-01-13T08:55:59+00:00weekly0.7https://www.medthority.com/journals/leukaemia/ponatinib-in-the-treatment-of-chronic-myeloid-leukemia-and-philadelphia-chromosome-positive-acute-lymphoblastic-leukemia-/2025-01-14T10:36:00+00:00weekly0.7https://www.medthority.com/journals/breast-cancer/neratinib-in-her2-positive-breast-cancer-patients-/2025-01-23T08:52:09+00:00weekly0.7https://www.medthority.com/journals/hepatitis/hepatitis-e-virus-entry-/2021-09-24T07:23:42+00:00weekly0.7https://www.medthority.com/journals/other-lower-respiratory-disease/pirfenidone-in-patients-with-idiopathic-pulmonary-fibrosis-and-more-advanced-lung-function-impairment-/2025-01-14T11:37:06+00:00weekly0.7https://www.medthority.com/journals/chronic-obstructive-pulmonary-disease-copd-and-bronchiectasis/sphingolipids-in-copd-/2022-11-29T13:05:15+00:00weekly0.7https://www.medthority.com/journals/coagulation-and-haemorrhagic-disorders/treatment-of-apixaban--and-rivaroxaban-associated-major-bleeding-using-4-factor-prothrombin-complex-concentrate-/2022-12-08T15:02:03+00:00weekly0.7https://www.medthority.com/journals/shock/patterns-of-intravenous-fluid-resuscitation-use-in-adult-intensive-care-patients-between-2007-and-2014--an-international-cross-sectional-study/2022-11-09T15:19:19+00:00weekly0.7https://www.medthority.com/journals/parkinsons-disease/triggers--facilitators--and-aggravators--redefining-parkinson-s-disease-pathogenesis-/2025-01-24T10:13:03+00:00weekly0.7https://www.medthority.com/journals/alzheimers-disease-and-dementia/minocycline-at-2-different-dosages-vs-placebo-for-patients-with-mild-alzheimer-disease--a-randomized-clinical-trial-/2025-01-16T10:24:35+00:00weekly0.7https://www.medthority.com/journals/asthma/effectiveness-and-safety-of-mepolizumab-in-severe-refractory-eosinophilic-asthma--results-in-clinical-practice-/2025-01-16T10:21:19+00:00weekly0.7https://www.medthority.com/journals/alzheimers-disease-and-dementia/microglia-in-alzheimer-disease--well-known-targets-and-new-opportunities-/2022-11-14T11:00:44+00:00weekly0.7https://www.medthority.com/journals/other-hereditary-or-degenerative-neurological-disorders/clinical-presentation-and-management-of-dyskinetic-cerebral-palsy-/2021-09-24T07:26:32+00:00weekly0.7https://www.medthority.com/journals/prostate-cancer/hemigland-cryoablation-of-localized-low--intermediate-and-high-risk-prostate-cancer--oncologic-and-functional-outcomes-at-5-years-/2025-01-14T09:11:32+00:00weekly0.7https://www.medthority.com/journals/other-hereditary-or-degenerative-neurological-disorders/nusinersen--a-novel-antisense-oligonucleotide-for-the-treatment-of-spinal-muscular-atrophy-/2021-09-24T07:26:32+00:00weekly0.7https://www.medthority.com/journals/metabolic-endocrine-and-nutritional-disorders/efficacy-of-high-dose-liraglutide-as-an-adjunct-for-weight-loss-in-patients-with-prior-bariatric-surgery-/2021-09-24T07:24:53+00:00weekly0.7https://www.medthority.com/journals/psoriasis/risankizumab-for-the-treatment-of-psoriasis/2026-01-29T16:02:38+00:00weekly0.7https://www.medthority.com/journals/multiple-myeloma/once-weekly-versus-twice-weekly-carfilzomib-dosing-in-patients-with-relapsed-and-refractory-multiple-myeloma--a-r-r-o-w----interim-analysis-results-of-a-randomised--phase-3-study-/2025-01-14T11:49:45+00:00weekly0.7https://www.medthority.com/journals/cystic-fibrosis/the-combination-of-tezacaftor-and-ivacaftor-in-the-treatment-of-patients-with-cystic-fibrosis--clinical-evidence-and-future-prospects-in-cystic-fibrosis-therapy-/2025-01-16T11:18:23+00:00weekly0.7https://www.medthority.com/journals/asthma/eosinophilic-and-noneosinophilic-asthma-/2025-01-16T10:55:22+00:00weekly0.7https://www.medthority.com/journals/skin-and-subcutaneous-tissue-infections/review-of-oritavancin-for-the-treatment-of-acute-bacterial-skin-and-skin-structure-infections-/2022-06-30T08:54:07+00:00weekly0.7https://www.medthority.com/journals/other-upper-respiratory-disease/nasal-instillation-of-probiotic-extracts-inhibits-experimental-allergic-rhinitis-/2025-01-14T08:32:49+00:00weekly0.7https://www.medthority.com/journals/psoriasis/tildrakizumab-for-the-treatment-of-psoriasis-/2025-01-13T14:15:58+00:00weekly0.7https://www.medthority.com/journals/other-nervous-system-disorders/fentanyl-buccal-tablet-for-breakthrough-cancer-pain-in-clinical-practice--results-of-the-non-interventional-prospective-study-erkentnis-/2024-02-27T13:03:22+00:00weekly0.7https://www.medthority.com/journals/regional-enteritis-and-ulcerative-colitis/increased-risk-of-chronic-fatigue-syndrome-in-patients-with-inflammatory-bowel-disease--a-population-based-retrospective-cohort-study-/2023-09-22T14:22:47+00:00weekly0.7https://www.medthority.com/journals/headache/safety-and-tolerability-of-calcitonin-gene-related-peptide-binding-monoclonal-antibodies-for-the-prevention-of-episodic-migraine---a-meta-analysis-of-randomized-controlled-trials-/2025-01-20T14:46:02+00:00weekly0.7https://www.medthority.com/journals/prostate-cancer/novel-insights-into-the-management-of-oligometastatic-prostate-cancer--a-comprehensive-review-/2022-06-28T08:55:35+00:00weekly0.7https://www.medthority.com/journals/bladder-cancer/fda-approval-summary--atezolizumab-for-the-treatment-of-patients-with-progressive-advanced-urothelial-carcinoma-after-platinum-containing-chemotherapy-/2025-01-13T14:30:32+00:00weekly0.7https://www.medthority.com/journals/coagulation-and-haemorrhagic-disorders/use-of-idarucizumab-in-reversing-dabigatran-anticoagulant-effect--a-critical-appraisal-/2022-12-05T10:26:28+00:00weekly0.7https://www.medthority.com/journals/parkinsons-disease/development-of-an-aggregate-selective--human-derived---synuclein-antibody-biib054-that-ameliorates-disease-phenotypes-in-parkinson-s-disease-models-/2022-11-01T14:12:31+00:00weekly0.7https://www.medthority.com/journals/epilepsy-convulsions/a-practical-guide-to-treatment-of-childhood-absence-epilepsy-/2021-09-24T07:23:00+00:00weekly0.7https://www.medthority.com/journals/asthma/different-endotypes-and-phenotypes-drive-the-heterogeneity-in-severe-asthma-/2025-01-16T10:35:11+00:00weekly0.7https://www.medthority.com/journals/psoriasis/biosimilar-drugs-for-psoriasis-principles-present-and-near-future/2021-10-19T09:07:30+00:00weekly0.7https://www.medthority.com/journals/diabetes-mellitus-without-complication/sustained-52-week-efficacy-and-safety-of-triple-therapy-with-dapagliflozin-plus-saxagliptin-versus-dual-therapy-with-sitagliptin-added-to-metformin-in-patients-with-uncontrolled-type-2-diabetes-/2025-01-16T11:50:59+00:00weekly0.7https://www.medthority.com/journals/prostate-cancer/diagnostic-properties-of-total-and-free-prostate-specific-antigen-to-predict-overall-and-clinically-significant-prostate-cancer-among-men-with-low-testosterone-and-prior-negative-biopsy-/2025-01-14T09:04:04+00:00weekly0.7https://www.medthority.com/journals/other-lower-respiratory-disease/comparison-of-disease-progression-subgroups-in-idiopathic-pulmonary-fibrosis-/2022-11-01T11:12:32+00:00weekly0.7https://www.medthority.com/journals/asthma/the-global-initiative-for-asthma--gina---25-years-later-/2022-11-16T14:26:58+00:00weekly0.7https://www.medthority.com/journals/cystic-fibrosis/the-future-of-cystic-fibrosis-care--a-global-perspective-/2021-09-24T07:22:13+00:00weekly0.7https://www.medthority.com/journals/psoriasis/association-of-serum-ustekinumab-levels-with-clinical-response-in-psoriasis/2025-01-30T10:20:03+00:00weekly0.7https://www.medthority.com/journals/other-lower-respiratory-disease/rationale--design-and-objectives-of-two-phase-iii--randomised--placebo-controlled-studies-of-glpg1690--a-novel-autotaxin-inhibitor--in-idiopathic-pulmonary-fibrosis--isabela-1-and-2--/2022-11-01T11:10:52+00:00weekly0.7https://www.medthority.com/journals/chronic-obstructive-pulmonary-disease-copd-and-bronchiectasis/inspiratory-muscle-training-improves-autonomic-modulation-and-exercise-tolerance-in-chronic-obstructive-pulmonary-disease-subjects--a-randomized-controlled-trial-/2022-11-29T13:53:36+00:00weekly0.7https://www.medthority.com/journals/parkinsons-disease/the-genetic-architecture-of-parkinson-s-disease-/2025-01-24T09:47:10+00:00weekly0.7https://www.medthority.com/journals/multiple-sclerosis/natalizumab--rituximab-and-fingolimod-as-escalation-therapy-in-multiple-sclerosis-/2025-01-21T15:15:12+00:00weekly0.7https://www.medthority.com/journals/rheumatoid-arthritis/upadacitinib-improves-patient-reported-outcomes-in-patients-with-rheumatoid-arthritis-and-inadequate-response-to-conventional-synthetic-disease-modifying-antirheumatic-drugs--results-from-select-next-/2022-11-09T11:31:37+00:00weekly0.7https://www.medthority.com/journals/gastric-cancer/ramucirumab-as-second-line-therapy-in-metastatic-gastric-cancer--real-world-data-from-the-ramoss-study-/2022-12-08T13:16:19+00:00weekly0.7https://www.medthority.com/journals/lung-cancer/lorlatinib-for-the-treatment-of-anaplastic-lymphoma-kinase-positive-non-small-cell-lung-cancer-/2025-01-28T16:09:23+00:00weekly0.7https://www.medthority.com/journals/alzheimers-disease-and-dementia/genetic-meta-analysis-of-diagnosed-alzheimer-s-disease-identifies-new-risk-loci-and-implicates-a---tau--immunity-and-lipid-processing-/2025-01-16T10:23:28+00:00weekly0.7https://www.medthority.com/journals/substance-related-disorders/the-impact-of-combinations-of-alcohol--nicotine-and-cannabis-on-dynamic-brain-connectivity-/2021-09-24T07:28:45+00:00weekly0.7https://www.medthority.com/journals/alzheimers-disease-and-dementia/symptoms-of-apathy-and-passivity-in-dementia--a-simultaneous-concept-analysis-/2025-01-16T10:04:57+00:00weekly0.7https://www.medthority.com/journals/other-lower-respiratory-disease/serum-prealbumin-is-a-prognostic-indicator-in-idiopathic-pulmonary-fibrosis-/2025-01-14T11:29:03+00:00weekly0.7https://www.medthority.com/journals/asthma/biologics-for-severe-asthma--treatment-specific-effects-are-important-in-choosing-a-specific-agent-/2025-01-23T13:32:40+00:00weekly0.7https://www.medthority.com/journals/alzheimers-disease-and-dementia/treatment-for-depression-comorbid-with-dementia-/2022-11-14T13:17:33+00:00weekly0.7https://www.medthority.com/journals/regional-enteritis-and-ulcerative-colitis/controversies-in-inflammatory-bowel-disease--exploring-clinical-dilemmas-using-cochrane-reviews-/2023-09-22T14:12:26+00:00weekly0.7https://www.medthority.com/journals/urticaria/predictors-of-response-to-omalizumab-and-relapse-in-chronic-spontaneous-urticaria--a-study-of-470-patients-/2025-01-23T11:08:10+00:00weekly0.7https://www.medthority.com/journals/other-lower-respiratory-disease/oxidant-antioxidant-disequilibrium-in-idiopathic-pulmonary-fibrosis-pathogenesis-/2022-11-01T10:36:58+00:00weekly0.7https://www.medthority.com/journals/alzheimers-disease-and-dementia/extra-virgin-olive-oil-for-potential-prevention-of-alzheimer-disease-/2022-11-14T10:59:49+00:00weekly0.7https://www.medthority.com/journals/asthma/long-term-safety-and-pharmacodynamics-of-mepolizumab-in-children-with-severe-asthma-with-an-eosinophilic-phenotype-/2025-01-16T10:40:33+00:00weekly0.7https://www.medthority.com/journals/genitourinary-symptoms/monosymptomatic-nocturnal-enuresis-in-pediatric-patients--multidisciplinary-assessment-and-effects-of-therapeutic-intervention/2022-12-08T15:27:49+00:00weekly0.7https://www.medthority.com/journals/other-upper-respiratory-disease/allergic-rhinitis-in-children-and-adolescents-/2022-06-23T12:40:41+00:00weekly0.7https://www.medthority.com/journals/acute-cerebrovascular-disease/epidemiology-of-stroke-in-europe-and-trends-for-the-21st-century-/2022-05-24T14:04:08+00:00weekly0.7https://www.medthority.com/journals/leukaemia/long-term-follow-up-of-lower-dose-dasatinib--50-mg-daily--as-frontline-therapy-in-newly-diagnosed-chronic-phase-chronic-myeloid-leukemia-/2025-01-14T10:37:20+00:00weekly0.7https://www.medthority.com/journals/behavioural-disorders/sustained-treatment-effect-in-attention-deficit-hyperactivity-disorder--focus-on-long-term-placebo-controlled-randomized-maintenance-withdrawal-and-open-label-studies-/2021-09-24T07:20:27+00:00weekly0.7https://www.medthority.com/journals/hepatitis/a-review-on-hepatitis-d--from-virology-to-new-therapies-/2021-09-24T07:23:42+00:00weekly0.7https://www.medthority.com/journals/hepatitis/autoimmune-hepatitis-in-828-brazilian-children-and-adolescents--clinical-and-laboratory-findings--histological-profile--treatments--and-outcomes-/2022-12-12T16:24:50+00:00weekly0.7https://www.medthority.com/journals/inflammation-or-infection-of-eye/efficacy-and-safety-of-adalimumab-in-the-treatment-of-non-infectious-uveitis--a-meta-analysis-and-systematic-review-/2021-09-24T07:23:58+00:00weekly0.7https://www.medthority.com/journals/hepatitis/an-update-on-the-pathogenesis-and-clinical-management-of-cirrhosis-with-refractory-ascites-/2025-01-17T10:43:52+00:00weekly0.7https://www.medthority.com/journals/leukaemia/novel-therapeutics-in-hairy-cell-leukemia-/2025-01-14T10:37:49+00:00weekly0.7https://www.medthority.com/journals/parkinsons-disease/immunotherapy-in-parkinson-s-disease--current-status-and-future-directions-/2021-09-24T07:27:28+00:00weekly0.7https://www.medthority.com/journals/parkinsons-disease/yoga-improves-balance-and-low-back-pain--but-not-anxiety--in-people-with-parkinson-s-disease-/2025-01-27T15:26:17+00:00weekly0.7https://www.medthority.com/journals/other-lower-respiratory-disease/common-pathogenic-mechanisms-between-idiopathic-pulmonary-fibrosis-and-lung-cancer-/2025-01-14T11:40:58+00:00weekly0.7https://www.medthority.com/journals/prostate-cancer/prostate-cancer-in-young-men--an-emerging-young-adult-and-older-adolescent-challenge-/2025-01-13T15:10:29+00:00weekly0.7https://www.medthority.com/journals/multiple-myeloma/ema-review-of-panobinostat--farydak--for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-multiple-myeloma-/2025-01-14T11:25:48+00:00weekly0.7https://www.medthority.com/journals/diabetes-mellitus-without-complication/altered-brain-structural-topological-properties-in-type-2-diabetes-mellitus-patients-without-complications-/2025-01-16T11:51:42+00:00weekly0.7https://www.medthority.com/journals/epilepsy-convulsions/deep-brain-stimulation-of-the-anterior-nucleus-of-the-thalamus-for-drug-resistant-epilepsy-/2021-09-24T07:22:59+00:00weekly0.7https://www.medthority.com/journals/alzheimers-disease-and-dementia/alcohol-consumption-and-risk-of-dementia-and-cognitive-decline-among-older-adults-with-or-without-mild-cognitive-impairment-/2022-11-14T10:14:19+00:00weekly0.7https://www.medthority.com/journals/prostate-cancer/prostate-radiotherapy-in-newly-diagnosed-metastatic-prostate-cancer-/2025-01-13T15:11:45+00:00weekly0.7https://www.medthority.com/journals/prostate-cancer/proton-versus-photon-based-radiation-therapy-for-prostate-cancer--emerging-evidence-and-considerations-in-the-era-of-value-based-cancer-care-/2022-06-27T15:46:00+00:00weekly0.7https://www.medthority.com/journals/other-lower-respiratory-disease/independent-clinical-factors-relevant-to-prognosis-of-patients-with-idiopathic-pulmonary-fibrosis-/2022-11-01T10:31:27+00:00weekly0.7https://www.medthority.com/journals/behavioural-disorders/pharmacogenetics-predictors-of-methylphenidate-efficacy-in-childhood-adhd-/2021-09-24T07:20:27+00:00weekly0.7https://www.medthority.com/journals/leukaemia/towards-a-better-understanding-of-cohesin-mutations-in-aml-/2022-10-18T14:37:27+00:00weekly0.7https://www.medthority.com/journals/alzheimers-disease-and-dementia/hospitalisation-rates-and-predictors-in-people-with-dementia--a-systematic-review-and-meta-analysis-/2022-11-14T10:01:19+00:00weekly0.7https://www.medthority.com/journals/cystinosis/teenagers-and-young-adults-with-nephropathic-cystinosis-display-significant-bone-disease-and-cortical-impairment-/2024-12-03T15:46:49+00:00weekly0.7https://www.medthority.com/journals/rheumatoid-arthritis/the-impact-of-biologics-and-tofacitinib-on-cardiovascular-risk-factors-and-outcomes-in-patients-with-rheumatic-disease--a-systematic-literature-review-/2022-11-09T10:56:27+00:00weekly0.7https://www.medthority.com/journals/psoriasis/risk-factors-for-the-development-of-psoriasis/2021-10-29T13:00:42+00:00weekly0.7https://www.medthority.com/journals/complications-of-birth/treatment-of-obstetric-hemorrhage-with-fibrinogen-concentrate-/2021-09-24T07:25:58+00:00weekly0.7https://www.medthority.com/journals/congestive-heart-failure/scheduled-intermittent-inotropes-for-ambulatory-advanced-heart-failure--the-relevant-hf-multicentre-collaboration/2025-01-14T10:21:26+00:00weekly0.7https://www.medthority.com/journals/urticaria/effectiveness-and-safety-of-omalizumab-in-the-treatment-of-chronic-spontaneous-urticaria--systematic-review-and-meta-analysis-/2024-01-16T15:41:21+00:00weekly0.7https://www.medthority.com/journals/diabetes-mellitus-without-complication/triple-therapy-with-low-dose-dapagliflozin-plus-saxagliptin-versus-dual-therapy-with-each-monocomponent--all-added-to-metformin--in-uncontrolled-type-2-diabetes-/2025-01-16T11:52:27+00:00weekly0.7https://www.medthority.com/journals/regional-enteritis-and-ulcerative-colitis/efficacy-and-safety-of-vedolizumab-subcutaneous-formulation-in-a-randomized-trial-of-patients-with-ulcerative-colitis-/2025-01-21T16:21:11+00:00weekly0.7https://www.medthority.com/journals/other-hereditary-or-degenerative-neurological-disorders/diagnosis-and-management-of-spinal-muscular-atrophy--part-1--recommendations-for-diagnosis--rehabilitation--orthopedic-and-nutritional-care-/2021-09-24T07:26:32+00:00weekly0.7https://www.medthority.com/journals/breast-cancer/efficacy-of-fulvestrant-in-the-treatment-of-postmenopausal-women-with-endocrine-resistant-advanced-breast-cancer-in-routine-clinical-practice-/2023-11-09T11:14:17+00:00weekly0.7https://www.medthority.com/journals/substance-related-disorders/management-of-opioid-addiction-with-opioid-substitution-treatments--beyond-methadone-and-buprenorphine-/2022-11-09T15:37:02+00:00weekly0.7https://www.medthority.com/journals/leukaemia/emerging-epigenetic-therapeutic-targets-in-acute-myeloid-leukemia-/2022-10-18T14:31:46+00:00weekly0.7https://www.medthority.com/journals/coagulation-and-haemorrhagic-disorders/the-effect-of-fibrinogen-concentrate-and-fresh-frozen-plasma-on-the-outcome-of-patients-with-acute-traumatic-coagulopathy--a-quasi-experimental-study-/2022-12-05T09:54:43+00:00weekly0.7https://www.medthority.com/journals/cerebrovascular-aneurysms/management-of-tiny-unruptured-intracranial-aneurysms--a-comparative-effectiveness-analysis-/2025-01-13T14:26:24+00:00weekly0.7https://www.medthority.com/journals/psoriasis/risankizumab-an-anti-il-23-antibody-for-the-treatment-of-psoriasis/2021-10-29T10:37:03+00:00weekly0.7https://www.medthority.com/journals/cystic-fibrosis/physical-activity-and-associations-with-clinical-outcome-measures-in-adults-with-cystic-fibrosis--a-systematic-review-/2025-01-16T12:49:57+00:00weekly0.7https://www.medthority.com/journals/diabetes-mellitus-without-complication/real-world-clinical-outcomes-and-predictors-of-glycaemic-and-weight-response-to-exenatide-once-weekly-in-patients-with-type-2-diabetes--the-cibeles-project-/2025-01-16T11:53:07+00:00weekly0.7https://www.medthority.com/journals/alzheimers-disease-and-dementia/non-steroidal-anti-inflammatory-drugs-use-in-older-adults-decreases-risk-of-alzheimer-s-disease-mortality-/2022-11-14T09:58:34+00:00weekly0.7https://www.medthority.com/journals/shock/levosimendan-in-patients-with-cardiogenic-shock-complicating-myocardial-infarction--a-meta-analysis-/2022-11-09T15:18:12+00:00weekly0.7https://www.medthority.com/journals/regional-enteritis-and-ulcerative-colitis/vedolizumab-versus-adalimumab-for-moderate-to-severe-ulcerative-colitis-/2025-01-23T08:58:59+00:00weekly0.7https://www.medthority.com/journals/epilepsy-convulsions/epilepsy-in-the-elderly--treatment-and-consideration-of-comorbid-diseases-/2021-09-24T07:22:58+00:00weekly0.7https://www.medthority.com/journals/headache/vitamin-d3-might-improve-headache-characteristics-and-protect-against-inflammation-in-migraine--a-randomized-clinical-trial-/2023-05-22T14:04:03+00:00weekly0.7https://www.medthority.com/journals/hepatitis/evaluation-of-cerebrovascular-reactivity-in-chronic-hepatitis-c-patients-using-transcranial-color-doppler-/2022-12-12T16:21:05+00:00weekly0.7https://www.medthority.com/journals/hyperplasia-of-prostate/silodosin-8-mg-improves-benign-prostatic-obstruction-in-caucasian-patients-with-lower-urinary-tract-symptoms-suggestive-of-benign-prostatic-enlargement--results-from-an-explorative-clinical-study-/2021-09-24T07:23:55+00:00weekly0.7https://www.medthority.com/journals/coagulation-and-haemorrhagic-disorders/idarucizumab-for-dabigatran-reversal-in-the-management-of-patients-with-gastrointestinal-bleeding-/2025-01-17T09:38:39+00:00weekly0.7https://www.medthority.com/journals/leukaemia/pegaspargase--a-review-in-acute-lymphoblastic-leukaemia-/2022-10-18T14:29:30+00:00weekly0.7https://www.medthority.com/journals/hiv-infection/doravirine-lamivudine-tenofovir-disoproxil-fumarate-is-non-inferior-to-efavirenz-emtricitabine-tenofovir-disoproxil-fumarate-in-treatment-naive-adults-with-human-immunodeficiency-virus-1-infection--week-48-results-of-the-drive-ahead-trial-/2022-10-17T14:26:07+00:00weekly0.7https://www.medthority.com/journals/hepatitis/human-albumin-in-the-management-of-complications-of-liver-cirrhosis/2024-12-06T08:15:25+00:00weekly0.7https://www.medthority.com/journals/psoriasis/ustekinumab-for-the-treatment-of-psoriasis-and-psoriatic-arthritis--a-drug-evaluation-and-literature-review-/2025-01-13T14:11:07+00:00weekly0.7https://www.medthority.com/journals/other-lower-respiratory-disease/interleukin-11-is-a-therapeutic-target-in-idiopathic-pulmonary-fibrosis-/2025-01-14T11:41:47+00:00weekly0.7https://www.medthority.com/journals/diabetes-mellitus-without-complication/sglt2-inhibitors-as-adjunctive-therapy-for-type-1-diabetes--balancing-benefits-and-risks-/2025-01-27T15:17:14+00:00weekly0.7https://www.medthority.com/journals/parkinsons-disease/focused-ultrasound-subthalamotomy-in-patients-with-asymmetric-parkinson-s-disease--a-pilot-study-/2025-01-24T09:48:43+00:00weekly0.7https://www.medthority.com/journals/parkinsons-disease/safety-and-efficacy-of-focused-ultrasound-thalamotomy-for-patients-with-medication-refractory--tremor-dominant-parkinson-disease--a-randomized-clinical-trial-/2025-01-14T13:46:59+00:00weekly0.7https://www.medthority.com/journals/multiple-sclerosis/analysis-of-mirna-signatures-in-csf-identifies-upregulation-of-mir-21-and-mir-146a-b-in-patients-with-multiple-sclerosis-and-active-lesions-/2023-09-05T08:39:16+00:00weekly0.7https://www.medthority.com/journals/other-lower-respiratory-disease/safety--tolerability--pharmacokinetics--and-pharmacodynamics-of-glpg1690--a-novel-autotaxin-inhibitor--to-treat-idiopathic-pulmonary-fibrosis--flora---a-phase-2a-randomised-placebo-controlled-trial-/2025-01-14T11:42:32+00:00weekly0.7https://www.medthority.com/journals/asthma/the-current-state-of-omics-technologies-in-the-clinical-management-of-asthma-and-allergic-diseases-/2025-01-16T10:41:15+00:00weekly0.7https://www.medthority.com/journals/asthma/real-world-evidence-effect-of-budesonide-formoterol-spiromax-on-patients-with-asthma-and-chronic-obstructive-pulmonary-disease-in-sweden-/2025-01-16T10:22:08+00:00weekly0.7https://www.medthority.com/journals/other-lower-respiratory-disease/gender-differences-at-presentation-of-idiopathic-pulmonary-fibrosis-in-sweden-/2022-11-01T10:15:41+00:00weekly0.7https://www.medthority.com/journals/parkinsons-disease/exercise-increases-caudate-dopamine-release-and-ventral-striatal-activation-in-parkinson-s-disease-/2025-01-27T15:27:02+00:00weekly0.7https://www.medthority.com/journals/congestive-heart-failure/ambulatory-intravenous-inotropic-support-and-or-levosimendan-in-pediatric-and-congenital-heart-failure--safety--survival--improvement--or-transplantation/2022-10-11T08:30:34+00:00weekly0.7https://www.medthority.com/journals/alzheimers-disease-and-dementia/amyloid---and-tau-complexity---towards-improved-biomarkers-and-targeted-therapies-/2022-11-14T09:56:26+00:00weekly0.7https://www.medthority.com/journals/sleep-apnea/diagnosis-and-management-of-central-sleep-apnea-syndrome-/2025-01-30T13:14:07+00:00weekly0.7https://www.medthority.com/journals/intracranial-injury/transfusion-in-trauma--thromboelastometry-guided-coagulation-factor-concentrate-based-therapy-versus-standard-fresh-frozen-plasma-based-therapy-/2024-10-01T09:12:40+00:00weekly0.7https://www.medthority.com/journals/other-hereditary-or-degenerative-neurological-disorders/short-term-optimization-of-glycaemic-control-using-insulin-improves-sympatho-vagal-tone-activities-in-patients-with-type-2-diabetes-/2021-09-24T07:26:32+00:00weekly0.7https://www.medthority.com/journals/hepatitis/the-role-of-senescence-in-the-development-of-non-alcoholic-fatty-liver-disease-and-progression-to-non-alcoholic-steatohepatitis-/2022-12-12T16:18:04+00:00weekly0.7https://www.medthority.com/journals/hepatitis/accelerating-the-elimination-of-viral-hepatitis--a-lancet-gastroenterology---hepatology-commission-/2025-01-17T10:44:18+00:00weekly0.7https://www.medthority.com/journals/essential-hypertension/endovascular-ultrasound-renal-denervation-to-treat-hypertension--radiance-htn-solo---a-multicentre--international--single-blind--randomised--sham-controlled-trial-/2025-01-16T11:49:21+00:00weekly0.7https://www.medthority.com/journals/leukaemia/impact-of-cd39-expression-on-cd4--t-lymphocytes-and-6q-deletion-on-outcome-of-patients-with-chronic-lymphocytic-leukemia-/2022-10-18T14:28:09+00:00weekly0.7https://www.medthority.com/journals/parkinsons-disease/the-efficacy-and-feasibility-of-aquatic-physiotherapy-for-people-with-parkinson-s-disease--a-systematic-review-/2025-01-14T13:47:59+00:00weekly0.7https://www.medthority.com/journals/allergic-reactions/spotlight-on-dupilumab-in-the-treatment-of-atopic-dermatitis--design--development--and-potential-place-in-therapy-/2024-02-19T14:17:08+00:00weekly0.7https://www.medthority.com/journals/arterial-aneurysms/fibrinogen-concentrate-administration-attributes-to-significant-reductions-of-blood-loss-and-transfusion-requirements-in-thoracic-aneurysm-repair-/2021-09-24T07:19:49+00:00weekly0.7https://www.medthority.com/journals/parkinsons-disease/deep-brain-stimulation-for-freezing-of-gait-in-parkinson-s-disease-with-early-motor-complications-/2025-01-27T15:28:02+00:00weekly0.7https://www.medthority.com/journals/multiple-sclerosis/virtual-reality-in-multiple-sclerosis-rehabilitation--a-review-on-cognitive-and-motor-outcomes-/2025-01-21T15:21:58+00:00weekly0.7https://www.medthority.com/journals/headache/long-term-treatment-patterns-of-prophylactic-and-acute-migraine-medications-and-incidence-of-opioid-related-adverse-events-in-patients-with-migraine-/2025-01-20T14:46:48+00:00weekly0.7https://www.medthority.com/journals/psoriasis/tnf-inhibitor-induced-psoriasis--a-decade-of-experience-at-the-cleveland-clinic/2025-01-13T14:12:25+00:00weekly0.7https://www.medthority.com/journals/multiple-sclerosis/risk-of-opportunistic-infections-in-patients-treated-with-alemtuzumab-for-multiple-sclerosis-/2025-01-21T14:46:13+00:00weekly0.7https://www.medthority.com/journals/other-upper-respiratory-disease/identifying-the-hidden-burden-of-allergic-rhinitis--ar--in-community-pharmacy--a-global-phenomenon-/2022-06-23T09:53:19+00:00weekly0.7https://www.medthority.com/journals/psoriasis/inflammatory-dietary-pattern-and-incident-psoriasis--psoriatic-arthritis--and-atopic-dermatitis-in-women--a-cohort-study-/2025-01-23T10:54:41+00:00weekly0.7https://www.medthority.com/journals/hepatitis/reversal-of-nash-fibrosis-with-pharmacotherapy-/2022-12-12T16:15:38+00:00weekly0.7https://www.medthority.com/journals/other-hereditary-or-degenerative-neurological-disorders/b-05-nusinersen-in-infants-who-initiate-treatment-in-a-presymptomatic-stage-of-spinal-muscular-atrophy--sma---interim-results-from-the-phase-2-nurture-study/2021-09-24T07:26:31+00:00weekly0.7https://www.medthority.com/journals/diabetes-mellitus-without-complication/sotagliflozin--first-global-approval-/2022-12-06T13:48:36+00:00weekly0.7https://www.medthority.com/journals/regional-enteritis-and-ulcerative-colitis/characterization-of-inflammatory-bowel-disease-management-by-vedolizumab-and-concomitant-treatments-in-real-life-clinical-practice-/2023-09-22T11:57:36+00:00weekly0.7https://www.medthority.com/journals/alzheimers-disease-and-dementia/relationship-between-long-non-coding-rnas-and-alzheimer-s-disease--a-systematic-review-/2022-11-14T09:48:30+00:00weekly0.7https://www.medthority.com/journals/other-hereditary-or-degenerative-neurological-disorders/the-heat-shock-response-in-neurons-and-astroglia-and-its-role-in-neurodegenerative-diseases-/2021-09-24T07:26:31+00:00weekly0.7https://www.medthority.com/journals/leukaemia/early-results-of-lower-dose-dasatinib--50-mg-daily--as-frontline-therapy-for-newly-diagnosed-chronic-phase-chronic-myeloid-leukemia-/2025-01-14T10:39:41+00:00weekly0.7https://www.medthority.com/journals/alzheimers-disease-and-dementia/a-pilot-study-of-exenatide-actions-in-alzheimer-s-disease-/2022-11-14T09:46:33+00:00weekly0.7https://www.medthority.com/journals/asthma/new-horizons-for-the-treatment-of-severe--eosinophilic-asthma--benralizumab--a-novel-precision-biologic-/2021-09-24T07:20:14+00:00weekly0.7https://www.medthority.com/journals/leukaemia/cellular-immunotherapy-for-acute-myeloid-leukemia--how-specific-should-it-be-/2022-10-18T14:15:38+00:00weekly0.7https://www.medthority.com/journals/psoriasis/efficacy-and-safety-of-mirikizumab-ly3074828-in-the-treatment-of-moderate-to-severe-plaque-psoriasis-results-from-a-randomised-phase-2-study/2025-01-13T09:20:21+00:00weekly0.7https://www.medthority.com/journals/other-hereditary-or-degenerative-neurological-disorders/nusinersen--a-treatment-for-spinal-muscular-atrophy-/2021-09-24T07:26:31+00:00weekly0.7https://www.medthority.com/journals/alzheimers-disease-and-dementia/the-promise-of-technology-in-the-future-of-dementia-care-/2022-11-14T09:45:34+00:00weekly0.7https://www.medthority.com/journals/alzheimers-disease-and-dementia/aggressive-behaviors-in-alzheimer-disease-and-mild-cognitive-impairment--systematic-review-and-meta-analysis-/2022-11-14T09:43:11+00:00weekly0.7https://www.medthority.com/journals/leukaemia/experience-with-ibrutinib-for-first-line-use-in-patients-with-chronic-lymphocytic-leukemia-/2025-01-14T11:10:13+00:00weekly0.7https://www.medthority.com/journals/other-nervous-system-disorders/pain--part-2a--trigeminal-anatomy-related-to-pain-/2021-09-24T07:26:55+00:00weekly0.7https://www.medthority.com/journals/other-liver-diseases/the-farnesoid-x-receptor-agonist-obeticholic-acid-upregulates-biliary-excretion-of-asymmetric-dimethylarginine-via-mate-1-during-hepatic-ischemia-reperfusion-injury-/2021-09-24T07:26:40+00:00weekly0.7https://www.medthority.com/journals/parkinsons-disease/safety-and-efficacy-of-cvt-301--levodopa-inhalation-powder--on-motor-function-during-off-periods-in-patients-with-parkinson-s-disease--a-randomised--double-blind--placebo-controlled-phase-3-trial-/2025-01-14T13:49:08+00:00weekly0.7https://www.medthority.com/journals/cystic-fibrosis/cystic-fibrosis-genetics--from-molecular-understanding-to-clinical-application/2022-12-05T16:02:19+00:00weekly0.7https://www.medthority.com/journals/hepatitis/outcomes-of-liver-transplantation-for-non-alcoholic-steatohepatitis--a-european-liver-transplant-registry-study-/2025-01-17T11:05:55+00:00weekly0.7https://www.medthority.com/journals/metabolic-endocrine-and-nutritional-disorders/comprehensive-long-term-efficacy-and-safety-of-recombinant-human-alpha-mannosidase--velmanase-alfa--treatment-in-patients-with-alpha-mannosidosis-/2022-10-25T08:47:03+00:00weekly0.7https://www.medthority.com/journals/prostate-cancer/photodynamic-therapy-for-prostate-cancer--a-systematic-review-and-meta-analysis-/2025-01-14T08:37:37+00:00weekly0.7https://www.medthority.com/journals/ovarian-cancer/prediction-of-clinical-response-to-drugs-in-ovarian-cancer-using-the-chemotherapy-resistance-test--ctr-test--/2021-09-24T07:27:22+00:00weekly0.7https://www.medthority.com/journals/other-hereditary-or-degenerative-neurological-disorders/spinal-muscular-atrophy--types-i-and-ii--what-are-the-differences-in-body-composition-and-resting-energy-expenditure-/2021-09-24T07:26:30+00:00weekly0.7https://www.medthority.com/journals/complications-of-surgical-procedures-or-medical-care/the-effects-of-perioperative-intravenous-fluid-administration-strategy-on-renal-outcomes-in-patients-undergoing-cardiovascular-surgery--an-observational-study-/2021-09-24T07:21:43+00:00weekly0.7https://www.medthority.com/journals/cystinosis/a-systematic-literature-review-of-cysteamine-bitartrate-in-the-treatment-of-nephropathic-cystinosis-/2025-01-27T15:36:38+00:00weekly0.7https://www.medthority.com/journals/metabolic-endocrine-and-nutritional-disorders/a-novel-blind-start-study-design-to-investigate-vestronidase-alfa-for-mucopolysaccharidosis-vii--an-ultra-rare-genetic-disease-/2022-10-25T08:35:19+00:00weekly0.7https://www.medthority.com/journals/alzheimers-disease-and-dementia/understanding-the-roles-of-mutations-in-the-amyloid-precursor-protein-in-alzheimer-disease-/2022-11-14T09:41:38+00:00weekly0.7https://www.medthority.com/journals/other-hereditary-or-degenerative-neurological-disorders/an-integrated-safety-analysis-of-infants-and-children-with-symptomatic-spinal-muscular-atrophy--sma--treated-with-nusinersen-in-seven-clinical-trials-/2024-12-30T14:59:19+00:00weekly0.7https://www.medthority.com/journals/diabetes-mellitus-without-complication/elevated-blood-apelin-levels-in-type-2-diabetes-mellitus--a-systematic-review-and-meta-analysis-/2025-01-16T12:40:06+00:00weekly0.7https://www.medthority.com/journals/hereditary-transthyretin-amyloidosis-hattr/association-of-patisiran--an-rna-interference-therapeutic--with-regional-left-ventricular-myocardial-strain-in-hereditary-transthyretin-amyloidosis--the-apollo-study-/2023-10-23T09:01:14+00:00weekly0.7https://www.medthority.com/journals/complications-of-surgical-procedures-or-medical-care/fibrinogen-concentrate-for-bleeding--a-systematic-review-/2021-09-24T07:21:42+00:00weekly0.7https://www.medthority.com/journals/ovarian-cancer/increased-rhamm-expression-relates-to-ovarian-cancer-progression-/2021-09-24T07:27:22+00:00weekly0.7https://www.medthority.com/journals/sleep-apnea/pathophysiology-of-adult-obstructive-sleep-apnea-/2021-10-05T14:06:15+00:00weekly0.7https://www.medthority.com/journals/leukaemia/serum-albumin-or-body-mass-index--which-prognostic-factor-for-survival-in-patients-with-acute-myeloblastic-leukaemia-/2025-01-14T10:40:38+00:00weekly0.7https://www.medthority.com/journals/schizophrenia/brexpiprazole-for-the-maintenance-treatment-of-adults-with-schizophrenia--an-evidence-based-review-and-place-in-therapy-/2022-11-09T14:17:02+00:00weekly0.7https://www.medthority.com/journals/prostate-cancer/association-of-glutathione-s-transferase-p1-gene-promoter-methylation-and-the-incidence-of-prostate-cancer--a-systematic-review-and-meta-analysis-/2022-06-27T15:28:36+00:00weekly0.7https://www.medthority.com/journals/psoriasis/the-human-il-17a-f-heterodimer--a-two-faced-cytokine-with-unique-receptor-recognition-properties/2022-05-13T10:15:37+00:00weekly0.7https://www.medthority.com/journals/leukaemia/daunorubicin-and-cytarabine-for-certain-types-of-poor-prognosis-acute-myeloid-leukemia--a-systematic-literature-review-/2025-01-14T10:41:25+00:00weekly0.7https://www.medthority.com/journals/allergic-reactions/microbiosis-in-pathogenesis-and-intervention-of-atopic-dermatitis-/2024-02-19T14:17:08+00:00weekly0.7https://www.medthority.com/journals/diabetes-mellitus-without-complication/an-update-on-the-safety-of-sglt2-inhibitors-/2025-01-16T12:41:07+00:00weekly0.7https://www.medthority.com/journals/behavioural-disorders/high-intelligence-and-the-risk-of-adhd-and-other-psychopathology-/2021-09-24T07:20:26+00:00weekly0.7https://www.medthority.com/journals/cystic-fibrosis/prevention-of-chronic-infection-with-pseudomonas-aeruginosa-infection-in-cystic-fibrosis-/2025-01-27T16:00:28+00:00weekly0.7https://www.medthority.com/journals/multiple-sclerosis/multiple-sclerosis--effect-of-beta-interferon-treatment-on-survival-/2023-09-05T08:10:18+00:00weekly0.7https://www.medthority.com/journals/non-traumatic-joint-disorders/improved-joint-health-in-subjects-with-severe-haemophilia-a-treated-prophylactically-with-recombinant-factor-viii-fc-fusion-protein-/2025-01-14T11:48:46+00:00weekly0.7https://www.medthority.com/journals/prostate-cancer/exploitation-of-cd133-for-the-targeted-imaging-of-lethal-prostate-cancer-/2025-01-14T08:36:32+00:00weekly0.7https://www.medthority.com/journals/urticaria/management-of-chronic-spontaneous-urticaria--a-worldwide-perspective-/2025-01-23T11:25:51+00:00weekly0.7https://www.medthority.com/journals/other-upper-respiratory-disease/the-relationship-between-il-17a-and-il-22-expression-and-clinical-severity-in-patients-with-moderate-severe-persistent-allergic-rhinitis-/2022-06-23T09:48:51+00:00weekly0.7https://www.medthority.com/journals/coagulation-and-haemorrhagic-disorders/protocol-for-a-phase-iii--non-inferiority--randomised-comparison-of-a-new-fibrinogen-concentrate-versus-cryoprecipitate-for-treating-acquired-hypofibrinogenaemia-in-bleeding-cardiac-surgical-patients--the-fibres-trial-/2025-01-16T10:50:07+00:00weekly0.7https://www.medthority.com/journals/other-lower-respiratory-disease/pamrevlumab--an-anti-connective-tissue-growth-factor-therapy--for-idiopathic-pulmonary-fibrosis--praise---a-phase-2--randomised--double-blind--placebo-controlled-trial-/2025-01-14T11:43:23+00:00weekly0.7https://www.medthority.com/journals/complications-of-surgical-procedures-or-medical-care/fibrinogen-concentrate-for-perioperative-bleeding--what-can-we-learn-from-the-clinical-trials-/2021-09-24T07:21:42+00:00weekly0.7https://www.medthority.com/journals/parkinsons-disease/the-key-role-of-t-cells-in-parkinson-s-disease-pathogenesis-and-therapy-/2025-01-24T09:49:43+00:00weekly0.7https://www.medthority.com/journals/coagulation-and-haemorrhagic-disorders/andexanet-alfa-for-reversal-of-factor-xa-inhibitors--a-critical-review-of-the-evidence-/2025-01-17T09:40:32+00:00weekly0.7https://www.medthority.com/journals/bladder-cancer/diagnostic-accuracy-of-c-11-choline-and-c-11-acetate-for-lymph-node-staging-in-patients-with-bladder-cancer--a-systematic-review-and-meta-analysis-/2022-05-03T13:10:53+00:00weekly0.7https://www.medthority.com/journals/headache/beta-blockers-for-migraine-prevention--a-review-article-/2025-01-20T15:31:50+00:00weekly0.7https://www.medthority.com/journals/congestive-heart-failure/the-cardiomems-system-in-the-clinical-management-of-end-stage-heart-failure-patients--three-case-reports-/2022-10-10T15:30:52+00:00weekly0.7https://www.medthority.com/journals/hidradenitis-suppurativa/hurley-staging-refined--a-proposal-by-the-dutch-hidradenitis-suppurativa-expert-group-/2021-09-24T07:23:49+00:00weekly0.7https://www.medthority.com/journals/gastric-cancer/ramucirumab-for-the-treatment-of-patients-with-gastric-or-gastroesophageal-junction-cancer-in-community-oncology-practices-/2022-12-08T13:03:28+00:00weekly0.7https://www.medthority.com/journals/leukaemia/selinexor-in-combination-with-decitabine-in-patients-with-acute-myeloid-leukemia--results-from-a-phase-1-study-/2025-01-14T10:42:07+00:00weekly0.7https://www.medthority.com/journals/essential-hypertension/effect-of-renal-denervation-on-blood-pressure-in-the-presence-of-antihypertensive-drugs--6-month-efficacy-and-safety-results-from-the-spyral-htn-on-med-proof-of-concept-randomised-trial-/2025-01-16T11:14:34+00:00weekly0.7https://www.medthority.com/journals/asthma/asthma-exacerbation-trajectories-and-their-predictors-in-children-with-incident-asthma-/2025-01-16T10:41:51+00:00weekly0.7https://www.medthority.com/journals/psoriasis/itch-an-under-recognized-problem-in-psoriasis/2025-01-13T08:57:37+00:00weekly0.7https://www.medthority.com/journals/psoriasis/secukinumab-in-the-treatment-of-psoriasis-and-psoriatic-arthritis-a-review-of-the-literature/2021-11-09T09:28:37+00:00weekly0.7https://www.medthority.com/journals/congestive-heart-failure/haemodynamic-effects-of-levosimendan-in-advanced-but-stable-chronic-heart-failure-/2025-01-14T10:22:55+00:00weekly0.7https://www.medthority.com/journals/urticaria/treatment-of-refractory-chronic-urticaria--current-and-future-therapeutic-options-/2024-01-16T15:41:21+00:00weekly0.7https://www.medthority.com/journals/asthma/asthma-control-in-children--body-plethysmography-in-addition-to-spirometry-/2025-01-16T10:42:48+00:00weekly0.7https://www.medthority.com/journals/other-upper-respiratory-disease/current-therapeutical-strategies-for-allergic-rhinitis-/2025-01-13T15:24:35+00:00weekly0.7https://www.medthority.com/journals/asthma/smoking-and-lung-function-among-adults-with-newly-onset-asthma-/2024-03-05T12:07:08+00:00weekly0.7https://www.medthority.com/journals/hidradenitis-suppurativa/hidradenitis-suppurativa--hs--prevalence--demographics-and-management-pathways-in-australia--a-population-based-cross-sectional-study-/2021-09-24T07:23:49+00:00weekly0.7https://www.medthority.com/journals/allergic-reactions/biological-therapies-for-atopic-dermatitis--an-update-/2024-02-19T14:17:08+00:00weekly0.7https://www.medthority.com/journals/essential-hypertension/azilsartan-medoxomil-in-the-management-of-hypertension--an-evidence-based-review-of-its-place-in-therapy-/2022-12-07T15:34:01+00:00weekly0.7https://www.medthority.com/journals/hepatitis/serum-c16-1n7-c16-0-ratio-as-a-diagnostic-marker-for-non-alcoholic-steatohepatitis-/2025-01-17T10:45:29+00:00weekly0.7https://www.medthority.com/journals/prostate-cancer/what-is-oligometastatic-prostate-cancer-/2025-01-13T15:14:46+00:00weekly0.7https://www.medthority.com/journals/other-hereditary-or-degenerative-neurological-disorders/progressive-supranuclear-palsy-and-idiopathic-parkinson-s-disease-are-associated-with-local-reduction-of-in-vivo-brain-viscoelasticity-/2021-09-24T07:26:29+00:00weekly0.7https://www.medthority.com/journals/coagulation-and-haemorrhagic-disorders/antidotes-for-reversal-of-direct-oral-anticoagulants-/2022-11-30T15:16:31+00:00weekly0.7https://www.medthority.com/journals/venous-thromboembolism-vte/accidental-rivaroxaban-overdose-in-a-patient-with-pulmonary-embolism--some-lessons-for-managing-new-oral-anticoagulants/2024-01-23T14:52:09+00:00weekly0.7https://www.medthority.com/journals/alzheimers-disease-and-dementia/heterogeneity-of-alzheimer-s-disease--consequence-for-drug-trials-/2022-11-10T16:14:35+00:00weekly0.7https://www.medthority.com/journals/urticaria/efficacy-of-autologous-whole-blood-or-serum-therapy-for-chronic-spontaneous-urticaria--a-systematic-review-and-meta-analysis-/2025-01-23T11:10:30+00:00weekly0.7https://www.medthority.com/journals/epilepsy-convulsions/no-prevention-or-cure-of-epilepsy-as-yet-/2021-09-24T07:22:58+00:00weekly0.7https://www.medthority.com/journals/epilepsy-convulsions/epilepsy-genetics--clinical-impacts-and-biological-insights-/2025-01-24T09:53:00+00:00weekly0.7https://www.medthority.com/journals/shock/shock-etiologies-and-fluid-management-in-liver-failure-/2021-09-24T07:28:33+00:00weekly0.7https://www.medthority.com/journals/headache/recent-advances-in-migraine-therapy-/2025-01-20T14:56:03+00:00weekly0.7https://www.medthority.com/journals/other-lower-respiratory-disease/effectiveness-of-non-pharmacological-nursing-interventions-to-improve-the-quality-of-life-of-patients-with-idiopathic-pulmonary-fibrosis--a-systematic-review-/2025-01-14T11:44:16+00:00weekly0.7https://www.medthority.com/journals/psoriasis/safety-and-efficacy-of-brodalumab-for-moderate-to-severe-plaque-psoriasis-a-systematic-review-and-meta-analysis/2021-11-08T13:56:26+00:00weekly0.7https://www.medthority.com/journals/chronic-obstructive-pulmonary-disease-copd-and-bronchiectasis/predicting-response-to-benralizumab-in-chronic-obstructive-pulmonary-disease--analyses-of-galathea-and-terranova-studies-/2025-01-16T11:07:48+00:00weekly0.7https://www.medthority.com/journals/rheumatoid-arthritis/modulation-of-innate-and-adaptive-immune-responses-by-tofacitinib-cp-690-550/2025-01-13T10:32:22+00:00weekly0.7https://www.medthority.com/journals/genitourinary-symptoms/desmopressin-for-treating-nocturia-in-men-/2025-01-17T10:48:43+00:00weekly0.7https://www.medthority.com/journals/alzheimers-disease-and-dementia/association-between-polypharmacy-and-dementia---a-systematic-review-and-metaanalysis-/2025-01-14T12:44:56+00:00weekly0.7https://www.medthority.com/journals/prostate-cancer/genomics-of-lethal-prostate-cancer-at-diagnosis-and-castration-resistance-/2022-06-27T14:41:55+00:00weekly0.7https://www.medthority.com/journals/hiv-infection/switching-to-fixed-dose-bictegravir--emtricitabine--and-tenofovir-alafenamide-from-dolutegravir-plus-abacavir-and-lamivudine-in-virologically-suppressed-adults-with-hiv-1--48-week-results-of-a-randomised--double-blind--multicentre--active-controlled--phas/2025-01-14T10:07:37+00:00weekly0.7https://www.medthority.com/journals/leukaemia/ras-mutations-in-acute-myeloid-leukaemia-patients--a-review-and-meta-analysis-/2022-10-18T14:04:08+00:00weekly0.7https://www.medthority.com/journals/acute-cerebrovascular-disease/reversal-of-oral-anticoagulation-in-patients-with-acute-intracerebral-hemorrhage-/2021-10-14T13:30:48+00:00weekly0.7https://www.medthority.com/journals/headache/a-new-era-for-migraine--pharmacokinetic-and-pharmacodynamic-insights-into-monoclonal-antibodies-with-a-focus-on-galcanezumab--an-anti-cgrp-antibody-/2025-01-20T14:47:33+00:00weekly0.7https://www.medthority.com/journals/allergic-reactions/the-impact-of-lifestyle-factors-on-evolution-of-atopic-dermatitis--an-alternative-approach-/2024-02-19T14:17:08+00:00weekly0.7https://www.medthority.com/journals/urticaria/emerging-therapies-in-chronic-spontaneous-urticaria-/2024-01-16T15:41:21+00:00weekly0.7https://www.medthority.com/journals/other-upper-respiratory-disease/serum-il-1--can-be-a-biomarker-in-children-with-severe-persistent-allergic-rhinitis-/2022-11-15T15:04:14+00:00weekly0.7https://www.medthority.com/journals/parkinsons-disease/towards-understanding-neural-network-signatures-of-motor-skill-learning-in-parkinson-s-disease-and-healthy-aging-/2025-01-14T13:54:14+00:00weekly0.7https://www.medthority.com/journals/alzheimers-disease-and-dementia/rivastigmine--the-advantages-of-dual-inhibition-of-acetylcholinesterase-and-butyrylcholinesterase-and-its-role-in-subcortical-vascular-dementia-and-parkinson-s-disease-dementia-/2022-11-10T16:11:57+00:00weekly0.7https://www.medthority.com/journals/behavioural-disorders/european-consensus-statement-on-diagnosis-and-treatment-of-adult-adhd--the-european-network-adult-adhd-/2021-09-24T07:20:25+00:00weekly0.7https://www.medthority.com/journals/asthma/the-frequency-of-asthma-exacerbations-and-healthcare-utilization-in-patients-with-asthma-from-the-uk-and-usa-/2022-11-15T14:59:33+00:00weekly0.7https://www.medthority.com/journals/arterial-aneurysms/the-relationship-between-fibrinogen-and-in-hospital-mortality-in-patients-with-type-a-acute-aortic-dissection-/2022-09-15T10:43:03+00:00weekly0.7https://www.medthority.com/journals/alzheimers-disease-and-dementia/a-systematic-review-of-the-integration-of-palliative-care-in-dementia-management-/2022-11-10T15:38:26+00:00weekly0.7https://www.medthority.com/journals/polycystic-kidney-disease/tolvaptan-in-the-treatment-of-autosomal-dominant-polycystic-kidney-disease--patient-selection-and-special-considerations-/2022-05-20T09:55:50+00:00weekly0.7https://www.medthority.com/journals/other-hereditary-or-degenerative-neurological-disorders/discovery-of-small-molecule-splicing-modulators-of-survival-motor-neuron-2--smn2--for-the-treatment-of-spinal-muscular-atrophy--sma--/2021-09-24T07:26:28+00:00weekly0.7https://www.medthority.com/journals/asthma/the-prostaglandin-d2-receptor-2-pathway-in-asthma--a-key-player-in-airway-inflammation-/2021-09-24T07:20:10+00:00weekly0.7https://www.medthority.com/journals/chronic-obstructive-pulmonary-disease-copd-and-bronchiectasis/roflumilast-in-patients-with-advanced-chronic-obstructive-pulmonary-disease--towards-a-better-targeted-use-/2025-01-16T11:08:41+00:00weekly0.7https://www.medthority.com/journals/regional-enteritis-and-ulcerative-colitis/short-term-outcomes-of-inflammatory-bowel-disease-after-roux-en-y-gastric-bypass-vs-sleeve-gastrectomy-/2025-01-21T16:21:59+00:00weekly0.7https://www.medthority.com/journals/alzheimers-disease-and-dementia/role-of-monocarboxylate-transporter-4-in-alzheimer-disease-/2022-11-10T15:27:10+00:00weekly0.7https://www.medthority.com/journals/other-lower-respiratory-disease/idiopathic-pulmonary-fibrosis-and-lung-cancer--a-systematic-review-and-meta-analysis-/2025-01-14T11:45:07+00:00weekly0.7https://www.medthority.com/journals/metabolic-endocrine-and-nutritional-disorders/enzyme-replacement-therapy-with-velmanase-alfa--human-recombinant-alpha-mannosidase---novel-global-treatment-response-model-and-outcomes-in-patients-with-alpha-mannosidosis-/2022-10-24T14:53:50+00:00weekly0.7https://www.medthority.com/journals/urticaria/assessing-changes-in-chronic-spontaneous-idiopathic-urticaria--comparisons-of-patient-reported-outcomes-using-latent-growth-modeling-/2024-01-16T15:41:21+00:00weekly0.7https://www.medthority.com/journals/asthma/current-and-future-targeted-therapies-for-severe-asthma--managing-treatment-with-biologics-based-on-phenotypes-and-biomarkers-/2022-11-15T14:54:22+00:00weekly0.7https://www.medthority.com/journals/cardiac-dysrhythmias/current-evidence-based-understanding-of-the-epidemiology--prevention--and-treatment-of-atrial-fibrillation-/2022-11-22T14:16:32+00:00weekly0.7https://www.medthority.com/journals/non-epithelial-cancer-of-skin/cemiplimab-for-the-treatment-of-advanced-cutaneous-squamous-cell-carcinoma-/2022-10-27T11:43:30+00:00weekly0.7https://www.medthority.com/journals/cystic-fibrosis/inflammatory-role-of-extracellular-sphingolipids-in-cystic-fibrosis-/2021-09-24T07:22:10+00:00weekly0.7https://www.medthority.com/journals/psoriasis/risankizumab-vs-ustekinumab-for-plaque-psoriasis-a-critical-appraisal/2025-01-13T09:56:15+00:00weekly0.7https://www.medthority.com/journals/coagulation-and-haemorrhagic-disorders/evaluation-of-the-use-of-low-dose-4-factor-prothrombin-complex-concentrate-in-the-reversal-of-direct-oral-anticoagulants-in-bleeding-patients-/2025-01-17T09:43:53+00:00weekly0.7https://www.medthority.com/journals/psoriatic-arthritis/low-doses-of-etanercept-can-be-effective-to-maintain-remission-in-psoriatic-arthritis-patients/2025-01-13T08:55:00+00:00weekly0.7https://www.medthority.com/journals/hiv-infection/doravirine-dose-selection-and-96-week-safety-and-efficacy-versus-efavirenz-in-antiretroviral-therapy-naive-adults-with-hiv-1-infection-in-a-phase-iib-trial-/2025-01-14T09:49:02+00:00weekly0.7https://www.medthority.com/journals/congestive-heart-failure/the-impact-of-heart-failure-and-chronic-obstructive-pulmonary-disease-on-mortality-in-patients-presenting-with-breathlessness-/2022-10-10T14:04:37+00:00weekly0.7https://www.medthority.com/journals/psoriasis/psoriasis-and-microbiota-a-systematic-review/2021-10-28T11:55:56+00:00weekly0.7https://www.medthority.com/journals/other-lower-respiratory-disease/the-leading-role-of-epithelial-cells-in-the-pathogenesis-of-idiopathic-pulmonary-fibrosis-/2021-09-24T07:26:44+00:00weekly0.7https://www.medthority.com/journals/cardiac-dysrhythmias/patient-factors-associated-with-quality-of-life-in-atrial-fibrillation-/2022-11-22T14:15:17+00:00weekly0.7https://www.medthority.com/journals/leukaemia/immunotherapy-in-acute-myeloid-leukemia-and-myelodysplastic-syndromes--the-dawn-of-a-new-era-/2022-10-18T14:00:06+00:00weekly0.7https://www.medthority.com/journals/headache/current-understanding-of-cortical-structure-and-function-in-migraine-/2025-01-20T14:48:36+00:00weekly0.7https://www.medthority.com/journals/diabetes-mellitus-without-complication/treatment-of-type-2-diabetes-with-the-designer-cytokine-ic7fc-/2024-03-07T14:06:38+00:00weekly0.7https://www.medthority.com/journals/parkinsons-disease/investigation-of-the-roles-of-dysbindin-1-and-satb2-in-the-progression-of-parkinson-s-disease-/2021-09-24T07:27:27+00:00weekly0.7https://www.medthority.com/journals/leukaemia/microrna-as-a-diagnostic-biomarker-in-childhood-acute-lymphoblastic-leukemia--systematic-review--meta-analysis-and-recommendations-/2022-10-18T13:58:05+00:00weekly0.7https://www.medthority.com/journals/other-upper-respiratory-disease/recent-developments-and-highlights-in-rhinitis-and-allergen-immunotherapy-/2025-01-13T15:25:53+00:00weekly0.7https://www.medthority.com/journals/other-hereditary-or-degenerative-neurological-disorders/perspectives-in-genetic-counseling-for-spinal-muscular-atrophy-in-the-new-therapeutic-era--early-pre-symptomatic-intervention-and-test-in-minors-/2021-09-24T07:26:28+00:00weekly0.7https://www.medthority.com/journals/arterial-aneurysms/low-preoperative-fibrinogen-level-is-risk-factor-for-neurological-complications-in-acute-aortic-dissection-/2025-01-27T15:13:04+00:00weekly0.7https://www.medthority.com/journals/chronic-obstructive-pulmonary-disease-copd-and-bronchiectasis/the-comorbidity-of-chronic-obstructive-pulmonary-disease-and-peripheral-artery-disease---a-systematic-review-/2025-01-16T11:09:35+00:00weekly0.7https://www.medthority.com/journals/hepatitis/mack-3--combination-of-homa--ast-and-ck18---a-promising-novel-biomarker-for-fibrotic-non-alcoholic-steatohepatitis-/2025-01-17T10:34:02+00:00weekly0.7https://www.medthority.com/journals/other-nervous-system-disorders/subcutaneous-immunoglobulin-for-maintenance-treatment-in-chronic-inflammatory-demyelinating-polyneuropathy--path---a-randomised--double-blind--placebo-controlled--phase-3-trial-/2021-09-24T07:26:54+00:00weekly0.7https://www.medthority.com/journals/cystic-fibrosis/advances-in-gene-therapy-for-cystic-fibrosis-lung-disease-/2021-09-24T07:22:09+00:00weekly0.7https://www.medthority.com/journals/urticaria/analysis-of-the-association-of-chronic-spontaneous-urticaria-with-interlekin-4---10--transforming-growth-factor--1--interferon----interleukin-17a-and--23-by-autologous-serum-skin-test-/2024-01-16T15:41:21+00:00weekly0.7https://www.medthority.com/journals/leukaemia/allogeneic-transplantation-outcomes-amongst-a-contemporary-cohort-of-high-risk-myelodysplastic-syndrome-and-acute-myeloid-leukemia-patients-aged--70-years-/2022-09-28T14:33:48+00:00weekly0.7https://www.medthority.com/journals/melanomas-of-skin/encorafenib-binimetinib-for-the-treatment-of-braf-mutant-advanced--unresectable--or-metastatic-melanoma--design--development--and-potential-place-in-therapy-/2022-10-20T09:50:11+00:00weekly0.7https://www.medthority.com/journals/psoriasis/ixekizumab-provides-superior-efficacy-compared-with-ustekinumab-over-52-weeks-of-treatment-results-from-ixora-s-a-phase-3-study/2025-01-30T15:08:01+00:00weekly0.7https://www.medthority.com/journals/alzheimers-disease-and-dementia/alzheimer-s-disease-and-other-neurodegenerative-dementias-in-comorbidity--a-clinical-and-neuropathological-overview-/2022-11-10T15:26:23+00:00weekly0.7https://www.medthority.com/journals/cystic-fibrosis/the-role-of-endothelial-cells-in-cystic-fibrosis-/2021-09-24T07:22:09+00:00weekly0.7https://www.medthority.com/journals/chronic-obstructive-pulmonary-disease-copd-and-bronchiectasis/clinical-effects-of-lentinan-combined-with-budesonide-inhalation-in-treating-acute-exacerbation-of-chronic-obstructive-pulmonary-disease-under-mechanical-ventilation-/2022-11-24T08:59:10+00:00weekly0.7https://www.medthority.com/journals/regional-enteritis-and-ulcerative-colitis/anti-interleukin-12-and-anti-interleukin-23-agents-in-crohn-s-disease-/2025-01-21T16:26:09+00:00weekly0.7https://www.medthority.com/journals/behavioural-disorders/sex-differences-in-aripiprazole-sensitization-from-adolescence-to-adulthood-/2021-09-24T07:20:25+00:00weekly0.7https://www.medthority.com/journals/bladder-cancer/the-anti-pd-1-era---an-opportunity-to-enhance-radiotherapy-for-patients-with-bladder-cancer-/2022-05-03T12:51:12+00:00weekly0.7https://www.medthority.com/journals/psoriatic-arthritis/minimal-disease-activity-is-a-stable-measure-of-therapeutic-response-in-psoriatic-arthritis-patients-receiving-treatment-with-adalimumab/2021-10-27T11:04:30+00:00weekly0.7https://www.medthority.com/journals/cancer-of-colon/colon-cleansing-efficacy-and-safety-with-1-l-ner1006-versus-2-l-polyethylene-glycol---ascorbate--a-randomized-phase-3-trial-/2022-11-21T14:56:53+00:00weekly0.7https://www.medthority.com/journals/headache/remote-electrical-neuromodulation--ren--for-the-acute-treatment-of-migraine-/2025-01-20T16:17:01+00:00weekly0.7https://www.medthority.com/journals/prostate-cancer/abiraterone-acetate-in-the-treatment-of-prostate-cancer-/2022-06-27T14:33:06+00:00weekly0.7https://www.medthority.com/journals/allergic-reactions/jak-stat-inhibitors-for-the-treatment-of-atopic-dermatitis-/2025-01-23T10:38:21+00:00weekly0.7https://www.medthority.com/journals/prostate-cancer/processed-and-raw-tomato-consumption-and-risk-of-prostate-cancer--a-systematic-review-and-dose-response-meta-analysis-/2022-06-27T14:30:20+00:00weekly0.7https://www.medthority.com/journals/birth-trauma/the-effectiveness-of-prehospital-hypertonic-saline-for-hypotensive-trauma-patients--a-systematic-review-and-meta-analysis/2022-05-17T13:04:39+00:00weekly0.7https://www.medthority.com/journals/epilepsy-convulsions/surgical-treatment-for-refractory-epilepsy-/2021-09-24T07:22:57+00:00weekly0.7https://www.medthority.com/journals/other-hereditary-or-degenerative-neurological-disorders/complete-sequencing-of-the-smn2-gene-in-sma-patients-detects-smn-gene-deletion-junctions-and-variants-in-smn2-that-modify-the-sma-phenotype-/2024-12-30T14:50:34+00:00weekly0.7https://www.medthority.com/journals/leukaemia/towards-a-personalized-treatment-of-patients-with-chronic-myeloid-leukemia-/2022-10-18T13:55:37+00:00weekly0.7https://www.medthority.com/journals/regional-enteritis-and-ulcerative-colitis/clinical-disease-activity-and-endoscopic-severity-correlate-poorly-in-children-newly-diagnosed-with-crohn-s-disease-/2025-01-21T16:15:53+00:00weekly0.7https://www.medthority.com/journals/headache/early-onset-of-efficacy-with-fremanezumab-for-the-preventive-treatment-of-chronic-migraine-/2025-01-20T14:49:35+00:00weekly0.7https://www.medthority.com/journals/rheumatoid-arthritis/update-on-subcutaneous-methotrexate-for-inflammatory-arthritis-and-psoriasis-/2021-09-24T07:28:18+00:00weekly0.7https://www.medthority.com/journals/venous-thromboembolism-vte/rivaroxaban-or-aspirin-for-extended-treatment-of-venous-thromboembolism-/2025-01-23T13:08:16+00:00weekly0.7https://www.medthority.com/journals/leukaemia/the-leukaemia-stem-cell--similarities--differences-and-clinical-prospects-in-cml-and-aml-/2022-10-18T13:54:47+00:00weekly0.7https://www.medthority.com/journals/complications-of-surgical-procedures-or-medical-care/reexploration-for-bleeding-is-a-risk-factor-for-adverse-outcomes-after-cardiac-operations-/2024-03-11T10:06:51+00:00weekly0.7https://www.medthority.com/journals/cystic-fibrosis/aztreonam-lysine-inhalation-solution-in-cystic-fibrosis-/2021-09-24T07:22:09+00:00weekly0.7https://www.medthority.com/journals/coagulation-and-haemorrhagic-disorders/safety-of-4-factor-prothrombin-complex-concentrate--4f-pcc--for-emergent-reversal-of-factor-xa-inhibitors-/2022-11-22T09:51:16+00:00weekly0.7https://www.medthority.com/journals/solid-organ-transplantation/risk-factors-for-survival-after-heart-transplantation-in-children-and-young-adults--a-22-year-study-of-179-transplants-/2025-01-14T08:49:30+00:00weekly0.7https://www.medthority.com/journals/diabetes-mellitus-without-complication/newer-therapeutic-approaches-towards-the-management-of-diabetes-mellitus--an-update-/2021-09-24T07:22:45+00:00weekly0.7https://www.medthority.com/journals/headache/migraine-pathophysiology--anatomy-of-the-trigeminovascular-pathway-and-associated-neurological-symptoms--csd--sensitization-and-modulation-of-pain-/2025-01-20T14:27:20+00:00weekly0.7https://www.medthority.com/journals/other-upper-respiratory-disease/recent-advances-in-the-diagnosis-of-allergic-rhinitis-/2025-01-13T15:26:32+00:00weekly0.7https://www.medthority.com/journals/melanomas-of-skin/first-line-treatment-of-metastatic-melanoma--role-of-nivolumab-/2022-10-20T09:41:30+00:00weekly0.7https://www.medthority.com/journals/asthma/reducing-childhood-respiratory-morbidity-and-mortality-in-low-and-middle-income-countries--a-current-challenge-/2021-09-24T07:20:09+00:00weekly0.7https://www.medthority.com/journals/multiple-sclerosis/a-comprehensive-review-on-the-treatment-approaches-of-multiple-sclerosis--currently-and-in-the-future-/2023-09-04T11:34:27+00:00weekly0.7https://www.medthority.com/journals/hepatitis/occurrence-of-hepatocellular-carcinoma-after-direct-acting-antiviral-therapy-for-hepatitis-c-virus-infection--literature-review-and-risk-analysis-/2025-01-17T10:35:21+00:00weekly0.7https://www.medthority.com/journals/alzheimers-disease-and-dementia/diffusion-tensor-imaging-of-white-matter-degeneration-in-early-stage-of-alzheimer-s-disease--a-review-/2025-01-14T12:45:48+00:00weekly0.7https://www.medthority.com/journals/acute-coronary-syndrome/optimal-pharmacological-therapy-in-st-elevation-myocardial-infarction-a-review-a-review-of-antithrombotic-therapies-in-stemi-/2025-01-13T10:15:37+00:00weekly0.7https://www.medthority.com/journals/other-nervous-system-disorders/sublingual-sufentanil-for-postoperative-pain-relief--first-clinical-experiences-/2024-02-27T11:32:28+00:00weekly0.7https://www.medthority.com/journals/leukaemia/efficacy-of-venetoclax-in-relapsed-chronic-lymphocytic-leukemia-is-influenced-by-disease-and-response-variables-/2025-01-14T10:43:37+00:00weekly0.7https://www.medthority.com/journals/cardiac-dysrhythmias/interaction-of-obesity-and-atrial-fibrillation--an-overview-of-pathophysiology-and-clinical-management-/2025-01-16T11:19:32+00:00weekly0.7https://www.medthority.com/journals/cevical-cancer/bevacizumab-for-recurrent--persistent-or-advanced-cervical-cancer--reproducibility-of-gog-240-study-results-in--real-world--patients-/2022-11-23T14:16:21+00:00weekly0.7https://www.medthority.com/journals/hepatitis/glecaprevir-pibrentasvir-expands-reach-while-reducing-cost-and-duration-of-hepatitis-c-virus-therapy-/2022-12-12T15:34:15+00:00weekly0.7https://www.medthority.com/journals/other-hereditary-or-degenerative-neurological-disorders/treatment-algorithm-for-infants-diagnosed-with-spinal-muscular-atrophy-through-newborn-screening-/2024-10-01T10:34:58+00:00weekly0.7https://www.medthority.com/journals/regional-enteritis-and-ulcerative-colitis/comorbidities-in-inflammatory-bowel-disease--a-call-for-action-/2025-01-21T16:17:23+00:00weekly0.7https://www.medthority.com/journals/headache/the-treatment-efficacy-of-galcanezumab-for-migraine--a-meta-analysis-of-randomized-controlled-trials-/2025-01-20T14:28:11+00:00weekly0.7https://www.medthority.com/journals/asthma/targeting-nlrp3-inflammasome-activation-in-severe-asthma-/2021-09-24T07:20:08+00:00weekly0.7https://www.medthority.com/journals/cystic-fibrosis/ar-13-reduces-antibiotic-resistant-bacterial-burden-in-cystic-fibrosis-phagocytes-and-improves-cystic-fibrosis-transmembrane-conductance-regulator-function-/2025-01-16T09:58:30+00:00weekly0.7https://www.medthority.com/journals/complication-of-device-implant-or-graft/faecal-microbiota-transplantation--a-regulatory-hurdle-/2024-09-30T15:26:24+00:00weekly0.7https://www.medthority.com/journals/psoriasis/tildrakizumab--a-review-of-phase-ii-and-iii-clinical-trials-/2025-01-13T14:16:48+00:00weekly0.7https://www.medthority.com/journals/headache/the-pathophysiology-of-migraine--implications-for-clinical-management-/2025-01-20T14:50:32+00:00weekly0.7https://www.medthority.com/journals/cystic-fibrosis/is-it-cystic-fibrosis--the-challenges-of-diagnosing-cystic-fibrosis-/2022-12-05T15:38:07+00:00weekly0.7https://www.medthority.com/journals/leukaemia/comparative-features-and-outcomes-between-paediatric-t-cell-and-b-cell-acute-lymphoblastic-leukaemia-/2025-01-14T10:44:12+00:00weekly0.7https://www.medthority.com/journals/congestive-heart-failure/levosimendan-in-pulmonary-hypertension-and-right-heart-failure/2025-01-14T09:15:12+00:00weekly0.7https://www.medthority.com/journals/solid-organ-transplantation/long-term-assessment-of-nsaid-prescriptions-and-potential-nephrotoxicity-risk-in-adult-kidney-transplant-recipients-/2025-01-14T08:48:11+00:00weekly0.7https://www.medthority.com/journals/regional-enteritis-and-ulcerative-colitis/mucosal-biomarker-of-innate-immune-activation-predicts-response-to-vedolizumab-in-crohn-s-disease-/2023-09-22T09:12:03+00:00weekly0.7https://www.medthority.com/journals/multiple-myeloma/management-of-adverse-events-associated-with-ixazomib-plus-lenalidomide-dexamethasone-in-relapsed-refractory-multiple-myeloma-/2025-01-14T11:22:23+00:00weekly0.7https://www.medthority.com/journals/intracranial-injury/benzodiazepine-associated-delirium-in-critically-ill-adults-/2021-09-24T07:24:03+00:00weekly0.7https://www.medthority.com/journals/prostate-cancer/biological-evolution-of-castration-resistant-prostate-cancer-/2025-01-13T15:15:49+00:00weekly0.7https://www.medthority.com/journals/allergic-reactions/disease-trajectories-in-childhood-atopic-dermatitis--an-update-and-practitioner-s-guide-/2025-01-23T10:37:35+00:00weekly0.7https://www.medthority.com/journals/chronic-obstructive-pulmonary-disease-copd-and-bronchiectasis/functional-benefit-of-smoking-cessation-in-severe-copd-patients-undergoing-bronchial-valve-implantation-/2025-01-16T11:00:04+00:00weekly0.7https://www.medthority.com/journals/regional-enteritis-and-ulcerative-colitis/infliximab-in-inflammatory-bowel-disease-/2025-01-21T16:03:29+00:00weekly0.7https://www.medthority.com/journals/leukaemia/a-decrease-in-vitamin-d-levels-is-associated-with-methotrexate-induced-oral-mucositis-in-children-with-acute-lymphoblastic-leukemia-/2022-10-18T13:31:56+00:00weekly0.7https://www.medthority.com/journals/lung-cancer/spotlight-on-dabrafenib-trametinib-in-the-treatment-of-non-small-cell-lung-cancer--place-in-therapy-/2021-09-24T07:24:25+00:00weekly0.7https://www.medthority.com/journals/congestive-heart-failure/evaluation-of-ventriculo-arterial-coupling-in-st-elevation-myocardial-infarction-with-left-ventricular-dysfunction-treated-with-levosimendan-/2025-01-14T08:45:26+00:00weekly0.7https://www.medthority.com/journals/coagulation-and-haemorrhagic-disorders/eltrombopag-in-immune-thrombocytopenia--efficacy-review-and-update-on-drug-safety-/2025-01-16T10:52:05+00:00weekly0.7https://www.medthority.com/journals/multiple-sclerosis/functional-and-structural-changes-in-the-visual-pathway-in-multiple-sclerosis-/2025-01-21T14:21:06+00:00weekly0.7https://www.medthority.com/journals/psoriasis/oxidative-stress-involvement-in-psoriasis-a-systematic-review/2025-01-13T08:53:44+00:00weekly0.7https://www.medthority.com/journals/prostate-cancer/darolutamide-in-nonmetastatic--castration-resistant-prostate-cancer-/2025-01-13T15:16:38+00:00weekly0.7https://www.medthority.com/journals/congestive-heart-failure/systolic-mitral-annulus-velocity-is-a-sensitive-index-for-changes-in-left-ventricular-systolic-function-during-inotropic-therapy-in-patients-with-acute-heart-failure/2025-01-14T09:50:07+00:00weekly0.7https://www.medthority.com/journals/regional-enteritis-and-ulcerative-colitis/real-world-effectiveness-and-safety-of-vedolizumab-for-the-treatment-of-inflammatory-bowel-disease--the-scottish-vedolizumab-cohort-/2023-09-22T08:59:40+00:00weekly0.7https://www.medthority.com/journals/acute-cerebrovascular-disease/the-ischemic-penumbra--correlates-in-imaging-and-implications-for-treatment-of-ischemic-stroke--the-johann-jacob-wepfer-award-2011-/2021-10-14T13:31:24+00:00weekly0.7https://www.medthority.com/journals/coagulation-and-haemorrhagic-disorders/reversal-strategies-for-intracranial-hemorrhage-related-to-direct-oral-anticoagulant-medications-/2025-01-16T10:52:28+00:00weekly0.7https://www.medthority.com/journals/prostate-cancer/metabolic-biosynthesis-pathways-identified-from-fecal-microbiome-associated-with-prostate-cancer-/2025-01-13T15:18:11+00:00weekly0.7https://www.medthority.com/journals/regional-enteritis-and-ulcerative-colitis/the-role-of-integrins-in-the-pathogenesis-of-inflammatory-bowel-disease--approved-and-investigational-anti-integrin-therapies-/2025-01-21T16:18:14+00:00weekly0.7https://www.medthority.com/journals/psoriasis/itch-relief-in-patients-with-psoriasis-effectiveness-of-calcipotriol-plus-betamethasone-dipropionate-foam/2025-01-13T08:58:14+00:00weekly0.7https://www.medthority.com/journals/parkinsons-disease/young-onset-parkinson-s-disease--its-unique-features-and-their-impact-on-quality-of-life-/2025-01-24T09:50:14+00:00weekly0.7https://www.medthority.com/journals/coagulation-and-haemorrhagic-disorders/modified-approach-to-fibrinogen-replacement-in-the-setting-of-dysfibrinogenaemia-/2022-11-30T15:32:37+00:00weekly0.7https://www.medthority.com/journals/alzheimers-disease-and-dementia/review--clinical--neuropathological-and-genetic-features-of-lewy-body-dementias-/2025-01-14T13:11:40+00:00weekly0.7https://www.medthority.com/journals/asthma/biological-treatments-for-severe-asthma-/2025-01-28T16:07:10+00:00weekly0.7https://www.medthority.com/journals/complications-of-surgical-procedures-or-medical-care/impact-of-preemptive-fibrinogen-concentrate-on-transfusion-requirements-in-liver-transplantation--a-multicenter--randomized--double-blind--placebo-controlled-trial-/2021-09-24T07:21:39+00:00weekly0.7https://www.medthority.com/journals/leukaemia/chronic-lymphocytic-leukaemia--the-role-of-t-cells-in-a-b-cell-disease-/2025-01-14T10:45:01+00:00weekly0.7https://www.medthority.com/journals/chronic-obstructive-pulmonary-disease-copd-and-bronchiectasis/intensity-of-physical-exercise-and-its-effect-on-functional-capacity-in-copd--systematic-review-and-meta-analysis-/2022-11-23T16:26:17+00:00weekly0.7https://www.medthority.com/journals/headache/effect-of-galcanezumab-following-treatment-cessation-in-patients-with-migraine--results-from-2-randomized-phase-3-trials-/2025-01-17T11:05:01+00:00weekly0.7https://www.medthority.com/journals/epilepsy-convulsions/autoimmune-epilepsy-/2021-09-24T07:22:57+00:00weekly0.7https://www.medthority.com/journals/regional-enteritis-and-ulcerative-colitis/vedolizumab-use-after-failure-of-tnf---antagonists-in-children-and-adolescents-with-inflammatory-bowel-disease-/2023-09-21T14:36:48+00:00weekly0.7https://www.medthority.com/journals/parkinsons-disease/utility-and-implications-of-exome-sequencing-in-early-onset-parkinson-s-disease-/2025-01-27T15:28:44+00:00weekly0.7https://www.medthority.com/journals/psoriasis/long-term-efficacy-and-safety-of-brodalumab-in-the-treatment-of-psoriasis-120-week-results-from-the-randomized-double-blind-placebo-and-active-comparator-controlled-phase-3-amagine-2-trial/2025-01-30T15:05:47+00:00weekly0.7https://www.medthority.com/journals/asthma/asthma-/2021-09-24T07:20:07+00:00weekly0.7https://www.medthority.com/journals/behavioural-disorders/attention-deficit-hyperactivity-disorder--treatment-discontinuation-in-adolescents-and-young-adults-/2021-09-24T07:20:25+00:00weekly0.7https://www.medthority.com/journals/solid-organ-transplantation/women-on-the-liver-transplantation-waitlist-are-at-increased-risk-of-hospitalization-compared-to-men-/2022-09-28T14:07:39+00:00weekly0.7https://www.medthority.com/journals/chronic-obstructive-pulmonary-disease-copd-and-bronchiectasis/multi-target-natural-products-as-alternatives-against-oxidative-stress-in-chronic-obstructive-pulmonary-disease--copd--/2022-11-23T16:15:48+00:00weekly0.7https://www.medthority.com/journals/behavioural-disorders/the-age-dependent-decline-of-attention-deficit-hyperactivity-disorder--a-meta-analysis-of-follow-up-studies-/2021-09-24T07:20:25+00:00weekly0.7https://www.medthority.com/journals/headache/erenumab-for-episodic-migraine-prophylaxis-/2025-01-17T11:04:20+00:00weekly0.7https://www.medthority.com/journals/ovarian-cancer/circulating-cell-free-dna-and-circulating-tumor-cells--the--liquid-biopsies--in-ovarian-cancer-/2021-09-24T07:27:21+00:00weekly0.7https://www.medthority.com/journals/prostate-cancer/psa-response-to-cabazitaxel-is-associated-with-improved-progression-free-survival-in-metastatic-castration-resistant-prostate-cancer--the-non-interventional-qolitime-study-/2022-06-27T13:55:41+00:00weekly0.7https://www.medthority.com/journals/hepatitis/pregenomic-rna--how-to-assist-the-management-of-chronic-hepatitis-b-/2025-01-17T10:36:20+00:00weekly0.7https://www.medthority.com/journals/headache/trp-channels-and-migraine--recent-developments-and-new-therapeutic-opportunities-/2023-05-22T13:34:27+00:00weekly0.7https://www.medthority.com/journals/cardiac-dysrhythmias/cost-of-illness-of-atrial-fibrillation--a-nationwide-study-of-societal-impact-/2022-11-22T13:27:45+00:00weekly0.7https://www.medthority.com/journals/parkinsons-disease/pain-in-parkinson-s-disease--new-concepts-in-pathogenesis-and-treatment-/2025-01-27T15:29:24+00:00weekly0.7https://www.medthority.com/journals/other-nervous-system-disorders/with-concerns-over-opioids--could-novel-receptors-be-useful-/2021-09-24T07:26:53+00:00weekly0.7https://www.medthority.com/journals/sleep-apnea/durability-of-treatment-effects-of-the-sleep-position-trainer-versus-oral-appliance-therapy-in-positional-osa--12-month-follow-up-of-a-randomized-controlled-trial-/2021-10-05T08:37:32+00:00weekly0.7https://www.medthority.com/journals/other-lower-respiratory-disease/antifibrotic-therapy-for-idiopathic-pulmonary-fibrosis--time-to-treat-/2021-09-24T07:26:43+00:00weekly0.7https://www.medthority.com/journals/other-upper-respiratory-disease/immunotherapy-with-grass-pollen-tablets-reduces-medication-dispensing-for-allergic-rhinitis-and-asthma--a-retrospective-database-study-in-france-/2025-01-13T15:27:04+00:00weekly0.7https://www.medthority.com/journals/headache/transient-neurologic-dysfunction-in-migraine-/2023-05-22T13:31:22+00:00weekly0.7https://www.medthority.com/journals/multiple-sclerosis/early-imaging-predictors-of-long-term-outcomes-in-relapse-onset-multiple-sclerosis-/2023-09-04T11:25:19+00:00weekly0.7https://www.medthority.com/journals/multiple-sclerosis/positive-impact-of-cladribine-on-quality-of-life-in-people-with-relapsing-multiple-sclerosis-/2025-01-21T14:24:07+00:00weekly0.7https://www.medthority.com/journals/other-upper-respiratory-disease/increased-salivary-fluid-flow-in-children-with-newly-diagnosed-allergic-rhinitis-/2022-06-23T09:26:28+00:00weekly0.7https://www.medthority.com/journals/leukaemia/efficacy-and-safety-of-bispecific-t-cell-engager--bite--antibody-blinatumomab-for-the-treatment-of-relapsed-refractory-acute-lymphoblastic-leukemia-and-non-hodgkin-s-lymphoma--a-systemic-review-and-meta-analysis-/2025-01-14T10:54:16+00:00weekly0.7https://www.medthority.com/journals/neoplasms-of-unspecified-nature-or-uncertain-behaviour/treatment-of-essential-thrombocythemia-in-europe--a-prospective-long-term-observational-study-of-3649-high-risk-patients-in-the-evaluation-of-anagrelide-efficacy-and-long-term-safety-study-/2024-12-30T12:01:35+00:00weekly0.7https://www.medthority.com/journals/regional-enteritis-and-ulcerative-colitis/the-role-of-the-radiologist-in-determining-disease-severity-in-inflammatory-bowel-diseases-/2023-09-21T13:52:49+00:00weekly0.7https://www.medthority.com/journals/sleep-apnea/obstructive-sleep-apnea-current-perspectives/2021-10-05T08:34:01+00:00weekly0.7https://www.medthority.com/journals/urticaria/expert-opinion--defining-response-to-omalizumab-in-patients-with-chronic-spontaneous-urticaria-/2024-01-16T15:41:21+00:00weekly0.7https://www.medthority.com/journals/mood-disorders/esketamine-a-novel-option-for-treatment-resistant-depression-/2025-01-24T10:53:02+00:00weekly0.7https://www.medthority.com/journals/other-gastrointestinal-disorders/general-and-abdominal-obesity-in-relation-to-the-prevalence-of-irritable-bowel-syndrome-/2025-01-14T11:47:55+00:00weekly0.7https://www.medthority.com/journals/prostate-cancer/prostate-specific-markers-to-identify-rare-prostate-cancer-cells-in-liquid-biopsies-/2022-06-27T13:54:27+00:00weekly0.7https://www.medthority.com/journals/headache/migraine--multiple-processes--complex-pathophysiology-/2023-05-22T13:26:06+00:00weekly0.7https://www.medthority.com/journals/parkinsons-disease/haplotype-specific-mapt-exon-3-expression-regulated-by-common-intronic-polymorphisms-associated-with-parkinsonian-disorders-/2022-11-01T14:01:33+00:00weekly0.7https://www.medthority.com/journals/complications-of-birth/viscoelastometric-guided-early-fibrinogen-concentrate-replacement-during-postpartum-haemorrhage--obs2--a-double-blind-randomized-controlled-trial-/2025-01-16T10:14:38+00:00weekly0.7https://www.medthority.com/journals/cystic-fibrosis/current-practices-and-potential-nanotechnology-perspectives-for-pain-related-to-cystic-fibrosis-/2021-09-24T07:22:07+00:00weekly0.7https://www.medthority.com/journals/regional-enteritis-and-ulcerative-colitis/biosimilars-for-inflammatory-bowel-disease--how-can-healthcare-professionals-help-address-patients--concerns-/2025-01-21T15:37:20+00:00weekly0.7https://www.medthority.com/journals/cystinosis/skeletal-consequences-of-nephropathic-cystinosis-/2025-01-27T15:37:59+00:00weekly0.7https://www.medthority.com/journals/epilepsy-convulsions/vagus-nerve-stimulation-for-the-treatment-of-epilepsy-/2021-09-24T07:22:56+00:00weekly0.7https://www.medthority.com/journals/other-lower-respiratory-disease/long-term-treatment-with-recombinant-human-pentraxin-2-protein-in-patients-with-idiopathic-pulmonary-fibrosis--an-open-label-extension-study-/2025-01-14T11:45:44+00:00weekly0.7https://www.medthority.com/journals/prostate-cancer/the-microbiome-in-prostate-inflammation-and-prostate-cancer-/2022-06-27T13:51:34+00:00weekly0.7https://www.medthority.com/journals/asthma/mast-cells-and-their-progenitors-in-allergic-asthma-/2022-11-15T09:34:22+00:00weekly0.7https://www.medthority.com/journals/asthma/distinct-nasal-airway-bacterial-microbiota-differentially-relate-to-exacerbation-in-pediatric-asthma-/2025-01-16T09:51:54+00:00weekly0.7https://www.medthority.com/journals/leukaemia/somatic-and-germline-genomics-in-paediatric-acute-lymphoblastic-leukaemia-/2022-10-18T13:26:00+00:00weekly0.7https://www.medthority.com/journals/other-hereditary-or-degenerative-neurological-disorders/aav9-vector--a-novel-modality-in-gene-therapy-for-spinal-muscular-atrophy-/2025-01-03T10:52:27+00:00weekly0.7https://www.medthority.com/journals/coagulation-and-haemorrhagic-disorders/reversal-agents-for-direct-oral-anticoagulants--considerations-for-hospital-physicians-and-intensivists-/2025-01-17T09:41:14+00:00weekly0.7https://www.medthority.com/journals/regional-enteritis-and-ulcerative-colitis/adalimumab-effectiveness-up-to-six-years-in-adalimumab-na-ve-patients-with-crohn-s-disease--results-of-the-pyramid-registry-/2023-09-21T13:48:45+00:00weekly0.7https://www.medthority.com/journals/prostate-cancer/enzalutamide-in-men-with-nonmetastatic--castration-resistant-prostate-cancer-/2025-01-13T15:19:06+00:00weekly0.7https://www.medthority.com/journals/coagulation-and-haemorrhagic-disorders/do-we-still-need-cryoprecipitate--cryoprecipitate-and-fibrinogen-concentrate-as-treatments-for-major-hemorrhage---how-do-they-compare-/2025-01-16T11:48:25+00:00weekly0.7https://www.medthority.com/journals/alzheimers-disease-and-dementia/review-of-current-strategies-for-delivering-alzheimer-s-disease-drugs-across-the-blood-brain-barrier-/2022-11-10T15:10:16+00:00weekly0.7https://www.medthority.com/journals/diabetes-mellitus-without-complication/relationship-between-bullying-and-type-1-diabetes-mellitus-in-children-and-adolescents--a-systematic-review-/2022-12-06T10:52:52+00:00weekly0.7https://www.medthority.com/journals/breast-cancer/neoadjuvant-talazoparib-for-patients-with-operable-breast-cancer-with-a-germline-brca-pathogenic-variant-/2025-01-23T10:04:35+00:00weekly0.7https://www.medthority.com/journals/epilepsy-convulsions/the-paroxysmal-depolarization-shift--reconsidering-its-role-in-epilepsy--epileptogenesis-and-beyond-/2021-09-24T07:22:56+00:00weekly0.7https://www.medthority.com/journals/allergic-reactions/real-life-experience-on-effectiveness-and-safety-of-dupilumab-in-adult-patients-with-moderate-to-severe-atopic-dermatitis-/2025-01-23T10:36:39+00:00weekly0.7https://www.medthority.com/journals/allergic-reactions/efficacy-and-safety-of-oral-janus-kinase-1-inhibitor-abrocitinib-for-patients-with-atopic-dermatitis--a-phase-2-randomized-clinical-trial-/2025-01-23T09:27:44+00:00weekly0.7https://www.medthority.com/journals/allergic-reactions/evaluating-crisaborole-as-a-treatment-option-for-atopic-dermatitis-/2025-01-23T10:35:44+00:00weekly0.7https://www.medthority.com/journals/alzheimers-disease-and-dementia/effects-of-dementia-knowledge-and-dementia-fear-on-comfort-with-people-having-dementia--implications-for-dementia-friendly-communities-/2025-01-14T13:16:41+00:00weekly0.7https://www.medthority.com/journals/ovarian-cancer/rucaparib-in-the-landscape-of-parp-inhibition-in-ovarian-cancer-/2025-01-28T14:18:04+00:00weekly0.7https://www.medthority.com/journals/congestive-heart-failure/levosimendan-as-rescue-therapy-for-acute-heart-failure-in-a-patient-with-duchenne-muscular-dystrophy-/2022-10-07T12:18:39+00:00weekly0.7https://www.medthority.com/journals/parkinsons-disease/clinical-pharmacokinetics-and-pharmacodynamics-of-safinamide-/2021-09-24T07:27:26+00:00weekly0.7https://www.medthority.com/journals/urticaria/ige-mediated-autoallergy-against-thyroid-peroxidase---a-novel-pathomechanism-of-chronic-spontaneous-urticaria-/2024-01-16T15:41:21+00:00weekly0.7https://www.medthority.com/journals/urticaria/biomarkers-in-chronic-spontaneous-urticaria--current-targets-and-clinical-implications-/2024-01-16T15:41:21+00:00weekly0.7https://www.medthority.com/journals/parkinsons-disease/long-term-effects-of-exercise-and-physical-therapy-in-people-with-parkinson-disease-/2021-09-24T07:27:26+00:00weekly0.7https://www.medthority.com/journals/epilepsy-convulsions/epilepsy-genetics--current-knowledge--applications--and-future-directions-/2025-01-27T15:32:33+00:00weekly0.7https://www.medthority.com/journals/melanomas-of-skin/adverse-events-associated-with-encorafenib-plus-binimetinib-in-the-columbus-study--incidence--course-and-management-/2025-01-14T11:23:40+00:00weekly0.7https://www.medthority.com/journals/urticaria/ligelizumab-for-chronic-spontaneous-urticaria-/2025-01-23T13:15:02+00:00weekly0.7https://www.medthority.com/journals/asthma/stability-of-peripheral-blood-immune-markers-in-patients-with-asthma-/2022-11-15T09:05:47+00:00weekly0.7https://www.medthority.com/journals/epilepsy-convulsions/cannabidiol--a-review-of-clinical-efficacy-and-safety-in-epilepsy-/2025-01-24T09:53:45+00:00weekly0.7https://www.medthority.com/journals/prostate-cancer/increased-expression-of-mir-153-predicts-poor-prognosis-for-patients-with-prostate-cancer-/2025-01-14T08:34:41+00:00weekly0.7https://www.medthority.com/journals/leukaemia/prognostic-and-therapeutic-role-of-clec12a-in-acute-myeloid-leukemia-/2022-10-18T13:21:56+00:00weekly0.7https://www.medthority.com/journals/congestive-heart-failure/the-new-heart-failure-association-definition-of-advanced-heart-failure-/2022-10-07T12:15:11+00:00weekly0.7https://www.medthority.com/journals/coagulation-and-haemorrhagic-disorders/current-evidence-for-pharmacologic-reversal-using-direct-oral-anticoagulants--what-s-new-/2022-12-08T13:27:27+00:00weekly0.7https://www.medthority.com/journals/allergic-reactions/the-emerging-role-of-skin-microbiome-in-atopic-dermatitis-and-its-clinical-implication-/2025-01-23T10:25:38+00:00weekly0.7https://www.medthority.com/journals/allergic-reactions/atopic-dermatitis--a-review-of-evolving-targeted-therapies-/2025-01-23T10:25:00+00:00weekly0.7https://www.medthority.com/journals/cystic-fibrosis/ten-years-of-chest-mri-for-patients-with-cystic-fibrosis---translation-from-the-bench-to-clinical-routine-/2021-09-24T07:22:07+00:00weekly0.7https://www.medthority.com/journals/urticaria/retrospective-case-note-review-of-chronic-spontaneous-urticaria-outcomes-and-adverse-effects-in-patients-treated-with-omalizumab-or-ciclosporin-in-uk-secondary-care-/2024-01-16T15:41:21+00:00weekly0.7https://www.medthority.com/journals/parkinsons-disease/nadph-oxidases-in-parkinson-s-disease--a-systematic-review-/2021-09-24T07:27:26+00:00weekly0.7https://www.medthority.com/journals/prostate-cancer/infiltrating-cd4--t-cells-attenuate-chemotherapy-sensitivity-in-prostate-cancer-via-ccl5-signaling-/2025-01-13T15:19:51+00:00weekly0.7https://www.medthority.com/journals/rheumatoid-arthritis/rituximab-in-clinical-practice--dosage--drug-adherence--ig-levels--infections--and-drug-antibodies-/2022-11-09T10:26:32+00:00weekly0.7https://www.medthority.com/journals/multiple-sclerosis/effectiveness-of-alternative-dose-fingolimod-for-multiple-sclerosis-/2025-01-21T14:25:37+00:00weekly0.7https://www.medthority.com/journals/leukaemia/dual-flt3-inhibitors--against-the-drug-resistance-of-acute-myeloid-leukemia-in-recent-decade-/2022-10-18T13:18:42+00:00weekly0.7https://www.medthority.com/journals/intestinal-infection/bezlotoxumab-for-prevention-of-recurrent-clostridium-difficile-infection-/2021-09-24T07:24:01+00:00weekly0.7https://www.medthority.com/journals/urticaria/real-life-data-on-the-effectiveness-and-safety-of-omalizumab-in-monotherapy-or-combined-for-chronic-spontaneous-urticaria--a-retrospective-cohort-study-/2025-01-23T11:13:50+00:00weekly0.7https://www.medthority.com/journals/multiple-sclerosis/how-people-with-multiple-sclerosis-experience-the-influence-of-nutrition-and-lifestyle-factors-on-the-disease-/2025-01-21T14:51:43+00:00weekly0.7https://www.medthority.com/journals/cancer-of-colon/regorafenib-therapy-in-metastatic-colorectal-cancer-patients--markers-and-outcome-in-an-actual-clinical-setting-/2022-11-21T14:52:59+00:00weekly0.7https://www.medthority.com/journals/sleep-apnea/a-survey-on-sleep-assessment-methods/2021-10-11T14:21:17+00:00weekly0.7https://www.medthority.com/journals/coagulation-and-haemorrhagic-disorders/clot-waveform-analysis-in-clauss-fibrinogen-assay-contributes-to-classification-of-fibrinogen-disorders-/2025-01-16T13:06:38+00:00weekly0.7https://www.medthority.com/journals/diabetes-mellitus-without-complication/sglt2-inhibitors--cardiovascular-benefits-beyond-hba1c-translating-evidence-into-practice-/2021-09-24T07:22:43+00:00weekly0.7https://www.medthority.com/journals/prostate-cancer/alternative-splicing-in-prostate-cancer-/2022-06-27T13:37:13+00:00weekly0.7https://www.medthority.com/journals/chronic-obstructive-pulmonary-disease-copd-and-bronchiectasis/genetic-landscape-of-chronic-obstructive-pulmonary-disease-identifies-heterogeneous-cell-type-and-phenotype-associations-/2025-01-16T10:56:05+00:00weekly0.7https://www.medthority.com/journals/complications-of-surgical-procedures-or-medical-care/management-of-bleeding-in-vascular-surgery-/2021-09-24T07:21:36+00:00weekly0.7https://www.medthority.com/journals/other-upper-respiratory-disease/recent-developments-and-highlights-in-allergic-rhinitis-/2025-01-13T15:27:37+00:00weekly0.7https://www.medthority.com/journals/other-upper-respiratory-disease/effectiveness-of-hypertonic-saline-nasal-irrigation-for-alleviating-allergic-rhinitis-in-children--a-systematic-review-and-meta-analysis-/2022-06-23T09:13:27+00:00weekly0.7https://www.medthority.com/journals/hidradenitis-suppurativa/population-pharmacokinetics-and-immunogenicity-of-adalimumab-in-adult-patients-with-moderate-to-severe-hidradenitis-suppurativa/2021-09-24T07:23:48+00:00weekly0.7https://www.medthority.com/journals/urticaria/current-and-emerging-treatments-for-chronic-spontaneous-urticaria-/2025-01-23T10:21:14+00:00weekly0.7https://www.medthority.com/journals/hepatitis/mixed-micelles-loaded-with-the-5-benzylidenethiazolidine-2-4-dione-derivative-sklb023-for-efficient-treatment-of-non-alcoholic-steatohepatitis-/2022-12-12T15:17:49+00:00weekly0.7https://www.medthority.com/journals/epilepsy-convulsions/gluten-sensitivity-and-epilepsy--a-systematic-review-/2025-01-28T15:53:24+00:00weekly0.7https://www.medthority.com/journals/allergic-reactions/treatment-of-atopic-dermatitis-with-ruxolitinib-cream--jak1-jak2-inhibitor--or-triamcinolone-cream-/2025-01-23T10:23:59+00:00weekly0.7https://www.medthority.com/journals/cancer-of-colon/regorafenib--a-review-in-metastatic-colorectal-cancer-/2022-11-21T14:51:50+00:00weekly0.7https://www.medthority.com/journals/parkinsons-disease/chronic-use-of---blockers-and-the-risk-of-parkinson-s-disease-/2021-09-24T07:27:26+00:00weekly0.7https://www.medthority.com/journals/cystic-fibrosis/emerging-gene-therapies-for-cystic-fibrosis-/2025-01-27T16:03:08+00:00weekly0.7https://www.medthority.com/journals/other-lower-respiratory-disease/real-life-comparison-of-pirfenidone-and-nintedanib-in-patients-with-idiopathic-pulmonary-fibrosis--a-24-month-assessment-/2025-01-14T11:47:18+00:00weekly0.7https://www.medthority.com/journals/diabetes-mellitus-without-complication/changing-the-landscape-for-type-1-diabetes--the-first-step-to-prevention-/2025-01-16T12:42:52+00:00weekly0.7https://www.medthority.com/journals/leukaemia/new-treatment-options-in-hairy-cell-leukemia-with-focus-on-braf-inhibitors-/2025-01-14T11:04:05+00:00weekly0.7https://www.medthority.com/journals/other-lower-respiratory-disease/remarkable-improvement-in-a-patient-with-idiopathic-pulmonary-fibrosis-after-treatment-with-nintedanib-/2021-09-24T07:26:42+00:00weekly0.7https://www.medthority.com/journals/hiv-infection/efficacy-and-safety-of-switching-to-fixed-dose-bictegravir--emtricitabine--and-tenofovir-alafenamide-from-boosted-protease-inhibitor-based-regimens-in-virologically-suppressed-adults-with-hiv-1--48-week-results-of-a-randomised--open-label--multicentre--ph/2025-01-14T10:14:21+00:00weekly0.7https://www.medthority.com/journals/peritonitis-and-intestinal-abscess/recent-developments-in-the-surgical-management-of-complex-intra-abdominal-infection-/2021-09-24T07:27:31+00:00weekly0.7https://www.medthority.com/journals/other-upper-respiratory-disease/epigenetic-changes--an-emerging-potential-pharmacological-target-in-allergic-rhinitis-/2022-06-23T09:11:38+00:00weekly0.7https://www.medthority.com/journals/leukaemia/renal-dysfunction-and-anemia-associated-with-long-term-imatinib-treatment-in-patients-with-chronic-myelogenous-leukemia-/2022-10-18T10:17:03+00:00weekly0.7https://www.medthority.com/journals/alzheimers-disease-and-dementia/novel-approaches-for-the-treatment-of-alzheimer-s-and-parkinson-s-disease-/2021-09-24T07:19:37+00:00weekly0.7https://www.medthority.com/journals/other-hereditary-or-degenerative-neurological-disorders/nusinersen-treatment-of-spinal-muscular-atrophy--current-knowledge-and-existing-gaps-/2025-01-27T15:30:20+00:00weekly0.7https://www.medthority.com/journals/asthma/advances-in-nanotechnology-and-asthma-/2021-09-24T07:19:52+00:00weekly0.7https://www.medthority.com/journals/hepatitis/administration-of-methyl-palmitate-prevents-non-alcoholic-steatohepatitis--nash--by-induction-of-ppar---/2022-12-12T15:16:03+00:00weekly0.7https://www.medthority.com/journals/cystic-fibrosis/a-phase-3-study-of-tezacaftor-in-combination-with-ivacaftor-in-children-aged-6-through-11-years-with-cystic-fibrosis-/2025-01-16T12:50:42+00:00weekly0.7https://www.medthority.com/journals/intracranial-injury/early-fibrinogen-concentrate-therapy-for-major-haemorrhage-in-trauma--e-fit-1---results-from-a-uk-multi-centre--randomised--double-blind--placebo-controlled-pilot-trial-/2021-09-24T07:24:02+00:00weekly0.7https://www.medthority.com/journals/epilepsy-convulsions/the-safety-of-treating-newly-diagnosed-epilepsy-/2025-01-27T15:33:21+00:00weekly0.7https://www.medthority.com/journals/complication-of-device-implant-or-graft/the-role-of-b-cell-immunity-in-vca-graft-rejection-and-acceptance-/2024-02-20T14:34:43+00:00weekly0.7https://www.medthority.com/journals/prostate-cancer/effectiveness--safety-and-cost-of-abiraterone-acetate-in-patients-with-metastatic-castration-resistant-prostate-cancer--a-real-world-data-analysis-/2022-06-27T13:35:16+00:00weekly0.7https://www.medthority.com/journals/other-upper-respiratory-disease/early-molecular-biomarkers-predicting-the-evolution-of-allergic-rhinitis-and-its-comorbidities--a-longitudinal-multicenter-study-of-a-patient-cohort-/2025-01-13T15:28:28+00:00weekly0.7https://www.medthority.com/journals/hepatitis/microbiota-and-nonalcoholic-fatty-liver-disease-nonalcoholic-steatohepatitis--nafld-nash--/2022-12-12T15:12:53+00:00weekly0.7https://www.medthority.com/journals/psoriasis/impact-of-previous-biologic-use-on-the-efficacy-and-safety-of-brodalumab-and-ustekinumab-in-patients-with-moderate-to-severe-plaque-psoriasis-integrated-analysis-of-the-randomized-controlled-trials-amagine-2-and-amagine-3/2025-01-13T09:03:41+00:00weekly0.7https://www.medthority.com/journals/headache/long-term-safety-evaluation-of-ubrogepant-for-the-acute-treatment-of-migraine--phase-3--randomized--52-week-extension-trial-/2025-01-17T11:03:24+00:00weekly0.7https://www.medthority.com/journals/alzheimers-disease-and-dementia/impaired-brain-plasticity-as-a-potential-therapeutic-target-for-treatment-and-prevention-of-dementia-/2025-01-14T12:46:50+00:00weekly0.7https://www.medthority.com/journals/sleep-apnea/a-custom-made-mandibular-repositioning-device-for-obstructive-sleep-apnoea-hypopnoea-syndrome--the-orcades-study-/2021-10-05T08:08:14+00:00weekly0.7https://www.medthority.com/journals/alzheimers-disease-and-dementia/diagnostic-value-of-cerebro-spinal-fluid-biomarkers-in-dementia-with-lewy-bodies-/2022-11-10T14:58:32+00:00weekly0.7https://www.medthority.com/journals/cardiac-dysrhythmias/evaluation-of-the-safety-and-efficacy-of-an-edoxaban-based-antithrombotic-regimen-in-patients-with-atrial-fibrillation-following-successful-percutaneous-coronary-intervention--pci--with-stent-placement--rationale-and-design-of-the-entrust-af-pci-trial-/2022-11-22T08:59:38+00:00weekly0.7https://www.medthority.com/journals/rheumatoid-arthritis/upadacitinib-for-the-treatment-of-rheumatoid-arthritis-/2025-01-14T13:43:37+00:00weekly0.7https://www.medthority.com/journals/other-lower-respiratory-disease/safety-and-survival-data-in-patients-with-idiopathic-pulmonary-fibrosis-treated-with-nintedanib--pooled-data-from-six-clinical-trials-/2022-11-01T09:39:32+00:00weekly0.7https://www.medthority.com/journals/other-upper-respiratory-disease/effect-of-high-intensity-focused-ultrasound-versus-plasma-radiofrequency-ablation-on-recurrent-allergic-rhinitis-/2022-06-23T09:08:13+00:00weekly0.7https://www.medthority.com/journals/regional-enteritis-and-ulcerative-colitis/the-value-of-mrna-expression-of-s100a8-and-s100a9-as-blood-based-biomarkers-of-inflammatory-bowel-disease-/2023-09-21T13:45:46+00:00weekly0.7https://www.medthority.com/journals/asthma/the-effects-of-obesity-in-asthma-/2022-11-14T15:24:28+00:00weekly0.7https://www.medthority.com/journals/asthma/efficacy-of-bronchial-thermoplasty-in-patients-with-severe-asthma-/2025-01-16T09:55:35+00:00weekly0.7https://www.medthority.com/journals/allergic-reactions/towards-personalized-treatment-in-atopic-dermatitis-/2025-01-23T10:22:16+00:00weekly0.7https://www.medthority.com/journals/leukaemia/gilteritinib-or-chemotherapy-for-relapsed-or-refractory-flt3-mutated-aml-/2025-01-14T10:27:38+00:00weekly0.7https://www.medthority.com/journals/alzheimers-disease-and-dementia/a-vaccine-against-alzheimer-s-disease--anything-left-but-faith-/2025-01-14T12:43:04+00:00weekly0.7https://www.medthority.com/journals/headache/increased-risk-of-migraine-in-patients-with-psoriasis--a-longitudinal-follow-up-study-using-a-national-sample-cohort-/2025-01-17T10:59:24+00:00weekly0.7https://www.medthority.com/journals/hepatitis/the-role-of-innate-immune-cells-in-nonalcoholic-steatohepatitis-/2022-12-12T15:11:17+00:00weekly0.7https://www.medthority.com/journals/other-lower-respiratory-disease/cell-based-therapy-for-idiopathic-pulmonary-fibrosis-/2021-09-24T07:26:42+00:00weekly0.7https://www.medthority.com/journals/urticaria/antihistamine-resistant-chronic-spontaneous-urticaria--1-year-data-from-the-aware-study-/2025-01-23T11:12:36+00:00weekly0.7https://www.medthority.com/journals/shock/impact-of-intravenous-fluid-composition-on-outcomes-in-patients-with-systemic-inflammatory-response-syndrome/2022-11-09T14:54:44+00:00weekly0.7https://www.medthority.com/journals/other-lower-respiratory-disease/risk-factors-for-diagnostic-delay-in-idiopathic-pulmonary-fibrosis-/2022-11-01T09:35:12+00:00weekly0.7https://www.medthority.com/journals/chronic-obstructive-pulmonary-disease-copd-and-bronchiectasis/prognostic-models-for-outcome-prediction-in-patients-with-chronic-obstructive-pulmonary-disease--systematic-review-and-critical-appraisal-/2022-11-23T14:42:49+00:00weekly0.7https://www.medthority.com/journals/regional-enteritis-and-ulcerative-colitis/fecal-microbiota-profiles-in-treatment-na-ve-pediatric-inflammatory-bowel-disease---associations-with-disease-phenotype--treatment--and-outcome-/2023-09-21T13:41:36+00:00weekly0.7https://www.medthority.com/journals/multiple-sclerosis/ocrelizumab-and-other-cd20--b-cell-depleting-therapies-in-multiple-sclerosis-/2023-09-04T11:02:51+00:00weekly0.7https://www.medthority.com/journals/coagulation-and-haemorrhagic-disorders/clinical-pharmacology--efficacy-and-safety-study-of-a-triple-secured-fibrinogen-concentrate-in-adults-and-adolescent-patients-with-congenital-fibrinogen-deficiency-/2025-01-16T11:05:20+00:00weekly0.7https://www.medthority.com/journals/leukaemia/gilteritinib--a-novel-flt3-inhibitor-for-acute-myeloid-leukemia-/2022-10-18T10:11:57+00:00weekly0.7https://www.medthority.com/journals/prostate-cancer/emerging-therapeutic-targets-for-patients-with-advanced-prostate-cancer-/2025-01-13T15:21:29+00:00weekly0.7https://www.medthority.com/journals/regional-enteritis-and-ulcerative-colitis/phase-ii-evaluation-of-anti-madcam-antibody-pf-00547659-in-the-treatment-of-crohn-s-disease--report-of-the-opera-study-/2023-09-21T13:39:19+00:00weekly0.7https://www.medthority.com/journals/prostate-cancer/a-phase-ii-trial-of-8-weeks-of-degarelix-for-prostate-volume-reduction--efficacy-and-hormonal-recovery-/2025-01-13T15:22:21+00:00weekly0.7https://www.medthority.com/journals/lung-cancer/clinical-activity--tolerability--and-long-term-follow-up-of-durvalumab-in-patients-with-advanced-nsclc-/2025-01-14T10:24:16+00:00weekly0.7https://www.medthority.com/journals/multiple-sclerosis/paediatric-multiple-sclerosis--a-new-era-in-diagnosis-and-treatment-/2025-01-21T14:52:54+00:00weekly0.7https://www.medthority.com/journals/psoriasis/ixekizumab-for-the-treatment-of-psoriasis-an-update-on-new-data-since-first-approval/2025-01-13T08:56:50+00:00weekly0.7https://www.medthority.com/journals/behavioural-disorders/methylphenidate-hydrochloride-modified-release-in-adults-with-attention-deficit-hyperactivity-disorder--a-randomized-double-blind-placebo-controlled-trial-/2021-12-28T15:50:20+00:00weekly0.7https://www.medthority.com/journals/asthma/novel-insights-on-sex-related-differences-in-asthma-/2022-11-14T14:51:08+00:00weekly0.7https://www.medthority.com/journals/hepatitis/potential-nephrotoxicity-of-sofosbuvir-based-treatment-in-patients-infected-with-hepatitis-c-virus--a-review-on-incidence--type-and-risk-factors-/2025-01-17T10:37:10+00:00weekly0.7https://www.medthority.com/journals/ovarian-cancer/early-and-consistent-overexpression-of-adrm1-in-ovarian-high-grade-serous-carcinoma-/2021-09-24T07:27:21+00:00weekly0.7https://www.medthority.com/journals/complications-of-surgical-procedures-or-medical-care/evaluation-and-management-of-bleeding-during-cardiac-surgery-/2021-09-24T07:21:35+00:00weekly0.7https://www.medthority.com/journals/psoriasis/the-comparative-efficacy-of-brodalumab-in-patients-with-moderate-to-severe-psoriasis--a-systemic-literature-review-and-network-meta-analysis/2025-01-13T14:17:37+00:00weekly0.7https://www.medthority.com/journals/other-upper-respiratory-disease/the-impact-of-serum-25-hydroxyvitamin-d3-levels-on-allergic-rhinitis-/2025-01-13T15:29:05+00:00weekly0.7https://www.medthority.com/journals/epilepsy-convulsions/emergency-management-of-epilepsy-and-seizures-/2021-09-24T07:22:55+00:00weekly0.7https://www.medthority.com/journals/coagulation-and-haemorrhagic-disorders/fibrinogen-concentrate-vs--fresh-frozen-plasma-for-the-management-of-coagulopathy-during-thoraco-abdominal-aortic-aneurysm-surgery--a-pilot-randomised-controlled-trial-/2025-01-16T11:06:05+00:00weekly0.7https://www.medthority.com/journals/leukaemia/moxetumomab-pasudotox--a-first-in-class-treatment-for-hairy-cell-leukemia-/2025-01-14T10:28:27+00:00weekly0.7https://www.medthority.com/journals/parkinsons-disease/the-association-between-vitamin-d-status--vitamin-d-supplementation--sunlight-exposure--and-parkinson-s-disease--a-systematic-review-and-meta-analysis-/2022-11-01T13:59:22+00:00weekly0.7https://www.medthority.com/journals/alzheimers-disease-and-dementia/a-randomized--single-ascending-dose-study-of-intravenous-biib092-in-healthy-participants-/2022-11-10T16:26:32+00:00weekly0.7https://www.medthority.com/journals/multiple-sclerosis/oligoclonal-bands-in-multiple-sclerosis--functional-significance-and-therapeutic-implications--does-the-specificity-matter-/2025-01-21T14:47:20+00:00weekly0.7https://www.medthority.com/journals/chronic-obstructive-pulmonary-disease-copd-and-bronchiectasis/benefits-of-different-intensities-of-pulmonary-rehabilitation-for-patients-with-moderate-to-severe-copd-according-to-the-gold-stage--a-prospective--multicenter--single-blinded--randomized--controlled-trial-/2022-11-24T09:55:41+00:00weekly0.7https://www.medthority.com/journals/polycystic-kidney-disease/is-the-light-at-the-end-of-the-tunnel-nigh--a-review-of-adpkd-focusing-on-the-burden-of-disease-and-tolvaptan-as-a-new-treatment-/2022-05-20T10:06:58+00:00weekly0.7https://www.medthority.com/journals/psoriasis/guselkumab-versus-secukinumab-for-the-treatment-of-moderate-to-severe-psoriasis-eclipse-results-from-a-phase-3-randomised-controlled-trial/2025-01-13T09:06:27+00:00weekly0.7https://www.medthority.com/journals/asthma/nocturnal-asthma-is-affected-by-genetic-interactions-between-rora-and-npsr1-/2025-01-16T10:47:04+00:00weekly0.7https://www.medthority.com/journals/polycystic-kidney-disease/tolvaptan-in-patients-with-autosomal-dominant-polycystic-kidney-disease-/2025-01-13T12:07:45+00:00weekly0.7https://www.medthority.com/journals/complications-of-surgical-procedures-or-medical-care/prophylactic-fibrinogen-infusion-reduces-bleeding-after-coronary-artery-bypass-surgery--a-prospective-randomised-pilot-study-/2021-09-24T07:21:42+00:00weekly0.7https://www.medthority.com/journals/multiple-sclerosis/interleukin-18-polymorphisms-and-its-serum-level-in-patients-with-multiple-sclerosis-/2025-01-21T14:19:59+00:00weekly0.7https://www.medthority.com/journals/prostate-cancer/silencing-ttk-expression-inhibits-the-proliferation-and-progression-of-prostate-cancer-/2022-06-27T15:13:40+00:00weekly0.7https://www.medthority.com/journals/diabetes-mellitus-without-complication/role-of-diet-in-type-2-diabetes-incidence--umbrella-review-of-meta-analyses-of-prospective-observational-studies-/2022-12-06T12:57:22+00:00weekly0.7https://www.medthority.com/journals/metabolic-endocrine-and-nutritional-disorders/efficacy-and-safety-of-velmanase-alfa-in-the-treatment-of-patients-with-alpha-mannosidosis--results-from-the-core-and-extension-phase-analysis-of-a-phase-iii-multicentre--double-blind--randomised--placebo-controlled-trial-/2022-10-25T08:16:43+00:00weekly0.7https://www.medthority.com/journals/headache/migraine-in-childhood--an-organic--biobehavioral--or-psychosomatic-disorder-/2023-05-22T13:57:12+00:00weekly0.7https://www.medthority.com/journals/cardiac-arrest-and-ventricular-fibrillation/perioperative-use-of-levosimendan-improves-clinical-outcomes-in-patients-post-cardiac-surgery--a-systematic-review-and-meta-analysis-/2025-01-16T11:12:19+00:00weekly0.7https://www.medthority.com/journals/epilepsy-convulsions/personality-functioning-in-adults-with-refractory-epilepsy-and-community-adults--implications-for-health-related-quality-of-life-/2024-03-07T14:46:22+00:00weekly0.7https://www.medthority.com/journals/headache/migraine-and-the-risk-of-cardiovascular-and-cerebrovascular-events--a-meta-analysis-of-16-cohort-studies-including-1-152-407-subjects-/2023-05-22T13:55:56+00:00weekly0.7https://www.medthority.com/journals/alzheimers-disease-and-dementia/alzheimer-s-disease-pathogenesis--the-role-of-disturbed-sleep-in-attenuated-brain-plasticity-and-neurodegenerative-processes-/2022-11-10T16:25:01+00:00weekly0.7https://www.medthority.com/journals/multiple-sclerosis/metabolic-defects-in-multiple-sclerosis-/2023-09-04T11:54:52+00:00weekly0.7https://www.medthority.com/journals/cystic-fibrosis/a-systematic-review-of-the-clinical-efficacy-and-safety-of-cftr-modulators-in-cystic-fibrosis-/2021-09-24T07:22:10+00:00weekly0.7https://www.medthority.com/journals/psoriasis/il-17a-inhibition-by-secukinumab-induces-early-clinical-histopathologic-and-molecular-resolution-of-psoriasis/2025-01-13T09:04:45+00:00weekly0.7https://www.medthority.com/journals/cystic-fibrosis/beyond-cystic-fibrosis-transmembrane-conductance-regulator-therapy--a-perspective-on-gene-therapy-and-small-molecule-treatment-for-cystic-fibrosis-/2022-12-05T15:54:29+00:00weekly0.7https://www.medthority.com/journals/epilepsy-convulsions/regression-in-children-with-epilepsy-/2021-09-24T07:22:58+00:00weekly0.7https://www.medthority.com/journals/prostate-cancer/abiraterone-is-effective-and-should-be-considered-for-the-treatment-of-metastatic-castrate-na-ve-prostate-cancer-/2025-01-13T15:12:39+00:00weekly0.7https://www.medthority.com/journals/inflammation-or-infection-of-eye/olopatadine-hydrochloride-ophthalmic-solution-for-the-treatment-of-allergic-conjunctivitis-/2021-09-24T07:23:58+00:00weekly0.7https://www.medthority.com/journals/cystic-fibrosis/newborn-screening-for-cystic-fibrosis--is-there-benefit-for-everyone-/2021-09-24T07:22:10+00:00weekly0.7https://www.medthority.com/journals/prostate-cancer/role-of-androgen-receptor-in-prostate-cancer--a-review-/2022-06-27T15:07:03+00:00weekly0.7https://www.medthority.com/journals/prostate-cancer/obesity--inflammation--and-prostate-cancer-/2022-06-27T15:06:35+00:00weekly0.7https://www.medthority.com/journals/alzheimers-disease-and-dementia/gray-matter-changes-associated-with-the-development-of-delusions-in-alzheimer-disease-/2022-11-10T16:21:24+00:00weekly0.7https://www.medthority.com/journals/essential-hypertension/medicinal-plants-with-concomitant-anti-diabetic-and-anti-hypertensive-effects-as-potential-sources-of-dual-acting-therapies-against-diabetes-and-hypertension--a-review-/2022-12-08T08:33:09+00:00weekly0.7https://www.medthority.com/journals/breast-cancer/synergistic-antitumor-activity-by-combining-trastuzumab-with-retinoic-acid-in-her2-positive-human-breast-cancer-cells-/2023-11-09T10:49:37+00:00weekly0.7https://www.medthority.com/journals/psoriasis/risankizumab-compared-with-adalimumab-in-patients-with-moderate-to-severe-plaque-psoriasis-immvent-a-randomised-double-blind-active-comparator-controlled-phase-3-trial/2025-01-13T09:59:30+00:00weekly0.7https://www.medthority.com/journals/alzheimers-disease-and-dementia/identification-of-evolutionarily-conserved-gene-networks-mediating-neurodegenerative-dementia-/2022-11-10T16:20:20+00:00weekly0.7https://www.medthority.com/journals/other-upper-respiratory-disease/oral-antihistamines-alone-vs-in-combination-with-leukotriene-receptor-antagonists-for-allergic-rhinitis--a-meta-analysis/2025-01-13T15:24:02+00:00weekly0.7https://www.medthority.com/journals/bladder-cancer/long-noncoding-rna-hotair-is-a-prognostic-biomarker-and-inhibits-chemosensitivity-to-doxorubicin-in-bladder-transitional-cell-carcinoma-/2022-05-03T13:05:14+00:00weekly0.7https://www.medthority.com/journals/bladder-cancer/adjuvant-sandwich-chemotherapy-plus-radiotherapy-vs-adjuvant-chemotherapy-alone-for-locally-advanced-bladder-cancer-after-radical-cystectomy--a-randomized-phase-2-trial-/2025-01-13T14:43:01+00:00weekly0.7https://www.medthority.com/journals/other-lower-respiratory-disease/viral-infection-increases-the-risk-of-idiopathic-pulmonary-fibrosis--a-meta-analysis-/2025-01-14T13:18:18+00:00weekly0.7https://www.medthority.com/journals/venous-thromboembolism-vte/edoxaban--a-direct-oral-anticoagulant-/2024-01-23T14:52:09+00:00weekly0.7https://www.medthority.com/journals/hepatitis/present-and-emerging-pharmacotherapies-for-non-alcoholic-steatohepatitis-in-adults-/2025-01-17T10:44:57+00:00weekly0.7https://www.medthority.com/journals/hepatitis/current-status-in-testing-for-nonalcoholic-fatty-liver-disease--nafld--and-nonalcoholic-steatohepatitis--nash--/2022-12-12T15:56:12+00:00weekly0.7https://www.medthority.com/journals/diabetes-mellitus-without-complication/intensive-glucose-control-in-patients-with-type-2-diabetes---15-year-follow-up-/2025-01-17T09:41:50+00:00weekly0.7https://www.medthority.com/journals/multiple-sclerosis/long-range-connections-are-more-severely-damaged-and-relevant-for-cognition-in-multiple-sclerosis-/2023-09-04T11:47:46+00:00weekly0.7https://www.medthority.com/journals/asthma/a-review-on-the-pathophysiology-of-asthma-remission-/2021-09-24T07:20:13+00:00weekly0.7https://www.medthority.com/journals/parkinsons-disease/deep-brain-stimulation-and-genetic-variability-in-parkinson-s-disease--a-review-of-the-literature-/2021-09-24T07:27:27+00:00weekly0.7https://www.medthority.com/journals/ovarian-cancer/a-comprehensive-overview-of-exosomes-in-ovarian-cancer--emerging-biomarkers-and-therapeutic-strategies-/2021-09-24T07:27:21+00:00weekly0.7https://www.medthority.com/journals/asthma/understanding-asthma-phenotypes--endotypes--and-mechanisms-of-disease-/2021-09-24T07:20:13+00:00weekly0.7https://www.medthority.com/journals/schizophrenia/brexpiprazole--a-review-in-schizophrenia-/2021-09-24T07:28:26+00:00weekly0.7https://www.medthority.com/journals/melanomas-of-skin/adjuvant-dabrafenib-plus-trametinib-in-stage-iii-braf-mutated-melanoma-/2025-01-14T11:24:53+00:00weekly0.7https://www.medthority.com/journals/headache/symptoms-related-to-the-visual-system-in-migraine-/2023-05-22T13:54:54+00:00weekly0.7https://www.medthority.com/journals/inflammation-or-infection-of-eye/topical-olopatadine-hydrochloride-versus-ketotifen-fumarate-for-allergic-conjunctivitis-/2021-09-24T07:23:58+00:00weekly0.7https://www.medthority.com/journals/other-nervous-system-disorders/pharmacovigilance-in-hospice-palliative-care--net-effect-of-pregabalin-for-neuropathic-pain-/2021-09-24T07:26:54+00:00weekly0.7https://www.medthority.com/journals/other-hereditary-or-degenerative-neurological-disorders/diagnosis-and-management-of-spinal-muscular-atrophy--part-2--pulmonary-and-acute-care--medications--supplements-and-immunizations--other-organ-systems--and-ethics-/2021-09-24T07:26:29+00:00weekly0.7https://www.medthority.com/journals/coagulation-and-haemorrhagic-disorders/andexanet-alfa-for-the-reversal-of-factor-xa-inhibitors-/2025-01-17T09:39:48+00:00weekly0.7https://www.medthority.com/journals/hepatitis/in-pursuit-of-control-and-elimination--update-on-hepatitis-a-and-b-epidemiology-and-prevention-strategies-/2025-01-17T10:43:25+00:00weekly0.7https://www.medthority.com/journals/psoriasis/efficacy-of-secukinumab-for-moderate-to-severe-head-and-neck-psoriasis-over-52-weeks-pooled-analysis-of-four-phase-3-studies/2021-10-22T09:40:47+00:00weekly0.7https://www.medthority.com/journals/breast-cancer/the-concomitant-use-of-lapatinib-and-paracetamol---the-risk-of-interaction-/2023-11-09T11:24:01+00:00weekly0.7https://www.medthority.com/journals/psoriasis/infliximab-is-associated-with-an-increased-risk-of-serious-infection-in-patients-with-psoriasis-in-the-united-kingdom-and-republic-of-ireland-results-from-the-british-association-of-dermatologists-biologic-interventions-register-badbir/2025-01-13T09:01:13+00:00weekly0.7https://www.medthority.com/journals/cardiac-dysrhythmias/dabigatran-dual-therapy-with-ticagrelor-or-clopidogrel-after-percutaneous-coronary-intervention-in-atrial-fibrillation-patients-with-or-without-acute-coronary-syndrome--a-subgroup-analysis-from-the-re-dual-pci-trial-/2022-11-22T14:54:35+00:00weekly0.7https://www.medthority.com/journals/complications-of-surgical-procedures-or-medical-care/early-activation-of-hemostasis-during-cardiopulmonary-bypass--evidence-for-thrombin-mediated-hyperfibrinolysis-/2021-09-24T07:21:44+00:00weekly0.7https://www.medthority.com/journals/psoriatic-arthritis/mini-review-new-treatments-in-psoriatic-arthritis-focus-on-the-il-23-17-axis/2021-10-27T10:56:34+00:00weekly0.7https://www.medthority.com/journals/other-upper-respiratory-disease/autophagy-is-involved-in-allergic-rhinitis-by-inducing-airway-remodeling-/2025-01-16T10:12:00+00:00weekly0.7https://www.medthority.com/journals/bladder-cancer/immunotherapy-in-metastatic-urothelial-carcinoma--focus-on-immune-checkpoint-inhibition-/2022-05-03T13:23:25+00:00weekly0.7https://www.medthority.com/journals/regional-enteritis-and-ulcerative-colitis/a-review-of-the-clinical-pharmacokinetics--pharmacodynamics--and-immunogenicity-of-vedolizumab-/2023-09-22T12:41:49+00:00weekly0.7https://www.medthority.com/journals/prostate-cancer/the-functional-role-of-prostate-cancer-metastasis-related-micro-rnas-/2022-06-28T08:20:38+00:00weekly0.7https://www.medthority.com/journals/urticaria/rituximab-in-refractory-chronic-spontaneous-urticaria--an-encouraging-therapeutic-approach-/2024-01-16T15:41:21+00:00weekly0.7https://www.medthority.com/journals/epilepsy-convulsions/comparison-of-new-onset-and-persistent-epilepsy-in-the-elderly-/2025-01-27T15:31:52+00:00weekly0.7https://www.medthority.com/journals/rheumatoid-arthritis/effects-of-upadacitinib-on-patient-reported-outcomes--results-from-select-beyond--a-phase-3-randomized-trial-in-patients-with-rheumatoid-arthritis-and-inadequate-responses-to-biologic-disease-modifying-antirheumatic-drugs-/2022-11-09T11:06:32+00:00weekly0.7https://www.medthority.com/journals/diabetes-mellitus-without-complication/a-molecular-approach-on-the-protective-effects-of-mangiferin-against-diabetes-and-diabetes-related-complications-/2025-01-16T11:17:28+00:00weekly0.7https://www.medthority.com/journals/prostate-cancer/apalutamide--emerging-therapy-for-non-metastatic-castration-resistant-prostate-cancer-/2022-06-28T08:21:09+00:00weekly0.7https://www.medthority.com/journals/cardiac-dysrhythmias/role-of-rivaroxaban-in-the-management-of-atrial-fibrillation--insights-from-clinical-practice-/2022-11-22T16:13:50+00:00weekly0.7https://www.medthority.com/journals/leukaemia/clinical-considerations-for-the-use-of-flt3-inhibitors-in-acute-myeloid-leukemia-/2022-10-19T08:49:04+00:00weekly0.7https://www.medthority.com/journals/cystic-fibrosis/prevention-of-malnutrition-in-cystic-fibrosis-/2025-01-27T15:59:35+00:00weekly0.7https://www.medthority.com/journals/ovarian-cancer/rucaparib--a-novel-parp-inhibitor-for-brca-advanced-ovarian-cancer-/2021-09-24T07:27:23+00:00weekly0.7https://www.medthority.com/journals/breast-cancer/safety-and-efficacy-profile-of-neratinib--a-systematic-review-and-meta-analysis-of-23-prospective-clinical-trials-/2023-11-09T15:36:58+00:00weekly0.7https://www.medthority.com/journals/shock/aggressive-fluid-management-in-the-critically-ill--pro-/2021-09-24T07:28:35+00:00weekly0.7https://www.medthority.com/journals/leukaemia/venetoclax-in-the-treatment-of-chronic-lymphocytic-leukemia-/2025-01-14T11:19:08+00:00weekly0.7https://www.medthority.com/journals/cardiac-dysrhythmias/vernakalant-is-superior-to-ibutilide-for-achieving-sinus-rhythm-in-patients-with-recent-onset-atrial-fibrillation--a-randomized-controlled-trial-at-the-emergency-department-/2022-11-22T16:12:10+00:00weekly0.7https://www.medthority.com/journals/epilepsy-convulsions/responsive-neurostimulation-for-the-treatment-of-epilepsy-/2021-09-24T07:23:01+00:00weekly0.7https://www.medthority.com/journals/leukaemia/targeting-apoptotic-pathways-in-acute-myeloid-leukaemia-/2022-10-19T08:46:44+00:00weekly0.7https://www.medthority.com/journals/bladder-cancer/spotlight-on-atezolizumab-and-its-potential-in-the-treatment-of-advanced-urothelial-bladder-cancer-/2022-05-03T13:30:25+00:00weekly0.7https://www.medthority.com/journals/leukaemia/efficacy-of-venetoclax-monotherapy-in-patients-with-relapsed-chronic-lymphocytic-leukaemia-in-the-post-bcr-inhibitor-setting--a-uk-wide-analysis-/2025-01-14T11:20:25+00:00weekly0.7https://www.medthority.com/journals/cerebrovascular-aneurysms/experiences-with-tachosil--in-microneurosurgery-/2022-05-18T14:33:49+00:00weekly0.7https://www.medthority.com/journals/prostate-cancer/targeting-dna-repair-defects-for-precision-medicine-in-prostate-cancer-/2022-06-28T14:13:40+00:00weekly0.7https://www.medthority.com/journals/hepatitis/screening-and-prophylaxis-to-prevent-hepatitis-b-reactivation--introduction-and-immunology-/2021-09-24T07:23:45+00:00weekly0.7https://www.medthority.com/journals/psoriasis/interleukin-17-receptor-d-constitutes-an-alternative-receptor-for-interleukin-17a-important-in-psoriasis-like-skin-inflammation/2025-01-13T09:00:23+00:00weekly0.7https://www.medthority.com/journals/other-hereditary-or-degenerative-neurological-disorders/safety-and-efficacy-of-edaravone-in-well-defined-patients-with-amyotrophic-lateral-sclerosis--a-randomised--double-blind--placebo-controlled-trial-/2021-09-24T07:26:39+00:00weekly0.7https://www.medthority.com/journals/gestational-diabetes/efficacy-of-probiotic-supplement-for-gestational-diabetes-mellitus--a-systematic-review-and-meta-analysis-/2025-01-17T10:37:54+00:00weekly0.7https://www.medthority.com/journals/headache/migraine-associated-with-gastrointestinal-disorders--a-pathophysiological-explanation-/2025-01-20T14:36:02+00:00weekly0.7https://www.medthority.com/journals/cystic-fibrosis/children-with-cystic-fibrosis-are-infected-with-multiple-subpopulations-of-mycobacterium-abscessus-with-different-antimicrobial-resistance-profiles-/2022-12-06T09:50:38+00:00weekly0.7https://www.medthority.com/journals/headache/global--regional--and-national-incidence--prevalence--and-years-lived-with-disability-for-310-diseases-and-injuries--1990-2015--a-systematic-analysis-for-the-global-burden-of-disease-study-2015-/2025-01-20T14:36:45+00:00weekly0.7https://www.medthority.com/journals/other-upper-respiratory-disease/cromolyn-crosslinked-chitosan-nanoparticles-for-the-treatment-of-allergic-rhinitis-/2022-06-23T13:09:35+00:00weekly0.7https://www.medthority.com/journals/chronic-obstructive-pulmonary-disease-copd-and-bronchiectasis/resistance-exercise-training-improves-mucociliary-clearance-in-subjects-with-copd--a-randomized-clinical-trial-/2022-11-29T15:33:20+00:00weekly0.7https://www.medthority.com/journals/complications-of-surgical-procedures-or-medical-care/the-effect-of-fibrinogen-on-blood-loss-after-lumbar-surgery--a-double-blind-randomized-clinical-trial-/2025-01-03T09:19:05+00:00weekly0.7https://www.medthority.com/journals/other-hereditary-or-degenerative-neurological-disorders/prevalence--incidence-and-carrier-frequency-of-5q-linked-spinal-muscular-atrophy---a-literature-review-/2021-09-24T07:26:39+00:00weekly0.7https://www.medthority.com/journals/hepatitis/a-structured-literature-review-of-the-epidemiology-and-disease-burden-of-non-alcoholic-steatohepatitis--nash--/2021-12-29T11:06:52+00:00weekly0.7https://www.medthority.com/journals/asthma/ers-eaaci-statement-on-severe-exacerbations-in-asthma-in-adults--facts--priorities-and-key-research-questions-/2022-11-17T10:06:04+00:00weekly0.7https://www.medthority.com/journals/alzheimers-disease-and-dementia/dementia--new-vistas-and-opportunities-/2022-11-14T14:23:07+00:00weekly0.7https://www.medthority.com/journals/psoriasis/psoriatic-skin-molecular-and-histopathologic-profiles-after-treatment-with-risankizumab-versus-ustekinumab/2025-01-13T08:48:22+00:00weekly0.7https://www.medthority.com/journals/asthma/current-state-and-future-prospect-of-the-therapeutic-strategy-targeting-cysteinyl-leukotriene-metabolism-in-asthma-/2022-11-17T10:05:09+00:00weekly0.7https://www.medthority.com/journals/urticaria/a-review-of-international-recommendations-for-the-diagnosis-and-management-of-chronic-urticaria-/2024-01-16T15:41:21+00:00weekly0.7https://www.medthority.com/journals/other-hereditary-or-degenerative-neurological-disorders/systemic-nature-of-spinal-muscular-atrophy-revealed-by-studying-insurance-claims-/2021-09-24T07:26:39+00:00weekly0.7https://www.medthority.com/journals/other-lower-respiratory-disease/efficacy-and-safety-of-nintedanib-in-idiopathic-pulmonary-fibrosis-/2025-01-14T11:24:39+00:00weekly0.7https://www.medthority.com/journals/rheumatoid-arthritis/long-term-effectiveness-of-adalimumab-in-patients-with-rheumatoid-arthritis--an-observational-analysis-from-the-corrona-rheumatoid-arthritis-registry-/2022-11-09T11:57:02+00:00weekly0.7https://www.medthority.com/journals/other-hereditary-or-degenerative-neurological-disorders/two-breakthrough-gene-targeted-treatments-for-spinal-muscular-atrophy--challenges-remain-/2021-09-24T07:26:39+00:00weekly0.7https://www.medthority.com/journals/lung-cancer/brigatinib--novel-alk-inhibitor-for-non-small-cell-lung-cancer-/2025-01-28T16:10:03+00:00weekly0.7https://www.medthority.com/journals/gynaecological-cancers/bevacizumab-added-to-moderate-dose-chemotherapy-for-refractory-uterine-cancer-/2021-09-24T07:23:18+00:00weekly0.7https://www.medthority.com/journals/other-hereditary-or-degenerative-neurological-disorders/safety-of-the-tau-directed-monoclonal-antibody-biib092-in-progressive-supranuclear-palsy--a-randomised--placebo-controlled--multiple-ascending-dose-phase-1b-trial-/2021-09-24T07:26:39+00:00weekly0.7https://www.medthority.com/journals/complications-of-surgical-procedures-or-medical-care/randomized-evaluation-of-fibrinogen-versus-placebo-in-complex-cardiovascular-surgery--post-hoc-analysis-and-interpretation-of-phase-iii-results-/2021-09-24T07:21:48+00:00weekly0.7https://www.medthority.com/journals/behavioural-disorders/lifespan-persistence-of-adhd--the-life-transition-model-and-its-application-/2021-09-24T07:20:28+00:00weekly0.7https://www.medthority.com/journals/psoriatic-arthritis/prevalence-of-psoriatic-arthritis-in-patients-with-psoriasis-a-systematic-review-and-meta-analysis-of-observational-and-clinical-studies/2025-01-13T08:50:28+00:00weekly0.7https://www.medthority.com/journals/hepatitis/histological-improvement-of-non-alcoholic-steatohepatitis-with-a-prebiotic--a-pilot-clinical-trial-/2021-09-24T07:23:44+00:00weekly0.7https://www.medthority.com/journals/leukaemia/the-cell-of-origin-and-the-leukemia-stem-cell-in-acute-myeloid-leukemia-/2025-01-14T11:21:17+00:00weekly0.7https://www.medthority.com/journals/parkinsons-disease/environment--lifestyle--and-parkinson-s-disease--implications-for-prevention-in-the-next-decade-/2025-01-27T16:11:33+00:00weekly0.7https://www.medthority.com/journals/prostate-cancer/theranostics-for-advanced-prostate-cancer--current-indications-and-future-developments-/2022-06-28T14:10:10+00:00weekly0.7https://www.medthority.com/journals/coagulation-and-haemorrhagic-disorders/performance-of-idarucizumab-as-antidote-of-dabigatran-in-daily-clinical-practice-/2022-12-08T14:26:43+00:00weekly0.7https://www.medthority.com/journals/headache/calcitonin-gene-related-peptide--cgrp---a-new-target-for-migraine-/2023-05-22T14:26:47+00:00weekly0.7https://www.medthority.com/journals/parkinsons-disease/safety-and-tolerability-of-pharmacotherapies-for-parkinson-s-disease-in-geriatric-patients-/2021-09-24T07:27:30+00:00weekly0.7https://www.medthority.com/journals/leukaemia/gilteritinib-for-the-treatment-of-relapsed-and-or-refractory-flt3-mutated-acute-myeloid-leukemia-/2025-01-14T10:30:45+00:00weekly0.7https://www.medthority.com/journals/hepatitis/treatment-of-nash-with-gastric-bypass-/2021-09-24T07:23:44+00:00weekly0.7https://www.medthority.com/journals/cancer-of-colon/prediction-of-novel-target-genes-and-pathways-involved-in-bevacizumab-resistant-colorectal-cancer-/2022-11-21T15:03:41+00:00weekly0.7https://www.medthority.com/journals/behavioural-disorders/non-pharmacological-interventions-for-cognitive-difficulties-in-adhd--a-systematic-review-and-meta-analysis-/2021-09-24T07:20:28+00:00weekly0.7https://www.medthority.com/journals/leukaemia/safety-and-efficacy-of-bosutinib-in-fourth-line-therapy-of-chronic-myeloid-leukemia-patients-/2022-10-19T08:27:19+00:00weekly0.7https://www.medthority.com/journals/psoriasis/risankizumab-in-the-treatment-of-psoriasis-literature-review/2021-10-29T09:57:39+00:00weekly0.7https://www.medthority.com/journals/behavioural-disorders/neuropsychological-deficits-in-adults-age-60-and-above-with-attention-deficit-hyperactivity-disorder-/2021-09-24T07:20:28+00:00weekly0.7https://www.medthority.com/journals/leukaemia/flt3-inhibitors-in-acute-myeloid-leukemia--current-and-future-/2025-01-14T10:31:36+00:00weekly0.7https://www.medthority.com/journals/regional-enteritis-and-ulcerative-colitis/environmental-triggers-in-ibd--a-review-of-progress-and-evidence-/2023-09-22T14:52:48+00:00weekly0.7https://www.medthority.com/journals/behavioural-disorders/underdiagnosis-of-attention-deficit-hyperactivity-disorder-in-adult-patients--a-review-of-the-literature-/2021-09-24T07:20:28+00:00weekly0.7https://www.medthority.com/journals/urticaria/benefits-and-harms-of-omalizumab-treatment-in-adolescent-and-adult-patients-with-chronic-idiopathic--spontaneous--urticaria--a-meta-analysis-of--real-world--evidence-/2025-01-23T11:27:23+00:00weekly0.7https://www.medthority.com/journals/cystic-fibrosis/augmentation-of-cftr-function-in-human-bronchial-epithelial-cells-via-slc6a14-dependent-amino-acid-uptake--implications-for-treatment-of-cystic-fibrosis-/2025-01-16T12:47:21+00:00weekly0.7https://www.medthority.com/journals/headache/does-the-migraine-attack-start-in-the-cortex-and-is-the-cortex-critical-in-the-migraine-process-/2023-05-22T14:23:44+00:00weekly0.7https://www.medthority.com/journals/melanomas-of-skin/encorafenib-in-combination-with-binimetinib-for-unresectable-or-metastatic-melanoma-with-braf-mutations-/2025-01-14T11:17:04+00:00weekly0.7https://www.medthority.com/journals/shock/non-oncotic-properties-of-albumin--a-multidisciplinary-vision-about-the-implications-for-critically-ill-patients-/2025-01-14T13:40:46+00:00weekly0.7https://www.medthority.com/journals/other-hereditary-or-degenerative-neurological-disorders/anti-inflammatory-drug-use-and-progressive-supranuclear-palsy-/2021-09-24T07:26:38+00:00weekly0.7https://www.medthority.com/journals/leukaemia/probiotic-supplementation-decreases-chemotherapy-induced-gastrointestinal-side-effects-in-patients-with-acute-leukemia-/2025-01-14T10:32:33+00:00weekly0.7https://www.medthority.com/journals/prostate-cancer/androgen-targeted-therapy-in-men-with-prostate-cancer--evolving-practice-and-future-considerations-/2022-06-28T14:05:55+00:00weekly0.7https://www.medthority.com/journals/coronary-atherosclerosis/efficacy-and-safety-of-further-lowering-of-low-density-lipoprotein-cholesterol-in-patients-starting-with-very-low-levels--a-meta-analysis-/2022-12-05T14:44:57+00:00weekly0.7https://www.medthority.com/journals/chronic-obstructive-pulmonary-disease-copd-and-bronchiectasis/efficacy-and-safety-of-glycopyrrolate-in-patients-with-copd-by-reversibility--pooled-analysis-of-gem1-and-gem2-12-week-studies-/2022-11-29T15:24:31+00:00weekly0.7https://www.medthority.com/journals/other-lower-respiratory-disease/thoracic-skeletal-muscle-quantification--low-muscle-mass-is-related-with-worse-prognosis-in-idiopathic-pulmonary-fibrosis-patients-/2022-11-01T11:36:19+00:00weekly0.7https://www.medthority.com/journals/alzheimers-disease-and-dementia/identification-of-the-early-stage-of-alzheimer-s-disease-using-structural-mri-and-resting-state-fmri-/2022-11-14T14:19:27+00:00weekly0.7https://www.medthority.com/journals/alzheimers-disease-and-dementia/influence-of-microglia-and-astrocyte-activation-in-the-neuroinflammatory-pathogenesis-of-alzheimer-s-disease--rational-insights-for-the-therapeutic-approaches-/2025-01-16T10:00:23+00:00weekly0.7https://www.medthority.com/journals/coagulation-and-haemorrhagic-disorders/andexanet-alfa-for-reversing-factor-xa-inhibition-/2025-01-17T09:33:44+00:00weekly0.7https://www.medthority.com/journals/other-hereditary-or-degenerative-neurological-disorders/abnormal-fatty-acid-metabolism-is-a-core-component-of-spinal-muscular-atrophy-/2021-09-24T07:26:38+00:00weekly0.7https://www.medthority.com/journals/multiple-sclerosis/alemtuzumab-for-the-treatment-of-multiple-sclerosis-/2025-01-21T15:09:34+00:00weekly0.7https://www.medthority.com/journals/hiv-infection/switching-to-doravirine-lamivudine-tenofovir-disoproxil-fumarate--dor-3tc-tdf--maintains-hiv-1-virologic-suppression-through-48-weeks--results-of-the-drive-shift-trial-/2025-01-14T09:56:08+00:00weekly0.7https://www.medthority.com/journals/psoriasis/comparative-effectiveness-of-abatacept-apremilast-secukinumab-and-ustekinumab-treatment-of-psoriatic-arthritis-a-systematic-review-and-network-meta-analysis/2021-10-19T13:14:14+00:00weekly0.7https://www.medthority.com/journals/other-upper-respiratory-disease/effects-of-serum-vitamin-d-and-efficacy-of-subcutaneous-immunotherapy-in-adult-patients-with-allergic-rhinitis-/2022-06-23T13:04:53+00:00weekly0.7https://www.medthority.com/journals/coagulation-and-haemorrhagic-disorders/acute-reversal-of-dabigatran-with-idarucizumab-for-intravenous-thrombolysis-as-acute-stroke-treatment-/2025-01-16T12:51:44+00:00weekly0.7https://www.medthority.com/journals/epilepsy-convulsions/neuroinflammatory-pathways-as-treatment-targets-and-biomarkers-in-epilepsy-/2021-09-24T07:23:01+00:00weekly0.7https://www.medthority.com/journals/chronic-obstructive-pulmonary-disease-copd-and-bronchiectasis/no-impact-of-exacerbation-frequency-and-severity-on-the-physical-activity-decline-in-copd--a-long-term-observation-/2022-11-29T14:59:50+00:00weekly0.7https://www.medthority.com/journals/cystic-fibrosis/vitamin-k-and-cystic-fibrosis--a-gordian-knot-that-deserves-our-attention-/2021-09-24T07:22:14+00:00weekly0.7https://www.medthority.com/journals/asthma/the-role-of-histamine-and-histamine-receptors-in-mast-cell-mediated-allergy-and-inflammation--the-hunt-for-new-therapeutic-targets-/2022-11-17T09:14:20+00:00weekly0.7https://www.medthority.com/journals/coagulation-and-haemorrhagic-disorders/reversal-strategies-in-patients-treated-with-direct-oral-anticoagulants-/2025-01-16T12:52:43+00:00weekly0.7https://www.medthority.com/journals/psoriasis/greater-cumulative-benefits-from-ixekizumab-versus-ustekinumab-treatment-over-52-weeks-for-patients-with-moderate-to-severe-psoriasis-in-a-randomized-double-blinded-phase-3b-clinical-tria-/2025-01-13T09:17:57+00:00weekly0.7https://www.medthority.com/journals/leukaemia/insights-into-the-optimal-use-of-ponatinib-in-patients-with-chronic-phase-chronic-myeloid-leukaemia-/2025-01-14T11:09:45+00:00weekly0.7https://www.medthority.com/journals/epilepsy-convulsions/global--regional--and-national-burden-of-epilepsy--1990-2016--a-systematic-analysis-for-the-global-burden-of-disease-study-2016-/2025-01-24T10:13:57+00:00weekly0.7https://www.medthority.com/journals/lung-cancer/clinical-management-of-adverse-events-associated-with-lorlatinib-/2025-01-30T09:08:43+00:00weekly0.7https://www.medthority.com/journals/bladder-cancer/molecular-mechanism-of-pd-1-pd-l1-blockade-via-anti-pd-l1-antibodies-atezolizumab-and-durvalumab-/2022-05-03T13:28:06+00:00weekly0.7https://www.medthority.com/journals/cystic-fibrosis/disease-progression-in-patients-with-cystic-fibrosis-treated-with-ivacaftor--data-from-national-us-and-uk-registries-/2025-01-16T12:49:17+00:00weekly0.7https://www.medthority.com/journals/chronic-obstructive-pulmonary-disease-copd-and-bronchiectasis/when-to-use-single-inhaler-triple-therapy-in-copd--a-practical-approach-for-primary-care-health-care-professionals-/2022-11-29T14:58:13+00:00weekly0.7https://www.medthority.com/journals/prostate-cancer/metastatic-prostate-cancer-remains-incurable--why-/2022-06-28T14:01:47+00:00weekly0.7https://www.medthority.com/journals/other-perinatal-conditions/glutathione-s-transferase-genotype-protects-against-in-utero-tobacco-linked-lung-function-deficits-/2025-01-16T10:13:04+00:00weekly0.7https://www.medthority.com/journals/headache/surgical-management-of-migraine-headaches--a-systematic-review-and-meta-analysis-/2025-01-20T14:42:41+00:00weekly0.7https://www.medthority.com/journals/asthma/asthma--moving-toward-a-global-children-s-charter-/2025-01-23T13:31:36+00:00weekly0.7https://www.medthority.com/journals/hiv-infection/darunavir-for-the-treatment-of-hiv-infection-/2025-01-28T14:11:14+00:00weekly0.7https://www.medthority.com/journals/urticaria/effect-of-diet-in-chronic-spontaneous-urticaria--a-systematic-review-/2024-01-16T15:41:21+00:00weekly0.7https://www.medthority.com/journals/alzheimers-disease-and-dementia/a-systematic-review-of-evidence-for-a-role-of-rest-activity-rhythms-in-dementia-/2022-11-14T14:16:43+00:00weekly0.7https://www.medthority.com/journals/congestive-heart-failure/predictors-of-30-day-mortality-in-patients-admitted-to-ed-for-acute-heart-failure-/2022-10-11T11:06:38+00:00weekly0.7https://www.medthority.com/journals/cystic-fibrosis/identification-of-a-novel-large-deletion-and-other-copy-number-variations-in-the-cftr-gene-in-patients-with-cystic-fibrosis-from-a-multiethnic-population-/2025-01-16T12:48:09+00:00weekly0.7https://www.medthority.com/journals/alzheimers-disease-and-dementia/neuropsychiatric-symptoms-and-executive-function-impairments-in-alzheimer-s-disease-and-vascular-dementia--the-role-of-subcortical-circuits-/2022-11-14T14:15:41+00:00weekly0.7https://www.medthority.com/journals/other-nervous-system-disorders/a-brief-history-of-the-opioid-epidemic-and-strategies-for-pain-medicine-/2021-09-24T07:26:59+00:00weekly0.7https://www.medthority.com/journals/alzheimers-disease-and-dementia/targeted-metabolomic-analysis-of-nitric-oxide-l-arginine-pathway-metabolites-in-dementia--association-with-pathology--severity--and-structural-brain-changes-/2022-11-14T14:10:30+00:00weekly0.7https://www.medthority.com/journals/chronic-obstructive-pulmonary-disease-copd-and-bronchiectasis/the-airways--mechanical-stress-in-lung-disease--implications-for-copd-pathophysiology-and-treatment-evaluation-/2025-01-16T10:56:26+00:00weekly0.7https://www.medthority.com/journals/other-hereditary-or-degenerative-neurological-disorders/essential-tremor-and-parkinson-s-disease--exploring-the-relationship-/2021-09-24T07:26:37+00:00weekly0.7https://www.medthority.com/journals/asthma/efficacy-and-safety-of-a-first-in-class-inhaled-pde3-4-inhibitor--ensifentrine--vs-salbutamol-in-asthma-/2022-11-16T16:44:10+00:00weekly0.7https://www.medthority.com/journals/prostate-cancer/prostate-cancer-radiation-and-urethral-strictures--a-systematic-review-and-meta-analysis-/2022-06-28T13:55:43+00:00weekly0.7https://www.medthority.com/journals/multiple-sclerosis/imaging-the-multiple-sclerosis-lesion--insights-into-pathogenesis--progression-and-repair-/2025-01-21T15:12:51+00:00weekly0.7https://www.medthority.com/journals/other-liver-diseases/aisf-simti-position-paper--the-appropriate-use-of-albumin-in-patients-with-liver-cirrhosis/2024-02-27T11:12:42+00:00weekly0.7https://www.medthority.com/journals/prostate-cancer/further-application-of-hyperbaric-oxygen-in-prostate-cancer-/2025-01-14T09:31:13+00:00weekly0.7https://www.medthority.com/journals/sleep-apnea/the-epidemiology-of-adult-obstructive-sleep-apnea/2021-10-12T09:00:07+00:00weekly0.7https://www.medthority.com/journals/headache/some-aspects-on-the-pathophysiology-of-migraine-and-a-review-of-device-therapies-for-migraine-and-cluster-headache-/2023-05-22T14:17:16+00:00weekly0.7https://www.medthority.com/journals/urticaria/factors-related-to-omalizumab-resistance-in-chronic-spontaneous-urticaria-/2025-01-23T11:28:35+00:00weekly0.7https://www.medthority.com/journals/cardiac-dysrhythmias/effects-of-non-vitamin-k-antagonist-oral-anticoagulants-versus-warfarin-in-patients-with-atrial-fibrillation-and-valvular-heart-disease--a-systematic-review-and-meta-analysis-/2025-01-17T10:53:58+00:00weekly0.7https://www.medthority.com/journals/other-nervous-system-disorders/cebranopadol--a-novel--first-in-class--strong-analgesic--results-from-a-randomized-phase-iia-clinical-trial-in-postoperative-acute-pain-/2022-06-22T13:08:07+00:00weekly0.7https://www.medthority.com/journals/prostate-cancer/the-molecular-biology-of-prostate-cancer--current-understanding-and-clinical-implications-/2022-06-28T13:48:30+00:00weekly0.7https://www.medthority.com/journals/coagulation-and-haemorrhagic-disorders/full-study-report-of-andexanet-alfa-for-bleeding-associated-with-factor-xa-inhibitors-/2025-01-17T09:46:04+00:00weekly0.7https://www.medthority.com/journals/coagulation-and-haemorrhagic-disorders/reversal-agents-for-oral-anticoagulant-associated-major-or-life-threatening-bleeding-/2022-12-08T15:11:01+00:00weekly0.7https://www.medthority.com/journals/alzheimers-disease-and-dementia/assessment-of-memory-impairment-in-early-diagnosis-of-alzheimer-s-disease-/2022-11-14T14:07:21+00:00weekly0.7https://www.medthority.com/journals/rheumatoid-arthritis/era-of-biosimilars-in-rheumatology--reshaping-the-healthcare-environment-/2024-03-07T15:30:56+00:00weekly0.7https://www.medthority.com/journals/congestive-heart-failure/the-efficacy-of-simendan-in-the-treatment-of-acute-heart-failure-and-its-impact-on-nt-probnp-/2022-10-11T11:02:31+00:00weekly0.7https://www.medthority.com/journals/epilepsy-convulsions/evolution-of-concepts-in-epilepsy-surgery-/2021-09-24T07:23:00+00:00weekly0.7https://www.medthority.com/journals/psoriasis/long-term-efficacy-of-novel-therapies-in-moderate-to-severe-plaque-psoriasis-a-systematic-review-and-network-meta-analysis-of-pasi-response/2025-01-13T10:17:25+00:00weekly0.7https://www.medthority.com/journals/asthma/prevalence-and-management-of-severe-asthma-in-primary-care--an-observational-cohort-study-in-sweden--pacehr--/2022-11-16T16:19:34+00:00weekly0.7https://www.medthority.com/journals/headache/placebo-and-nocebo-phenomena-in-anti--cgrp-monoclonal-antibody-trials-for-migraine-prevention--a-meta-analysis-/2023-05-22T14:18:06+00:00weekly0.7https://www.medthority.com/journals/complications-of-surgical-procedures-or-medical-care/the-role-of-fibrinogen-and-fibrinogen-concentrate-in-cardiac-surgery--an-international-consensus-statement-from-the-haemostasis-and-transfusion-scientific-subcommittee-of-the-european-association-of-cardiothoracic-anaesthesiology-/2021-09-24T07:21:47+00:00weekly0.7https://www.medthority.com/journals/multiple-sclerosis/natalizumab-promotes-activation-and-pro-inflammatory-differentiation-of-peripheral-b-cells-in-multiple-sclerosis-patients-/2023-09-05T09:47:21+00:00weekly0.7https://www.medthority.com/journals/parkinsons-disease/safinamide--first-global-approval-/2021-09-24T07:27:29+00:00weekly0.7https://www.medthority.com/journals/leukaemia/real-world-data-confirming-the-efficacy-and-safety-of-decitabine-in-acute-myeloid-leukaemia---results-from-a-retrospective-belgian-registry-study-/2025-01-14T10:33:08+00:00weekly0.7https://www.medthority.com/journals/prostate-cancer/enzalutamide--targeting-the-androgen-signalling-pathway-in-metastatic-castration-resistant-prostate-cancer-/2022-06-28T13:08:44+00:00weekly0.7https://www.medthority.com/journals/regional-enteritis-and-ulcerative-colitis/novel-therapies-for-immune-mediated-inflammatory-diseases--what-can-we-learn-from-their-use-in-rheumatoid-arthritis--spondyloarthritis--systemic-lupus-erythematosus--psoriasis--crohn-s-disease-and-ulcerative-colitis-/2023-09-21T13:17:04+00:00weekly0.7https://www.medthority.com/journals/intracranial-injury/cryoprecipitate-therapy-/2021-09-24T07:24:04+00:00weekly0.7https://www.medthority.com/journals/congestive-heart-failure/efficacy-and-safety-of-intermittent-intravenous-outpatient-administration-of-levosimendan-in-patients-with-advanced-heart-failure--the-lion-heart-multicentre-randomised-trial-/2025-01-14T10:17:13+00:00weekly0.7https://www.medthority.com/journals/diabetes-mellitus-without-complication/type-1-and-2-diabetes-mellitus--a-review-on-current-treatment-approach-and-gene-therapy-as-potential-intervention-/2022-12-07T14:21:56+00:00weekly0.7https://www.medthority.com/journals/hiv-infection/hiv-1-remission-following-ccr5-32--32-haematopoietic-stem-cell-transplantation-/2025-01-24T10:05:40+00:00weekly0.7https://www.medthority.com/journals/prostate-cancer/uhrf1-overexpression-is-involved-in-cell-proliferation-and-biochemical-recurrence-in-prostate-cancer-after-radical-prostatectomy-/2022-06-28T13:05:08+00:00weekly0.7https://www.medthority.com/journals/alzheimers-disease-and-dementia/essential-oils-as-treatment-strategy-for-alzheimer-s-disease--current-and-future-perspectives-/2022-11-14T14:00:43+00:00weekly0.7https://www.medthority.com/journals/cystic-fibrosis/prevention-of-drug-related-complications-in-cystic-fibrosis-/2025-01-13T14:09:49+00:00weekly0.7https://www.medthority.com/journals/alzheimers-disease-and-dementia/the-roles-of-apathy-and-depression-in-predicting-alzheimer-disease--a-longitudinal-analysis-in-older-adults-with-mild-cognitive-impairment-/2022-11-14T13:57:50+00:00weekly0.7https://www.medthority.com/journals/multiple-sclerosis/safety-and-efficacy-of-ozanimod-versus-interferon-beta-1a-in-relapsing-multiple-sclerosis--sunbeam---a-multicentre--randomised--minimum-12-month--phase-3-trial-/2025-01-21T15:13:52+00:00weekly0.7https://www.medthority.com/journals/prostate-cancer/prostate-specific-membrane-antigen-guided-surgery-/2022-06-28T13:02:21+00:00weekly0.7https://www.medthority.com/journals/diabetes-mellitus-without-complication/using-dpp-4-inhibitors-to-modulate-beta-cell-function-in-type-1-diabetes-and-in-the-treatment-of-diabetic-kidney-disease-/2025-01-16T11:50:06+00:00weekly0.7https://www.medthority.com/journals/ovarian-cancer/rucaparib--an-emerging-parp-inhibitor-for-treatment-of-recurrent-ovarian-cancer-/2025-01-23T13:29:16+00:00weekly0.7https://www.medthority.com/journals/sleep-apnea/advanced-concepts-in-the-pathophysiology-of-obstructive-sleep-apnea-/2021-10-11T14:45:22+00:00weekly0.7https://www.medthority.com/journals/alzheimers-disease-and-dementia/a-novel-therapeutic-potential-of-cysteinyl-leukotrienes-and-their-receptors-modulation-in-the-neurological-complications-associated-with-alzheimer-s-disease-/2022-11-14T13:50:28+00:00weekly0.7https://www.medthority.com/journals/leukaemia/recent-treatment-advances-and-the-role-of-nanotechnology--combination-products--and-immunotherapy-in-changing-the-therapeutic-landscape-of-acute-myeloid-leukemia-/2022-10-18T14:59:06+00:00weekly0.7https://www.medthority.com/journals/metabolic-endocrine-and-nutritional-disorders/burosumab--first-global-approval-/2021-09-24T07:24:58+00:00weekly0.7https://www.medthority.com/journals/coagulation-and-haemorrhagic-disorders/congenital-fibrinogen-disorders--an-update-/2022-12-05T11:00:55+00:00weekly0.7https://www.medthority.com/journals/psoriasis/secukinumab-versus-ustekinumab-for-skin-clearance-in-patients-with-moderate-to-severe-psoriasis-after-a-year-of-treatment-real-world-practice/2025-01-13T09:52:27+00:00weekly0.7https://www.medthority.com/journals/cardiac-dysrhythmias/safety-and-efficacy-of-antithrombotic-strategies-in-patients-with-atrial-fibrillation-undergoing-percutaneous-coronary-intervention--a-network-meta-analysis-of-randomized-controlled-trials-/2022-11-22T15:36:41+00:00weekly0.7https://www.medthority.com/journals/cancer-of-colon/circulating-plasma-levels-of-mir-20b--mir-29b-and-mir-155-as-predictors-of-bevacizumab-efficacy-in-patients-with-metastatic-colorectal-cancer-/2022-11-21T15:00:49+00:00weekly0.7https://www.medthority.com/journals/prostate-cancer/the-role-of-gut-microbiome-in-the-pathogenesis-of-prostate-cancer--a-prospective--pilot-study-/2025-01-14T09:01:43+00:00weekly0.7https://www.medthority.com/journals/breast-cancer/fulvestrant-500-milligrams-as-endocrine-therapy-for-endocrine-sensitive-advanced-breast-cancer-patients-in-the-real-world--the-ful500-prospective-observational-trial-/2023-11-09T15:10:13+00:00weekly0.7https://www.medthority.com/journals/regional-enteritis-and-ulcerative-colitis/the-safety-profile-of-vedolizumab-in-ulcerative-colitis-and-crohn-s-disease--4-years-of-global-post-marketing-data-/2023-09-22T14:48:41+00:00weekly0.7https://www.medthority.com/journals/urticaria/usefulness-of-a-short-course-of-oral-prednisone-in-antihistamine-resistant-chronic-urticaria--a-retrospective-analysis-/2024-01-16T15:41:21+00:00weekly0.7https://www.medthority.com/journals/alzheimers-disease-and-dementia/efficacy-and-safety-of-brexpiprazole-for-the-treatment-of-agitation-in-alzheimer-s-dementia--two-12-week--randomized--double-blind--placebo-controlled-trials-/2022-11-14T13:48:47+00:00weekly0.7https://www.medthority.com/journals/rheumatoid-arthritis/doses-of-rituximab-for-retreatment-in-rheumatoid-arthritis--influence-on-maintenance-and-risk-of-serious-infection-/2022-11-09T11:40:44+00:00weekly0.7https://www.medthority.com/journals/urticaria/detection-of-low-molecular-weight-mast-cell-activating-factors-in-serum-from-patients-with-chronic-spontaneous-urticaria-/2024-01-16T15:41:21+00:00weekly0.7https://www.medthority.com/journals/congestive-heart-failure/effect-of-levosimendan-in-patients-with-acute-decompensated-heart-failure--a-meta-analysis-/2022-10-11T10:28:30+00:00weekly0.7https://www.medthority.com/journals/venous-thromboembolism-vte/edoxaban-in-atrial-fibrillation-and-venous-thromboembolism-ten-key-questions-and-answers--a-practical-guide-/2024-01-23T14:47:27+00:00weekly0.7https://www.medthority.com/journals/allergic-reactions/relative-efficacy-of-systemic-treatments-for-atopic-dermatitis-/2025-01-23T10:59:48+00:00weekly0.7https://www.medthority.com/journals/multiple-sclerosis/cannabis-and-multiple-sclerosis-/2023-09-05T09:40:23+00:00weekly0.7https://www.medthority.com/journals/mood-disorders/efficacy-and-safety-of-intranasal-esketamine-for-the-treatment-of-major-depressive-disorder-/2025-01-24T10:51:31+00:00weekly0.7https://www.medthority.com/journals/congestive-heart-failure/use-of-levosimendan-in-cardiac-surgery--an-update-after-the-levo-cts--cheetah--and-licorn-trials-in-the-light-of-clinical-practice-/2025-01-14T10:18:03+00:00weekly0.7https://www.medthority.com/journals/alzheimers-disease-and-dementia/potential-therapeutic-roles-of-retinoids-for-prevention-of-neuroinflammation-and-neurodegeneration-in-alzheimer-s-disease-/2025-01-16T10:03:16+00:00weekly0.7https://www.medthority.com/journals/ovarian-cancer/rucaparib--a-review-in-ovarian-cancer-/2021-09-24T07:27:22+00:00weekly0.7https://www.medthority.com/journals/coagulation-and-haemorrhagic-disorders/effect-of-fibrinogen-concentrate-vs-cryoprecipitate-on-blood-component-transfusion-after-cardiac-surgery--the-fibres-randomized-clinical-trial-/2022-12-05T10:35:33+00:00weekly0.7https://www.medthority.com/journals/epilepsy-convulsions/sudden-unexpected-death-in-epilepsy--the-neuro-cardio-respiratory-connection-/2025-01-24T09:50:57+00:00weekly0.7https://www.medthority.com/journals/regional-enteritis-and-ulcerative-colitis/fatigue-in-children-and-adolescents-with-inflammatory-bowel-disease-/2023-09-22T14:46:30+00:00weekly0.7https://www.medthority.com/journals/alzheimers-disease-and-dementia/randomized-trial-of-verubecestat-for-prodromal-alzheimer-s-disease-/2025-01-16T10:04:07+00:00weekly0.7https://www.medthority.com/journals/coagulation-and-haemorrhagic-disorders/direct-acting-oral-anticoagulants-and-their-reversal-agents-an-update-/2022-12-08T15:04:35+00:00weekly0.7https://www.medthority.com/journals/leukaemia/clinical-features-and-outcomes-of-patients-with-shwachman-diamond-syndrome-and-myelodysplastic-syndrome-or-acute-myeloid-leukaemia--a-multicentre--retrospective--cohort-study-/2025-01-14T10:33:44+00:00weekly0.7https://www.medthority.com/journals/psoriasis/topology-of-psoriasis-in-routine-care--results-from-high-resolution-analysis-of-2009-patients-/2025-01-14T10:15:22+00:00weekly0.7https://www.medthority.com/journals/prostate-cancer/apalutamide-and-its-use-in-the-treatment-of-prostate-cancer-/2025-01-14T09:50:59+00:00weekly0.7https://www.medthority.com/journals/intracranial-injury/updated-concepts-on-the-pathophysiology-and-the-clinical-management-of-trauma-hemorrhage-and-coagulopathy-/2021-09-24T07:24:04+00:00weekly0.7https://www.medthority.com/journals/regional-enteritis-and-ulcerative-colitis/association-between-cannabis-use-and-complications-related-to-crohn-s-disease--a-retrospective-cohort-study-/2023-09-22T14:44:20+00:00weekly0.7https://www.medthority.com/journals/other-hereditary-or-degenerative-neurological-disorders/nusinersen-versus-sham-control-in-infantile-onset-spinal-muscular-atrophy-/2021-09-24T07:26:36+00:00weekly0.7https://www.medthority.com/journals/urticaria/relationship-between-vitamin-d-and-chronic-spontaneous-urticaria--a-systematic-review-/2025-01-23T11:29:20+00:00weekly0.7https://www.medthority.com/journals/congestive-heart-failure/levosimendan-use-in-patients-with-preoperative-low-ejection-fraction-undergoing-cardiac-surgery--a-systematic-review-with-meta-analysis-and-trial-sequential-analysis/2022-10-11T10:17:19+00:00weekly0.7https://www.medthority.com/journals/allergic-reactions/an-update-on-the-topical-and-oral-therapy-options-for-treating-pediatric-atopic-dermatitis-/2025-01-23T10:58:48+00:00weekly0.7https://www.medthority.com/journals/prostate-cancer/mediterranean-dietary-pattern-and-the-risk-of-prostate-cancer--a-meta-analysis-/2025-01-14T09:32:04+00:00weekly0.7https://www.medthority.com/journals/other-upper-respiratory-disease/platelet-activating-factor--paf--in-allergic-rhinitis--clinical-and-therapeutic-implications-/2022-06-23T12:49:39+00:00weekly0.7https://www.medthority.com/journals/headache/familial-hemiplegic-migraine-with-a-prrt2-mutation--phenotypic-variations-and-carbamazepine-efficacy-/2025-01-20T14:44:09+00:00weekly0.7https://www.medthority.com/journals/other-hereditary-or-degenerative-neurological-disorders/therapies-targeting-dna-and-rna-in-huntington-s-disease-/2021-09-24T07:26:36+00:00weekly0.7https://www.medthority.com/journals/hiv-infection/doravirine-versus-ritonavir-boosted-darunavir-in-antiretroviral-naive-adults-with-hiv-1--drive-forward---48-week-results-of-a-randomised--double-blind--phase-3--non-inferiority-trial-/2025-01-14T10:00:48+00:00weekly0.7https://www.medthority.com/journals/non-epithelial-cancer-of-skin/systemic-immunotherapy-for-advanced-cutaneous-squamous-cell-carcinoma-/2021-09-24T07:25:29+00:00weekly0.7https://www.medthority.com/journals/other-hereditary-or-degenerative-neurological-disorders/nusinersen-versus-sham-control-in-later-onset-spinal-muscular-atrophy-/2021-09-24T07:26:36+00:00weekly0.7https://www.medthority.com/journals/alzheimers-disease-and-dementia/neuroimaging-in-dementias-/2022-11-14T13:28:53+00:00weekly0.7https://www.medthority.com/journals/hepatitis/genetic-variability-and-evolution-of-hepatitis-e-virus-/2021-09-24T07:23:44+00:00weekly0.7https://www.medthority.com/journals/other-hereditary-or-degenerative-neurological-disorders/nusinersen-in-later-onset-spinal-muscular-atrophy--long-term-results-from-the-phase-1-2-studies-/2021-09-24T07:26:37+00:00weekly0.7https://www.medthority.com/journals/other-upper-respiratory-disease/multicentre--non-interventional-study-to-assess-the-profile-of-patients-with-uncontrolled-rhinitis-prescribed-a-novel-formulation-of-azelastine-hydrochloride-and-fluticasone-propionate-in-a-single-spray-in-routine-clinical-practice-in-the-uk-/2022-06-23T12:52:34+00:00weekly0.7https://www.medthority.com/journals/complications-of-birth/haematological-and-fibrinolytic-status-of-nigerian-women-with-post-partum-haemorrhage-/2021-09-24T07:25:58+00:00weekly0.7https://www.medthority.com/journals/asthma/a-review-of-the-efficacy-and-safety-of-once-daily-tiotropium-respimat-2-5-micrograms-in-adults-and-adolescents-with-asthma-/2022-11-16T15:49:18+00:00weekly0.7https://www.medthority.com/journals/diabetes-mellitus-without-complication/liraglutide-improves-the-beta-cell-function-without-increasing-insulin-secretion-during-a-mixed-meal-in-patients--who-exhibit-well-controlled-type-2-diabetes-and-coronary-artery-disease-/2022-12-07T14:10:03+00:00weekly0.7https://www.medthority.com/journals/behavioural-disorders/diagnostic-accuracy-of-a-brief-screening-tool-for-attention-deficit-hyperactivity-disorder-in-uk-prison-inmates-/2021-09-24T07:20:27+00:00weekly0.7https://www.medthority.com/journals/other-hereditary-or-degenerative-neurological-disorders/the-role-of-rehabilitation-in-patients-with-progressive-supranuclear-palsy--a-narrative-review-/2021-09-24T07:26:36+00:00weekly0.7https://www.medthority.com/journals/epilepsy-convulsions/epigenetics-and-epilepsy-prevention--the-therapeutic-potential-of-adenosine-and-metabolic-therapies-/2021-09-24T07:23:00+00:00weekly0.7https://www.medthority.com/journals/behavioural-disorders/long-term-efficacy-and-safety-of-treatment-with-stimulants-and-atomoxetine-in-adult-adhd--a-review-of-controlled-and-naturalistic-studies-/2021-09-24T07:20:27+00:00weekly0.7https://www.medthority.com/journals/other-hereditary-or-degenerative-neurological-disorders/biomarkers-and-the-development-of-a-personalized-medicine-approach-in-spinal-muscular-atrophy-/2021-09-24T07:26:36+00:00weekly0.7https://www.medthority.com/journals/other-hereditary-or-degenerative-neurological-disorders/the-role-of-survival-motor-neuron-protein--smn--in-protein-homeostasis-/2021-09-24T07:26:36+00:00weekly0.7https://www.medthority.com/journals/epilepsy-convulsions/efficacy--retention--and-safety-of-brivaracetam-in-adult-patients-with-genetic-generalized-epilepsy-/2025-01-24T09:51:37+00:00weekly0.7https://www.medthority.com/journals/leukaemia/asciminib-in-chronic-myeloid-leukemia-after-abl-kinase-inhibitor-failure-/2025-01-27T15:31:09+00:00weekly0.7https://www.medthority.com/journals/leukaemia/role-of-micrornas-in-chronic-lymphocytic-leukemia-pathogenesis-/2022-10-18T14:52:26+00:00weekly0.7https://www.medthority.com/journals/other-lower-respiratory-disease/gastrointestinal-adverse-effects-of-nintedanib-and-the-associated-risk-factors-in-patients-with-idiopathic-pulmonary-fibrosis-/2022-11-01T11:23:59+00:00weekly0.7https://www.medthority.com/journals/melanomas-of-skin/encorafenib-plus-binimetinib-versus-vemurafenib-or-encorafenib-in-patients-with-braf-mutant-melanoma--columbus---a-multicentre--open-label--randomised-phase-3-trial-/2025-01-14T11:17:49+00:00weekly0.7https://www.medthority.com/journals/headache/advance-in-genetics-of-migraine-/2025-01-20T14:45:16+00:00weekly0.7https://www.medthority.com/journals/coagulation-and-haemorrhagic-disorders/fibrinogen-concentrates-in-hereditary-fibrinogen-disorders--past--present-and-future-/2025-01-16T13:00:29+00:00weekly0.7https://www.medthority.com/journals/prostate-cancer/p53-status-in-the-primary-tumor-predicts-efficacy-of-subsequent-abiraterone-and-enzalutamide-in-castration-resistant-prostate-cancer-/2022-06-28T09:11:52+00:00weekly0.7https://www.medthority.com/journals/regional-enteritis-and-ulcerative-colitis/vedolizumab--an-option-in-patients-with-inflammatory-bowel-disease-intolerant-to-thiopurines-and-refractory-to-biological-agents-/2023-09-22T14:26:49+00:00weekly0.7https://www.medthority.com/journals/glomerulonephritis/sparsentan-versus-irbesartan-in-focal-segmental-glomerulosclerosis/2025-01-24T12:17:48+00:00weekly0.7https://www.medthority.com/journals/glomerulonephritis/iga-nephropathy-in-adults-treatment-standard/2025-01-13T09:15:56+00:00weekly0.7https://www.medthority.com/journals/glomerulonephritis/iga-nephropathy/2025-01-13T09:15:56+00:00weekly0.7https://www.medthority.com/journals/glomerulonephritis/glomerulonephritis-immunopathogenesis-and-immunotherapy/2025-01-13T09:15:56+00:00weekly0.7https://www.medthority.com/journals/glomerulonephritis/treatment-of-lupus-nephritis-consensus-evidence-and-perspectives/2025-01-13T09:15:55+00:00weekly0.7https://www.medthority.com/journals/glomerulonephritis/long-term-outcomes-in-iga-nephropathy/2025-01-27T15:19:17+00:00weekly0.7https://www.medthority.com/journals/glomerulonephritis/treatment-of-iga-nephropathy-a-rapidly-evolving-field/2025-01-24T12:18:59+00:00weekly0.7https://www.medthority.com/journals/glomerulonephritis/non-immunosuppressive-treatment-for-iga-nephropathy/2025-01-24T12:18:21+00:00weekly0.7https://www.medthority.com/journals/chronic-obstructive-pulmonary-disease-copd-and-bronchiectasis/pathophysiology-therapeutic-targets-and-future-therapeutic-alternatives-in-copd-focus-on-the-importance-of-the-cholinergic-system/2025-01-13T09:15:16+00:00weekly0.7https://www.medthority.com/journals/chronic-obstructive-pulmonary-disease-copd-and-bronchiectasis/20-years-of-neuromuscular-electrical-stimulation-in-copd/2025-01-13T09:15:17+00:00weekly0.7https://www.medthority.com/journals/chronic-obstructive-pulmonary-disease-copd-and-bronchiectasis/mucolytics-for-acute-exacerbations-of-chronic-obstructive-pulmonary-disease-a-meta-analysis/2025-01-13T09:15:17+00:00weekly0.7https://www.medthority.com/journals/chronic-obstructive-pulmonary-disease-copd-and-bronchiectasis/real-world-comparative-effectiveness-of-three-single-inhaler-dual-bronchodilators-for-the-treatment-of-copd/2025-01-13T09:15:16+00:00weekly0.7https://www.medthority.com/journals/chronic-obstructive-pulmonary-disease-copd-and-bronchiectasis/exploring-the-role-of-gut-lung-interactions-in-copd-pathogenesis-a-comprehensive-review-on-microbiota-characteristics-and-inflammation-modulation/2025-01-13T09:15:17+00:00weekly0.7https://www.medthority.com/journals/chronic-obstructive-pulmonary-disease-copd-and-bronchiectasis/exacerbations-and-real-world-outcomes-after-single-inhaler-triple-therapy-of-budesonideglycopyrrolateformoterol-fumarate-among-patients-with-copd-results-from-the-eros-us-study/2025-01-13T09:15:18+00:00weekly0.7https://www.medthority.com/journals/chronic-obstructive-pulmonary-disease-copd-and-bronchiectasis/inhaled-versus-systemic-corticosteroids-for-acute-exacerbations-of-copd-a-systematic-review-and-meta-analysis/2025-01-13T09:15:17+00:00weekly0.7https://www.medthority.com/journals/chronic-obstructive-pulmonary-disease-copd-and-bronchiectasis/how-inhaled-corticosteroids-target-inflammation-in-copd/2025-01-13T09:15:18+00:00weekly0.7https://www.medthority.com/journals/chronic-obstructive-pulmonary-disease-copd-and-bronchiectasis/the-persistent-inflammation-in-copd-is-autoimmunity-the-core-mechanism/2025-01-13T09:15:18+00:00weekly0.7https://www.medthority.com/journals/growth-hormone-deficiency/efficacy-safety-and-patient-satisfaction-of-norditropin-and-sogroya-in-patients-with-growth-hormone-deficiency-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials/2025-01-13T09:16:05+00:00weekly0.7https://www.medthority.com/journals/growth-hormone-deficiency/utilizing-somapacitan-a-long-acting-growth-hormone-formulation-for-the-treatment-of-adult-growth-hormone-deficiency-a-guide-for-clinicians/2025-01-24T12:15:43+00:00weekly0.7https://www.medthority.com/journals/growth-hormone-deficiency/sex-differences-in-long-term-safety-and-tolerability-of-gh-replacement-therapy-in-gh-deficient-adults/2025-01-13T09:16:04+00:00weekly0.7https://www.medthority.com/journals/growth-hormone-deficiency/exploring-the-sex-difference-in-cardiovascular-risk-during-growth-hormone-therapy-in-adults/2025-01-13T09:16:06+00:00weekly0.7https://www.medthority.com/journals/growth-hormone-deficiency/long-term-pegylated-gh-for-children-with-gh-deficiency-a-large-prospective-real-world-study/2025-01-13T09:16:06+00:00weekly0.7https://www.medthority.com/journals/growth-hormone-deficiency/factors-associated-with-response-to-growth-hormone-in-pediatric-growth-disorders-results-of-a-5-year-registry-analysis/2025-01-13T09:16:05+00:00weekly0.7https://www.medthority.com/journals/growth-hormone-deficiency/somatrogon-injection-for-the-treatment-of-pediatric-growth-hormone-deficiency-with-comparison-to-other-lagh-products/2025-01-24T12:17:01+00:00weekly0.7https://www.medthority.com/journals/growth-hormone-deficiency/long-acting-growth-hormone-in-the-treatment-of-growth-hormone-deficiency-in-children-a-systematic-literature-review-and-network-meta-analysis/2025-01-13T09:16:06+00:00weekly0.7https://www.medthority.com/journals/growth-hormone-deficiency/weekly-somapacitan-in-gh-deficiency-4-year-efficacy-safety-and-treatmentdisease-burden-results-from-real-3/2025-01-13T09:16:06+00:00weekly0.7https://www.medthority.com/journals/pompe-disease/efficacy-and-safety-of-avalglucosidase-alfa-in-patients-with-late-onset-pompe-disease-after-97-weeks-a-phase-3-randomized-clinical-trial/2025-01-13T09:17:04+00:00weekly0.7https://www.medthority.com/journals/pompe-disease/advances-in-pompe-disease-treatment-from-enzyme-replacement-to-gene-therapy/2025-01-13T09:17:03+00:00weekly0.7https://www.medthority.com/journals/pompe-disease/home-based-infusion-of-alglucosidase-alfa-can-safely-be-implemented-in-adults-with-late-onset-pompe-disease-lessons-learned-from-18380-infusions/2025-01-13T09:17:03+00:00weekly0.7https://www.medthority.com/journals/growth-hormone-deficiency/long-term-mortality-after-childhood-growth-hormone-treatment-the-saghe-cohort-study/2025-01-27T15:03:29+00:00weekly0.7https://www.medthority.com/journals/pompe-disease/104-week-efficacy-and-safety-of-cipaglucosidase-alfa-plus-miglustat-in-adults-with-late-onset-pompe-disease/2025-01-13T09:17:03+00:00weekly0.7https://www.medthority.com/journals/cushings-syndrome/global-cushings-disease-epidemiology-a-systematic-review-and-meta-analysis-of-observational-studies/2025-01-13T09:15:23+00:00weekly0.7https://www.medthority.com/journals/cushings-syndrome/cushing-syndrome-a-review/2025-01-27T14:57:37+00:00weekly0.7https://www.medthority.com/journals/cushings-syndrome/complications-and-mortality-of-cushings-disease-report-on-data-collected-over-a-20-year-period-at-a-referral-centre/2025-01-13T09:15:23+00:00weekly0.7https://www.medthority.com/journals/cushings-syndrome/long-term-consequences-of-cushing-syndrome-a-systematic-literature-review/2025-01-27T14:58:34+00:00weekly0.7https://www.medthority.com/journals/cushings-syndrome/treatment-modalities-and-outcomes-in-pediatric-cushings-disease---report-of-three-cases-and-literature-review/2025-01-13T09:15:22+00:00weekly0.7https://www.medthority.com/journals/cushings-syndrome/mri-for-cushing-disease-a-systematic-review/2025-01-13T09:15:22+00:00weekly0.7https://www.medthority.com/journals/cushings-syndrome/long-term-efficacy-and-safety-of-subcutaneous-pasireotide-alone-or-in-combination-with-cabergoline-in-cushings-disease/2025-01-13T09:15:22+00:00weekly0.7https://www.medthority.com/journals/cushings-syndrome/improvement-in-clinical-features-of-hypercortisolism-during-osilodrostat-treatment-findings-from-the-phase-iii-linc-3-trial-in-cushings-disease/2025-01-13T09:15:21+00:00weekly0.7https://www.medthority.com/journals/cystinosis/cystinosis-a-review-of-disease-pathogenesis-management-and-future-treatment-options/2025-01-13T09:15:25+00:00weekly0.7https://www.medthority.com/journals/cystinosis/nephropathic-cystinosis-an-update-on-genetic-conditioning/2025-01-13T09:15:25+00:00weekly0.7https://www.medthority.com/journals/cystinosis/gastrointestinal-challenges-in-nephropathic-cystinosis-clinical-perspectives/2025-01-13T09:15:24+00:00weekly0.7https://www.medthority.com/journals/myasthenia-gravis/patient-reported-impact-of-myasthenia-gravis-in-the-real-world-findings-from-a-digital-observational-survey-based-study-myrealworld-mg/2025-01-13T09:16:44+00:00weekly0.7https://www.medthority.com/journals/myasthenia-gravis/cross-sectional-analysis-of-the-myasthenia-gravis-patient-registry-disability-and-treatment/2025-01-21T14:40:31+00:00weekly0.7https://www.medthority.com/journals/myasthenia-gravis/eculizumab-versus-rituximab-in-generalised-myasthenia-gravis/2025-01-13T09:16:44+00:00weekly0.7https://www.medthority.com/journals/myasthenia-gravis/titin-antibodies-in-seronegative-myasthenia-gravis--a-new-role-for-an-old-antigen/2025-01-21T12:40:28+00:00weekly0.7https://www.medthority.com/journals/myasthenia-gravis/screening-for-lipoprotein-receptor-related-protein-4--agrin--and-titin-antibodies-and-exploring-the-autoimmune-spectrum-in-myasthenia-gravis/2025-01-13T09:16:43+00:00weekly0.7https://www.medthority.com/journals/myasthenia-gravis/spontaneous-resolution-of-a-mediastinal-mass-in-a-woman-with-myasthenia-gravis/2025-01-13T09:16:43+00:00weekly0.7https://www.medthority.com/journals/myasthenia-gravis/efficacy-and-safety-of-rituximab-for-new-onset-generalized-myasthenia-gravis-the-rinomax-randomized-clinical-trial/2025-01-13T09:16:43+00:00weekly0.7https://www.medthority.com/journals/myasthenia-gravis/neuromuscular-junction-disorders-beyond-myasthenia-gravis/2025-01-21T12:15:35+00:00weekly0.7https://www.medthority.com/journals/myasthenia-gravis/myasthenia-gravis-autoantibody-specificities-and-their-role-in-mg-management/2025-01-13T09:16:32+00:00weekly0.7https://www.medthority.com/journals/myasthenia-gravis/autoimmune-attack-of-the-neuromuscular-junction-in-myasthenia-gravis-nicotinic-acetylcholine-receptors-and-other-targets/2025-01-21T15:23:16+00:00weekly0.7https://www.medthority.com/journals/myasthenia-gravis/autoantibody-specificities-in-myasthenia-gravis-implications-for-improved-diagnostics-and-therapeutics/2025-01-13T09:16:31+00:00weekly0.7https://www.medthority.com/journals/myasthenia-gravis/myasthenia-gravis-and-congenital-myasthenic-syndromes/2025-01-21T15:07:20+00:00weekly0.7https://www.medthority.com/journals/myasthenia-gravis/autoimmune-pathology-in-myasthenia-gravis-disease-subtypes-is-governed-by-divergent-mechanisms-of-immunopathology/2025-01-13T09:16:31+00:00weekly0.7https://www.medthority.com/journals/myasthenia-gravis/understanding-the-burden-of-refractory-myasthenia-gravis/2025-01-21T14:34:48+00:00weekly0.7https://www.medthority.com/journals/myasthenia-gravis/myasthenia-gravis-epidemiology-pathophysiology-and-clinical-manifestations/2025-01-13T09:16:31+00:00weekly0.7https://www.medthority.com/journals/myasthenia-gravis/conventional-and-emerging-treatments-and-controversies-in-myasthenia-gravis/2025-01-21T15:02:30+00:00weekly0.7https://www.medthority.com/journals/myasthenia-gravis/myasthenia-gravis-subgroup-classification-and-therapeutic-strategies/2025-01-21T15:01:28+00:00weekly0.7https://www.medthority.com/journals/myasthenia-gravis/myasthenia-gravis-pathogenic-effects-of-autoantibodies-on-neuromuscular-architecture/2025-01-13T09:16:30+00:00weekly0.7https://www.medthority.com/journals/myasthenia-gravis/a-practical-approach-to-managing-patients-with-myasthenia-gravis-opinions-and-a-review-of-the-literature/2025-01-13T09:16:37+00:00weekly0.7https://www.medthority.com/journals/myasthenia-gravis/myasthenia-gravis-and-lambert-eaton-myasthenic-syndrome-new-developments-in-diagnosis-and-treatment/2025-01-13T09:16:37+00:00weekly0.7https://www.medthority.com/journals/myasthenia-gravis/understanding-the-symptom-burden-and-impact-of-myasthenia-gravis-from-the-patients-perspective-a-qualitative-study/2025-01-13T09:16:36+00:00weekly0.7https://www.medthority.com/journals/myasthenia-gravis/measuring-overall-severity-of-myasthenia-gravis-mg-evidence-for-the-added-value-of-the-mg-symptoms-pro/2025-01-13T09:16:36+00:00weekly0.7https://www.medthority.com/journals/myasthenia-gravis/detection-and-characterization-of-blocking-type-anti-acetylcholine-receptor-antibodies-in-sera-from-patients-with-myasthenia-gravis/2025-01-13T09:16:36+00:00weekly0.7https://www.medthority.com/journals/myasthenia-gravis/myasthenia-gravis-and-autoantibodies-pathophysiology-of-the-different-subtypes/2025-01-13T09:16:35+00:00weekly0.7https://www.medthority.com/journals/myasthenia-gravis/ocular-myasthenia-gravis-a-current-overview/2025-01-13T09:16:35+00:00weekly0.7https://www.medthority.com/journals/myasthenia-gravis/structural-mechanisms-of-the-agrin-lrp4-musk-signaling-pathway-in-neuromuscular-junction-differentiation/2025-01-13T09:16:35+00:00weekly0.7https://www.medthority.com/journals/myasthenia-gravis/the-epidemiology-of-myasthenia-gravis/2025-01-21T12:18:11+00:00weekly0.7https://www.medthority.com/journals/myasthenia-gravis/hospital-and-healthcare-insurance-system-record-based-epidemiological-study-of-myasthenia-gravis-in-southern-and-northern-china/2025-01-13T09:16:33+00:00weekly0.7https://www.medthority.com/journals/myasthenia-gravis/frequency-and-clinical-features-of-treatment-refractory-myasthenia-gravis/2025-01-13T09:16:33+00:00weekly0.7https://www.medthority.com/journals/myasthenia-gravis/burden-of-disease-in-myasthenia-gravis-taking-the-patients-perspective/2025-01-13T09:16:33+00:00weekly0.7https://www.medthority.com/journals/myasthenia-gravis/treatment-of-myasthenia-gravis/2025-01-13T09:16:38+00:00weekly0.7https://www.medthority.com/journals/myasthenia-gravis/current-treatment-of-myasthenia-gravis/2025-01-13T09:16:38+00:00weekly0.7https://www.medthority.com/journals/myasthenia-gravis/tracking-eye-movements-for-diagnosis-in-myasthenia-gravis-a-comprehensive-review/2025-01-21T12:33:57+00:00weekly0.7https://www.medthority.com/journals/myasthenia-gravis/a-study-of-comorbidities-in-myasthenia-gravis/2025-01-13T09:16:37+00:00weekly0.7https://www.medthority.com/journals/myasthenia-gravis/novel-immunotherapies-for-myasthenia-gravis/2025-01-13T09:16:37+00:00weekly0.7https://www.medthority.com/journals/myasthenia-gravis/safety-efficacy-and-tolerability-of-efgartigimod-in-patients-with-generalised-myasthenia-gravis-adapt-a-multicentre-randomised-placebo-controlled-phase-3-trial/2025-01-21T12:37:07+00:00weekly0.7https://www.medthority.com/journals/myasthenia-gravis/pharmacotherapy-of-generalized-myasthenia-gravis-with-special-emphasis-on-newer-biologicals/2025-01-13T09:16:40+00:00weekly0.7https://www.medthority.com/journals/myasthenia-gravis/summary-of-research-terminal-complement-inhibitor-ravulizumab-in-generalized-myasthenia-gravis/2025-01-13T09:16:40+00:00weekly0.7https://www.medthority.com/journals/myasthenia-gravis/post-intervention-status-in-patients-with-refractory-myasthenia-gravis-treated-with-eculizumab-during-regain-and-its-open-label-extension/2025-01-21T14:36:05+00:00weekly0.7https://www.medthority.com/journals/myasthenia-gravis/plasma-exchange-for-myasthenia-gravis/2025-01-21T15:32:38+00:00weekly0.7https://www.medthority.com/journals/myasthenia-gravis/immunosuppressive-agents-for-myasthenia-gravis/2025-01-21T12:36:18+00:00weekly0.7https://www.medthority.com/journals/myasthenia-gravis/preliminary-results-of-a-double-blind-randomized-placebo-controlled-trial-of-cyclosporine-in-myasthenia-gravis/2025-01-21T12:00:20+00:00weekly0.7https://www.medthority.com/journals/myasthenia-gravis/treatment-of-myasthenia-gravis-focus-on-pyridostigmine/2025-01-13T09:16:38+00:00weekly0.7https://www.medthority.com/journals/myasthenia-gravis/phase-2-trial-of-rituximab-in-acetylcholine-receptor-antibody-positive-generalized-myasthenia-gravis-the-beatmg-study/2025-01-21T14:39:36+00:00weekly0.7https://www.medthority.com/journals/myasthenia-gravis/rituximab-treatment-of-myasthenia-gravis-a-systematic-review/2025-01-21T12:14:44+00:00weekly0.7https://www.medthority.com/journals/myasthenia-gravis/rituximab-as-treatment-for-anti-musk-myasthenia-gravis-multicenter-blinded-prospective-review/2025-01-21T12:39:09+00:00weekly0.7https://www.medthority.com/journals/myasthenia-gravis/randomized-trial-of-thymectomy-in-myasthenia-gravis/2025-01-21T12:00:41+00:00weekly0.7https://www.medthority.com/journals/myasthenia-gravis/antagonism-of-the-neonatal-fc-receptor-as-an-emerging-treatment-for-myasthenia-gravis/2025-01-13T09:16:42+00:00weekly0.7https://www.medthority.com/journals/myasthenia-gravis/efficacy-and-safety-of-rozanolixizumab-in-moderate-to-severe-generalized-myasthenia-gravis-a-phase-2-randomized-control-trial/2025-01-21T14:38:01+00:00weekly0.7https://www.medthority.com/journals/myasthenia-gravis/safety-and-efficacy-of-rozanolixizumab-in-patients-with-generalised-myasthenia-gravis-mycaring-a-randomised-double-blind-placebo-controlled-adaptive-phase-3-study/2025-01-21T12:37:46+00:00weekly0.7https://www.medthority.com/journals/myasthenia-gravis/safety-and-efficacy-of-eculizumab-in-anti-acetylcholine-receptor-antibody-positive-refractory-generalised-myasthenia-gravis-regain-a-phase-3-randomised-double-blind-placebo-controlled-multicentre-study/2025-01-21T12:35:28+00:00weekly0.7https://www.medthority.com/journals/myasthenia-gravis/efgartigimod-improved-health-related-quality-of-life-in-generalized-myasthenia-gravis-results-from-a-randomized-double-blind-placebo-controlled-phase-3-study-adapt/2025-01-13T09:16:41+00:00weekly0.7https://www.medthority.com/journals/multiple-sclerosis/therapeutic-advances-in-multiple-sclerosis/2025-01-13T09:16:29+00:00weekly0.7https://www.medthority.com/journals/multiple-sclerosis/multiple-sclerosis-progression-time-for-a-new-mechanism-driven-framework/2025-01-21T14:53:33+00:00weekly0.7https://www.medthority.com/journals/multiple-sclerosis/the-immune-response-in-multiple-sclerosis/2025-01-13T09:16:28+00:00weekly0.7https://www.medthority.com/journals/multiple-sclerosis/smouldering-multiple-sclerosis-the-real-ms/2025-01-21T14:32:06+00:00weekly0.7https://www.medthority.com/journals/multiple-sclerosis/lifestyle-and-environmental-factors-in-multiple-sclerosis/2025-01-13T09:16:27+00:00weekly0.7https://www.medthority.com/journals/multiple-sclerosis/rising-prevalence-of-multiple-sclerosis-worldwide-insights-from-the-atlas-of-ms-third-edition/2025-01-21T14:31:21+00:00weekly0.7https://www.medthority.com/journals/multiple-sclerosis/update-on-treatment-in-multiple-sclerosis/2025-01-13T09:16:27+00:00weekly0.7https://www.medthority.com/journals/multiple-sclerosis/emerging-therapies-to-target-cns-pathophysiology-in-multiple-sclerosis/2025-01-13T09:16:27+00:00weekly0.7https://www.medthority.com/journals/myasthenia-gravis/safety-and-efficacy-of-zilucoplan-in-patients-with-generalised-myasthenia-gravis-raise-a-randomised-double-blind-placebo-controlled-phase-3-study/2025-01-21T12:41:50+00:00weekly0.7https://www.medthority.com/journals/myasthenia-gravis/clinical-effects-of-the-self-administered-subcutaneous-complement-inhibitor-zilucoplan-in-patients-with-moderate-to-severe-generalized-myasthenia-gravis-results-of-a-phase-2-randomized-double-blind-placebo-controlled-multicenter-clinical-trial/2025-01-13T09:16:45+00:00weekly0.7https://www.medthority.com/journals/myasthenia-gravis/a-retrospective-longitudinal-cohort-study-of-the-clinical-burden-in-myasthenia-gravis/2025-01-13T09:16:45+00:00weekly0.7https://www.medthority.com/journals/myasthenia-gravis/long-term-outcome-in-patients-with-myasthenia-gravis-one-decade-longitudinal-study/2025-01-13T09:16:45+00:00weekly0.7https://www.medthority.com/journals/myasthenia-gravis/guidelines-for-the-treatment-of-autoimmune-neuromuscular-transmission-disorders-2006/2025-01-21T15:00:26+00:00weekly0.7https://www.medthority.com/journals/myasthenia-gravis/guidelines-for-treatment-of-autoimmune-neuromuscular-transmission-disorders-2010/2025-01-21T14:54:43+00:00weekly0.7https://www.medthority.com/journals/regional-enteritis-and-ulcerative-colitis/advances-in-pharmacotherapy-for-ulcerative-colitis-a-focus-on-jak1-inhibitors/2025-01-21T15:48:18+00:00weekly0.7https://www.medthority.com/journals/regional-enteritis-and-ulcerative-colitis/artificial-intelligence-enabled-histological-prediction-of-remission-or-activity-and-clinical-outcomes-in-ulcerative-colitis/2025-01-21T16:19:31+00:00weekly0.7https://www.medthority.com/journals/regional-enteritis-and-ulcerative-colitis/etrasimod-for-the-treatment-of-ulcerative-colitis/2025-01-21T15:47:22+00:00weekly0.7https://www.medthority.com/journals/regional-enteritis-and-ulcerative-colitis/etrasimod-as-induction-and-maintenance-therapy-for-ulcerative-colitis-elevate-two-randomised-double-blind-placebo-controlled-phase-3-studies/2025-01-21T15:46:34+00:00weekly0.7https://www.medthority.com/journals/regional-enteritis-and-ulcerative-colitis/role-of-interleukin-22-in-ulcerative-colitis/2025-01-13T09:17:16+00:00weekly0.7https://www.medthority.com/journals/regional-enteritis-and-ulcerative-colitis/reappraising-remission-in-ulcerative-colitis/2025-01-13T09:17:16+00:00weekly0.7https://www.medthority.com/journals/regional-enteritis-and-ulcerative-colitis/comparative-efficacy-of-advanced-treatments-in-biologic-naive-or-biologic-experienced-patients-with-ulcerative-colitis-a-systematic-review-and-network-meta-analysis/2025-01-13T09:17:16+00:00weekly0.7https://www.medthority.com/journals/regional-enteritis-and-ulcerative-colitis/the-role-of-upadacitinib-in-the-treatment-of-ulcerative-colitis/2025-01-21T15:45:52+00:00weekly0.7https://www.medthority.com/journals/regional-enteritis-and-ulcerative-colitis/medical-consultation-in-ulcerative-colitis-key-elements-for-improvement/2025-01-13T09:17:16+00:00weekly0.7https://www.medthority.com/journals/regional-enteritis-and-ulcerative-colitis/diagnosis-of-ulcerative-colitis-and-crohns-disease-using-transabdominal-ultrasonography/2025-01-13T09:17:17+00:00weekly0.7https://www.medthority.com/journals/regional-enteritis-and-ulcerative-colitis/presenting-symptoms-in-inflammatory-bowel-disease-descriptive-analysis-of-a-community-based-inception-cohort/2025-01-13T09:17:13+00:00weekly0.7https://www.medthority.com/journals/regional-enteritis-and-ulcerative-colitis/uncovering-the-cause-of-ulcerative-colitis/2025-01-21T16:05:57+00:00weekly0.7https://www.medthority.com/journals/regional-enteritis-and-ulcerative-colitis/new-developments-in-ulcerative-colitis-latest-evidence-on-management-treatment-and-maintenance/2025-01-13T09:17:14+00:00weekly0.7https://www.medthority.com/journals/regional-enteritis-and-ulcerative-colitis/interventions-for-the-management-of-abdominal-pain-in-ulcerative-colitis/2025-01-21T16:04:25+00:00weekly0.7https://www.medthority.com/journals/regional-enteritis-and-ulcerative-colitis/unmet-medical-needs-in-ulcerative-colitis-an-expert-group-consensus/2025-01-13T09:17:14+00:00weekly0.7https://www.medthority.com/journals/regional-enteritis-and-ulcerative-colitis/what-are-the-unmet-needs-and-most-relevant-treatment-outcomes-according-to-patients-with-inflammatory-bowel-disease-a-qualitative-patient-preference-study/2025-01-13T09:17:14+00:00weekly0.7https://www.medthority.com/journals/al-amyloidosis/diagnostic-and-treatment-strategies-for-al-amyloidosis-in-an-era-of-therapeutic-innovation/2025-01-21T15:49:07+00:00weekly0.7https://www.medthority.com/journals/regional-enteritis-and-ulcerative-colitis/a-comprehensive-review-and-update-on-ulcerative-colitis/2025-01-13T09:17:13+00:00weekly0.7https://www.medthority.com/journals/multiple-sclerosis/ageing-and-multiple-sclerosis/2025-01-21T16:01:34+00:00weekly0.7https://www.medthority.com/journals/multiple-sclerosis/multiple-sclerosis-pathogenesis-and-updates-in-targeted-therapeutic-approaches/2025-01-13T09:16:26+00:00weekly0.7https://www.medthority.com/journals/multiple-sclerosis/efficacy-and-safety-of-ofatumumab-in-recently-diagnosed-treatment-naive-patients-with-multiple-sclerosis-results-from-asclepios-i-and-ii/2025-01-21T15:28:04+00:00weekly0.7https://www.medthority.com/journals/multiple-sclerosis/long-term-follow-up-of-patients-with-relapsing-multiple-sclerosis-from-the-clarityclarity-extension-cohort-of-classic-ms-an-ambispective-study/2025-01-21T15:27:20+00:00weekly0.7https://www.medthority.com/journals/multiple-sclerosis/a-pro-inflammatory-diet-in-people-with-multiple-sclerosis-is-associated-with-an-increased-rate-of-relapse-and-increased-flair-lesion-volume-on-mri-in-early-multiple-sclerosis-a-prospective-cohort-study/2025-01-21T15:26:24+00:00weekly0.7https://www.medthority.com/journals/multiple-sclerosis/safety-experience-with-continued-exposure-to-ofatumumab-in-patients-with-relapsing-forms-of-multiple-sclerosis-for-up-to-3.5-years2025-01-21T15:26:00+00:00weekly0.7https://www.medthority.com/journals/multiple-sclerosis/ocrelizumab-treated-patients-with-relapsing-multiple-sclerosis-show-volume-loss-rates-similar-to-healthy-aging/2025-01-21T15:25:39+00:00weekly0.7https://www.medthority.com/journals/multiple-sclerosis/early-non-disabling-relapses-are-important-predictors-of-disability-accumulation-in-people-with-relapsing-remitting-multiple-sclerosis/2025-01-21T15:25:04+00:00weekly0.7https://www.medthority.com/journals/multiple-sclerosis/real-world-evaluation-of-ocrelizumab-in-multiple-sclerosis-a-systematic-review/2025-01-21T16:08:27+00:00weekly0.7https://www.medthority.com/journals/multiple-sclerosis/updates-and-advances-in-multiple-sclerosis-neurotherapeutics/2025-01-21T16:07:46+00:00weekly0.7https://www.medthority.com/journals/multiple-sclerosis/epstein-barr-virus-as-a-cause-of-multiple-sclerosis-opportunities-for-prevention-and-therapy/2025-01-21T16:00:58+00:00weekly0.7https://www.medthority.com/journals/multiple-sclerosis/immunopathogenesis-diagnosis-and-treatment-of-multiple-sclerosis-a-clinical-update/2025-01-13T09:16:24+00:00weekly0.7https://www.medthority.com/journals/multiple-sclerosis/association-of-early-progression-independent-of-relapse-activity-with-long-term-disability-after-a-first-demyelinating-event-in-multiple-sclerosis/2025-01-13T09:16:24+00:00weekly0.7https://www.medthority.com/journals/al-amyloidosis/light-chain-cardiac-amyloidosis-for-the-non-expert-pearls-and-pitfalls/2025-01-13T09:14:30+00:00weekly0.7https://www.medthority.com/journals/al-amyloidosis/individualized-approach-to-management-of-light-chain-amyloidosis/2025-01-13T09:14:30+00:00weekly0.7https://www.medthority.com/journals/al-amyloidosis/advancements-and-future-trends-of-immunotherapy-in-light-chain-amyloidosis/2025-01-13T09:14:29+00:00weekly0.7https://www.medthority.com/journals/al-amyloidosis/localized-light-chain-amyloidosis-a-self-limited-plasmacytic-b-cell-lymphoproliferative-disorder/2025-01-13T09:14:29+00:00weekly0.7https://www.medthority.com/journals/al-amyloidosis/treatment-of-amyloid-light-chain-cardiac-amyloidosis-systematic-review-and-future-directions/2025-01-13T09:14:29+00:00weekly0.7https://www.medthority.com/journals/al-amyloidosis/cardiovascular-magnetic-resonance-in-light-chain-amyloidosis-to-guide-treatment/2025-01-13T09:14:29+00:00weekly0.7https://www.medthority.com/journals/al-amyloidosis/phase-1ab-study-of-monoclonal-antibody-cael-101-11-1f4-in-patients-with-al-amyloidosis/2025-01-21T16:06:45+00:00weekly0.7https://www.medthority.com/journals/al-amyloidosis/feasibility-of-a-novel-academic-bcma-cart-hbi0101-for-the-treatment-of-relapsed-and-refractory-al-amyloidosis/2025-01-21T15:54:29+00:00weekly0.7https://www.medthority.com/journals/al-amyloidosis/immunoglobulin-light-chain-amyloidosis-2022-update-on-diagnosis-prognosis-and-treatment/2025-01-21T15:53:17+00:00weekly0.7https://www.medthority.com/journals/al-amyloidosis/the-hematologists-role-in-amyloidosis-management-disease-awareness-diagnostic-workup-and-practice-patterns/2025-01-13T09:14:28+00:00weekly0.7https://www.medthority.com/journals/al-amyloidosis/systemic-immunoglobulin-light-chain-amyloidosis/2025-01-13T09:14:32+00:00weekly0.7https://www.medthority.com/journals/al-amyloidosis/management-of-al-amyloidosis-in-2020/2025-01-21T16:00:11+00:00weekly0.7https://www.medthority.com/journals/al-amyloidosis/how-i-treat-al-amyloidosis/2025-01-21T15:59:10+00:00weekly0.7https://www.medthority.com/journals/al-amyloidosis/bortezomib-melphalan-and-dexamethasone-for-light-chain-amyloidosis/2025-01-21T15:57:56+00:00weekly0.7https://www.medthority.com/journals/al-amyloidosis/a-randomized-phase-3-study-of-ixazomib-dexamethasone-versus-physicians-choice-in-relapsed-or-refractory-al-amyloidosis/2025-01-13T09:14:31+00:00weekly0.7https://www.medthority.com/journals/al-amyloidosis/daratumumab-based-treatment-for-immunoglobulin-light-chain-amyloidosis/2025-01-21T15:56:57+00:00weekly0.7https://www.medthority.com/journals/al-amyloidosis/artificial-intelligence-enhanced-electrocardiogram-for-the-early-detection-of-cardiac-amyloidosis/2025-01-21T15:56:07+00:00weekly0.7https://www.medthority.com/journals/regional-enteritis-and-ulcerative-colitis/colectomy-rates-in-ulcerative-colitis-a-systematic-review-and-meta-analysis/2025-01-21T15:45:03+00:00weekly0.7https://www.medthority.com/journals/regional-enteritis-and-ulcerative-colitis/a-critical-review-of-upadacitinib-for-the-treatment-of-adults-with-moderately-to-severely-active-ulcerative-colitis/2025-01-21T15:44:10+00:00weekly0.7https://www.medthority.com/journals/regional-enteritis-and-ulcerative-colitis/the-role-of-nrf2-in-the-pathogenesis-and-treatment-of-ulcerative-colitis/2025-01-13T09:17:18+00:00weekly0.7https://www.medthority.com/journals/regional-enteritis-and-ulcerative-colitis/exploring-the-pipeline-of-novel-therapies-for-inflammatory-bowel-disease-state-of-the-art-review/2025-01-13T09:17:18+00:00weekly0.7https://www.medthority.com/journals/hereditary-transthyretin-amyloidosis-hattr/transthyretin-cardiac-amyloidosis/2025-01-13T09:16:13+00:00weekly0.7https://www.medthority.com/journals/hereditary-transthyretin-amyloidosis-hattr/optimal-practices-for-the-management-of-hereditary-transthyretin-amyloidosis-real-world-experience-from-japan-brazil-and-portugal/2025-01-13T09:16:13+00:00weekly0.7https://www.medthority.com/journals/hereditary-transthyretin-amyloidosis-hattr/prevalence-and-clinical-outcomes-of-transthyretin-amyloidosis-a-systematic-review-and-meta-analysis/2025-01-23T08:53:45+00:00weekly0.7https://www.medthority.com/journals/hereditary-transthyretin-amyloidosis-hattr/characteristics-and-natural-history-of-early-stage-cardiac-transthyretin-amyloidosis/2025-01-13T09:16:13+00:00weekly0.7https://www.medthority.com/journals/hereditary-transthyretin-amyloidosis-hattr/novel-approaches-to-diagnosis-and-management-of-hereditary-transthyretin-amyloidosis/2025-01-13T09:16:12+00:00weekly0.7https://www.medthority.com/journals/hereditary-transthyretin-amyloidosis-hattr/phenotype-and-clinical-outcomes-of-glu89lys-hereditary-transthyretin-amyloidosis-a-new-endemic-variant-in-spain/2025-01-21T16:24:54+00:00weekly0.7https://www.medthority.com/journals/hereditary-transthyretin-amyloidosis-hattr/comparison-between-tafamidis-and-liver-transplantation-as-first-line-therapy-for-hereditary-transthyretin-amyloidosis/2025-01-21T16:24:28+00:00weekly0.7https://www.medthority.com/journals/hereditary-transthyretin-amyloidosis-hattr/distribution-and-progression-of-cerebral-amyloid-angiopathy-in-early-onset-v30m-p.v50m-hereditary-attr-amyloidosis2025-01-21T16:23:40+00:00weekly0.7https://www.medthority.com/journals/hereditary-transthyretin-amyloidosis-hattr/treatment-response-and-neurofilament-light-chain-levels-with-long-term-patisiran-in-hereditary-transthyretin-mediated-amyloidosis-with-polyneuropathy-24-month-results-of-an-open-label-extension-study/2025-01-23T08:56:21+00:00weekly0.7https://www.medthority.com/journals/hereditary-transthyretin-amyloidosis-hattr/efficacy-and-safety-of-vutrisiran-for-patients-with-hereditary-transthyretin-mediated-amyloidosis-with-polyneuropathy-a-randomized-clinical-trial/2025-01-23T08:55:39+00:00weekly0.7https://www.medthority.com/journals/hereditary-transthyretin-amyloidosis-hattr/hereditary-transthyretin-cardiac-amyloidosis-proven-by-endomyocardial-biopsy-a-single-centre-retrospective-study-and-literature-review/2025-01-23T08:54:32+00:00weekly0.7https://www.medthority.com/journals/hereditary-transthyretin-amyloidosis-hattr/hereditary-transthyretin-amyloidosis-overview/2025-01-13T09:16:12+00:00weekly0.7https://www.medthority.com/journals/acute-hepatic-porphyria/pain-in-acute-hepatic-porphyrias-updates-on-pathophysiology-and-management/2025-01-13T09:14:16+00:00weekly0.7https://www.medthority.com/journals/breast-cancer/systemic-therapy-for-hormone-receptor-positivehuman-epidermal-growth-factor-receptor-2-negative-early-stage-and-metastatic-breast-cancer/2025-01-23T08:50:08+00:00weekly0.7https://www.medthority.com/journals/acute-hepatic-porphyria/hyperhomocysteinemia-in-acute-hepatic-porphyria-ahp-and-implications-for-treatment-with-givosiran/2025-01-23T08:47:57+00:00weekly0.7https://www.medthority.com/journals/acute-hepatic-porphyria/acute-hepatic-porphyrias-purple-flags-clinical-features-that-should-prompt-specific-diagnostic-testing/2025-01-23T11:02:34+00:00weekly0.7https://www.medthority.com/journals/acute-hepatic-porphyria/risk-of-primary-liver-cancer-in-acute-hepatic-porphyria-patients-a-matched-cohort-study-of-1244-individuals/2025-01-23T09:28:55+00:00weekly0.7https://www.medthority.com/journals/acute-hepatic-porphyria/the-acute-hepatic-porphyrias/2025-01-13T09:14:17+00:00weekly0.7https://www.medthority.com/journals/acute-hepatic-porphyria/acute-hepatic-porphyria-pathophysiological-basis-of-neuromuscular-manifestations/2025-01-13T09:14:17+00:00weekly0.7https://www.medthority.com/journals/acute-hepatic-porphyria/spotlight-on-givosiran-as-a-treatment-option-for-adults-with-acute-hepatic-porphyria-design-development-and-place-in-therapy/2025-01-13T09:14:17+00:00weekly0.7https://www.medthority.com/journals/acute-hepatic-porphyria/patient-perspective-on-acute-hepatic-porphyria-with-sporadic-attacks-a-chronic-disease-with-substantial-health-related-quality-of-life-impacts/2025-01-13T09:14:16+00:00weekly0.7https://www.medthority.com/journals/acute-hepatic-porphyria/efficacy-and-safety-of-givosiran-for-acute-hepatic-porphyria-final-results-of-the-randomized-phase-iii-envision-trial/2025-01-23T08:49:11+00:00weekly0.7https://www.medthority.com/journals/acute-hepatic-porphyria/rna-interference-therapy-in-acute-hepatic-porphyrias/2025-01-24T12:05:38+00:00weekly0.7https://www.medthority.com/journals/breast-cancer/omitting-radiotherapy-after-breast-conserving-surgery-in-luminal-a-breast-cancer/2025-01-23T08:59:32+00:00weekly0.7https://www.medthority.com/journals/breast-cancer/trastuzumab-deruxtecan-in-previously-treated-her2-low-advanced-breast-cancer/2025-01-23T09:58:49+00:00weekly0.7https://www.medthority.com/journals/breast-cancer/targeting-breast-cancer-stem-cells/2025-01-13T09:14:54+00:00weekly0.7https://www.medthority.com/journals/breast-cancer/breast-cancer-breast-cancer-directed-radiation-therapy-and-risk-of-hypothyroidism-a-systematic-review-and-meta-analysis/2025-01-23T09:29:59+00:00weekly0.7https://www.medthority.com/journals/breast-cancer/targeting-her2-positive-breast-cancer-advances-and-future-directions/2025-01-13T09:14:54+00:00weekly0.7https://www.medthority.com/journals/breast-cancer/risk-factors-for-breast-cancer-in-women-an-update-review/2025-01-13T09:14:55+00:00weekly0.7https://www.medthority.com/journals/breast-cancer/does-age-affect-outcome-with-breast-cancer/2025-01-23T10:03:33+00:00weekly0.7https://www.medthority.com/journals/breast-cancer/individualising-radiation-therapy-decisions-in-breast-cancer-patients-based-on-tumour-infiltrating-lymphocytes-and-genomic-biomarkers/2025-01-23T10:02:36+00:00weekly0.7https://www.medthority.com/journals/breast-cancer/capivasertib-in-hormone-receptor-positive-advanced-breast-cancer/2025-01-23T09:00:17+00:00weekly0.7https://www.medthority.com/journals/regional-enteritis-and-ulcerative-colitis/clinical-effect-of-mirikizumab-treatment-on-bowel-urgency-in-patients-with-moderately-to-severely-active-ulcerative-colitis-and-the-clinical-relevance-of-bowel-urgency-improvement-for-disease-remission/2025-01-13T09:17:19+00:00weekly0.7https://www.medthority.com/journals/urticaria/efficacy-and-safety-of-ligelizumab-in-adults-and-adolescents-with-chronic-spontaneous-urticaria-results-of-two-phase-3-randomised-controlled-trials/2025-01-23T13:46:35+00:00weekly0.7https://www.medthority.com/journals/urticaria/efficacy-and-safety-of-up-dosed-second-generation-antihistamines-in-uncontrolled-chronic-spontaneous-urticaria-a-review/2025-01-13T09:17:28+00:00weekly0.7https://www.medthority.com/journals/pompe-disease/induced-pluripotent-stem-cell-for-modeling-pompe-disease/2025-01-13T09:17:07+00:00weekly0.7https://www.medthority.com/journals/pompe-disease/long-term-safety-and-efficacy-of-avalglucosidase-alfa-in-patients-with-late-onset-pompe-disease/2025-01-20T15:25:13+00:00weekly0.7https://www.medthority.com/journals/pompe-disease/therapeutic-thoroughfares-for-adults-living-with-pompe-disease/2025-01-20T15:43:16+00:00weekly0.7https://www.medthority.com/journals/pompe-disease/acid-maltase-deficiency-in-adults-studies-in-four-cases-of-a-syndrome-which-may-mimic-muscular-dystrophy-or-other-myopathies/2025-01-13T09:17:06+00:00weekly0.7https://www.medthority.com/journals/pompe-disease/glycogen-storage-disease-type-ii/2025-01-13T09:17:06+00:00weekly0.7https://www.medthority.com/journals/pompe-disease/association-between-changes-in-pulmonary-function-and-in-patient-reported-outcomes-during-enzyme-therapy-of-adult-patients-with-late-onset-pompe-disease/2025-01-20T15:43:53+00:00weekly0.7https://www.medthority.com/journals/pompe-disease/macroglossia-a-potentially-severe-complication-of-late-onset-pompe-disease/2025-01-20T15:47:57+00:00weekly0.7https://www.medthority.com/journals/pompe-disease/long-term-follow-up-of-64-children-with-classical-infantile-onset-pompe-disease-since-2004-a-french-real-life-observational-study/2025-01-20T15:48:41+00:00weekly0.7https://www.medthority.com/journals/pompe-disease/physical-training-and-high-protein-diet-improved-muscle-strength-parent-reported-fatigue-and-physical-quality-of-life-in-children-with-pompe-disease/2025-01-20T15:49:24+00:00weekly0.7https://www.medthority.com/journals/pompe-disease/in-utero-enzyme-replacement-therapy-for-infantile-onset-pompes-disease/2025-01-21T12:01:46+00:00weekly0.7https://www.medthority.com/journals/pompe-disease/pompe-disease-a-clinical-diagnostic-and-therapeutic-overview/2025-01-13T09:17:08+00:00weekly0.7https://www.medthority.com/journals/pompe-disease/diffusion-tensor-imaging-of-the-brain-in-pompe-disease/2025-01-13T09:17:08+00:00weekly0.7https://www.medthority.com/journals/pompe-disease/lysosomal-glycogen-accumulation-in-pompe-disease-results-in-disturbed-cytoplasmic-glycogen-metabolism/2025-01-20T15:24:13+00:00weekly0.7https://www.medthority.com/journals/pompe-disease/pompe-disease-ascertained-through-the-lantern-project-2018-2021-next-generation-sequencing-and-enzymatic-testing-to-overcome-obstacles-to-diagnosis/2025-01-13T09:17:07+00:00weekly0.7https://www.medthority.com/journals/pompe-disease/whats-new-and-whats-next-for-gene-therapy-in-pompe-disease/2025-01-20T15:42:35+00:00weekly0.7https://www.medthority.com/journals/pompe-disease/therapeutic-options-for-the-management-of-pompe-disease-current-challenges-and-clinical-evidence-in-therapeutics-and-clinical-risk-management/2025-01-13T09:17:07+00:00weekly0.7https://www.medthority.com/journals/pompe-disease/clinical-efficacy-of-the-enzyme-replacement-therapy-in-patients-with-late-onset-pompe-disease-a-systematic-review-and-a-meta-analysis/2025-01-13T09:17:04+00:00weekly0.7https://www.medthority.com/journals/pompe-disease/expert-group-consensus-on-early-diagnosis-and-management-of-infantile-onset-pompe-disease-in-the-gulf-region/2025-01-13T09:17:04+00:00weekly0.7https://www.medthority.com/journals/osteoarthritis/osteoarthritis-year-in-review-2022-rehabilitation/2025-01-20T15:41:54+00:00weekly0.7https://www.medthority.com/journals/osteoarthritis/inflammaging-and-osteoarthritis/2025-01-13T09:16:54+00:00weekly0.7https://www.medthority.com/journals/osteoarthritis/osteoarthritis-gene-therapy-in-2022/2025-01-21T12:11:14+00:00weekly0.7https://www.medthority.com/journals/osteoarthritis/osteoarthritis-year-in-review-2022-imaging/2025-01-21T12:12:19+00:00weekly0.7https://www.medthority.com/journals/osteoarthritis/inflammation-in-osteoarthritis-the-latest-progress-and-ongoing-challenges/2025-01-21T12:13:15+00:00weekly0.7https://www.medthority.com/journals/osteoarthritis/osteoarthritis-a-narrative-review-of-molecular-approaches-to-disease-management/2025-01-13T09:16:54+00:00weekly0.7https://www.medthority.com/journals/osteoarthritis/the-role-of-ferroptosis-in-the-pathogenesis-of-osteoarthritis/2025-01-13T09:16:53+00:00weekly0.7https://www.medthority.com/journals/osteoarthritis/lubricants-for-osteoarthritis-treatment-from-natural-to-bioinspired-and-alternative-strategies/2025-01-13T09:16:53+00:00weekly0.7https://www.medthority.com/journals/osteoarthritis/the-role-of-genetics-and-epigenetic-regulation-in-the-pathogenesis-of-osteoarthritis/2025-01-13T09:16:53+00:00weekly0.7https://www.medthority.com/journals/osteoarthritis/how-does-hip-osteoarthritis-differ-from-knee-osteoarthritis/2025-01-21T12:44:21+00:00weekly0.7https://www.medthority.com/journals/osteoarthritis/osteoarthritis-year-in-review-2022-genetics-genomics-and-epigenetics/2025-01-21T12:43:49+00:00weekly0.7https://www.medthority.com/journals/osteoarthritis/mechanosignalling-in-cartilage-an-emerging-target-for-the-treatment-of-osteoarthritis/2025-01-13T09:16:52+00:00weekly0.7https://www.medthority.com/journals/osteoarthritis/cytokines-and-chemokines-involved-in-osteoarthritis-pathogenesis/2025-01-13T09:16:52+00:00weekly0.7https://www.medthority.com/journals/osteoarthritis/obesity-inflammation-and-immune-system-in-osteoarthritis/2025-01-13T09:16:52+00:00weekly0.7https://www.medthority.com/journals/osteoarthritis/erosive-hand-osteoarthritis-latest-findings-and-outlook/2025-01-13T09:16:52+00:00weekly0.7https://www.medthority.com/journals/osteoarthritis/ribosome-dysfunction-in-osteoarthritis/2025-01-21T15:33:46+00:00weekly0.7https://www.medthority.com/journals/osteoarthritis/bone-in-osteoarthritis-imaging-and-interventions/2025-01-21T12:42:40+00:00weekly0.7https://www.medthority.com/journals/osteoarthritis/association-of-physical-activity-with-physical-function-and-quality-of-life-in-people-with-hip-and-knee-osteoarthritis-longitudinal-analysis-of-a-population-based-cohort/2025-01-13T09:16:51+00:00weekly0.7https://www.medthority.com/journals/osteoarthritis/whole-grain-consumption-and-risk-of-radiographic-knee-osteoarthritis-a-prospective-study-from-the-osteoarthritis-initiative/2025-01-13T09:16:51+00:00weekly0.7https://www.medthority.com/journals/osteoarthritis/to-what-extent-is-severe-osteoarthritis-preventable-occupational-and-non-occupational-risk-factors-for-knee-and-hip-osteoarthritis/2025-01-13T09:16:50+00:00weekly0.7https://www.medthority.com/journals/osteoarthritis/neurobiology-of-osteoarthritis-a-systematic-review-and-activation-likelihood-estimation-meta-analysis/2025-01-13T09:16:50+00:00weekly0.7https://www.medthority.com/journals/alopecia-areata/alopecia-areata-a-multifactorial-autoimmune-condition/2025-01-13T09:14:40+00:00weekly0.7https://www.medthority.com/journals/alopecia-areata/alopecia-areata/2025-01-13T09:14:40+00:00weekly0.7https://www.medthority.com/journals/alopecia-areata/alopecia-areata-a-review-of-the-role-of-oxidative-stress-possible-biomarkers-and-potential-novel-therapeutic-approaches/2025-01-13T09:14:40+00:00weekly0.7https://www.medthority.com/journals/alopecia-areata/alopecia-areata---current-understanding-and-management/2025-01-20T15:01:23+00:00weekly0.7https://www.medthority.com/journals/alopecia-areata/objective-outcome-measures-collecting-meaningful-data-on-alopecia-areata/2025-01-17T10:57:14+00:00weekly0.7https://www.medthority.com/journals/alopecia-areata/systematic-review-of-psychological-interventions-for-qol-mental-health-and-hair-growth-in-alopecia-areata-and-scarring-alopecia/2025-01-13T09:14:39+00:00weekly0.7https://www.medthority.com/journals/alopecia-areata/two-phase-3-trials-of-baricitinib-for-alopecia-areata/2025-01-17T11:08:29+00:00weekly0.7https://www.medthority.com/journals/alopecia-areata/treatment-of-pediatric-alopecia-areata-a-systematic-review/2025-01-17T10:57:10+00:00weekly0.7https://www.medthority.com/journals/alopecia-areata/lifestyle-factors-involved-in-the-pathogenesis-of-alopecia-areata/2025-01-13T09:14:38+00:00weekly0.7https://www.medthority.com/journals/alopecia-areata/alopecia-areata-recent-advances-and-emerging-therapies/2025-01-13T09:14:38+00:00weekly0.7https://www.medthority.com/journals/alopecia-areata/phase-2a-randomized-clinical-trial-of-dupilumab-anti-il-4r-for-alopecia-areata-patients/2025-01-20T14:31:39+00:00weekly0.7https://www.medthority.com/journals/alopecia-areata/emerging-drugs-for-the-treatment-of-alopecia-areata/2025-01-17T10:41:20+00:00weekly0.7https://www.medthority.com/journals/alopecia-areata/an-overview-of-jakstat-pathways-and-jak-inhibition-in-alopecia-areata/2025-01-13T09:14:37+00:00weekly0.7https://www.medthority.com/journals/alopecia-areata/the-epidemiology-of-alopecia-areata-a-population-based-cohort-study-in-uk-primary-care/2025-01-13T09:14:42+00:00weekly0.7https://www.medthority.com/journals/alopecia-areata/epidemiology-and-burden-of-alopecia-areata-a-systematic-review/2025-01-13T09:14:41+00:00weekly0.7https://www.medthority.com/journals/alopecia-areata/alopecia-areata-whats-new-in-epidemiology-pathogenesis-diagnosis-and-therapeutic-options/2025-01-20T15:02:14+00:00weekly0.7https://www.medthority.com/journals/alopecia-areata/prediction-of-the-risk-of-alopecia-areata-progressing-to-alopecia-totalis-and-alopecia-universalis-biomarker-development-with-bioinformatics-analysis-and-machine-learning/2025-01-13T09:14:41+00:00weekly0.7https://www.medthority.com/journals/eosinophilic-gastrointestinal-diseases-egids/dupilumab-leads-to-clinical-improvements-including-the-acquisition-of-tolerance-to-causative-foods-in-non-eosinophilic-esophagitis-eosinophilic-gastrointestinal-disorders/2025-01-13T09:15:34+00:00weekly0.7https://www.medthority.com/journals/eosinophilic-gastrointestinal-diseases-egids/eosinophilic-gastrointestinal-diseases-the-pathogenesis-diagnosis-and-treatment/2025-01-13T09:15:37+00:00weekly0.7https://www.medthority.com/journals/eosinophilic-gastrointestinal-diseases-egids/biologics-in-eosinophilic-gastrointestinal-diseases/2025-01-20T15:18:25+00:00weekly0.7https://www.medthority.com/journals/alopecia-areata/quality-of-life-in-children-and-adolescents-with-alopecia-areata-a-systematic-review/2025-01-20T15:00:43+00:00weekly0.7https://www.medthority.com/journals/alopecia-areata/the-efficacy-and-safety-of-jak-inhibitors-for-alopecia-areata-a-systematic-review-and-meta-analysis-of-prospective-studies/2025-01-13T09:14:37+00:00weekly0.7https://www.medthority.com/journals/headache/migraine-and-the-trigeminovascular-system-40-years-and-counting/2025-01-20T14:31:03+00:00weekly0.7https://www.medthority.com/journals/headache/global-regional-and-national-burden-of-migraine-and-tension-type-headache-1990-2016-a-systematic-analysis-for-the-global-burden-of-disease-study-2016/2025-01-20T14:29:33+00:00weekly0.7https://www.medthority.com/journals/headache/alcohol-as-a-trigger-of-migraine-attacks-in-people-with-migraine.-results-from-a-large-prospective-cohort-study-in-english-speaking-countries2025-01-20T14:38:28+00:00weekly0.7https://www.medthority.com/journals/headache/the-role-of-avoiding-known-triggers-embracing-protectors-and-adhering-to-healthy-lifestyle-recommendations-in-migraine-prophylaxis-insights-from-a-prospective-cohort-of-1125-people-with-episodic-migraine/2025-01-20T15:00:30+00:00weekly0.7https://www.medthority.com/journals/headache/validity-of-self-reported-migraine-in-adolescents-and-children/2025-01-20T14:59:34+00:00weekly0.7https://www.medthority.com/journals/headache/genetics-of-migraine-where-are-we-now/2025-01-13T09:16:11+00:00weekly0.7https://www.medthority.com/journals/headache/role-of-pacap-in-migraine-an-alternative-to-cgrp/2025-01-13T09:16:10+00:00weekly0.7https://www.medthority.com/journals/headache/migraine-as-an-inflammatory-disorder-with-microglial-activation-as-a-prime-candidate/2025-01-17T10:58:52+00:00weekly0.7https://www.medthority.com/journals/headache/characterization-of-the-biochemical-and-behavioral-effects-of-cannabidiol-implications-for-migraine/2025-01-13T09:16:10+00:00weekly0.7https://www.medthority.com/journals/headache/erenumab-efficacy-in-migraine-headache-prophylaxis-a-systematic-review/2025-01-13T09:16:10+00:00weekly0.7https://www.medthority.com/journals/headache/shared-and-independent-roles-of-cgrp-and-pacap-in-migraine-pathophysiology/2025-01-13T09:16:09+00:00weekly0.7https://www.medthority.com/journals/headache/evaluating-the-efficacy-of-cgrp-mabs-and-gepants-for-the-preventive-treatment-of-migraine-a-systematic-review-and-network-meta-analysis-of-phase-3-randomised-controlled-trials/2025-01-17T11:10:34+00:00weekly0.7https://www.medthority.com/journals/headache/potent-dual-maglfaah-inhibitor-aku-005-engages-endocannabinoids-to-diminish-meningeal-nociception-implicated-in-migraine-pain/2025-01-13T09:16:09+00:00weekly0.7https://www.medthority.com/journals/headache/the-sense-of-stopping-migraine-prophylaxis/2025-01-13T09:16:09+00:00weekly0.7https://www.medthority.com/journals/headache/a-study-of-differential-microrna-expression-profile-in-migraine-the-micromig-exploratory-study/2025-01-13T09:16:09+00:00weekly0.7https://www.medthority.com/journals/headache/prolactin-and-oxytocin-potential-targets-for-migraine-treatment/2025-01-13T09:16:11+00:00weekly0.7https://www.medthority.com/journals/headache/onabotulinumtoxina-still-the-present-for-chronic-migraine/2025-01-13T09:16:11+00:00weekly0.7https://www.medthority.com/journals/headache/role-of-atp-in-migraine-mechanisms-focus-on-p2x3-receptors/2025-01-13T09:16:11+00:00weekly0.7https://www.medthority.com/journals/headache/cgrp-physiology-pharmacology-and-therapeutic-targets-migraine-and-beyond/2025-01-17T10:58:17+00:00weekly0.7https://www.medthority.com/journals/headache/european-headache-federation-ehf-critical-re-appraisal-and-meta-analysis-of-oral-drugs-in-migraine-prevention-part-1-amitriptyline/2025-01-13T09:16:07+00:00weekly0.7https://www.medthority.com/journals/headache/european-headache-federation-ehf-consensus-on-the-definition-of-effective-treatment-of-a-migraine-attack-and-of-triptan-failure/2025-01-13T09:16:07+00:00weekly0.7https://www.medthority.com/journals/chronic-cough/cough-desensitization-treatment-a-randomized-sham-controlled-pilot-trial-for-patients-with-refractory-chronic-cough/2025-01-27T15:18:41+00:00weekly0.7https://www.medthority.com/journals/chronic-cough/chronic-cough/2025-01-13T09:14:57+00:00weekly0.7https://www.medthority.com/journals/chronic-cough/prevalence-and-burden-of-chronic-cough-in-the-united-states/2025-01-27T15:05:56+00:00weekly0.7https://www.medthority.com/journals/chronic-cough/chronic-cough-the-limitation-and-advances-in-assessment-techniques/2025-01-13T09:15:00+00:00weekly0.7https://www.medthority.com/journals/chronic-cough/risk-factors-for-chronic-cough-in-adults-a-systematic-review-and-meta-analysis/2025-01-27T15:07:06+00:00weekly0.7https://www.medthority.com/journals/chronic-cough/efficacy-and-safety-of-gefapixant-a-p2x3-receptor-antagonist-in-refractory-chronic-cough-and-unexplained-chronic-cough-cough-1-and-cough-2-results-from-two-double-blind-randomised-parallel-group-placebo-controlled-phase-3-trials/2025-01-27T15:07:58+00:00weekly0.7https://www.medthority.com/journals/chronic-cough/gerd-related-chronic-cough-possible-mechanism-diagnosis-and-treatment/2025-01-13T09:14:59+00:00weekly0.7https://www.medthority.com/journals/chronic-cough/atp-an-attractive-target-for-the-treatment-of-refractory-chronic-cough/2025-01-13T09:14:59+00:00weekly0.7https://www.medthority.com/journals/chronic-cough/gender-difference-in-chronic-cough-are-women-more-likely-to-cough/2025-01-13T09:14:59+00:00weekly0.7https://www.medthority.com/journals/chronic-cough/mechanisms-and-rationale-for-targeted-therapies-in-refractory-and-unexplained-chronic-cough/2025-01-27T15:17:54+00:00weekly0.7https://www.medthority.com/journals/chronic-cough/chronic-cough-new-insights-and-future-prospects/2025-01-13T09:14:58+00:00weekly0.7https://www.medthority.com/journals/chronic-cough/the-evolving-clinical-practice-of-chronic-cough/2025-01-27T15:08:41+00:00weekly0.7https://www.medthority.com/journals/eosinophilic-gastrointestinal-diseases-egids/treatment-trends-for-eosinophilic-esophagitis-and-the-other-eosinophilic-gastrointestinal-diseases-systematic-review-of-clinical-trials/2025-01-20T15:20:09+00:00weekly0.7https://www.medthority.com/journals/chronic-cough/clinical-phenotypes-of-chronic-cough-categorised-by-cluster-analysis/2025-01-13T09:14:57+00:00weekly0.7https://www.medthority.com/journals/chronic-cough/chronic-cough-related-differences-in-brain-morphometry-in-adults-a-population-based-study/2025-01-27T15:09:39+00:00weekly0.7https://www.medthority.com/journals/chronic-cough/cough-hypersensitivity-and-chronic-cough/2025-01-13T09:15:01+00:00weekly0.7https://www.medthority.com/journals/eosinophilic-gastrointestinal-diseases-egids/eosinophilic-gastrointestinal-diseases-in-inborn-errors-of-immunity/2025-01-13T09:15:36+00:00weekly0.7https://www.medthority.com/journals/eosinophilic-gastrointestinal-diseases-egids/eosinophilic-gastrointestinal-diseases-beyond-eosinophilic-esophagitis/2025-01-20T15:03:38+00:00weekly0.7https://www.medthority.com/journals/eosinophilic-gastrointestinal-diseases-egids/eosinophilic-gastrointestinal-diseases-beyond-the-esophagus-an-evolving-field-and-nomenclature/2025-01-13T09:15:35+00:00weekly0.7https://www.medthority.com/journals/eosinophilic-gastrointestinal-diseases-egids/non-oesophageal-eosinophilic-gastrointestinal-diseases-are-undersuspected-clinically-and-underdiagnosed-pathologically/2025-01-20T15:02:55+00:00weekly0.7https://www.medthority.com/journals/eosinophilic-gastrointestinal-diseases-egids/dupilumab-in-adults-and-adolescents-with-eosinophilic-esophagitis/2025-01-17T11:08:59+00:00weekly0.7https://www.medthority.com/journals/eosinophilic-gastrointestinal-diseases-egids/benralizumab-completely-depletes-gastrointestinal-tissue-eosinophils-and-improves-symptoms-in-eosinophilic-gastrointestinal-disease/2025-01-20T15:19:22+00:00weekly0.7https://www.medthority.com/journals/coagulation-and-haemorrhagic-disorders/real-world-experience-with-a-human-fibrinogen-concentrate-clinical-data-from-adult-and-pediatric-patients-requiring-fibrinogen-for-bleeding-control-and-prevention/2025-01-24T10:44:17+00:00weekly0.7https://www.medthority.com/journals/coagulation-and-haemorrhagic-disorders/role-of-fibrinogen-in-trauma-induced-coagulopathy/2025-01-24T10:43:18+00:00weekly0.7https://www.medthority.com/journals/non-hodgkin-lymphoma/fda-approval-summary-brentuximab-vedotin-in-first-line-treatment-of-peripheral-t-cell-lymphoma/2025-01-13T09:16:47+00:00weekly0.7https://www.medthority.com/journals/non-hodgkin-lymphoma/the-echelon-2-trial-5-year-results-of-a-randomized-phase-iii-study-of-brentuximab-vedotin-with-chemotherapy-for-cd30-positive-peripheral-t-cell-lymphoma/2025-01-27T16:14:22+00:00weekly0.7https://www.medthority.com/journals/hodgkins-disease/effectiveness-of-brentuximab-vedotin-monotherapy-in-relapsed-or-refractory-hodgkin-lymphoma-a-systematic-review-and-meta-analysis/2025-01-24T11:57:21+00:00weekly0.7https://www.medthority.com/journals/non-hodgkin-lymphoma/three-year-follow-up-analysis-of-axicabtagene-ciloleucel-in-relapsedrefractory-indolent-non-hodgkin-lymphoma-zuma-5/2025-01-27T14:32:44+00:00weekly0.7https://www.medthority.com/journals/non-hodgkin-lymphoma/tafasitamab-for-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-final-5-year-efficacy-and-safety-findings-in-the-phase-ii-l-mind-study/2025-01-13T09:16:48+00:00weekly0.7https://www.medthority.com/journals/non-hodgkin-lymphoma/combination-of-acalabrutinib-with-lenalidomide-and-rituximab-in-relapsedrefractory-aggressive-b-cell-non-hodgkin-lymphoma-a-single-arm-phase-ii-trial/2025-01-13T09:16:48+00:00weekly0.7https://www.medthority.com/journals/non-hodgkin-lymphoma/radiotherapy-in-younger-patients-with-advanced-aggressive-b-cell-lymphoma-long-term-results-from-the-phase-3-r-megachoep-trial/2025-01-13T09:16:48+00:00weekly0.7https://www.medthority.com/journals/non-hodgkin-lymphoma/clinical-efficacy-and-safety-of-subcutaneous-rituximab-in-non-hodgkin-lymphoma-a-systematic-literature-review-and-meta-analysis/2025-01-24T12:00:18+00:00weekly0.7https://www.medthority.com/journals/non-hodgkin-lymphoma/efficacy-of-salvage-treatments-in-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-including-chimeric-antigen-receptor-t-cell-therapy-a-systematic-review-and-meta-analysis/2025-01-13T09:16:47+00:00weekly0.7https://www.medthority.com/journals/hodgkins-disease/classic-hodgkin-lymphoma-in-adolescents-and-young-adults/2025-01-24T11:56:14+00:00weekly0.7https://www.medthority.com/journals/hodgkins-disease/safety-and-efficacy-of-pd-1-and-pd-l1-inhibitors-in-relapsed-and-refractory-hodgkins-lymphoma-a-systematic-review-and-meta-analysis-of-20-prospective-studies/2025-01-24T11:51:51+00:00weekly0.7https://www.medthority.com/journals/hodgkins-disease/distinct-hodgkin-lymphoma-subtypes-defined-by-noninvasive-genomic-profiling/2025-01-13T09:16:15+00:00weekly0.7https://www.medthority.com/journals/hodgkins-disease/hodgkin-lymphoma-review-on-pathogenesis-diagnosis-current-and-future-treatment-approaches-for-adult-patients/2025-01-13T09:16:16+00:00weekly0.7https://www.medthority.com/journals/non-hodgkin-lymphoma/frontline-management-of-nodal-peripheral-t-cell-lymphomas/2025-01-24T10:36:12+00:00weekly0.7https://www.medthority.com/journals/non-hodgkin-lymphoma/brentuximab-vedotin-with-chemotherapy-for-cd30-positive-peripheral-t-cell-lymphoma-echelon-2-a-global-double-blind-randomised-phase-3-trial/2025-01-24T12:08:20+00:00weekly0.7https://www.medthority.com/journals/non-hodgkin-lymphoma/management-considerations-for-patients-with-primary-refractory-and-early-relapsed-diffuse-large-b-cell-lymphoma/2025-01-24T12:02:03+00:00weekly0.7https://www.medthority.com/journals/non-hodgkin-lymphoma/outcomes-in-patients-with-dlbcl-treated-with-commercial-car-t-cells-compared-with-alternate-therapies/2025-01-27T14:33:28+00:00weekly0.7https://www.medthority.com/journals/non-hodgkin-lymphoma/primary-analysis-of-zuma-7-a-phase-3-randomized-trial-of-axicabtagene-ciloleucel-axi-cel-versus-standard-of-care-therapy-in-patients-with-relapsedrefractory-large-b-cell-lymphoma/2025-01-24T12:01:16+00:00weekly0.7https://www.medthority.com/journals/non-hodgkin-lymphoma/bi--and-tri-specific-antibodies-in-non-hodgkin-lymphoma-current-data-and-perspectives/2025-01-13T09:16:48+00:00weekly0.7https://www.medthority.com/journals/hodgkins-disease/socioeconomic-impact-of-hodgkin-lymphoma-in-adult-patients-a-systematic-literature-review/2025-01-28T15:00:24+00:00weekly0.7https://www.medthority.com/journals/hodgkins-disease/latest-advances-in-the-management-of-classical-hodgkin-lymphoma-the-era-of-novel-therapies/2025-01-13T09:16:17+00:00weekly0.7https://www.medthority.com/journals/hodgkins-disease/hope-after-salvage-therapy-fails-novel-agents-for-relapsedrefractory-hodgkin-lymphoma/2025-01-13T09:16:17+00:00weekly0.7https://www.medthority.com/journals/hodgkins-disease/brentuximab-vedotin-in-combination-with-nivolumab-in-relapsed-or-refractory-hodgkin-lymphoma-3-year-study-results/2025-01-24T11:59:10+00:00weekly0.7https://www.medthority.com/journals/menopausal-disorders/efficacy-and-safety-of-fezolinetant-for-the-treatment-of-menopause-associated-vasomotor-symptoms-a-meta-analysis/2025-01-24T10:04:31+00:00weekly0.7https://www.medthority.com/journals/menopausal-disorders/systematic-review-of-neurokinin-3-receptor-antagonists-for-the-management-of-vasomotor-symptoms-of-menopause/2025-01-24T10:41:52+00:00weekly0.7https://www.medthority.com/journals/menopausal-disorders/menopause-and-the-role-of-physical-activity---the-views-and-knowledge-of-women-aged-40-65/2025-01-24T10:37:47+00:00weekly0.7https://www.medthority.com/journals/menopausal-disorders/cognitive-decline-in-early-and-premature-menopause/2025-01-13T09:16:22+00:00weekly0.7https://www.medthority.com/journals/menopausal-disorders/menopause-transition-physiology-and-symptoms/2025-01-13T09:16:22+00:00weekly0.7https://www.medthority.com/journals/menopausal-disorders/early-menopause-is-associated-with-increased-risk-of-heart-failure-and-atrial-fibrillation-a-systematic-review-and-meta-analysis/2025-01-24T10:41:04+00:00weekly0.7https://www.medthority.com/journals/menopausal-disorders/rethinking-menopausal-hormone-therapy-for-whom-what-when-and-how-long/2025-01-24T12:09:07+00:00weekly0.7https://www.medthority.com/journals/menopausal-disorders/prevalence-and-quality-of-life-burden-of-vasomotor-symptoms-associated-with-menopause-a-european-cross-sectional-survey/2025-01-24T10:39:03+00:00weekly0.7https://www.medthority.com/journals/menopausal-disorders/fezolinetant-for-treatment-of-moderate-to-severe-vasomotor-symptoms-associated-with-menopause-skylight-1-a-phase-3-randomised-controlled-study/2025-01-24T10:39:53+00:00weekly0.7https://www.medthority.com/journals/menopausal-disorders/management-of-menopausal-symptoms-a-review/2025-01-13T09:16:21+00:00weekly0.7https://www.medthority.com/journals/chronic-obstructive-pulmonary-disease-copd-and-bronchiectasis/blood-eosinophil-guided-oral-prednisolone-for-copd-exacerbations-in-primary-care-in-the-uk-starr2-a-non-inferiority-multicentre-double-blind-placebo-controlled-randomised-controlled-trial/2025-01-24T12:19:38+00:00weekly0.7https://www.medthority.com/journals/chronic-obstructive-pulmonary-disease-copd-and-bronchiectasis/dupilumab-for-copd-with-type-2-inflammation-indicated-by-eosinophil-counts/2025-01-28T16:08:41+00:00weekly0.7https://www.medthority.com/journals/chronic-obstructive-pulmonary-disease-copd-and-bronchiectasis/airway-occluding-mucus-plugs-and-mortality-in-patients-with-chronic-obstructive-pulmonary-disease/2025-01-13T09:15:19+00:00weekly0.7https://www.medthority.com/journals/allergic-reactions/effect-of-upadacitinib-on-atopic-hand-eczema-in-patients-with-moderate-to-severe-atopic-dermatitis-results-from-two-randomized-phase-3-trials/2025-01-24T12:20:27+00:00weekly0.7https://www.medthority.com/journals/epidermolysis-bullosa/epidermolysis-bullosa-two-rare-case-reports-of-col7a1-and-ebs-gen-sev-krt14-variants-with-review-of-literature/2025-01-13T09:15:38+00:00weekly0.7https://www.medthority.com/journals/epidermolysis-bullosa/successful-treatment-of-epidermolysis-bullosa-pruriginosa-by-dupilumab/2025-01-24T12:14:45+00:00weekly0.7https://www.medthority.com/journals/epidermolysis-bullosa/type-vii-collagen-deficiency-in-the-oncogenesis-of-cutaneous-squamous-cell-carcinoma-in-dystrophic-epidermolysis-bullosa/2025-01-24T12:13:09+00:00weekly0.7https://www.medthority.com/journals/epidermolysis-bullosa/orofacial-anomalies-in-kindler-epidermolysis-bullosa/2025-01-13T09:15:37+00:00weekly0.7https://www.medthority.com/journals/epidermolysis-bullosa/emerging-gene-therapeutics-for-epidermolysis-bullosa-under-development/2025-01-13T09:15:40+00:00weekly0.7https://www.medthority.com/journals/epidermolysis-bullosa/advances-in-treatments-for-epidermolysis-bullosa-eb-emphasis-on-stem-cell-based-therapy/2025-01-13T09:15:40+00:00weekly0.7https://www.medthority.com/journals/epidermolysis-bullosa/epidermolysis-bullosa-practical-clinical-tips-from-the-field/2025-01-13T09:15:40+00:00weekly0.7https://www.medthority.com/journals/epidermolysis-bullosa/efficacy-and-safety-of-oleogel-s10-birch-triterpenes-for-epidermolysis-bullosa-results-from-the-phase-iii-randomized-double-blind-phase-of-the-ease-study/2025-01-13T09:15:39+00:00weekly0.7https://www.medthority.com/journals/epidermolysis-bullosa/trial-of-beremagene-geperpavec-b-vec-for-dystrophic-epidermolysis-bullosa/2025-01-24T12:13:57+00:00weekly0.7https://www.medthority.com/journals/epidermolysis-bullosa/in-vivo-topical-gene-therapy-for-recessive-dystrophic-epidermolysis-bullosa-a-phase-1-and-2-trial/2025-01-13T09:15:39+00:00weekly0.7https://www.medthority.com/journals/primary-hyperoxaluria/phyox2-a-pivotal-randomized-study-of-nedosiran-in-primary-hyperoxaluria-type-1-or-2/2025-01-28T15:37:16+00:00weekly0.7https://www.medthority.com/journals/primary-hyperoxaluria/nedosiran-safety-and-efficacy-in-ph1-interim-analysis-of-phyox3/2025-01-28T15:39:36+00:00weekly0.7https://www.medthority.com/journals/primary-hyperoxaluria/lumasiran-for-advanced-primary-hyperoxaluria-type-1-phase-3-illuminate-c-trial/2025-01-28T15:40:32+00:00weekly0.7https://www.medthority.com/journals/primary-hyperoxaluria/distinguishing-characteristics-of-pediatric-patients-with-primary-hyperoxaluria-type-1-in-pedsnet/2025-01-28T15:38:49+00:00weekly0.7https://www.medthority.com/journals/primary-hyperoxaluria/multicenter-long-term-real-world-data-on-treatment-with-lumasiran-in-patients-with-primary-hyperoxaluria-type-1/2025-01-28T15:37:56+00:00weekly0.7https://www.medthority.com/journals/primary-hyperoxaluria/three-tesla-magnetic-resonance-imaging-detects-oxalate-osteopathy-in-patients-with-primary-hyperoxaluria-type-i/2025-01-13T09:17:09+00:00weekly0.7https://www.medthority.com/journals/lung-cancer/nsclc-immunotherapy-efficacy-and-antibiotic-use-a-systematic-review-and-meta-analysis/2025-01-24T11:51:09+00:00weekly0.7https://www.medthority.com/journals/allergic-reactions/management-of-chronic-hand-and-foot-eczema.-an-australianew-zealand-clinical-narrative2025-01-24T11:49:36+00:00weekly0.7https://www.medthority.com/journals/allergic-reactions/a-review-of-existing-and-new-treatments-for-the-management-of-hand-eczema/2025-01-24T12:04:28+00:00weekly0.7https://www.medthority.com/journals/allergic-reactions/characterizing-demographics-and-cost-of-care-for-dyshidrotic-eczema/2025-01-24T11:46:22+00:00weekly0.7https://www.medthority.com/journals/allergic-reactions/dupilumab-treatment-improves-signs-symptoms-quality-of-life-and-work-productivity-in-patients-with-atopic-hand-and-foot-dermatitis-results-from-a-phase-3-randomized-double-blind-placebo-controlled-trial/2025-01-24T11:45:12+00:00weekly0.7https://www.medthority.com/journals/allergic-reactions/hand-and-foot-dermatitis-in-patients-referred-for-patch-testing-analysis-of-north-american-contact-dermatitis-group-data-2001-2018/2025-01-24T11:43:25+00:00weekly0.7https://www.medthority.com/journals/allergic-reactions/impact-of-an-ehealth-smartphone-app-on-quality-of-life-and-clinical-outcome-of-patients-with-hand-and-foot-eczema-prospective-randomized-controlled-intervention-study/2025-01-13T09:14:36+00:00weekly0.7https://www.medthority.com/journals/acute-hepatic-porphyria/obstacles-to-early-diagnosis-of-acute-hepatic-porphyria-current-perspectives-on-improving-early-diagnosis-and-clinical-management/2025-01-13T09:14:15+00:00weekly0.7https://www.medthority.com/journals/acute-hepatic-porphyria/acute-hepatic-porphyrias-a-guide-for-hepatologists/2025-01-24T11:50:17+00:00weekly0.7https://www.medthority.com/journals/acute-hepatic-porphyria/case-based-discussion-of-the-acute-hepatic-porphyrias-updates-on-pathogenesis-diagnosis-and-management/2025-01-24T12:21:08+00:00weekly0.7https://www.medthority.com/journals/acute-hepatic-porphyria/acute-hepatic-porphyrias-recommendations-for-diagnosis-and-management-with-real-world-examples/2025-01-13T09:14:14+00:00weekly0.7https://www.medthority.com/journals/allergic-reactions/children-with-atopic-dermatitis-should-always-be-patch-tested-if-they-have-hand-or-foot-dermatitis/2025-01-13T09:14:36+00:00weekly0.7https://www.medthority.com/journals/lung-cancer/perioperative-toripalimab-plus-chemotherapy-for-patients-with-resectable-non-small-cell-lung-cancer-the-neotorch-randomized-clinical-trial/2025-01-13T09:16:20+00:00weekly0.7https://www.medthority.com/journals/lung-cancer/neoadjuvant-egfr-tki-therapy-for-egfr-mutant-nsclc-a-systematic-review-and-pooled-analysis-of-five-prospective-clinical-trials/2025-01-13T09:16:19+00:00weekly0.7https://www.medthority.com/journals/lung-cancer/first-line-osimertinib-for-previously-untreated-patients-with-nsclc-and-uncommon-egfr-mutations-the-unicorn-phase-2-nonrandomized-clinical-trial/2025-01-13T09:16:19+00:00weekly0.7https://www.medthority.com/journals/lung-cancer/efficacy-and-safety-of-intrathecal-pemetrexed-for-tki-failed-leptomeningeal-metastases-from-egfr-nsclc-an-expanded-single-arm-phase-ii-clinical-trial/2025-01-24T12:07:45+00:00weekly0.7https://www.medthority.com/journals/lung-cancer/challenges-and-controversies-in-resectable-non-small-cell-lung-cancer-a-clinicians-perspective/2025-01-24T12:07:14+00:00weekly0.7https://www.medthority.com/journals/lung-cancer/new-systemic-treatment-paradigms-in-resectable-non-small-cell-lung-cancer-and-variations-in-patient-access-across-europe/2025-01-24T12:06:18+00:00weekly0.7https://www.medthority.com/journals/allergic-reactions/etfadeadv-eczema-task-force-2020-position-paper-on-diagnosis-and-treatment-of-atopic-dermatitis-in-adults-and-children/2025-01-24T11:42:26+00:00weekly0.7https://www.medthority.com/journals/allergic-reactions/quick-treatment-of-very-severe-refractory-hand-and-foot-eczema-with-dupilumab-a-case-report-and-literature-review/2025-01-13T09:14:34+00:00weekly0.7https://www.medthority.com/journals/allergic-reactions/real-world-clinical-experience-of-dupilumab-in-the-treatment-of-chronic-palmo-plantar-eczema-in-patients-with-moderate-severe-atopic-dermatitis-52-week-follow-up/2025-01-24T11:48:49+00:00weekly0.7https://www.medthority.com/journals/allergic-reactions/nine-cases-of-chronic-hand-and-foot-eczema-treated-with-baricitinib/2025-01-24T11:47:29+00:00weekly0.7https://www.medthority.com/journals/allergic-reactions/pediatric-chronic-hand-eczema-epidemiology-clinical-presentation-and-management/2025-01-24T12:05:06+00:00weekly0.7https://www.medthority.com/journals/allergic-reactions/efficacy-and-safety-of-dupilumab-in-patients-with-severe-chronic-hand-eczema-with-inadequate-response-or-intolerance-to-alitretinoin-a-randomized-double-blind-placebo-controlled-phase-iib-proof-of-concept-study/2025-01-13T09:14:33+00:00weekly0.7https://www.medthority.com/journals/allergic-reactions/new-perspectives-in-the-management-of-chronic-hand-eczema-lessons-from-pathogenesis/2025-01-13T09:14:33+00:00weekly0.7https://www.medthority.com/journals/alpha-1-antitrypsin-deficiency/alpha-1-antitrypsin-deficiency-is-under-recognized-in-individuals-with-cirrhosis-undergoing-liver-transplantation/2025-01-14T08:58:20+00:00weekly0.7https://www.medthority.com/journals/alpha-1-antitrypsin-deficiency/long-term-results-of-liver-transplantation-for-alpha-1-antitrypsin-deficiency/2025-01-14T08:56:18+00:00weekly0.7https://www.medthority.com/journals/alpha-1-antitrypsin-deficiency/disease-progression-in-patients-with-pizz-alpha-1-antitrypsin-deficiency/2025-01-14T08:52:13+00:00weekly0.7https://www.medthority.com/journals/alpha-1-antitrypsin-deficiency/lung-and-liver-transplantation-in-patients-with-alpha-1-antitrypsin-deficiency/2025-01-14T09:24:52+00:00weekly0.7https://www.medthority.com/journals/alpha-1-antitrypsin-deficiency/alpha-1-antitrypsin-deficiency-liver-disease/2025-01-13T09:14:45+00:00weekly0.7https://www.medthority.com/journals/alpha-1-antitrypsin-deficiency/alpha-1-antitrypsin-deficiency/2025-01-13T09:14:45+00:00weekly0.7https://www.medthority.com/journals/alpha-1-antitrypsin-deficiency/alpha-1-antitrypsin-deficiency2/2025-01-14T10:26:05+00:00weekly0.7https://www.medthority.com/journals/alpha-1-antitrypsin-deficiency/known-mutations-at-the-cause-of-alpha-1-antitrypsin-deficiency-an-updated-overview-of-serpina1-variation-spectrum/2025-01-13T09:14:45+00:00weekly0.7https://www.medthority.com/journals/alpha-1-antitrypsin-deficiency/alpha-1-antitrypsin-deficiency-mediated-liver-toxicity-why-do-some-patients-do-poorly-what-do-we-know-so-far/2025-01-13T09:14:44+00:00weekly0.7https://www.medthority.com/journals/alpha-1-antitrypsin-deficiency/heterozygosity-for-the-alpha-1-antitrypsin-z-allele-in-cirrhosis-is-associated-with-more-advanced-disease/2025-01-13T09:14:44+00:00weekly0.7https://www.medthority.com/journals/alpha-1-antitrypsin-deficiency/clinical-considerations-in-individuals-with--1-antitrypsin-pisz-genotype/2025-01-13T09:14:44+00:00weekly0.7https://www.medthority.com/journals/alpha-1-antitrypsin-deficiency/estimated-prevalence-and-number-of-pimz-genotypes-of-alpha-1-antitrypsin-in-seventy-four-countries-worldwide/2025-01-13T09:14:44+00:00weekly0.7https://www.medthority.com/journals/alpha-1-antitrypsin-deficiency/european-respiratory-society-statement-diagnosis-and-treatment-of-pulmonary-disease-in--1-antitrypsin-deficiency/2025-01-13T09:14:44+00:00weekly0.7https://www.medthority.com/journals/alpha-1-antitrypsin-deficiency/fazirsiran-for-liver-disease-associated-with-alpha-1-antitrypsin-deficiency/2025-01-14T10:25:11+00:00weekly0.7https://www.medthority.com/journals/alpha-1-antitrypsin-deficiency/alpha-1-antitrypsin-deficiency-a-re-surfacing-adult-liver-disorder/2025-01-14T08:59:42+00:00weekly0.7https://www.medthority.com/journals/bladder-cancer/the-emerging-roles-of-exosomal-long-non-coding-rnas-in-bladder-cancer/2025-01-13T14:27:23+00:00weekly0.7https://www.medthority.com/journals/bladder-cancer/management-of-bladder-cancer-in-older-patients/2025-01-13T09:14:49+00:00weekly0.7https://www.medthority.com/journals/bladder-cancer/evolution-of-immunotherapy-in-the-treatment-of-non-muscle-invasive-bladder-cancer/2025-01-13T14:18:18+00:00weekly0.7https://www.medthority.com/journals/bladder-cancer/the-role-of-tumour-microenvironment-driven-mirnas-in-the-chemoresistance-of-muscle-invasive-bladder-cancer-a-review/2025-01-13T09:14:49+00:00weekly0.7https://www.medthority.com/journals/bladder-cancer/updated-pathology-reporting-standards-for-bladder-cancer-biopsies-transurethral-resections-and-radical-cystectomies/2025-01-13T09:14:49+00:00weekly0.7https://www.medthority.com/journals/bladder-cancer/bladder-cancer-biomarker-screening-based-on-non-targeted-urine-metabolomics/2025-01-13T09:14:48+00:00weekly0.7https://www.medthority.com/journals/bladder-cancer/adjuvant-chemotherapy-for-muscle-invasive-bladder-cancer-a-systematic-review-and-meta-analysis-of-individual-participant-data-from-randomised-controlled-trials/2025-01-13T09:14:48+00:00weekly0.7https://www.medthority.com/journals/bladder-cancer/targeted-therapies-for-cancer/2025-01-13T09:14:47+00:00weekly0.7https://www.medthority.com/journals/bladder-cancer/liquid-biopsy-in-bladder-cancer-state-of-the-art-and-future-perspectives/2025-01-13T09:14:51+00:00weekly0.7https://www.medthority.com/journals/bladder-cancer/immunotherapy-for-non-muscle-invasive-bladder-cancer-from-the-origins-of-bcg-to-novel-therapies/2025-01-13T14:19:49+00:00weekly0.7https://www.medthority.com/journals/bladder-cancer/diagnosis-and-staging-of-bladder-cancer/2025-01-13T09:14:51+00:00weekly0.7https://www.medthority.com/journals/bladder-cancer/advances-in-bladder-cancer-biology-and-therapy/2025-01-13T09:14:51+00:00weekly0.7https://www.medthority.com/journals/bladder-cancer/the-inequality-of-females-in-bladder-cancer/2025-01-13T14:18:59+00:00weekly0.7https://www.medthority.com/journals/bladder-cancer/urinary-biomarkers-in-bladder-cancer-a-review-of-the-current-landscape-and-future-directions/2025-01-13T09:14:50+00:00weekly0.7https://www.medthority.com/journals/bladder-cancer/targeted-therapy-in-metastatic-bladder-cancer-present-status-and-future-directions/2025-01-13T09:14:53+00:00weekly0.7https://www.medthority.com/journals/bladder-cancer/developing-precision-medicine-for-bladder-cancer/2025-01-13T09:14:53+00:00weekly0.7https://www.medthority.com/journals/bladder-cancer/new-directions-and-challenges-in-targeted-therapies-of-advanced-bladder-cancer-the-role-of-fgfr-inhibitors/2025-01-13T09:14:53+00:00weekly0.7https://www.medthority.com/journals/bladder-cancer/global-cancer-statistics-2020-globocan-estimates-of-incidence-and-mortality-worldwide-for-36-cancers-in-185-countries/2025-01-13T14:20:47+00:00weekly0.7https://www.medthority.com/journals/bladder-cancer/immune-checkpoint-inhibitors-in-advanced-bladder-cancer-seize-the-day/2025-01-13T09:14:52+00:00weekly0.7https://www.medthority.com/journals/bladder-cancer/pharmacometabolomics-applied-to-personalized-medicine-in-urological-cancers/2025-01-13T09:14:52+00:00weekly0.7https://www.medthority.com/journals/bladder-cancer/the-new-age-of-omics-in-urothelial-cancer-re-wording-its-diagnosis-and-treatment/2025-01-13T14:28:17+00:00weekly0.7https://www.medthority.com/journals/bladder-cancer/approaches-to-non-muscle-invasive-bladder-cancer/2025-01-13T09:14:52+00:00weekly0.7https://www.medthority.com/journals/bladder-cancer/advances-in-management-of-bladder-cancer-the-role-of-photodynamic-therapy/2025-01-13T09:14:51+00:00weekly0.7https://www.medthority.com/journals/retinal-dystrophy/syndromic-inherited-retinal-diseases-genetic-clinical-and-diagnostic-aspects/2023-05-26T12:59:30+00:00weekly0.7https://www.medthority.com/journals/macular-degeneration/levodopa-positively-affects-neovascular-age-related-macular-degeneration/2025-01-30T14:52:09+00:00weekly0.7https://www.medthority.com/journals/macular-degeneration/age-related-macular-degeneration-masqueraders-from-the-obvious-to-the-obscure/2025-01-30T14:51:17+00:00weekly0.7https://www.medthority.com/journals/macular-degeneration/anti-retinal-autoantibodies-in-myopic-macular-degeneration-a-pilot-study/2021-09-24T07:24:29+00:00weekly0.7https://www.medthority.com/journals/macular-degeneration/influence-of-myopic-macular-degeneration-severity-on-treatment-outcomes-with-intravitreal-aflibercept-in-the-myrror-study/2025-01-30T12:29:19+00:00weekly0.7https://www.medthority.com/journals/macular-degeneration/genetic-variants-linked-to-myopic-macular-degeneration-in-persons-with-high-myopia-cream-consortium/2021-09-24T07:24:29+00:00weekly0.7https://www.medthority.com/journals/macular-degeneration/prevalence-of-myopic-macular-degeneration-worldwide-a-systematic-review-and-meta-analysis/2021-09-24T07:24:29+00:00weekly0.7https://www.medthority.com/journals/retinal-dystrophy/efficacy-and-safety-of-voretigene-neparvovec-aav2-hrpe65v2-in-patients-with-rpe65-mediated-inherited-retinal-dystrophy-a-randomised-controlled-open-label-phase-3-trial/2025-01-20T15:26:19+00:00weekly0.7https://www.medthority.com/journals/retinal-dystrophy/efficacy-safety-and-durability-of-voretigene-neparvovec-rzyl-in-rpe65-mutation-associated-inherited-retinal-dystrophy-results-of-phase-1-and-3-trials/2025-01-20T15:50:11+00:00weekly0.7https://www.medthority.com/journals/retinal-dystrophy/optical-gap-biomarker-in-cone-dominant-retinal-dystrophy/2025-01-20T16:13:57+00:00weekly0.7https://www.medthority.com/journals/retinal-dystrophy/differences-in-intraretinal-pigment-migration-across-inherited-retinal-dystrophies/2025-01-20T16:14:51+00:00weekly0.7https://www.medthority.com/journals/retinal-dystrophy/the-natural-history-of-inherited-retinal-dystrophy-due-to-biallelic-mutations-in-the-rpe65-gene/2025-01-20T15:27:24+00:00weekly0.7https://www.medthority.com/journals/retinal-dystrophy/gene-therapy-in-retinal-dystrophies/2023-05-26T13:02:55+00:00weekly0.7https://www.medthority.com/journals/retinal-dystrophy/innate-and-autoimmunity-in-the-pathogenesis-of-inherited-retinal-dystrophy/2023-05-26T13:02:38+00:00weekly0.7https://www.medthority.com/journals/retinal-dystrophy/rpe65-and-retinal-dystrophy-report-of-new-and-recurrent-mutations/2025-01-20T16:15:48+00:00weekly0.7https://www.medthority.com/journals/retinal-dystrophy/clinical-perspective-treating-rpe65-associated-retinal-dystrophy/2025-01-20T16:16:28+00:00weekly0.7https://www.medthority.com/journals/retinal-dystrophy/initial-results-from-a-first-in-human-gene-therapy-trial-on-x-linked-retinitis-pigmentosa-caused-by-mutations-in-rpgr/2023-05-26T13:00:32+00:00weekly0.7https://www.medthority.com/journals/retinal-dystrophy/clinical-characteristics-differential-diagnosis-and-genetic-analysis-of-concentric-retinitis-pigmentosa/2023-05-26T13:00:12+00:00weekly0.7https://www.medthority.com/journals/retinal-dystrophy/allele-specific-knockout-by-crisprcas-to-treat-autosomal-dominant-retinitis-pigmentosa-caused-by-the-g56r-mutation-in-nr2e3/2023-05-26T12:59:58+00:00weekly0.7https://www.medthority.com/journals/retinal-dystrophy/comparative-analysis-of-functional-and-structural-decline-in-retinitis-pigmentosas/2023-05-26T13:04:38+00:00weekly0.7https://www.medthority.com/journals/retinal-dystrophy/antioxidant-and-biological-properties-of-mesenchymal-cells-used-for-therapy-in-retinitis-pigmentosa/2023-05-26T13:04:20+00:00weekly0.7https://www.medthority.com/journals/retinal-dystrophy/voretigene-neparvovec-a-review-in-rpe65-mutation-associated-inherited-retinal-dystrophy/2023-05-26T13:07:25+00:00weekly0.7https://www.medthority.com/journals/retinal-dystrophy/retinal-structure-in-rpe65-associated-retinal-dystrophy/2023-05-26T13:06:52+00:00weekly0.7https://www.medthority.com/journals/retinal-dystrophy/imaging-in-inherited-retinal-disorders/2025-01-20T16:11:38+00:00weekly0.7https://www.medthority.com/journals/retinal-dystrophy/cone-dystrophy-with-supernormal-rod-responses-a-rare-kcnv2-gene-variant/2025-01-20T16:12:25+00:00weekly0.7https://www.medthority.com/journals/retinal-dystrophy/a-mutation-in-crx-causing-pigmented-paravenous-retinochoroidal-atrophy/2025-01-20T16:13:05+00:00weekly0.7https://www.medthority.com/journals/retinal-dystrophy/stationary-and-progressive-phenotypes-caused-by-the-p.g90d-mutation-in-rhodopsin-gene2023-05-26T13:05:49+00:00weekly0.7https://www.medthority.com/journals/retinal-dystrophy/gene-correction-recovers-phagocytosis-in-retinal-pigment-epithelium-derived-from-retinitis-pigmentosa-human-induced-pluripotent-stem-cells/2023-05-26T13:05:30+00:00weekly0.7https://www.medthority.com/journals/retinal-dystrophy/retinal-oxygenation-in-inherited-diseases-of-the-retina/2023-05-26T13:05:11+00:00weekly0.7https://www.medthority.com/journals/retinal-dystrophy/rpgr-associated-dystrophies-clinical-genetic-and-histopathological-features/2023-05-26T13:04:56+00:00weekly0.7https://www.medthority.com/journals/macular-degeneration/natural-course-of-acquired-vitelliform-lesions-associated-with-pigment-epithelial-detachments-in-dry-age-related-macular-degeneration/2025-01-28T14:44:54+00:00weekly0.7https://www.medthority.com/journals/macular-degeneration/the-role-of-hypoxia-inducible-factors-in-neovascular-age-related-macular-degeneration-a-gene-therapy-perspective/2021-09-24T07:24:31+00:00weekly0.7https://www.medthority.com/journals/macular-degeneration/longer-acting-treatments-for-neovascular-age-related-macular-degeneration-present-and-future/2021-09-24T07:24:30+00:00weekly0.7https://www.medthority.com/journals/macular-degeneration/influence-of-pigment-epithelial-detachment-on-visual-acuity-in-neovascular-age-related-macular-degeneration/2025-01-28T14:42:53+00:00weekly0.7https://www.medthority.com/journals/macular-degeneration/an-update-on-conbercept-to-treat-wet-age-related-macular-degeneration/2021-09-24T07:24:30+00:00weekly0.7https://www.medthority.com/journals/macular-degeneration/hawk-and-harrier-ninety-six-week-outcomes-from-the-phase-3-trials-of-brolucizumab-for-neovascular-age-related-macular-degeneration/2025-01-28T14:43:55+00:00weekly0.7https://www.medthority.com/journals/macular-degeneration/nanodiagnostics-and-nanotherapeutics-for-age-related-macular-degeneration/2021-09-24T07:24:29+00:00weekly0.7https://www.medthority.com/journals/nasal-polyposis/nasal-polyposis-insights-in-epithelial-mesenchymal-transition-and-differentiation-of-polyp-mesenchymal-stem-cells/2021-09-24T07:25:22+00:00weekly0.7https://www.medthority.com/journals/nasal-polyposis/role-of-epigenetics-in-the-pathogenesis-of-chronic-rhinosinusitis-with-nasal-polyps/2021-09-24T07:25:22+00:00weekly0.7https://www.medthority.com/journals/macular-degeneration/a-systems-biology-approach-towards-understanding-and-treating-non-neovascular-age-related-macular-degeneration/2021-09-24T07:24:31+00:00weekly0.7https://www.medthority.com/journals/macular-degeneration/the-cytoskeleton-of-the-retinal-pigment-epithelium-from-normal-aging-to-age-related-macular-degeneration/2021-09-24T07:24:31+00:00weekly0.7https://www.medthority.com/journals/macular-degeneration/pharmacological-advances-in-the-treatment-of-age-related-macular-degeneration/2021-09-24T07:24:31+00:00weekly0.7https://www.medthority.com/journals/macular-degeneration/the-role-of-lipocalin-2-in-age-related-macular-degeneration-amd/2021-09-24T07:24:30+00:00weekly0.7https://www.medthority.com/journals/macular-degeneration/the-role-of-lymphocytes-and-phagocytes-in-age-related-macular-degeneration-amd/2021-09-24T07:24:30+00:00weekly0.7https://www.medthority.com/journals/macular-degeneration/mitochondrial-dysfunction-in-age-related-macular-degeneration-melatonin-as-a-potential-treatment/2025-01-28T14:41:15+00:00weekly0.7https://www.medthority.com/journals/macular-degeneration/prevalence-and-incidence-of-age-related-macular-degeneration-in-europe-a-systematic-review-and-meta-analysis/2021-09-24T07:24:30+00:00weekly0.7https://www.medthority.com/journals/macular-degeneration/matrix-metalloproteinases-in-age-related-macular-degeneration-amd/2021-09-24T07:24:30+00:00weekly0.7https://www.medthority.com/journals/macular-degeneration/epigenetics-in-age-related-macular-degeneration-new-discoveries-and-future-perspectives/2021-09-24T07:24:30+00:00weekly0.7https://www.medthority.com/journals/macular-degeneration/age-related-macular-degeneration-a-review-of-current-therapies-and-new-treatments/2022-01-04T13:47:49+00:00weekly0.7https://www.medthority.com/journals/macular-degeneration/age-related-macular-degeneration-therapy-a-review/2025-01-28T16:02:12+00:00weekly0.7https://www.medthority.com/journals/macular-degeneration/neovascular-age-related-macular-degeneration-therapeutic-management-and-new-upcoming-approaches/2021-09-24T07:24:30+00:00weekly0.7https://www.medthority.com/journals/macular-degeneration/nanotechnology-revolutionising-the-delivery-of-drugs-to-treat-age-related-macular-degeneration/2025-01-28T14:42:00+00:00weekly0.7https://www.medthority.com/journals/macular-degeneration/gene-therapy-for-neovascular-age-related-macular-degeneration-rationale-clinical-trials-and-future-directions/2021-09-24T07:24:30+00:00weekly0.7https://www.medthority.com/journals/macular-degeneration/effects-of-lutein-supplementation-in-age-related-macular-degeneration/2021-09-24T07:24:31+00:00weekly0.7https://www.medthority.com/journals/nasal-polyposis/therapeutic-antibodies-for-nasal-polyposis-treatment-where-are-we-headed/2026-02-02T09:17:52+00:00weekly0.7https://www.medthority.com/journals/nasal-polyposis/montelukast-has-no-impact-on-the-systemic-production-of-tgf-1-in-patients-with-nasal-polyposis-associated-with-aspirin-intolerance/2021-09-24T07:25:22+00:00weekly0.7https://www.medthority.com/journals/nasal-polyposis/targetable-pathogenic-mechanisms-in-nasal-polyposis/2025-01-30T13:06:02+00:00weekly0.7https://www.medthority.com/journals/nasal-polyposis/effect-of-oral-steroids-on-olfactory-function-in-chronic-rhinosinusitis-with-nasal-polyps/2021-09-24T07:25:22+00:00weekly0.7https://www.medthority.com/journals/nasal-polyposis/systematic-literature-review-of-the-epidemiology-and-clinical-burden-of-chronic-rhinosinusitis-with-nasal-polyposis/2025-01-30T09:22:29+00:00weekly0.7https://www.medthority.com/journals/nasal-polyposis/monoclonal-antibodies-for-the-treatment-of-chronic-rhinosinusitis-with-nasal-polyposis-a-systematic-review/2026-02-02T10:05:18+00:00weekly0.7https://www.medthority.com/journals/nasal-polyposis/efficacy-and-safety-of-omalizumab-in-nasal-polyposis-2-randomized-phase-3-trials/2025-01-30T09:21:27+00:00weekly0.7https://www.medthority.com/journals/nasal-polyposis/effectiveness-of-omalizumab-in-severe-allergic-asthma-and-nasal-polyposis-a-real-life-study/2021-09-24T07:25:23+00:00weekly0.7https://www.medthority.com/journals/nasal-polyposis/dupilumab-improves-upper-and-lower-airway-disease-control-in-chronic-rhinosinusitis-with-nasal-polyps-and-asthma/2025-01-28T14:10:18+00:00weekly0.7https://www.medthority.com/journals/nasal-polyposis/chronic-rhinosinusitis-with-nasal-polyps-in-older-adults-clinical-presentation-pathophysiology-and-comorbidity/2021-09-24T07:25:23+00:00weekly0.7https://www.medthority.com/journals/nasal-polyposis/the-role-of-epigenetics-in-the-chronic-sinusitis-with-nasal-polyp/2021-09-24T07:25:23+00:00weekly0.7https://www.medthority.com/journals/nasal-polyposis/a-critical-look-at-the-efficacy-and-costs-of-biologic-therapy-for-chronic-rhinosinusitis-with-nasal-polyposis/2026-01-26T09:25:04+00:00weekly0.7https://www.medthority.com/journals/nasal-polyposis/the-efficiency-of-routine-histopathological-examination-for-bilateral-nasal-polyposis/2025-01-28T14:22:19+00:00weekly0.7https://www.medthority.com/journals/nasal-polyposis/chronic-rhinosinusitis-with-nasal-polyps-targeting-ige-with-anti-ige-omalizumab-therapy/2026-02-02T10:52:22+00:00weekly0.7https://www.medthority.com/journals/nasal-polyposis/effects-of-omalizumab-treatment-in-patients-with-recalcitrant-nasal-polyposis-and-mild-asthma-a-multicenter-retrospective-study/2025-01-28T14:58:17+00:00weekly0.7https://www.medthority.com/journals/ovarian-cancer/the-prevalence-risk-factors-and-prognostic-value-of-venous-thromboembolism-in-ovarian-cancer-patients-receiving-chemotherapy-a-systematic-review-and-meta-analysis/2021-09-24T07:27:18+00:00weekly0.7https://www.medthority.com/journals/ovarian-cancer/ovarian-cancer-risk-in-relation-to-blood-lipid-levels-and-hyperlipidemia-a-systematic-review-and-meta-analysis-of-observational-epidemiologic-studies/2025-01-28T14:14:59+00:00weekly0.7https://www.medthority.com/journals/ovarian-cancer/parp-inhibitors-as-maintenance-therapy-in-newly-diagnosed-advanced-ovarian-cancer-a-meta-analysis/2025-01-28T14:14:04+00:00weekly0.7https://www.medthority.com/journals/ovarian-cancer/risk-of-fatigue-with-parp-inhibitors-in-cancer-patients-a-systematic-review-and-meta-analysis-of-29-phase-iiiii-randomized-controlled-trials/2025-01-28T14:13:04+00:00weekly0.7https://www.medthority.com/journals/ovarian-cancer/randomized-phase-ii-trial-of-nivolumab-versus-nivolumab-and-ipilimumab-for-recurrent-or-persistent-ovarian-cancer-an-nrg-oncology-study/2025-01-27T16:15:10+00:00weekly0.7https://www.medthority.com/journals/ovarian-cancer/final-overall-survival-os-results-from-solo2engot-ov21-a-phase-iii-trial-assessing-maintenance-olaparib-in-patients-pts-with-platinum-sensitive-relapsed-ovarian-cancer-and-a-brca-mutation/2025-01-28T14:21:25+00:00weekly0.7https://www.medthority.com/journals/ovarian-cancer/adavosertib-plus-gemcitabine-for-platinum-resistant-or-platinum-refractory-recurrent-ovarian-cancer-a-double-blind-randomised-placebo-controlled-phase-2-trial/2025-01-27T16:16:12+00:00weekly0.7https://www.medthority.com/journals/ovarian-cancer/modified-intestinal-isolation-bag-as-promising-tool-in-promoting-bowel-resumption-after-ovarian-cancer-cytoreductive-surgery-a-randomized-clinical-trial/2021-09-24T07:27:17+00:00weekly0.7https://www.medthority.com/journals/systemic-lupus-erythematosus/association-of-systemic-lupus-erythematosus-with-hearing-loss-a-systemic-review-and-meta-analysis/2021-09-24T07:28:47+00:00weekly0.7https://www.medthority.com/journals/systemic-lupus-erythematosus/systematic-review-and-meta-analysis-of-hpv-vaccination-in-women-with-systemic-lupus-erythematosus-sle/2025-01-30T11:42:47+00:00weekly0.7https://www.medthority.com/journals/systemic-lupus-erythematosus/maternal-and-fetal-complications-associated-with-systemic-lupus-erythematosus-an-updated-meta-analysis-of-the-most-recent-studies-2017-2019/2025-01-30T12:19:09+00:00weekly0.7https://www.medthority.com/journals/systemic-lupus-erythematosus/risk-factors-for-mortality-of-diffuse-alveolar-hemorrhage-in-systemic-lupus-erythematosus-a-systematic-review-and-meta-analysis/2021-09-24T07:28:47+00:00weekly0.7https://www.medthority.com/journals/systemic-lupus-erythematosus/the-risk-of-infections-in-adult-patients-with-systemic-lupus-erythematosus-systematic-review-and-meta-analysis/2021-09-24T07:28:47+00:00weekly0.7https://www.medthority.com/journals/systemic-lupus-erythematosus/low-dose-glucocorticoid-should-be-withdrawn-or-continued-in-systemic-lupus-erythematosus-a-systematic-review-and-meta-analysis-on-risk-of-flare-and-damage-accrual/2021-09-24T07:28:47+00:00weekly0.7https://www.medthority.com/journals/systemic-lupus-erythematosus/the-association-between-interleukin-6-gene-polymorphisms-and-risk-of-systemic-lupus-erythematosus-a-meta-analysis-with-trial-sequential-analysis/2025-01-30T11:41:41+00:00weekly0.7https://www.medthority.com/journals/systemic-lupus-erythematosus/diagnostic-value-of-tweak-for-predicting-active-lupus-nephritis-in-patients-with-systemic-lupus-erythematosus-a-systematic-review-and-meta-analysis/2025-01-28T15:58:20+00:00weekly0.7https://www.medthority.com/journals/systemic-lupus-erythematosus/anifrolumab-a-monoclonal-antibody-to-the-type-i-interferon-receptor-subunit-1-for-the-treatment-of-systemic-lupus-erythematosus-an-overview-from-clinical-trials/2025-01-28T16:00:26+00:00weekly0.7https://www.medthority.com/journals/systemic-lupus-erythematosus/pharmacokinetics-pharmacodynamics-and-safety-of-subcutaneous-anifrolumab-in-patients-with-systemic-lupus-erythematosus-active-skin-disease-and-high-type-i-interferon-gene-signature-a-multicentre-randomised-double-blind-placebo-controlled-phase-2/2025-01-30T11:40:01+00:00weekly0.7https://www.medthority.com/journals/nasal-polyposis/mir-142-3p-regulates-inflammatory-response-by-contributing-to-increased-tnf--in-chronic-rhinosinusitis-with-nasal-polyposis/2025-01-28T14:16:29+00:00weekly0.7https://www.medthority.com/journals/nasal-polyposis/association-of-toll-like-receptor-polymorphisms-with-nasal-polyposis/2025-01-28T14:15:44+00:00weekly0.7https://www.medthority.com/journals/nasal-polyposis/eosinophils-in-the-field-of-nasal-polyposis-towards-a-better-understanding-of-biologic-therapies/2021-09-24T07:25:24+00:00weekly0.7https://www.medthority.com/journals/nasal-polyposis/open-prospective-multicenter-study-on-postoperative-intranasal-phototherapy-in-nasal-polyposis/2021-09-24T07:25:24+00:00weekly0.7https://www.medthority.com/journals/nasal-polyposis/ethmoid-to-maxillary-opacification-ratio-a-predictor-of-postoperative-olfaction-and-outcomes-in-nasal-polyposis/2025-01-28T14:22:57+00:00weekly0.7https://www.medthority.com/journals/primary-hyperoxaluria/clinical-characterization-of-primary-hyperoxaluria-type-3-in-comparison-to-types-1-and-2-a-retrospective-cohort-study/2021-09-24T07:27:35+00:00weekly0.7https://www.medthority.com/journals/primary-hyperoxaluria/plasma-oxalate-and-egfr-are-correlated-in-primary-hyperoxaluria-patients-with-maintained-kidney-function-data-from-three-placebo-controlled-studies/2021-09-24T07:27:35+00:00weekly0.7https://www.medthority.com/journals/primary-hyperoxaluria/primary-hyperoxaluria-diagnosed-late-in-systemic-oxalosis-stage/2021-09-24T07:27:35+00:00weekly0.7https://www.medthority.com/journals/primary-hyperoxaluria/is-stiripentol-truly-effective-for-treating-primary-hyperoxaluria/2021-09-24T07:27:35+00:00weekly0.7https://www.medthority.com/journals/nasal-polyposis/nasal-polyposis-or-chronic-olfactory-rhinitis/2021-09-24T07:25:25+00:00weekly0.7https://www.medthority.com/journals/nasal-polyposis/nasal-polyposis-pathophysiology-endotype-and-phenotype-open-issues/2021-09-24T07:25:25+00:00weekly0.7https://www.medthority.com/journals/nasal-polyposis/will-we-ever-cure-nasal-polyps/2025-01-28T14:30:32+00:00weekly0.7https://www.medthority.com/journals/nasal-polyposis/intraoperative-bacterial-analysis-in-nasal-polyposis-clinical-and-functional-impact/2021-09-24T07:25:25+00:00weekly0.7https://www.medthority.com/journals/nasal-polyposis/the-role-of-staphylococcus-aureus-in-patients-with-chronic-sinusitis-and-nasal-polyposis/2021-09-24T07:25:24+00:00weekly0.7https://www.medthority.com/journals/nasal-polyposis/efficacy-and-safety-of-dupilumab-in-patients-with-severe-chronic-rhinosinusitis-with-nasal-polyps-liberty-np-sinus-24-and-liberty-np-sinus-52-results-from-two-multicentre-randomised-double-blind-placebo-controlled-parallel-group-phase-3-trials/2025-01-28T15:01:17+00:00weekly0.7https://www.medthority.com/journals/nasal-polyposis/dupilumab-improves-health-related-quality-of-life-in-patients-with-chronic-rhinosinusitis-with-nasal-polyposis/2025-01-28T15:01:56+00:00weekly0.7https://www.medthority.com/journals/nasal-polyposis/role-of-biologics-in-chronic-rhinosinusitis-with-nasal-polyposis-state-of-the-art-review/2025-01-28T15:02:36+00:00weekly0.7https://www.medthority.com/journals/ovarian-cancer/co-expression-patterns-of-chimeric-antigen-receptor-car-t-cell-target-antigens-in-primary-and-recurrent-ovarian-cancer/2025-01-23T13:29:53+00:00weekly0.7https://www.medthority.com/journals/ovarian-cancer/genetically-predicted-circulating-protein-biomarkers-and-ovarian-cancer-risk/2025-01-14T09:16:46+00:00weekly0.7https://www.medthority.com/journals/ovarian-cancer/candidate-rna-biomarkers-in-biofluids-for-early-diagnosis-of-ovarian-cancer-a-systematic-review/2025-01-23T13:39:48+00:00weekly0.7https://www.medthority.com/journals/ovarian-cancer/current-ovarian-cancer-maintenance-strategies-and-promising-new-developments/2021-09-24T07:27:21+00:00weekly0.7https://www.medthority.com/journals/ovarian-cancer/efficacy-of-cancer-vaccines-in-selected-gynaecological-breast-and-ovarian-cancers-a-20-year-systematic-review-and-meta-analysis/2025-01-28T15:03:26+00:00weekly0.7https://www.medthority.com/journals/ovarian-cancer/potential-and-mechanism-of-mebendazole-for-treatment-and-maintenance-of-ovarian-cancer/2025-01-24T09:56:05+00:00weekly0.7https://www.medthority.com/journals/ovarian-cancer/clinical-perspectives-of-bet-inhibition-in-ovarian-cancer/2021-09-24T07:27:21+00:00weekly0.7https://www.medthority.com/journals/ovarian-cancer/the-current-landscape-of-molecular-profiling-in-the-treatment-of-epithelial-ovarian-cancer/2025-01-24T09:57:46+00:00weekly0.7https://www.medthority.com/journals/ovarian-cancer/nanotechnology-in-ovarian-cancer-diagnosis-and-treatment/2021-09-24T07:27:21+00:00weekly0.7https://www.medthority.com/journals/ovarian-cancer/emerging-role-of-immune-checkpoint-inhibitors-in-the-treatment-of-ovarian-cancer/2025-01-28T14:25:42+00:00weekly0.7https://www.medthority.com/journals/ovarian-cancer/newly-diagnosed-ovarian-cancer-which-first-line-treatment/2025-01-23T13:20:35+00:00weekly0.7https://www.medthority.com/journals/ovarian-cancer/therapeutic-options-following-second-line-platinum-based-chemotherapy-in-patients-with-recurrent-ovarian-cancer-comparison-of-active-surveillance-and-maintenance-treatment/2025-01-23T13:23:13+00:00weekly0.7https://www.medthority.com/journals/ovarian-cancer/treatment-of-epithelial-ovarian-cancer/2024-03-07T12:59:21+00:00weekly0.7https://www.medthority.com/journals/ovarian-cancer/overcoming-parp-inhibitor-resistance-in-ovarian-cancer-what-are-the-most-promising-strategies/2021-09-24T07:27:19+00:00weekly0.7https://www.medthority.com/journals/ovarian-cancer/targeting-the-pi3k-pathway-and-dna-damage-response-as-a-therapeutic-strategy-in-ovarian-cancer/2025-01-24T10:14:41+00:00weekly0.7https://www.medthority.com/journals/ovarian-cancer/epigenetic-attire-in-ovarian-cancer-the-emperors-new-clothes/2021-09-24T07:27:19+00:00weekly0.7https://www.medthority.com/journals/ovarian-cancer/emerging-drugs-for-the-treatment-of-ovarian-cancer-a-focused-review-of-parp-inhibitors/2025-01-28T14:24:13+00:00weekly0.7https://www.medthority.com/journals/ovarian-cancer/genetic-testing-for-epithelial-ovarian-cancer/2021-09-24T07:27:19+00:00weekly0.7https://www.medthority.com/journals/ovarian-cancer/targeting-tumor-microenvironment-in-ovarian-cancer-premise-and-promise/2021-09-24T07:27:19+00:00weekly0.7https://www.medthority.com/journals/ovarian-cancer/endometriosis-and-risk-of-ovarian-cancer-what-do-we-know/2021-09-24T07:27:18+00:00weekly0.7https://www.medthority.com/journals/ovarian-cancer/the-forefront-of-ovarian-cancer-therapy-update-on-parp-inhibitors/2025-01-23T13:26:49+00:00weekly0.7https://www.medthority.com/journals/ovarian-cancer/low-grade-serous-ovarian-cancer-state-of-the-science/2025-01-23T13:28:13+00:00weekly0.7https://www.medthority.com/journals/ovarian-cancer/ovarian-cancer-screening-current-status-and-future-directions/2021-09-24T07:27:18+00:00weekly0.7https://www.medthority.com/journals/ovarian-cancer/veliparib-in-ovarian-cancer-a-new-synthetically-lethal-therapeutic-approach/2021-09-24T07:27:18+00:00weekly0.7https://www.medthority.com/journals/mood-disorders/european-clinical-practice-guidelines-for-depression-in-adults-are-they-good-enough/2021-09-24T07:25:06+00:00weekly0.7https://www.medthority.com/journals/systemic-lupus-erythematosus/long-term-outcomes-in-systemic-lupus-erythematosus-trends-over-time-and-major-contributors/2021-09-24T07:28:47+00:00weekly0.7https://www.medthority.com/journals/systemic-lupus-erythematosus/pulmonary-complications-of-systemic-lupus-erythematosus/2021-09-24T07:28:47+00:00weekly0.7https://www.medthority.com/journals/systemic-lupus-erythematosus/neurological-complications-in-patients-with-systemic-lupus-erythematosus/2021-09-24T07:28:47+00:00weekly0.7https://www.medthority.com/journals/systemic-lupus-erythematosus/ifn--kinoid-in-systemic-lupus-erythematosus-results-from-a-phase-iib-randomised-placebo-controlled-study/2021-09-24T07:28:48+00:00weekly0.7https://www.medthority.com/journals/systemic-lupus-erythematosus/a-review-and-meta-analysis-of-anti-ribosomal-p-autoantibodies-in-systemic-lupus-erythematosus/2021-09-24T07:28:48+00:00weekly0.7https://www.medthority.com/journals/systemic-lupus-erythematosus/t-cell-metabolism-new-insights-in-systemic-lupus-erythematosus-pathogenesis-and-therapy/2021-09-24T07:28:48+00:00weekly0.7https://www.medthority.com/journals/systemic-lupus-erythematosus/protecting-the-kidney-in-systemic-lupus-erythematosus-from-diagnosis-to-therapy/2021-09-24T07:28:48+00:00weekly0.7https://www.medthority.com/journals/systemic-lupus-erythematosus/update-on-antimalarials-and-systemic-lupus-erythematosus/2025-01-28T14:59:05+00:00weekly0.7https://www.medthority.com/journals/systemic-lupus-erythematosus/systemic-lupus-erythematosus-sle-therapy-the-old-and-the-new/2021-09-24T07:28:49+00:00weekly0.7https://www.medthority.com/journals/systemic-lupus-erythematosus/state-of-the-art-treatment-of-systemic-lupus-erythematosus/2025-01-28T14:24:56+00:00weekly0.7https://www.medthority.com/journals/systemic-lupus-erythematosus/non-pharmacologic-therapies-for-systemic-lupus-erythematosus/2025-01-28T15:05:06+00:00weekly0.7https://www.medthority.com/journals/systemic-lupus-erythematosus/novel-paradigms-in-systemic-lupus-erythematosus/2025-01-28T14:56:04+00:00weekly0.7https://www.medthority.com/journals/systemic-lupus-erythematosus/evaluation-of-belimumab-treatment-in-patients-with-systemic-lupus-erythematosus-in-a-clinical-practice-setting-results-from-a-24-month-observe-study-in-argentina/2025-01-28T15:05:46+00:00weekly0.7https://www.medthority.com/journals/systemic-lupus-erythematosus/sexual-dimorphism-in-sle-above-and-beyond-sex-hormones/2025-01-28T14:57:28+00:00weekly0.7https://www.medthority.com/journals/systemic-lupus-erythematosus/management-strategies-and-future-directions-for-systemic-lupus-erythematosus-in-adults/2025-01-24T09:55:08+00:00weekly0.7https://www.medthority.com/journals/systemic-lupus-erythematosus/new-insights-into-the-role-of-antinuclear-antibodies-in-systemic-lupus-erythematosus/2021-09-24T07:28:48+00:00weekly0.7https://www.medthority.com/journals/systemic-lupus-erythematosus/targeted-biologic-therapy-for-systemic-lupus-erythematosus-emerging-pathways-and-drug-pipeline/2021-09-24T07:28:48+00:00weekly0.7https://www.medthority.com/journals/systemic-lupus-erythematosus/th1-th2-and-th17-cytokines-in-systemic-lupus-erythematosus/2025-01-28T14:12:08+00:00weekly0.7https://www.medthority.com/journals/systemic-lupus-erythematosus/the-epigenetics-of-lupus-erythematosus/2021-09-24T07:28:48+00:00weekly0.7https://www.medthority.com/journals/mood-disorders/patient-reported-depression-severity-and-cognitive-symptoms-as-determinants-of-functioning-in-patients-with-major-depressive-disorder-a-secondary-analysis-of-the-2-year-prospective-perform-study/2021-09-24T07:25:05+00:00weekly0.7https://www.medthority.com/journals/mood-disorders/vagus-nerve-stimulation-for-treatment-resistant-depression-case-series-of-six-patients---retrospective-efficacy-and-safety-observation-after-one-year-follow-up/2021-09-24T07:25:05+00:00weekly0.7https://www.medthority.com/journals/mood-disorders/research-progress-on-classical-traditional-chinese-medicine-jieyu-pills-in-the-treatment-of-depression/2021-09-24T07:25:05+00:00weekly0.7https://www.medthority.com/journals/mood-disorders/metabolic-risk-factors-and-cardiovascular-safety-in-ketamine-use-for-treatment-resistant-depression/2021-09-24T07:25:05+00:00weekly0.7https://www.medthority.com/journals/mood-disorders/desynchronized-functional-activities-between-brain-white-and-gray-matter-in-major-depression-disorder/2025-01-27T15:57:11+00:00weekly0.7https://www.medthority.com/journals/mood-disorders/modulation-of-amygdala-reactivity-following-rapidly-acting-interventions-for-major-depression/2025-01-27T15:56:28+00:00weekly0.7https://www.medthority.com/journals/mood-disorders/right-unilateral-versus-bilateral-formula-based-electroconvulsive-therapy-in-the-treatment-of-major-depression-in-elderly-patients-a-randomised-open-label-pilot-controlled-trial/2025-01-28T14:26:32+00:00weekly0.7https://www.medthority.com/journals/mood-disorders/at-baseline-patients-treated-with-esketamine-have-higher-burden-of-disease-than-other-patients-with-treatment-resistant-depression-learnings-from-a-population-based-study/2025-01-30T09:13:19+00:00weekly0.7https://www.medthority.com/journals/mood-disorders/benefit-risk-assessment-of-esketamine-nasal-spray-vs.-placebo-in-treatment-resistant-depression2025-01-30T12:37:45+00:00weekly0.7https://www.medthority.com/journals/mood-disorders/efficacy-and-safety-of-tipepidine-as-adjunctive-therapy-in-major-depressive-disorder-a-randomized-double-blind-placebo-controlled-clinical-trial/2025-01-30T12:33:40+00:00weekly0.7https://www.medthority.com/journals/mood-disorders/serum-level-of-soluble-interleukin-6-receptor-is-a-useful-biomarker-for-identification-of-treatment-resistant-major-depressive-disorder/2025-01-30T12:32:34+00:00weekly0.7https://www.medthority.com/journals/mood-disorders/genetic-determinants-of-circulating-vegf-levels-in-major-depressive-disorder-and-electroconvulsive-therapy-response/2025-01-30T12:31:32+00:00weekly0.7https://www.medthority.com/journals/mood-disorders/clinically-meaningful-changes-on-depressive-symptom-measures-and-patient-reported-outcomes-in-patients-with-treatment-resistant-depression/2025-01-27T15:58:47+00:00weekly0.7https://www.medthority.com/journals/mood-disorders/continuation-phase-treatment-outcomes-for-switching-combining-or-augmenting-strategies-for-treatment-resistant-major-depressive-disorder-a-vast-d-report/2025-01-27T15:58:07+00:00weekly0.7https://www.medthority.com/journals/mood-disorders/efficacy-and-safety-of-olanzapinefluoxetine-combination-in-the-treatment-of-treatment-resistant-depression-a-meta-analysis-of-randomized-controlled-trials/2021-09-24T07:25:08+00:00weekly0.7https://www.medthority.com/journals/mood-disorders/electroconvulsive-therapy-ect-vs.-ketamine-in-patients-with-treatment-resistant-depression-the-elekt-d-study-protocol2021-09-24T07:25:08+00:00weekly0.7https://www.medthority.com/journals/mood-disorders/hormonal-treatments-for-major-depressive-disorder-state-of-the-art/2021-09-24T07:25:07+00:00weekly0.7https://www.medthority.com/journals/mood-disorders/accelerated-tms-for-depression-a-systematic-review-and-meta-analysis/2021-09-24T07:25:06+00:00weekly0.7https://www.medthority.com/journals/mood-disorders/esketamine-for-treatment-resistant-depression-a-trick-of-smoke-and-mirrors/2021-09-24T07:25:06+00:00weekly0.7https://www.medthority.com/journals/mood-disorders/a-preliminary-study-of-resting-brain-metabolism-in-treatment-resistant-depression-before-and-after-treatment-with-olanzapine-fluoxetine-combination/2021-09-24T07:25:08+00:00weekly0.7https://www.medthority.com/journals/mood-disorders/the-cellular-and-molecular-basis-of-major-depressive-disorder-towards-a-unified-model-for-understanding-clinical-depression/2021-09-24T07:25:08+00:00weekly0.7https://www.medthority.com/journals/mood-disorders/brexpiprazole-for-treatment-resistant-major-depressive-disorder/2025-01-27T16:01:28+00:00weekly0.7https://www.medthority.com/journals/mood-disorders/esketamine-for-treatment-resistant-depression/2025-01-24T10:55:40+00:00weekly0.7https://www.medthority.com/journals/mood-disorders/management-of-treatment-resistant-depression-challenges-and-strategies/2021-09-24T07:25:08+00:00weekly0.7https://www.medthority.com/journals/mood-disorders/treatment-resistant-depression-and-peripheral-c-reactive-protein/2021-09-24T07:25:08+00:00weekly0.7https://www.medthority.com/journals/solid-organ-transplantation/optnsrtr-2017-annual-data-report-liver/2025-01-27T16:06:58+00:00weekly0.7https://www.medthority.com/journals/solid-organ-transplantation/combined-and-sequential-liver-kidney-transplantation-in-children/2021-09-24T07:28:43+00:00weekly0.7https://www.medthority.com/journals/hepatic-liver-cancer/neoplastic-disease-after-liver-transplantation-focus-on-de-novo-neoplasms/2021-09-24T07:23:36+00:00weekly0.7https://www.medthority.com/journals/calculus-of-urinary-tract/gut-microbiome-and-kidney-stone-disease-not-just-an-oxalobacter-story/2025-01-24T10:47:30+00:00weekly0.7https://www.medthority.com/journals/primary-hyperoxaluria/specific-inhibition-of-hepatic-lactate-dehydrogenase-reduces-oxalate-production-in-mouse-models-of-primary-hyperoxaluria/2025-01-24T12:11:13+00:00weekly0.7https://www.medthority.com/journals/primary-hyperoxaluria/recovery-from-dialysis-in-patients-with-primary-hyperoxaluria-type-1-treated-with-pyridoxine-a-report-of-3-cases/2025-01-24T12:02:51+00:00weekly0.7https://www.medthority.com/journals/mood-disorders/augmentation-therapies-for-treatment-resistant-depression-systematic-review-and-meta-analysis/2021-09-24T07:25:09+00:00weekly0.7https://www.medthority.com/journals/mood-disorders/pharmacological-treatments-for-patients-with-treatment-resistant-depression/2021-09-24T07:25:09+00:00weekly0.7https://www.medthority.com/journals/mood-disorders/efficacy-of-repetitive-transcranial-magnetic-stimulation-in-treatment-resistant-depression-the-evidence-thus-far/2024-03-08T13:55:20+00:00weekly0.7https://www.medthority.com/journals/mood-disorders/defining-treatment-resistant-depression/2025-01-24T10:54:49+00:00weekly0.7https://www.medthority.com/journals/mood-disorders/effectiveness-of-psychotherapy-for-treatment-resistant-depression-a-meta-analysis-and-meta-regression/2021-09-24T07:25:09+00:00weekly0.7https://www.medthority.com/journals/primary-hyperoxaluria/multiple-mechanisms-of-action-of-pyridoxine-in-primary-hyperoxaluria-type-1/2021-09-24T07:27:36+00:00weekly0.7https://www.medthority.com/journals/primary-hyperoxaluria/a-20-year-experience-of-combined-liverkidney-transplantation-for-primary-hyperoxaluria-ph1-the-european-ph1-transplant-registry-experience-1984-2004/2021-09-24T07:27:36+00:00weekly0.7https://www.medthority.com/journals/calculus-of-urinary-tract/long-term-adherence-to-medications-in-secondary-prevention-of-urinary-tract-stones/2025-01-27T15:34:22+00:00weekly0.7https://www.medthority.com/journals/primary-hyperoxaluria/primary-hyperoxaluria-type-1-practical-and-ethical-issues/2021-09-24T07:27:37+00:00weekly0.7https://www.medthority.com/journals/primary-hyperoxaluria/importance-of-assessing-compliance-with-conservative-treatment-of-primary-hyperoxaluria-type-1-a-case-report-of-a-patient-with-i244tc.969-3cg-mutation2025-01-27T16:02:11+00:00weekly0.7https://www.medthority.com/journals/calculus-of-urinary-tract/nephrolithiasis/2021-09-24T07:20:38+00:00weekly0.7https://www.medthority.com/journals/primary-hyperoxaluria/primary-and-secondary-hyperoxaluria-understanding-the-enigma/2021-09-24T07:27:36+00:00weekly0.7https://www.medthority.com/journals/primary-hyperoxaluria/an-update-on-primary-hyperoxaluria/2021-09-24T07:27:36+00:00weekly0.7https://www.medthority.com/journals/primary-hyperoxaluria/transplantation-for-primary-hyperoxaluria-type-1-designing-new-strategies-in-the-era-of-promising-therapeutic-perspectives/2025-01-24T10:06:25+00:00weekly0.7https://www.medthority.com/journals/primary-hyperoxaluria/radiological-and-histological-improvement-of-oxalate-osteopathy-after-combined-liver-kidney-transplantation-in-primary-hyperoxaluria-type-1/2021-09-24T07:27:37+00:00weekly0.7https://www.medthority.com/journals/primary-hyperoxaluria/oxalate-kinetics-and-reversal-of-the-complications-after-orthotopic-liver-transplantation-in-a-patient-with-primary-hyperoxalosis-type-1-awaiting-renal-transplantation/2021-09-24T07:27:37+00:00weekly0.7https://www.medthority.com/journals/primary-hyperoxaluria/end-points-for-clinical-trials-in-primary-hyperoxaluria/2025-01-27T16:08:24+00:00weekly0.7https://www.medthority.com/journals/primary-hyperoxaluria/primary-hyperoxaluria-the-patient-and-caregiver-perspective/2025-01-27T16:07:34+00:00weekly0.7https://www.medthority.com/journals/primary-hyperoxaluria/oxalate-quantification-in-hemodialysate-to-assess-dialysis-adequacy-for-primary-hyperoxaluria/2021-09-24T07:27:37+00:00weekly0.7https://www.medthority.com/journals/primary-hyperoxaluria/clinical-spectrum-of-primary-hyperoxaluria-type-1-experience-of-a-tertiary-center/2021-09-24T07:27:37+00:00weekly0.7https://www.medthority.com/journals/primary-hyperoxaluria/plasma-oxalate-in-relation-to-egfr-in-patients-with-primary-hyperoxaluria-enteric-hyperoxaluria-and-urinary-stone-disease/2021-09-24T07:27:37+00:00weekly0.7https://www.medthority.com/journals/mood-disorders/the-genetics-of-treatment-resistant-depression-a-critical-review-and-future-perspectives/2021-09-24T07:25:09+00:00weekly0.7https://www.medthority.com/journals/mood-disorders/inflammatory-markers-and-treatment-outcome-in-treatment-resistant-depression-a-systematic-review/2021-09-24T07:25:09+00:00weekly0.7https://www.medthority.com/journals/primary-hyperoxaluria/primary-hyperoxaluria-type-1/2021-09-24T07:27:38+00:00weekly0.7https://www.medthority.com/journals/calculus-of-urinary-tract/a-diagnosticians-field-guide-to-crystalline-nephropathies/2021-09-24T07:20:38+00:00weekly0.7https://www.medthority.com/journals/calculus-of-urinary-tract/oxalate-toxicity-in-renal-cells/2024-03-08T13:06:32+00:00weekly0.7https://www.medthority.com/journals/primary-hyperoxaluria/recent-advances-in-the-identification-and-management-of-inherited-hyperoxalurias/2021-09-24T07:27:37+00:00weekly0.7https://www.medthority.com/journals/primary-hyperoxaluria/the-ocular-phenotype-in-primary-hyperoxaluria-type-1/2025-01-24T10:59:49+00:00weekly0.7https://www.medthority.com/journals/primary-hyperoxaluria/outcomes-of-liver-kidney-transplantation-in-patients-with-primary-hyperoxaluria-an-analysis-of-the-scientific-registry-of-transplant-recipients-database/2021-09-24T07:27:38+00:00weekly0.7https://www.medthority.com/journals/primary-hyperoxaluria/plasma-oxalate-as-a-predictor-of-kidney-function-decline-in-a-primary-hyperoxaluria-cohort/2021-09-24T07:27:38+00:00weekly0.7https://www.medthority.com/journals/primary-hyperoxaluria/structural-and-functional-insights-on-the-roles-of-molecular-chaperones-in-the-mistargeting-and-aggregation-phenotypes-associated-with-primary-hyperoxaluria-type-i/2021-09-24T07:27:38+00:00weekly0.7https://www.medthority.com/journals/primary-hyperoxaluria/molecular-basis-of-primary-hyperoxaluria-clues-to-innovative-treatments/2021-09-24T07:27:40+00:00weekly0.7https://www.medthority.com/journals/primary-hyperoxaluria/targeting-kidney-inflammation-as-a-new-therapy-for-primary-hyperoxaluria/2021-09-24T07:27:39+00:00weekly0.7https://www.medthority.com/journals/primary-hyperoxaluria/clinical-features-of-genetically-confirmed-patients-with-primary-hyperoxaluria-identified-by-clinical-indication-versus-familial-screening/2025-01-24T09:30:11+00:00weekly0.7https://www.medthority.com/journals/primary-hyperoxaluria/primary-hyperoxaluria-imaging-of-renal-oxalosis/2025-01-24T09:38:53+00:00weekly0.7https://www.medthority.com/journals/primary-hyperoxaluria/skin-microvascular-dysfunction-as-an-early-cardiovascular-marker-in-primary-hyperoxaluria-type-i/2021-09-24T07:27:40+00:00weekly0.7https://www.medthority.com/journals/primary-hyperoxaluria/investigational-therapies-for-primary-hyperoxaluria/2025-01-27T16:04:48+00:00weekly0.7https://www.medthority.com/journals/primary-hyperoxaluria/plasma-oxalate-levels-in-primary-hyperoxaluria-type-i-show-significant-intra-individual-variation-and-do-not-correlate-with-kidney-function/2021-09-24T07:27:39+00:00weekly0.7https://www.medthority.com/journals/primary-hyperoxaluria/novel-therapeutic-approaches-for-the-primary-hyperoxalurias/2021-09-24T07:27:39+00:00weekly0.7https://www.medthority.com/journals/primary-hyperoxaluria/effects-of-oxalobacter-formigenes-in-subjects-with-primary-hyperoxaluria-type-1-and-end-stage-renal-disease-a-phase-ii-study/2021-09-24T07:27:39+00:00weekly0.7https://www.medthority.com/journals/covid-19/sars-cov-2-immunity-review-and-applications-to-phase-3-vaccine-candidates/2025-01-30T11:50:03+00:00weekly0.7https://www.medthority.com/journals/covid-19/what-defines-an-efficacious-covid-19-vaccine-a-review-of-the-challenges-assessing-the-clinical-efficacy-of-vaccines-against-sars-cov-2/2025-01-30T14:48:43+00:00weekly0.7https://www.medthority.com/journals/covid-19/broad-and-strong-memory-cd4-and-cd8-t-cells-induced-by-sars-cov-2-in-uk-convalescent-individuals-following-covid-19/2021-09-24T07:22:04+00:00weekly0.7https://www.medthority.com/journals/covid-19/covid-19-a-review-of-the-proposed-pharmacological-treatments/2021-09-24T07:22:04+00:00weekly0.7https://www.medthority.com/journals/covid-19/prevalence-of-phenotypes-of-acute-respiratory-distress-syndrome-in-critically-ill-patients-with-covid-19-a-prospective-observational-study/2025-01-30T14:36:06+00:00weekly0.7https://www.medthority.com/journals/covid-19/lopinavir-ritonavir-in-patients-admitted-to-hospital-with-covid-19-recovery-a-randomised-controlled-open-label-platform-trial/2025-01-30T14:39:39+00:00weekly0.7https://www.medthority.com/journals/covid-19/prospect-of-sars-cov-2-spike-protein-potential-role-in-vaccine-and-therapeutic-development/2021-09-24T07:22:04+00:00weekly0.7https://www.medthority.com/journals/covid-19/safety-and-immunogenicity-of-sars-cov-2-mrna-1273-vaccine-in-older-adults/2025-01-30T11:50:53+00:00weekly0.7https://www.medthority.com/journals/covid-19/repurposed-antiviral-drugs-for-covid-19-interim-who-solidarity-trial-results/2025-01-30T10:25:09+00:00weekly0.7https://www.medthority.com/journals/covid-19/safety-and-immunogenicity-of-chadox1-ncov-19-vaccine-administered-in-a-prime-boost-regimen-in-young-and-old-adults-cov002-a-single-blind-randomised-controlled-phase-23-trial/2025-01-24T10:09:37+00:00weekly0.7https://www.medthority.com/journals/covid-19/physical-distancing-face-masks-and-eye-protection-to-prevent-person-to-person-transmission-of-sars-cov-2-and-covid-19-a-systematic-review-and-meta-analysis/2025-01-24T10:08:45+00:00weekly0.7https://www.medthority.com/journals/covid-19/emerging-pandemic-diseases-how-we-got-to-covid-19/2025-01-24T10:07:53+00:00weekly0.7https://www.medthority.com/journals/covid-19/robust-t-cell-immunity-in-convalescent-individuals-with-asymptomatic-or-mild-covid-19/2025-01-24T10:07:13+00:00weekly0.7https://www.medthority.com/journals/covid-19/clinical-characteristics-and-day-90-outcomes-of-4244-critically-ill-adults-with-covid-19-a-prospective-cohort-study/2021-09-24T07:22:06+00:00weekly0.7https://www.medthority.com/journals/covid-19/effect-of-tocilizumab-vs-usual-care-in-adults-hospitalized-with-covid-19-and-moderate-or-severe-pneumonia-a-randomized-clinical-trial/2021-09-24T07:22:06+00:00weekly0.7https://www.medthority.com/journals/covid-19/effect-of-hydrocortisone-on-21-day-mortality-or-respiratory-support-among-critically-ill-patients-with-covid-19-a-randomized-clinical-trial/2024-03-08T11:43:35+00:00weekly0.7https://www.medthority.com/journals/covid-19/elevated-calprotectin-and-abnormal-myeloid-cell-subsets-discriminate-severe-from-mild-covid-19/2025-01-24T10:11:13+00:00weekly0.7https://www.medthority.com/journals/covid-19/extracorporeal-membrane-oxygenation-for-severe-acute-respiratory-distress-syndrome-associated-with-covid-19-a-retrospective-cohort-study/2025-01-24T10:10:28+00:00weekly0.7https://www.medthority.com/journals/covid-19/transplacental-transmission-of-sars-cov-2-infection/2021-09-24T07:22:05+00:00weekly0.7https://www.medthority.com/journals/covid-19/characteristics-and-outcomes-of-asthmatic-patients-with-covid-19-pneumonia-who-require-hospitalisation/2021-09-24T07:22:05+00:00weekly0.7https://www.medthority.com/journals/venous-thromboembolism-vte/direct-oral-anticoagulants-for-treatment-and-prevention-of-venous-thromboembolism-in-cancer-patients/2024-01-23T14:52:09+00:00weekly0.7https://www.medthority.com/journals/venous-thromboembolism-vte/a-single-center-retrospective-cohort-study-comparing-low-molecular-weight-heparins-to-direct-oral-anticoagulants-for-the-treatment-of-venous-thromboembolism-in-patients-with-cancer---a-real-world-experience/2025-01-23T13:43:44+00:00weekly0.7https://www.medthority.com/journals/venous-thromboembolism-vte/prevention-and-treatment-of-cancer-associated-thrombosis/2024-01-23T14:52:09+00:00weekly0.7https://www.medthority.com/journals/venous-thromboembolism-vte/management-of-cancer-associated-thrombosis-an-evolving-area/2024-01-23T14:52:09+00:00weekly0.7https://www.medthority.com/journals/venous-thromboembolism-vte/direct-oral-anticoagulants-for-the-treatment-of-acute-venous-thromboembolism-associated-with-cancer-a-systematic-review-and-meta-analysis/2024-01-23T14:52:09+00:00weekly0.7https://www.medthority.com/journals/venous-thromboembolism-vte/mechanisms-and-biomarkers-of-cancer-associated-thrombosis/2025-01-23T13:42:57+00:00weekly0.7https://www.medthority.com/journals/venous-thromboembolism-vte/risk-factors-for-cancer-associated-thrombosis-in-patients-undergoing-treatment-with-immune-checkpoint-inhibitors/2024-01-23T14:52:09+00:00weekly0.7https://www.medthority.com/journals/venous-thromboembolism-vte/cancer-associated-thrombosis-in-everyday-practice-perspectives-from-garfield-vte/2024-01-23T14:52:09+00:00weekly0.7https://www.medthority.com/journals/venous-thromboembolism-vte/cosimo-patients-with-active-cancer-changing-to-rivaroxaban-for-the-treatment-and-prevention-of-recurrent-venous-thromboembolism-a-non-interventional-study/2024-01-23T14:52:09+00:00weekly0.7https://www.medthority.com/journals/venous-thromboembolism-vte/direct-oral-anticoagulants-and-cancer-associated-thrombosis-management/2025-01-23T11:22:45+00:00weekly0.7https://www.medthority.com/journals/venous-thromboembolism-vte/cancer-associated-venous-thromboembolism-treatment-and-prevention-with-rivaroxaban/2025-01-23T11:23:36+00:00weekly0.7https://www.medthority.com/journals/venous-thromboembolism-vte/treatment-of-cancer-associated-venous-thromboembolism-12-month-outcomes-of-the-placebo-versus-rivaroxaban-randomization-of-the-select-d-trial-select-d-12m/2025-01-23T13:41:12+00:00weekly0.7https://www.medthority.com/journals/venous-thromboembolism-vte/rivaroxaban-for-thromboprophylaxis-in-high-risk-ambulatory-patients-with-cancer/2025-01-23T13:13:47+00:00weekly0.7https://www.medthority.com/journals/venous-thromboembolism-vte/cancer-associated-thrombosis-the-when-how-and-why/2024-01-23T14:52:09+00:00weekly0.7https://www.medthority.com/journals/venous-thromboembolism-vte/predicting-vte-in-cancer-patients-candidate-biomarkers-and-risk-assessment-models/2024-01-23T14:52:09+00:00weekly0.7https://www.medthority.com/journals/venous-thromboembolism-vte/prevention-of-venous-thromboembolism-in-patients-with-cancer-with-direct-oral-anticoagulants-a-systematic-review-and-meta-analysis/2025-01-23T11:21:07+00:00weekly0.7https://www.medthority.com/journals/venous-thromboembolism-vte/development-and-validation-of-a-risk-score-for-prediction-of-venous-thromboembolism-in-patients-with-lung-cancer/2025-01-23T11:22:39+00:00weekly0.7https://www.medthority.com/journals/venous-thromboembolism-vte/evaluation-of-unmet-clinical-needs-in-prophylaxis-and-treatment-of-venous-thromboembolism-in-high-risk-patient-groups-cancer-and-critically-ill/2024-01-23T14:52:09+00:00weekly0.7https://www.medthority.com/journals/venous-thromboembolism-vte/the-khorana-score-for-prediction-of-venous-thromboembolism-in-cancer-patients-a-systematic-review-and-meta-analysis/2024-01-23T14:52:09+00:00weekly0.7https://www.medthority.com/journals/venous-thromboembolism-vte/apixaban-to-prevent-venous-thromboembolism-in-patients-with-cancer/2025-01-23T13:12:04+00:00weekly0.7https://www.medthority.com/journals/venous-thromboembolism-vte/apixaban-for-the-treatment-of-venous-thromboembolism-associated-with-cancer/2025-01-23T13:10:53+00:00weekly0.7https://www.medthority.com/journals/shingles/a-systematic-review-of-herpes-zoster-incidence-and-consensus-recommendations-on-vaccination-in-adult-patients-on-systemic-therapy-for-psoriasis-or-psoriatic-arthritis-from-the-medical-board-of-the-national-psoriasis-foundation/2025-01-28T16:01:25+00:00weekly0.7https://www.medthority.com/journals/shingles/shingrix-for-herpes-zoster-a-review/2021-09-24T07:28:31+00:00weekly0.7https://www.medthority.com/journals/shingles/recurrent-herpes-zoster-in-the-shingles-prevention-study-are-second-episodes-caused-by-the-same-varicella-zoster-virus-strain/2021-09-24T07:28:31+00:00weekly0.7https://www.medthority.com/journals/shingles/complications-of-herpes-zoster-in-immunocompetent-older-adults-incidence-in-vaccine-and-placebo-groups-in-two-large-phase-3-trials/2021-09-24T07:28:31+00:00weekly0.7https://www.medthority.com/journals/shingles/vaccines-for-preventing-herpes-zoster-in-older-adults/2025-01-24T10:12:06+00:00weekly0.7https://www.medthority.com/journals/shingles/risk-factors-for-herpes-zoster-infection-a-meta-analysis/2021-09-24T07:28:31+00:00weekly0.7https://www.medthority.com/journals/shingles/the-epidemiology-of-herpes-zoster-in-immunocompetent-unvaccinated-adults-50-years-old-incidence-complications-hospitalization-mortality-and-recurrence/2021-09-24T07:28:31+00:00weekly0.7https://www.medthority.com/journals/shingles/neurological-and-ophthalmological-manifestations-of-varicella-zoster-virus/2025-01-27T16:09:10+00:00weekly0.7https://www.medthority.com/journals/shingles/understanding-the-immunology-of-the-zostavax-shingles-vaccine/2021-09-24T07:28:32+00:00weekly0.7https://www.medthority.com/journals/shingles/diabetes-as-a-risk-factor-for-herpes-zoster-in-adults-a-synthetic-literature-review/2025-01-24T09:46:26+00:00weekly0.7https://www.medthority.com/journals/shingles/the-comparative-efficacy-and-safety-of-herpes-zoster-vaccines-a-network-meta-analysis/2021-09-24T07:28:32+00:00weekly0.7https://www.medthority.com/journals/shingles/long-term-effectiveness-of-zoster-vaccine-live-for-postherpetic-neuralgia-prevention/2021-09-24T07:28:32+00:00weekly0.7https://www.medthority.com/journals/shingles/varicella-zoster-virus-post-exposure-management-and-prophylaxis-a-review/2021-09-24T07:28:32+00:00weekly0.7https://www.medthority.com/journals/shingles/immune-responses-to-zoster-vaccines/2025-01-27T16:18:52+00:00weekly0.7https://www.medthority.com/journals/shingles/cerebrovascular-events-after-herpes-zoster-infection-a-risk-that-should-be-not-underestimated/2021-09-24T07:28:32+00:00weekly0.7https://www.medthority.com/journals/hiv-infection/dolutegravir-plus-lamivudine-versus-dolutegravir-plus-tenofovir-disoproxil-fumarate-and-emtricitabine-in-antiretroviral-naive-adults-with-hiv-1-infection-gemini-1-and-gemini-2/2025-01-10T09:34:59+00:00weekly0.7https://www.medthority.com/journals/hiv-infection/durable-efficacy-of-dolutegravir-plus-lamivudine-in-antiretroviral-treatment-naive-adults-with-hiv-1-infection-96-week-results-from-the-gemini-1-and-gemini-2-randomized-clinical-trials/2025-01-27T16:10:52+00:00weekly0.7https://www.medthority.com/journals/hiv-infection/efficacy-and-safety-of-switching-to-dolutegravirlamivudine-fixed-dose-two-drug-regimen-versus-continuing-a-tenofovir-alafenamide-based-three--or-four-drug-regimen-for-maintenance-of-virologic-suppression-in-adults-with-hiv-1/2021-09-24T07:23:51+00:00weekly0.7https://www.medthority.com/journals/hiv-infection/doing-more-with-less-review-of-dolutegravir-lamivudine-a-novel-single-tablet-regimen-for-antiretroviral-naive-adults-with-hiv-1-infection/2025-01-27T16:10:11+00:00weekly0.7https://www.medthority.com/journals/hiv-infection/perspectives-on-the-barrier-to-resistance-for-dolutegravir--lamivudine-a-two-drug-antiretroviral-therapy-for-hiv-1-infection/2025-01-27T16:05:45+00:00weekly0.7https://www.medthority.com/journals/hiv-infection/dolutegravir-plus-lamivudine-for-the-treatment-of-hiv-1-infection/2025-01-30T13:15:00+00:00weekly0.7https://www.medthority.com/journals/hiv-infection/long-term-data-on-the-efficacy-and-tolerability-of-lamivudine-plus-dolutegravir-as-a-switch-strategy-in-a-multi-centre-cohort-of-hiv-1-infected-virologically-suppressed-patients/2021-09-24T07:23:50+00:00weekly0.7https://www.medthority.com/journals/hiv-infection/two-drug-regimens-with-dolutegravir-plus-rilpivirine-or-lamivudine-in-hiv-1-treatment-naive-virologically-suppressed-patients-latest-evidence-from-the-literature-on-their-efficacy-and-safety/2021-09-24T07:23:50+00:00weekly0.7https://www.medthority.com/journals/hiv-infection/advances-toward-curing-hiv-1-infection-in-tissue-reservoirs/2025-01-30T12:19:58+00:00weekly0.7https://www.medthority.com/journals/hiv-infection/fostemsavir-in-adults-with-multidrug-resistant-hiv-1-infection/2025-01-30T10:24:00+00:00weekly0.7https://www.medthority.com/journals/hiv-infection/long-acting-cabotegravir-and-rilpivirine-for-maintenance-of-hiv-1-suppression/2025-01-10T09:32:43+00:00weekly0.7https://www.medthority.com/journals/hiv-infection/recent-advances-in-the-development-of-integrase-inhibitors-for-hiv-treatment/2021-09-24T07:23:50+00:00weekly0.7https://www.medthority.com/journals/hiv-infection/distinct-viral-reservoirs-in-individuals-with-spontaneous-control-of-hiv-1/2021-09-24T07:23:50+00:00weekly0.7https://www.medthority.com/journals/hiv-infection/safety-and-immunogenicity-of-two-heterologous-hiv-vaccine-regimens-in-healthy-hiv-uninfected-adults-traverse-a-randomised-parallel-group-placebo-controlled-double-blind-phase-12a-study/2025-01-10T09:33:29+00:00weekly0.7https://www.medthority.com/journals/hiv-infection/evidence-for-hiv-1-cure-after-ccr53232-allogeneic-haemopoietic-stem-cell-transplantation-30-months-post-analytical-treatment-interruption-a-case-report/2025-01-10T09:34:07+00:00weekly0.7https://www.medthority.com/journals/solid-organ-transplantation/pancreatic-transplantation-brief-review-of-the-current-evidence/2021-09-24T07:28:38+00:00weekly0.7https://www.medthority.com/journals/solid-organ-transplantation/pathophysiology-and-management-of-hyperammonemia-in-organ-transplant-patients/2025-01-23T13:35:29+00:00weekly0.7https://www.medthority.com/journals/solid-organ-transplantation/outcome-of-kidney-transplantation-using-organs-from-brain-dead-donors-older-than-75-years/2021-09-24T07:28:39+00:00weekly0.7https://www.medthority.com/journals/solid-organ-transplantation/single-and-double-lung-transplantation-have-equivalent-survival-for-idiopathic-pulmonary-fibrosis/2025-01-23T13:30:49+00:00weekly0.7https://www.medthority.com/journals/solid-organ-transplantation/portal-flow-modulation-in-living-donor-liver-transplantation-review-with-a-focus-on-splenectomy/2021-09-24T07:28:39+00:00weekly0.7https://www.medthority.com/journals/solid-organ-transplantation/current-status-of-combined-liver-kidney-transplantation/2021-09-24T07:28:39+00:00weekly0.7https://www.medthority.com/journals/solid-organ-transplantation/comparison-of-graft-outcome-between-donation-after-circulatory-death-and-living-donor-kidney-transplantation/2021-09-24T07:28:39+00:00weekly0.7https://www.medthority.com/journals/solid-organ-transplantation/effects-of-smoking-on-solid-organ-transplantation-outcomes/2025-01-23T13:38:21+00:00weekly0.7https://www.medthority.com/journals/solid-organ-transplantation/complications-of-solid-organ-transplantation-cardiovascular-neurologic-renal-and-gastrointestinal/2025-01-23T13:37:36+00:00weekly0.7https://www.medthority.com/journals/solid-organ-transplantation/late-conversion-to-sirolimus-or-everolimus-after-pancreas-transplant/2021-09-24T07:28:40+00:00weekly0.7https://www.medthority.com/journals/solid-organ-transplantation/long-term-clinical-significance-of-tacrolimus-trough-level-at-the-early-period-after-kidney-transplantation/2021-09-24T07:28:36+00:00weekly0.7https://www.medthority.com/journals/solid-organ-transplantation/tacrolimus-20-years-of-use-in-adult-kidney-transplantation.-what-we-should-know-about-its-nephrotoxicity2025-01-27T15:02:44+00:00weekly0.7https://www.medthority.com/journals/solid-organ-transplantation/intrapatient-variability-of-tacrolimus-exposure-in-solid-organ-transplantation-a-novel-marker-for-clinical-outcome/2025-01-27T15:00:38+00:00weekly0.7https://www.medthority.com/journals/solid-organ-transplantation/belatacept-based-immunosuppression-a-calcineurin-inhibitor-sparing-regimen-in-heart-transplant-recipients/2025-01-27T14:59:47+00:00weekly0.7https://www.medthority.com/journals/solid-organ-transplantation/sirolimus-and-mtor-inhibitors-a-review-of-side-effects-and-specific-management-in-solid-organ-transplantation/2021-09-24T07:28:37+00:00weekly0.7https://www.medthority.com/journals/solid-organ-transplantation/donor-specific-cell-free-dna-as-a-biomarker-in-solid-organ-transplantation.-a-systematic-review2025-01-27T15:44:53+00:00weekly0.7https://www.medthority.com/journals/solid-organ-transplantation/treatment-of-latent-tb-infection-and-the-risk-of-tuberculosis-after-solid-organ-transplantation-comprehensive-review/2025-01-27T14:53:08+00:00weekly0.7https://www.medthority.com/journals/solid-organ-transplantation/simultaneous-liver-kidney-transplantation/2025-01-27T14:51:26+00:00weekly0.7https://www.medthority.com/journals/solid-organ-transplantation/the-emerging-role-of-regulatory-t-cells-following-lung-transplantation/2025-01-27T15:44:14+00:00weekly0.7https://www.medthority.com/journals/solid-organ-transplantation/the-past-present-and-future-of-costimulation-blockade-in-organ-transplantation/2025-01-27T15:15:41+00:00weekly0.7https://www.medthority.com/journals/solid-organ-transplantation/mast-cell-mediated-mechanistic-pathways-in-organ-transplantation/2021-09-24T07:28:38+00:00weekly0.7https://www.medthority.com/journals/solid-organ-transplantation/transplant-immunosuppressive-drugs-in-urology/2021-09-24T07:28:36+00:00weekly0.7https://www.medthority.com/journals/solid-organ-transplantation/causes-of-late-transplant-failure-in-cyclosporine-treated-kidney-allograft-recipients/2021-09-24T07:28:36+00:00weekly0.7https://www.medthority.com/journals/solid-organ-transplantation/screening-of-donors-and-recipients-for-infections-prior-to-solid-organ-transplantation/2025-01-27T15:43:28+00:00weekly0.7https://www.medthority.com/journals/solid-organ-transplantation/the-role-of-major-histocompatibility-complex-in-organ-transplantation--donor-specific-anti-major-histocompatibility-complex-antibodies-analysis-goes-to-the-next-stage/2021-09-24T07:28:38+00:00weekly0.7https://www.medthority.com/journals/solid-organ-transplantation/the-evolving-roles-of-macrophages-in-organ-transplantation/2025-01-27T15:15:06+00:00weekly0.7https://www.medthority.com/journals/solid-organ-transplantation/opportunistic-infections-in-transplant-patients/2021-09-24T07:28:38+00:00weekly0.7https://www.medthority.com/journals/solid-organ-transplantation/pancreas-transplantation-indications-techniques-and-outcomes/2021-09-24T07:28:38+00:00weekly0.7https://www.medthority.com/journals/solid-organ-transplantation/efficacy-and-safety-of-everolimus-treatment-on-liver-transplant-recipients-a-meta-analysis/2025-01-27T15:41:47+00:00weekly0.7https://www.medthority.com/journals/solid-organ-transplantation/early-switch-from-tacrolimus-to-everolimus-after-liver-transplantation-outcomes-at-2-years/2021-09-24T07:28:40+00:00weekly0.7https://www.medthority.com/journals/solid-organ-transplantation/very-early-introduction-of-everolimus-in-de-novo-liver-transplantation-results-of-a-multicenter-prospective-randomized-trial/2021-09-24T07:28:40+00:00weekly0.7https://www.medthority.com/journals/solid-organ-transplantation/optimal-dose-of-everolimus-administered-with-tacrolimus-in-living-donor-kidney-transplantation/2021-09-24T07:28:40+00:00weekly0.7https://www.medthority.com/journals/solid-organ-transplantation/target-of-rapamycin-inhibitors-tor-i-sirolimus-and-everolimus-for-primary-immunosuppression-in-kidney-transplant-recipients/2025-01-23T13:36:29+00:00weekly0.7https://www.medthority.com/journals/solid-organ-transplantation/two-year-outcomes-in-de-novo-renal-transplant-recipients-receiving-everolimus-facilitated-calcineurin-inhibitor-reduction-regimen-from-the-transform-study/2025-01-27T15:42:35+00:00weekly0.7https://www.medthority.com/journals/solid-organ-transplantation/impact-of-pretransplant-antibodies-on-outcomes-after-heart-transplantation/2025-01-27T15:14:10+00:00weekly0.7https://www.medthority.com/journals/solid-organ-transplantation/the-ins-and-outs-of-engineering-functional-tissues-and-organs-evaluating-the-in-vitro-and-in-situ-processes/2025-01-27T15:13:43+00:00weekly0.7https://www.medthority.com/journals/solid-organ-transplantation/everolimus-eluting-second-generation-stents-for-treatment-of-de-novo-lesions-in-patients-with-cardiac-allograft-vasculopathy/2021-09-24T07:28:41+00:00weekly0.7https://www.medthority.com/journals/solid-organ-transplantation/impact-of-everolimus-based-immunosuppression-on-renal-function-in-liver-transplant-recipients/2021-09-24T07:28:41+00:00weekly0.7https://www.medthority.com/journals/solid-organ-transplantation/a-3-month-multicenter-randomized-open-label-study-to-evaluate-the-impact-on-wound-healing-of-the-early-vs-delayed-introduction-of-everolimus-in-de-novo-kidney-transplant-recipients-with-a-follow-up-evaluation-at-12-months-after-transplant-neverwound/2025-01-27T15:16:20+00:00weekly0.7https://www.medthority.com/journals/solid-organ-transplantation/conversion-to-everolimus-was-beneficial-and-safe-for-fast-and-slow-tacrolimus-metabolizers-after-renal-transplantation/2021-09-24T07:28:42+00:00weekly0.7https://www.medthority.com/journals/solid-organ-transplantation/everolimus-in-kidney-transplant-recipients-at-high-cardiovascular-risk-a-narrative-review/2021-09-24T07:28:42+00:00weekly0.7https://www.medthority.com/journals/solid-organ-transplantation/organ-transplantation-in-the-modern-era/2021-09-24T07:28:42+00:00weekly0.7https://www.medthority.com/journals/solid-organ-transplantation/solid-organ-transplantation-in-the-21-st-century/2021-09-24T07:28:42+00:00weekly0.7https://www.medthority.com/journals/hidradenitis-suppurativa/hidradenitis-suppurativa-current-understanding-diagnostic-and-surgical-challenges-and-developments-in-ultrasound-application/2025-01-30T13:11:25+00:00weekly0.7https://www.medthority.com/journals/hidradenitis-suppurativa/hidradenitis-suppurativa-is-an-autoinflammatory-keratinization-disease-a-review-of-the-clinical-histologic-and-molecular-evidence/2025-01-30T11:46:57+00:00weekly0.7https://www.medthority.com/journals/hidradenitis-suppurativa/surgical-management-of-advanced-hidradenitis-suppurativa-via-a-one-stage-procedure-a-single-center-experience/2025-01-30T13:12:29+00:00weekly0.7https://www.medthority.com/journals/hidradenitis-suppurativa/hidradenitis-suppurativa-basic-considerations-for-its-approach-a-narrative-review/2021-09-24T07:23:45+00:00weekly0.7https://www.medthority.com/journals/hidradenitis-suppurativa/the-inflammatory-proteome-of-hidradenitis-suppurativa-skin-is-more-expansive-than-that-of-psoriasis-vulgaris/2025-01-30T11:47:55+00:00weekly0.7https://www.medthority.com/journals/hidradenitis-suppurativa/serum-high-sensitivity-c-reactive-protein-tumor-necrosis-factor--interleukin-il-1-il-17a-and-il-23-levels-in-patients-with-hidradenitis-suppurativa/2021-09-24T07:23:45+00:00weekly0.7https://www.medthority.com/journals/hidradenitis-suppurativa/adalimumab-induces-a-wound-healing-profile-in-patients-with-hidradenitis-suppurativa-by-regulating-macrophage-differentiation-and-matrix-metalloproteinase-expression/2025-01-10T11:53:41+00:00weekly0.7https://www.medthority.com/journals/hidradenitis-suppurativa/intralesional-photodynamic-therapy-in-hidradenitis-suppurativa-getting-closer-to-the-target/2021-09-24T07:23:45+00:00weekly0.7https://www.medthority.com/journals/hidradenitis-suppurativa/review-of-imaging-technologies-used-in-hidradenitis-suppurativa/2025-01-30T11:46:02+00:00weekly0.7https://www.medthority.com/journals/hidradenitis-suppurativa/high-dose-high-frequency-infliximab-a-novel-treatment-paradigm-for-hidradenitis-suppurativa/2025-01-30T13:09:14+00:00weekly0.7https://www.medthority.com/journals/hidradenitis-suppurativa/evidence-for-a-window-of-opportunity-in-hidradenitis-suppurativa-treated-with-adalimumab-a-retrospective-real-life-multicentre-cohort-study/2025-01-30T10:23:10+00:00weekly0.7https://www.medthority.com/journals/hidradenitis-suppurativa/the-pharmacology-of-antibiotic-therapy-in-hidradenitis-suppurativa/2025-01-30T13:10:22+00:00weekly0.7https://www.medthority.com/journals/hidradenitis-suppurativa/emerging-drugs-for-the-treatment-of-hidradenitis-suppurativa/2025-01-30T10:21:49+00:00weekly0.7https://www.medthority.com/journals/hidradenitis-suppurativa/evaluating-patients-unmet-needs-in-hidradenitis-suppurativa-results-from-the-global-survey-of-impact-and-healthcare-needs-voice-project/2025-01-30T10:14:59+00:00weekly0.7https://www.medthority.com/journals/hidradenitis-suppurativa/hidradenitis-suppurativa-an-update-on-epidemiology-phenotypes-diagnosis-pathogenesis-comorbidities-and-quality-of-life/2025-01-30T12:38:25+00:00weekly0.7https://www.medthority.com/journals/hidradenitis-suppurativa/comorbidities-of-hidradenitis-suppurativa-a-review-of-the-literature/2021-09-24T07:23:47+00:00weekly0.7https://www.medthority.com/journals/hidradenitis-suppurativa/hidradenitis-suppurativa-from-pathogenesis-to-diagnosis-and-treatment/2021-09-24T07:23:47+00:00weekly0.7https://www.medthority.com/journals/hidradenitis-suppurativa/medical-and-surgical-management-of-hidradenitis-suppurativa-a-review-of-international-treatment-guidelines-and-implementation-in-general-dermatology-practice/2021-09-24T07:23:47+00:00weekly0.7https://www.medthority.com/journals/hidradenitis-suppurativa/hidradenitis-suppurativa-current-understanding-of-pathogenic-mechanisms-and-suggestion-for-treatment-algorithm/2021-09-24T07:23:47+00:00weekly0.7https://www.medthority.com/journals/hidradenitis-suppurativa/aetiology-and-pathogenesis-of-hidradenitis-suppurativa/2025-01-30T10:16:36+00:00weekly0.7https://www.medthority.com/journals/hidradenitis-suppurativa/immunopathogenesis-of-hidradenitis-suppurativa-and-response-to-anti-tnf--therapy/2021-09-24T07:23:47+00:00weekly0.7https://www.medthority.com/journals/hidradenitis-suppurativa/il-17-in-inflammatory-skin-diseases-psoriasis-and-hidradenitis-suppurativa/2025-01-30T11:48:56+00:00weekly0.7https://www.medthority.com/journals/hidradenitis-suppurativa/hidradenitis-suppurativa-epidemiology-clinical-presentation-and-pathogenesis/2025-01-30T13:07:01+00:00weekly0.7https://www.medthority.com/journals/hidradenitis-suppurativa/hidradenitis-suppurativa-current-and-emerging-treatments/2025-01-30T10:18:19+00:00weekly0.7https://www.medthority.com/journals/hidradenitis-suppurativa/hidradenitis-suppurativa-where-we-are-and-where-we-are-going/2021-09-24T07:23:46+00:00weekly0.7https://www.medthority.com/journals/chronic-kidney-disease/chronic-kidney-disease-and-kidney-stones/2025-01-30T15:16:34+00:00weekly0.7https://www.medthority.com/journals/chronic-kidney-disease/pain-management-in-patients-with-chronic-kidney-disease-and-end-stage-kidney-disease/2025-01-30T14:54:07+00:00weekly0.7https://www.medthority.com/journals/chronic-kidney-disease/disparities-in-chronic-kidney-disease-the-state-of-the-evidence/2025-01-30T14:54:52+00:00weekly0.7https://www.medthority.com/journals/chronic-kidney-disease/cardiovascular-autonomic-nervous-system-dysfunction-in-chronic-kidney-disease-and-end-stage-kidney-disease-disruption-of-the-complementary-forces/2025-01-13T12:52:27+00:00weekly0.7https://www.medthority.com/journals/chronic-kidney-disease/how-to-assess-quality-of-life-in-persons-with-chronic-kidney-disease/2025-01-13T12:53:22+00:00weekly0.7https://www.medthority.com/journals/chronic-kidney-disease/vascular-dysfunction-oxidative-stress-and-inflammation-in-chronic-kidney-disease/2025-01-31T09:11:38+00:00weekly0.7https://www.medthority.com/journals/chronic-kidney-disease/only-hyperuricemia-with-crystalluria-but-not-asymptomatic-hyperuricemia-drives-progression-of-chronic-kidney-disease/2025-01-13T12:54:13+00:00weekly0.7https://www.medthority.com/journals/chronic-kidney-disease/role-of-platelets-in-chronic-kidney-disease/2025-01-13T12:57:03+00:00weekly0.7https://www.medthority.com/journals/chronic-kidney-disease/effects-of-dapagliflozin-in-stage-4-chronic-kidney-disease/2025-01-13T12:57:46+00:00weekly0.7https://www.medthority.com/journals/chronic-kidney-disease/rationale-design-demographics-and-baseline-characteristics-of-the-randomised-controlled-phase-2b-sapphire-study-of-verinurad-plus-allopurinol-in-patients-with-chronic-kidney-disease-and-hyperuricaemia/2022-02-10T14:05:40+00:00weekly0.7https://www.medthority.com/journals/chronic-kidney-disease/genetic-testing-in-the-diagnosis-of-chronic-kidney-disease-recommendations-for-clinical-practice/2022-02-10T14:05:16+00:00weekly0.7https://www.medthority.com/journals/chronic-kidney-disease/early-detection-of-ckd-implications-for-low-income-middle-income-and-high-income-countries/2025-01-31T08:45:47+00:00weekly0.7https://www.medthority.com/journals/chronic-kidney-disease/sglt2-inhibition-and-chronic-kidney-disease-outcomes-in-diabetes-and-beyond/2025-01-30T15:13:19+00:00weekly0.7https://www.medthority.com/journals/chronic-kidney-disease/beyond-chronic-kidney-disease-the-diagnosis-of-renal-disease-in-the-elderly-as-an-unmet-need.-a-position-paper-endorsed-by-italian-society-of-nephrology-sin-and-italian-society-of-geriatrics-and-gerontology-sigg2022-02-10T14:27:23+00:00weekly0.7https://www.medthority.com/journals/chronic-kidney-disease/sleep-apnea-and-chronic-kidney-disease-a-state-of-the-art-review/2025-01-30T15:12:47+00:00weekly0.7https://www.medthority.com/journals/chronic-kidney-disease/management-of-hyperuricemia-in-patients-with-chronic-kidney-disease-a-focus-on-renal-protection/2022-02-10T14:26:26+00:00weekly0.7https://www.medthority.com/journals/chronic-kidney-disease/fluid-overload-as-a-therapeutic-target-for-the-preservative-management-of-chronic-kidney-disease/2025-01-30T15:14:57+00:00weekly0.7https://www.medthority.com/journals/chronic-kidney-disease/adiponectin-in-chronic-kidney-disease/2022-02-10T14:29:13+00:00weekly0.7https://www.medthority.com/journals/chronic-kidney-disease/integrated-multi-omics-approaches-to-improve-classification-of-chronic-kidney-disease/2022-02-10T14:29:02+00:00weekly0.7https://www.medthority.com/journals/chronic-kidney-disease/personalized-medicine-in-chronic-kidney-disease-by-detection-of-monogenic-mutations/2022-02-10T14:28:51+00:00weekly0.7https://www.medthority.com/journals/chronic-kidney-disease/chronic-kidney-disease-diagnosis-and-management-a-review/2022-02-10T14:28:38+00:00weekly0.7https://www.medthority.com/journals/chronic-kidney-disease/effectiveness-of-targeted-screening-for-chronic-kidney-disease-in-the-community-setting-a-systematic-review/2022-02-10T14:28:22+00:00weekly0.7https://www.medthority.com/journals/chronic-kidney-disease/regulation-and-effects-of-fgf23-in-chronic-kidney-disease/2022-02-10T14:33:11+00:00weekly0.7https://www.medthority.com/journals/chronic-kidney-disease/chronic-kidney-disease-and-the-gut-microbiome/2025-01-13T12:10:39+00:00weekly0.7https://www.medthority.com/journals/chronic-kidney-disease/targeting-the-progression-of-chronic-kidney-disease/2022-02-10T14:32:51+00:00weekly0.7https://www.medthority.com/journals/chronic-kidney-disease/sodium-intake-and-chronic-kidney-disease/2022-02-10T14:32:35+00:00weekly0.7https://www.medthority.com/journals/chronic-kidney-disease/helping-people-to-live-well-with-chronic-kidney-disease/2025-01-13T12:50:42+00:00weekly0.7https://www.medthority.com/journals/chronic-kidney-disease/nontraditional-non-western-pharmaceutical-treatments-for-chronic-kidney-disease/2022-02-10T14:32:13+00:00weekly0.7https://www.medthority.com/journals/chronic-kidney-disease/medication-burden-and-inappropriate-prescription-risk-among-elderly-with-advanced-chronic-kidney-disease/2022-02-10T14:32:04+00:00weekly0.7https://www.medthority.com/journals/chronic-kidney-disease/dna-methylation-dysfunction-in-chronic-kidney-disease/2022-02-10T14:31:56+00:00weekly0.7https://www.medthority.com/journals/chronic-kidney-disease/new-therapeutic-targets-in-chronic-kidney-disease-progression-and-renal-fibrosis/2025-01-13T12:51:41+00:00weekly0.7https://www.medthority.com/journals/chronic-kidney-disease/new-mineralocorticoid-receptor-antagonists-update-on-their-use-in-chronic-kidney-disease-and-heart-failure/2022-02-10T14:31:37+00:00weekly0.7https://www.medthority.com/journals/chronic-kidney-disease/plant-based-diets-for-kidney-disease-a-guide-for-clinicians/2025-01-13T12:00:48+00:00weekly0.7https://www.medthority.com/journals/chronic-kidney-disease/micrornas-in-chronic-kidney-disease-four-candidates-for-clinical-application/2022-02-10T14:29:32+00:00weekly0.7https://www.medthority.com/journals/chronic-kidney-disease/the-case-for-early-identification-and-intervention-of-chronic-kidney-disease-conclusions-from-a-kidney-disease-improving-global-outcomes-kdigo-controversies-conference/2025-01-31T08:43:24+00:00weekly0.7https://www.medthority.com/journals/lung-cancer/efficacy-of-selpercatinib-in-ret-fusion-positive-non-small-cell-lung-cancer/2025-01-10T09:28:38+00:00weekly0.7https://www.medthority.com/journals/lung-cancer/intracranial-efficacy-of-selpercatinib-in-ret-fusion-positive-non-small-cell-lung-cancers-on-the-libretto-001-trial/2021-09-24T07:24:21+00:00weekly0.7https://www.medthority.com/journals/lung-cancer/pralsetinib-for-ret-fusion-positive-non-small-cell-lung-cancer-arrow-a-multi-cohort-open-label-phase-12-study/2025-01-28T15:50:20+00:00weekly0.7https://www.medthority.com/journals/lung-cancer/the-biology-and-management-of-non-small-cell-lung-cancer/2021-09-24T07:24:21+00:00weekly0.7https://www.medthority.com/journals/lung-cancer/biomarker-testing-for-patients-with-advanced-non-small-cell-lung-cancer-real-world-issues-and-tough-choices/2025-01-28T15:33:57+00:00weekly0.7https://www.medthority.com/journals/lung-cancer/molecular-diagnosis-in-non-small-cell-lung-cancer-expert-opinion-on-alk-and-ros1-testing/2021-09-24T07:24:21+00:00weekly0.7https://www.medthority.com/journals/lung-cancer/clinical-development-of-ret-inhibitors-in-ret-rearranged-non-small-cell-lung-cancer-update/2021-09-24T07:24:21+00:00weekly0.7https://www.medthority.com/journals/lung-cancer/molecular-diagnostics-and-targeted-therapies-in-non-small-cell-lung-cancer-nsclc-an-update/2021-09-24T07:24:21+00:00weekly0.7https://www.medthority.com/journals/thyroid-cancer/pd-1-blockade-in-anaplastic-thyroid-carcinoma/2025-09-05T08:44:27+00:00weekly0.7https://www.medthority.com/journals/thyroid-cancer/efficacy-and-safety-of-vandetanib-in-progressive-and-symptomatic-medullary-thyroid-cancer-post-hoc-analysis-from-the-zeta-trial/2025-09-05T08:43:29+00:00weekly0.7https://www.medthority.com/journals/thyroid-cancer/evaluation-of-overall-survival-in-patients-with-anaplastic-thyroid-carcinoma-2000-2019/2021-09-24T07:28:50+00:00weekly0.7https://www.medthority.com/journals/thyroid-cancer/associations-between-artificial-light-at-night-and-risk-for-thyroid-cancer-a-large-us-cohort-study/2025-09-05T07:28:49+00:00weekly0.7https://www.medthority.com/journals/thyroid-cancer/open-label-single-arm-multicenter-phase-ii-trial-of-lenvatinib-for-the-treatment-of-patients-with-anaplastic-thyroid-cancer/2025-01-28T16:05:21+00:00weekly0.7https://www.medthority.com/journals/food-allergy/peanut-diversity-and-specific-activity-are-the-dominant-ige-characteristics-for-effector-cell-activation-in-children/2025-01-28T16:03:03+00:00weekly0.7https://www.medthority.com/journals/food-allergy/the-concept-of-pathogenic-th2-cells-collegium-internationale-allergologicum-update-2021/2021-09-24T07:23:04+00:00weekly0.7https://www.medthority.com/journals/thyroid-cancer/new-therapies-for-advanced-thyroid-cancer/2021-09-24T07:28:50+00:00weekly0.7https://www.medthority.com/journals/thyroid-cancer/cancer-stem-cells-in-thyroid-tumors-from-the-origin-to-metastasis/2021-09-24T07:28:51+00:00weekly0.7https://www.medthority.com/journals/thyroid-cancer/geographic-influences-in-the-global-rise-of-thyroid-cancer/2021-09-24T07:28:51+00:00weekly0.7https://www.medthority.com/journals/thyroid-cancer/screening-for-differentiated-thyroid-cancer-in-selected-populations/2025-09-05T08:45:51+00:00weekly0.7https://www.medthority.com/journals/thyroid-cancer/update-on-fundamental-mechanisms-of-thyroid-cancer/2021-09-24T07:28:50+00:00weekly0.7https://www.medthority.com/journals/thyroid-cancer/papillary-thyroid-cancer-genetic-alterations-and-molecular-biomarker-investigations/2021-09-24T07:28:52+00:00weekly0.7https://www.medthority.com/journals/thyroid-cancer/dna-methylation-in-thyroid-cancer/2021-09-24T07:28:51+00:00weekly0.7https://www.medthority.com/journals/thyroid-cancer/identifying-patients-with-ntrk-fusion-cancer/2021-09-24T07:28:51+00:00weekly0.7https://www.medthority.com/journals/thyroid-cancer/the-potential-of-metabolomics-in-the-diagnosis-of-thyroid-cancer/2021-09-24T07:28:51+00:00weekly0.7https://www.medthority.com/journals/thyroid-cancer/papillary-thyroid-cancer-aggressive-variants-and-impact-on-management-a-narrative-review/2021-09-24T07:28:51+00:00weekly0.7https://www.medthority.com/journals/thyroid-cancer/familial-non-medullary-thyroid-cancer-a-critical-review/2021-09-24T07:28:51+00:00weekly0.7https://www.medthority.com/journals/thyroid-cancer/non-coding-rna-in-thyroid-cancer-functions-and-mechanisms/2021-09-24T07:28:51+00:00weekly0.7https://www.medthority.com/journals/thyroid-cancer/interleukin-6-regulates-the-expression-of-programmed-cell-death-ligand-1-in-thyroid-cancer/2025-01-10T09:27:15+00:00weekly0.7https://www.medthority.com/journals/thyroid-cancer/hemithyroidectomy-for-thyroid-cancer-a-review/2021-09-24T07:28:51+00:00weekly0.7https://www.medthority.com/journals/thyroid-cancer/interleukins-in-thyroid-cancer-from-basic-researches-to-applications-in-clinical-practice/2021-09-24T07:28:51+00:00weekly0.7https://www.medthority.com/journals/thyroid-cancer/clinical-characteristics-and-prognostic-factors-of-hurthle-cell-carcinoma-a-population-based-study/2021-09-24T07:28:52+00:00weekly0.7https://www.medthority.com/journals/thyroid-cancer/evolving-understanding-of-the-epidemiology-of-thyroid-cancer/2021-09-24T07:28:52+00:00weekly0.7https://www.medthority.com/journals/thyroid-cancer/influencers-on-thyroid-cancer-onset-molecular-genetic-basis/2021-09-24T07:28:52+00:00weekly0.7https://www.medthority.com/journals/thyroid-cancer/contemporary-debates-in-adult-papillary-thyroid-cancer-management/2021-09-24T07:28:52+00:00weekly0.7https://www.medthority.com/journals/thyroid-cancer/long-noncoding-rnas-in-thyroid-cancer/2025-01-10T09:04:08+00:00weekly0.7https://www.medthority.com/journals/lung-cancer/lung-microbiome-alterations-in-nsclc-patients/2021-09-24T07:24:22+00:00weekly0.7https://www.medthority.com/journals/lung-cancer/immunotherapy-at-any-line-of-treatment-improves-survival-in-patients-with-advanced-metastatic-non-small-cell-lung-cancer-nsclc-compared-with-chemotherapy-quijote-clicap/2025-01-10T09:20:11+00:00weekly0.7https://www.medthority.com/journals/lung-cancer/final-overall-survival-and-safety-update-for-durvalumab-in-third--or-later-line-advanced-nsclc-the-phase-ii-atlantic-study/2025-01-10T09:05:41+00:00weekly0.7https://www.medthority.com/journals/lung-cancer/the-impact-of-osimertinib-line-on-clonal-evolution-in-egfrm-nsclc-through-ngs-based-liquid-biopsy-and-overcoming-strategies-for-resistance/2025-01-10T09:04:44+00:00weekly0.7https://www.medthority.com/journals/lung-cancer/development-and-evaluation-of-a-real-world-outcomes-based-tool-to-support-informed-clinical-decision-making-in-the-palliative-treatment-of-patients-with-metastatic-nsclc/2025-01-28T15:30:13+00:00weekly0.7https://www.medthority.com/journals/lung-cancer/five-year-outcomes-with-pembrolizumab-versus-chemotherapy-for-metastatic-non-small-cell-lung-cancer-with-pd-l1-tumor-proportion-score--50/2025-01-28T15:31:02+00:00weekly0.7https://www.medthority.com/journals/lung-cancer/randomized-phase-iii-study-of-pemetrexed-plus-cisplatin-versus-vinorelbine-plus-cisplatin-for-completely-resected-stage-ii-to-iiia-nonsquamous-non-small-cell-lung-cancer/2025-01-10T09:11:21+00:00weekly0.7https://www.medthority.com/journals/lung-cancer/osimertinib-for-patients-with-non-small-cell-lung-cancer-harboring-uncommon-egfr-mutations-a-multicenter-open-label-phase-ii-trial-kcsg-lu15-09/2025-01-10T09:10:42+00:00weekly0.7https://www.medthority.com/journals/lung-cancer/immune-checkpoint-inhibition-in-stage-iii-unresectable-nsclc-challenges-and-opportunities-in-the-post-pacific-era/2025-01-10T09:10:00+00:00weekly0.7https://www.medthority.com/journals/lung-cancer/tolerability-and-antitumor-activity-of-cemiplimab-a-human-monoclonal-anti-pd-1-as-monotherapy-in-patients-with-pretreated-non-small-cell-lung-cancer-nsclc-data-from-the-phase-1-nsclc-expansion-cohort/2025-01-10T09:09:24+00:00weekly0.7https://www.medthority.com/journals/lung-cancer/survival-analysis-for-non-squamous-nsclc-patients-harbored-stk11-or-keap1-mutation-receiving-atezolizumab/2025-01-10T09:07:11+00:00weekly0.7https://www.medthority.com/journals/lung-cancer/five-year-outcomes-from-the-randomized-phase-iii-trials-checkmate-017-and-057-nivolumab-versus-docetaxel-in-previously-treated-non-small-cell-lung-cancer/2025-01-28T15:28:40+00:00weekly0.7https://www.medthority.com/journals/lung-cancer/phase-iii-study-of-capmatinib-plus-erlotinib-in-patients-with-met-positive-non-small-cell-lung-cancer/2025-01-30T09:02:39+00:00weekly0.7https://www.medthority.com/journals/lung-cancer/gefitinib-versus-vinorelbine-plus-cisplatin-as-adjuvant-treatment-for-stage-ii-iiia-n1-n2-egfr-mutant-nsclc-final-overall-survival-analysis-of-ctong1104-phase-iii-trial/2025-01-28T15:29:30+00:00weekly0.7https://www.medthority.com/journals/lung-cancer/early-plasma-circulating-tumor-dna-ctdna-changes-predict-response-to-first-line-pembrolizumab-based-therapy-in-non-small-cell-lung-cancer-nsclc/2021-09-24T07:24:23+00:00weekly0.7https://www.medthority.com/journals/lung-cancer/the-impact-of-body-mass-index-on-the-efficacy-of-anti-pd-1pd-l1-antibodies-in-patients-with-non-small-cell-lung-cancer/2025-01-28T15:49:03+00:00weekly0.7https://www.medthority.com/journals/lung-cancer/phase-2-study-of-the-focal-adhesion-kinase-inhibitor-defactinib-vs-6063-in-previously-treated-advanced-kras-mutant-non-small-cell-lung-cancer/2025-01-30T09:07:30+00:00weekly0.7https://www.medthority.com/journals/lung-cancer/targeting-the-pi3kaktmtor-pathway-in-non-small-cell-lung-cancer-nsclc/2025-01-30T09:06:00+00:00weekly0.7https://www.medthority.com/journals/lung-cancer/choosing-the-best-first-line-therapy-nsclc-with-no-actionable-oncogenic-driver/2025-01-30T09:04:58+00:00weekly0.7https://www.medthority.com/journals/lung-cancer/efficacy-and-safety-of-tyrosine-kinase-inhibitors-in-advanced-non-small-cell-lung-cancer-harboring-epidermal-growth-factor-receptor-mutation-a-network-meta-analysis/2025-01-30T09:04:00+00:00weekly0.7https://www.medthority.com/journals/lung-cancer/two-year-survival-with-nivolumab-in-previously-treated-advanced-non-small-cell-lung-cancer-a-real-world-pooled-analysis-of-patients-from-france-germany-and-canada/2025-01-28T16:15:13+00:00weekly0.7https://www.medthority.com/journals/lung-cancer/the-evolving-landscape-of-biomarker-testing-for-non-small-cell-lung-cancer-in-europe/2025-01-28T15:20:42+00:00weekly0.7https://www.medthority.com/journals/lung-cancer/abdominal-lymph-node-metastasis-by-lymphatic-spread-through-the-thoracic-duct-in-patients-with-non-small-cell-lung-cancer/2025-01-28T15:26:02+00:00weekly0.7https://www.medthority.com/journals/lung-cancer/real-world-outcomes-of-immunotherapy-based-regimens-in-first-line-advanced-non-small-cell-lung-cancer/2025-01-28T15:27:46+00:00weekly0.7https://www.medthority.com/journals/lung-cancer/combination-of-egfr-tkis-and-chemotherapy-in-advanced-egfr-mutated-nsclc-review-of-the-literature-and-future-perspectives/2026-02-02T10:04:19+00:00weekly0.7https://www.medthority.com/journals/lung-cancer/targeted-therapies-in-early-stage-nsclc-hype-or-hope/2021-09-24T07:24:23+00:00weekly0.7https://www.medthority.com/journals/lung-cancer/kras-as-a-druggable-target-in-nsclc-rising-like-a-phoenix-after-decades-of-development-failures/2025-01-30T09:01:09+00:00weekly0.7https://www.medthority.com/journals/food-allergy/non-ige-mediated-food-allergy/2021-09-24T07:23:05+00:00weekly0.7https://www.medthority.com/journals/food-allergy/oral-immunotherapy-for-food-allergy/2021-09-24T07:23:05+00:00weekly0.7https://www.medthority.com/journals/food-allergy/ige-in-the-pathophysiology-and-therapy-of-food-allergy/2025-01-28T15:31:40+00:00weekly0.7https://www.medthority.com/journals/food-allergy/biomarkers-of-diagnosis-and-resolution-of-food-allergy/2025-01-28T15:32:23+00:00weekly0.7https://www.medthority.com/journals/food-allergy/advancing-food-allergy-through-omics-sciences/2025-01-28T15:56:01+00:00weekly0.7https://www.medthority.com/journals/food-allergy/clinical-relevance-of-cross-reactivity-in-food-allergy/2025-01-30T12:22:40+00:00weekly0.7https://www.medthority.com/journals/food-allergy/b-cells-and-the-microbiota-a-missing-connection-in-food-allergy/2021-09-24T07:23:05+00:00weekly0.7https://www.medthority.com/journals/food-allergy/practical-challenges-and-considerations-for-early-introduction-of-potential-food-allergens-for-prevention-of-food-allergy/2025-01-30T12:24:23+00:00weekly0.7https://www.medthority.com/journals/food-allergy/antigen-presenting-cells-in-food-tolerance-and-allergy/2021-09-24T07:23:05+00:00weekly0.7https://www.medthority.com/journals/food-allergy/update-on-food-allergy/2025-01-10T09:35:43+00:00weekly0.7https://www.medthority.com/journals/food-allergy/the-use-of-biologics-in-food-allergy/2025-01-28T16:04:35+00:00weekly0.7https://www.medthority.com/journals/food-allergy/predicting-food-allergy-the-value-of-patient-history-reinforced/2025-01-28T16:03:52+00:00weekly0.7https://www.medthority.com/journals/food-allergy/a-consensus-approach-to-the-primary-prevention-of-food-allergy-through-nutrition-guidance-from-the-american-academy-of-allergy-asthma-and-immunology-american-college-of-allergy-asthma-and-immunology-and-the-canadian-society-for-allergy-and-clinical/2025-01-30T12:20:49+00:00weekly0.7https://www.medthority.com/journals/food-allergy/immunomodulatory-effects-of-breast-milk-on-food-allergy/2025-01-28T15:54:23+00:00weekly0.7https://www.medthority.com/journals/food-allergy/pollen-food-allergy-syndrome-pfas-a-review-of-current-available-literature/2025-01-28T15:36:22+00:00weekly0.7https://www.medthority.com/journals/food-allergy/food-allergy-and-the-microbiome-current-understandings-and-future-directions/2025-01-10T09:27:55+00:00weekly0.7https://www.medthority.com/journals/food-allergy/new-developments-in-non-allergen-specific-therapy-for-the-treatment-of-food-allergy/2021-09-24T07:23:08+00:00weekly0.7https://www.medthority.com/journals/food-allergy/sublingual-and-patch-immunotherapy-for-food-allergy/2021-09-24T07:23:07+00:00weekly0.7https://www.medthority.com/journals/food-allergy/untargeted-metabolomic-profiling-identifies-disease-specific-signatures-in-food-allergy-and-asthma/2025-01-28T15:51:28+00:00weekly0.7https://www.medthority.com/journals/food-allergy/reaction-phenotypes-in-ige-mediated-food-allergy-and-anaphylaxis/2025-01-28T15:42:02+00:00weekly0.7https://www.medthority.com/journals/food-allergy/peanut-allergy-new-advances-and-ongoing-controversies/2021-09-24T07:23:06+00:00weekly0.7https://www.medthority.com/journals/food-allergy/recent-advances-in-mechanisms-of-food-allergy-and-anaphylaxis/2021-09-24T07:23:06+00:00weekly0.7https://www.medthority.com/journals/food-allergy/postbiotics-a-novel-strategy-in-food-allergy-treatment/2025-01-28T14:33:38+00:00weekly0.7https://www.medthority.com/journals/food-allergy/food-allergy-a-review/2025-01-28T16:06:30+00:00weekly0.7https://www.medthority.com/journals/food-allergy/immunoglobulin-e-ige-mediated-food-allergy-in-children-epidemiology-pathogenesis-diagnosis-prevention-and-management/2021-09-24T07:23:07+00:00weekly0.7https://www.medthority.com/journals/food-allergy/the-epigenetics-of-food-allergy/2021-09-24T07:23:07+00:00weekly0.7https://www.medthority.com/journals/food-allergy/prevention-of-food-allergy---skin-barrier-interventions/2021-09-24T07:23:07+00:00weekly0.7https://www.medthority.com/journals/food-allergy/epidemiology-and-burden-of-food-allergy/2021-09-24T07:23:07+00:00weekly0.7https://www.medthority.com/journals/food-allergy/advances-in-management-of-food-allergy-in-children/2021-09-24T07:23:07+00:00weekly0.7https://www.medthority.com/journals/food-allergy/new-perspectives-in-food-allergy/2021-09-24T07:23:07+00:00weekly0.7https://www.medthority.com/journals/food-allergy/food-allergy-immunotherapy-with-adjuvants/2021-09-24T07:23:07+00:00weekly0.7https://www.medthority.com/journals/food-allergy/novel-therapies-for-treatment-of-food-allergy/2021-09-24T07:23:07+00:00weekly0.7https://www.medthority.com/journals/glaucoma/low-energy-selective-laser-trabeculoplasty-repeated-annually-rationale-for-the-coast-trial/2025-01-13T13:47:09+00:00weekly0.7https://www.medthority.com/journals/glaucoma/evaluating-visual-field-progression-in-advanced-glaucoma-using-trend-analysis-of-targeted-mean-total-deviation/2025-01-13T13:45:13+00:00weekly0.7https://www.medthority.com/journals/glaucoma/early-results-of-irrigating-goniectomy-with-trabex-a-novel-device-for-the-treatment-of-open-angle-glaucoma/2025-01-13T13:44:00+00:00weekly0.7https://www.medthority.com/journals/glaucoma/three-month-randomized-trial-of-fixed-combination-brinzolamide-1-and-brimonidine-0.22025-01-13T09:15:48+00:00weekly0.7https://www.medthority.com/journals/glaucoma/the-surgical-management-of-glaucoma-a-review/2025-01-13T13:49:11+00:00weekly0.7https://www.medthority.com/journals/glaucoma/neuroprotection-in-glaucoma/2025-01-13T13:48:01+00:00weekly0.7https://www.medthority.com/journals/glaucoma/measures-of-disease-activity-in-glaucoma/2025-01-13T09:15:51+00:00weekly0.7https://www.medthority.com/journals/glaucoma/inflammation-in-glaucoma-from-the-back-to-the-front-of-the-eye-and-beyond/2025-01-13T09:15:50+00:00weekly0.7https://www.medthority.com/journals/glaucoma/ultrasound-biomicroscopy-in-glaucoma-assessment/2025-01-13T09:15:50+00:00weekly0.7https://www.medthority.com/journals/glaucoma/the-role-of-micrornas-in-glaucoma/2025-01-13T09:15:52+00:00weekly0.7https://www.medthority.com/journals/glaucoma/approach-to-childhood-glaucoma-a-review/2025-01-13T13:49:51+00:00weekly0.7https://www.medthority.com/journals/glaucoma/the-global-extent-of-undetected-glaucoma-in-adults-a-systematic-review-and-meta-analysis/2025-01-13T14:03:03+00:00weekly0.7https://www.medthority.com/journals/glaucoma/neuroprotection-in-glaucoma-old-concepts-new-ideas/2025-01-13T14:02:19+00:00weekly0.7https://www.medthority.com/journals/glaucoma/the-lancet-global-health-commission-on-global-eye-health-vision-beyond-2020/2025-01-13T14:31:40+00:00weekly0.7https://www.medthority.com/journals/glaucoma/glaucoma-biological-trabecular-and-neuroretinal-pathology-with-perspectives-of-therapy-innovation-and-preventive-diagnosis/2025-01-13T09:15:54+00:00weekly0.7https://www.medthority.com/journals/glaucoma/unmet-needs-in-ophthalmology-a-european-vision-institute-consensus-roadmap-2019-2025/2025-01-13T09:15:54+00:00weekly0.7https://www.medthority.com/journals/glaucoma/glaucoma-and-intraocular-pressure-in-epic-norfolk-eye-study-cross-sectional-study/2025-01-13T09:15:54+00:00weekly0.7https://www.medthority.com/journals/glaucoma/the-relationship-between-intraocular-pressure-and-glaucoma-in-a-defined-population.-data-from-the-egna-neumarkt-glaucoma-study2025-01-13T09:15:53+00:00weekly0.7https://www.medthority.com/journals/glaucoma/epidemiological-variations-and-trends-in-health-burden-of-glaucoma-worldwide/2025-01-13T14:01:10+00:00weekly0.7https://www.medthority.com/journals/glaucoma/prevalence-of-primary-open-angle-glaucoma-in-the-last-20-years-a-meta-analysis-and-systematic-review/2025-01-13T09:15:53+00:00weekly0.7https://www.medthority.com/journals/glaucoma/global-prevalence-of-glaucoma-and-projections-of-glaucoma-burden-through-2040-a-systematic-review-and-meta-analysis/2025-01-13T14:00:22+00:00weekly0.7https://www.medthority.com/journals/glaucoma/glaucoma-in-adults-screening-diagnosis-and-management-a-review/2025-01-13T09:15:52+00:00weekly0.7https://www.medthority.com/journals/glaucoma/ripasudil-hydrochloride-hydrate-in-the-treatment-of-glaucoma-safety-efficacy-and-patient-selection/2025-01-13T09:15:52+00:00weekly0.7https://www.medthority.com/journals/glaucoma/21st-century-glaucoma-care/2025-01-13T09:15:52+00:00weekly0.7https://www.medthority.com/journals/venous-thromboembolism-vte/endovascular-management-of-venous-thromboembolic-disease-in-the-oncologic-patient-population/2025-01-13T09:17:29+00:00weekly0.7https://www.medthority.com/journals/venous-thromboembolism-vte/venous-thrombosis/2025-01-13T09:17:31+00:00weekly0.7https://www.medthority.com/journals/venous-thromboembolism-vte/predicting-the-risk-of-venous-thromboembolism-recurrence/2025-01-23T11:24:16+00:00weekly0.7https://www.medthority.com/journals/venous-thromboembolism-vte/prediction-of-bleeding-events-using-the-vte-bleed-risk-score-in-patients-with-venous-thromboembolism-receiving-anticoagulant-therapy-review/2025-01-13T09:17:30+00:00weekly0.7https://www.medthority.com/journals/venous-thromboembolism-vte/overview-of-venous-thromboembolism/2025-01-13T09:17:30+00:00weekly0.7https://www.medthority.com/journals/venous-thromboembolism-vte/venous-thromboembolism-and-cancer-a-comprehensive-review-from-pathophysiology-to-novel-treatment/2025-01-13T09:17:30+00:00weekly0.7https://www.medthority.com/journals/venous-thromboembolism-vte/risk-for-recurrent-venous-thromboembolism-and-bleeding-with-apixaban-compared-with-rivaroxaban-an-analysis-of-real-world-data/2025-01-23T13:44:22+00:00weekly0.7https://www.medthority.com/journals/venous-thromboembolism-vte/venous-thromboembolism-recent-advancement-and-future-perspective/2025-01-23T13:45:06+00:00weekly0.7https://www.medthority.com/journals/venous-thromboembolism-vte/cancer-associated-venous-thromboembolism/2025-01-13T09:17:29+00:00weekly0.7https://www.medthority.com/journals/venous-thromboembolism-vte/treatment-strategies-for-proximal-deep-vein-thrombosis-a-network-meta-analysis-of-randomised-controlled-trials/2025-01-23T13:45:52+00:00weekly0.7https://www.medthority.com/journals/chronic-kidney-disease/the-efficacy-and-safety-of-roxadustat-for-anemia-in-patients-with-chronic-kidney-disease-a-meta-analysis/2025-01-13T09:15:02+00:00weekly0.7https://www.medthority.com/journals/chronic-kidney-disease/roxadustat-for-the-treatment-of-anemia-in-chronic-kidney-disease-patients-not-on-dialysis-a-phase-3-randomized-double-blind-placebo-controlled-study-alps/2025-01-13T09:15:02+00:00weekly0.7https://www.medthority.com/journals/chronic-kidney-disease/efficacy-and-safety-of-roxadustat-for-anaemia-in-dialysis-dependent-and-non-dialysis-dependent-chronic-kidney-disease-patients-a-systematic-review-and-meta-analysis/2025-01-13T14:05:07+00:00weekly0.7https://www.medthority.com/journals/polycystic-kidney-disease/tweak-signaling-pathway-blockade-slows-cyst-growth-and-disease-progression-in-autosomal-dominant-polycystic-kidney-disease/2025-01-13T12:46:40+00:00weekly0.7https://www.medthority.com/journals/polycystic-kidney-disease/insights-into-autosomal-dominant-polycystic-kidney-disease-from-genetic-studies/2025-01-13T12:45:56+00:00weekly0.7https://www.medthority.com/journals/chronic-kidney-disease/daprodustat-for-the-treatment-of-anemia-in-patients-undergoing-dialysis/2025-01-13T14:06:19+00:00weekly0.7https://www.medthority.com/journals/chronic-kidney-disease/global-phase-3-programme-of-vadadustat-for-treatment-of-anaemia-of-chronic-kidney-disease-rationale-study-design-and-baseline-characteristics-of-dialysis-dependent-patients-in-the-inno2vate-trials/2025-01-13T09:15:03+00:00weekly0.7https://www.medthority.com/journals/chronic-kidney-disease/burden-of-anemia-in-chronic-kidney-disease-beyond-erythropoietin/2025-01-13T09:15:03+00:00weekly0.7https://www.medthority.com/journals/chronic-kidney-disease/long-term-efficacy-and-safety-of-hypoxia-inducible-factor-prolyl-hydroxylase-inhibitors-in-anaemia-of-chronic-kidney-disease-a-meta-analysis-including-13146-patients/2025-01-13T14:21:45+00:00weekly0.7https://www.medthority.com/journals/chronic-kidney-disease/challenging-patient-phenotypes-in-the-management-of-anaemia-of-chronic-kidney-disease/2025-01-13T14:04:17+00:00weekly0.7https://www.medthority.com/journals/chronic-kidney-disease/managing-anemia-across-the-stages-of-kidney-disease-in-those-hyporesponsive-to-erythropoiesis-stimulating-agents/2025-01-13T09:15:05+00:00weekly0.7https://www.medthority.com/journals/chronic-kidney-disease/the-impact-of-ckd-anaemia-on-patients-incidence-risk-factors-and-clinical-outcomes-a-systematic-literature-review/2025-01-13T12:07:11+00:00weekly0.7https://www.medthority.com/journals/chronic-kidney-disease/iron-deficiency-in-chronic-kidney-disease-updates-on-pathophysiology-diagnosis-and-treatment/2025-01-13T12:06:33+00:00weekly0.7https://www.medthority.com/journals/chronic-kidney-disease/hypoxiainducible-factor-stabilisers-for-the-anaemia-of-chronic-kidney-disease/2025-01-13T12:42:49+00:00weekly0.7https://www.medthority.com/journals/chronic-kidney-disease/safety-and-efficacy-of-vadadustat-for-anemia-in-patients-undergoing-dialysis/2025-01-13T12:41:58+00:00weekly0.7https://www.medthority.com/journals/chronic-kidney-disease/vadadustat-in-patients-with-anemia-and-non-dialysis-dependent-ckd/2025-01-13T12:40:49+00:00weekly0.7https://www.medthority.com/journals/chronic-kidney-disease/daprodustat-for-the-treatment-of-anemia-in-patients-not-undergoing-dialysis/2025-01-13T14:07:28+00:00weekly0.7https://www.medthority.com/journals/polycystic-kidney-disease/staged-versus-concurrent-native-nephrectomy-and-renal-transplantation-in-patients-with-autosomal-dominant-polycystic-kidney-disease-a-systematic-review/2025-01-13T09:17:01+00:00weekly0.7https://www.medthority.com/journals/polycystic-kidney-disease/autosomic-dominant-polycystic-kidney-disease-and-metformin-old-knowledge-and-new-insights-on-retarding-progression-of-chronic-kidney-disease/2025-01-13T12:45:13+00:00weekly0.7https://www.medthority.com/journals/polycystic-kidney-disease/is-autosomal-dominant-polycystic-kidney-disease-an-early-sweet-disease/2025-01-13T09:17:01+00:00weekly0.7https://www.medthority.com/journals/polycystic-kidney-disease/renal-plasticity-revealed-through-reversal-of-polycystic-kidney-disease-in-mice/2025-01-13T09:17:01+00:00weekly0.7https://www.medthority.com/journals/polycystic-kidney-disease/assessing-risk-of-rapid-progression-in-autosomal-dominant-polycystic-kidney-disease-and-special-considerations-for-disease-modifying-therapy/2025-01-13T12:04:13+00:00weekly0.7https://www.medthority.com/journals/polycystic-kidney-disease/primary-results-of-the-randomized-trial-of-metformin-administration-in-polycystic-kidney-disease-tame-pkd/2025-01-13T12:44:17+00:00weekly0.7https://www.medthority.com/journals/polycystic-kidney-disease/recent-discoveries-in-epigenetic-modifications-of-polycystic-kidney-disease/2025-01-13T09:17:02+00:00weekly0.7https://www.medthority.com/journals/polycystic-kidney-disease/autosomal-recessive-polycystic-kidney-disease-the-clinical-aspects-and-diagnostic-challenges/2025-01-13T09:17:02+00:00weekly0.7https://www.medthority.com/journals/polycystic-kidney-disease/the-effect-of-tolvaptan-on-bp-in-polycystic-kidney-disease-a-post-hoc-analysis-of-the-tempo-34-trial/2025-01-13T12:48:19+00:00weekly0.7https://www.medthority.com/journals/polycystic-kidney-disease/epidemiology-of-autosomal-dominant-polycystic-kidney-disease-in-olmsted-county/2025-01-13T12:08:59+00:00weekly0.7https://www.medthority.com/journals/polycystic-kidney-disease/genetics-of-autosomal-recessive-polycystic-kidney-disease-and-its-differential-diagnoses/2025-01-13T09:16:58+00:00weekly0.7https://www.medthority.com/journals/polycystic-kidney-disease/unmet-needs-and-challenges-for-follow-up-and-treatment-of-autosomal-dominant-polycystic-kidney-disease-the-paediatric-perspective/2025-01-13T09:16:57+00:00weekly0.7https://www.medthority.com/journals/polycystic-kidney-disease/autosomal-dominant-polycystic-kidney-disease-core-curriculum-2016/2025-01-13T12:04:24+00:00weekly0.7https://www.medthority.com/journals/polycystic-kidney-disease/implications-of-early-diagnosis-of-autosomal-dominant-polycystic-kidney-disease-a-post-hoc-analysis-of-the-tempo-34-trial/2025-01-13T09:16:57+00:00weekly0.7https://www.medthority.com/journals/polycystic-kidney-disease/translational-research-approaches-to-study-pediatric-polycystic-kidney-disease/2025-01-13T09:16:57+00:00weekly0.7https://www.medthority.com/journals/polycystic-kidney-disease/advances-in-autosomal-dominant-polycystic-kidney-disease-a-clinical-review/2025-01-13T12:10:05+00:00weekly0.7https://www.medthority.com/journals/polycystic-kidney-disease/pro-tolvaptan-delays-the-progression-of-autosomal-dominant-polycystic-kidney-disease/2025-01-13T09:16:56+00:00weekly0.7https://www.medthority.com/journals/polycystic-kidney-disease/autosomal-dominant-polycystic-kidney-disease-possibly-the-least-silent-cause-of-chronic-kidney-disease/2025-01-13T09:16:58+00:00weekly0.7https://www.medthority.com/journals/polycystic-kidney-disease/drug-repurposing-in-autosomal-dominant-polycystic-kidney-disease-back-to-the-future-with-pioglitazone/2025-01-13T09:16:59+00:00weekly0.7https://www.medthority.com/journals/polycystic-kidney-disease/the-effect-of-trichlormethiazide-in-autosomal-dominant-polycystic-kidney-disease-patients-receiving-tolvaptan-a-randomized-crossover-controlled-trial/2025-01-13T09:16:59+00:00weekly0.7https://www.medthority.com/journals/polycystic-kidney-disease/cinacalcet-may-suppress-kidney-enlargement-in-hemodialysis-patients-with-autosomal-dominant-polycystic-kidney-disease/2025-01-13T09:16:59+00:00weekly0.7https://www.medthority.com/journals/polycystic-kidney-disease/multicenter-study-of-long-term-safety-of-tolvaptan-in-later-stage-autosomal-dominant-polycystic-kidney-disease/2025-01-13T12:08:26+00:00weekly0.7https://www.medthority.com/journals/fluid-and-electrolyte-disorders/long-term-safety-and-efficacy-of-sodium-zirconium-cyclosilicate-for-hyperkalaemia-in-patients-with-mildmoderate-versus-severeend-stage-chronic-kidney-disease-comparative-results-from-an-open-label-phase-3-study/2025-01-13T09:15:45+00:00weekly0.7https://www.medthority.com/journals/fluid-and-electrolyte-disorders/patiromer-for-the-treatment-of-hyperkalemia/2025-01-13T13:17:59+00:00weekly0.7https://www.medthority.com/journals/fluid-and-electrolyte-disorders/safety-and-tolerability-of-the-potassium-binder-patiromer-from-a-global-pharmacovigilance-database-collected-over-4-years-compared-with-data-from-the-clinical-trial-program/2025-01-13T09:15:46+00:00weekly0.7https://www.medthority.com/journals/fluid-and-electrolyte-disorders/management-of-hyperkalemia-in-patients-with-kidney-disease-a-position-paper-endorsed-by-the-italian-society-of-nephrology/2025-01-13T09:15:41+00:00weekly0.7https://www.medthority.com/journals/fluid-and-electrolyte-disorders/sodium-zirconium-cyclosilicate-for-the-management-of-chronic-hyperkalemia-in-kidney-disease-a-novel-agent/2025-01-13T13:16:52+00:00weekly0.7https://www.medthority.com/journals/fluid-and-electrolyte-disorders/current-management-of-hyperkalemia-in-non-dialysis-ckd-longitudinal-study-of-patients-receiving-stable-nephrology-care/2025-01-13T09:15:46+00:00weekly0.7https://www.medthority.com/journals/fluid-and-electrolyte-disorders/patterns-of-chronic-and-transient-hyperkalaemia-and-clinically-important-outcomes-in-patients-with-chronic-kidney-disease/2025-01-13T09:15:46+00:00weekly0.7https://www.medthority.com/journals/fluid-and-electrolyte-disorders/does-dietary-potassium-intake-associate-with-hyperkalemia-in-patients-with-chronic-kidney-disease/2025-01-13T09:15:47+00:00weekly0.7https://www.medthority.com/journals/chronic-kidney-disease/anemia-in-chronic-kidney-disease-from-pathophysiology-and-current-treatments-to-future-agents/2025-01-13T09:15:05+00:00weekly0.7https://www.medthority.com/journals/fluid-and-electrolyte-disorders/treatment-of-mild-hyperkalemia-in-hospitalized-patients-an-unnecessary-practice/2025-01-13T09:15:44+00:00weekly0.7https://www.medthority.com/journals/fluid-and-electrolyte-disorders/acute-hyperkalemia-in-the-emergency-department-a-summary-from-a-kidney-disease-improving-global-outcomes-conference/2025-01-31T09:06:19+00:00weekly0.7https://www.medthority.com/journals/fluid-and-electrolyte-disorders/hyperkalemia-with-raas-inhibition-mechanism-clinical-significance-and-management/2025-01-13T09:15:44+00:00weekly0.7https://www.medthority.com/journals/fluid-and-electrolyte-disorders/patiromer-and-sodium-zirconium-cyclosilicate-in-treatment-of-hyperkalemia-a-systematic-review-and-meta-analysis/2025-01-13T09:15:45+00:00weekly0.7https://www.medthority.com/journals/fluid-and-electrolyte-disorders/efficacy-and-safety-of-sodium-zirconium-cyclosilicate-for-hyperkalaemia-the-randomized-placebo-controlled-harmonize-global-study/2025-01-31T09:10:55+00:00weekly0.7https://www.medthority.com/journals/fluid-and-electrolyte-disorders/an-evidence-based-narrative-review-of-the-emergency-department-management-of-acute-hyperkalemia/2025-01-13T13:31:15+00:00weekly0.7https://www.medthority.com/journals/fluid-and-electrolyte-disorders/determinants-of-hyperkalemia-progression-among-patients-with-mild-hyperkalemia/2025-01-13T09:15:44+00:00weekly0.7https://www.medthority.com/journals/glomerulonephritis/the-implications-of-focal-segmental-glomerulosclerosis-in-children-with-iga-nephropathy/2025-01-13T09:16:00+00:00weekly0.7https://www.medthority.com/journals/glomerulonephritis/update-on-lupus-nephritis-looking-for-a-new-vision/2025-01-13T09:16:00+00:00weekly0.7https://www.medthority.com/journals/fluid-and-electrolyte-disorders/epidemiology-of-hyperkalemia-an-update/2025-01-17T09:47:37+00:00weekly0.7https://www.medthority.com/journals/fluid-and-electrolyte-disorders/hyperkalemia-in-patients-with-chronic-renal-failure/2025-01-13T09:15:42+00:00weekly0.7https://www.medthority.com/journals/fluid-and-electrolyte-disorders/clinical-management-of-hyperkalemia/2025-01-13T10:04:19+00:00weekly0.7https://www.medthority.com/journals/fluid-and-electrolyte-disorders/hyperkalemia-in-chronic-kidney-disease/2025-01-13T09:15:42+00:00weekly0.7https://www.medthority.com/journals/fluid-and-electrolyte-disorders/hyperkalemia-pathophysiology-risk-factors-and-consequences/2025-01-13T09:15:43+00:00weekly0.7https://www.medthority.com/journals/fluid-and-electrolyte-disorders/current-treatment-and-unmet-needs-of-hyperkalaemia-in-the-emergency-department/2025-01-13T09:15:43+00:00weekly0.7https://www.medthority.com/journals/fluid-and-electrolyte-disorders/management-of-chronic-hyperkalemia-in-patients-with-chronic-kidney-disease-an-old-problem-with-news-options/2025-01-13T09:15:43+00:00weekly0.7https://www.medthority.com/journals/glomerulonephritis/b-cell-depletion-or-belimumab-or-voclosporin-for-lupus-nephritis/2025-01-13T12:55:16+00:00weekly0.7https://www.medthority.com/journals/glomerulonephritis/lupus-nephritis-clinical-presentations-and-outcomes-in-the-21st-century/2025-01-13T09:16:00+00:00weekly0.7https://www.medthority.com/journals/glomerulonephritis/a-pre-specified-analysis-of-the-dapa-ckd-trial-demonstrates-the-effects-of-dapagliflozin-on-major-adverse-kidney-events-in-patients-with-iga-nephropathy/2025-01-13T12:56:01+00:00weekly0.7https://www.medthority.com/journals/glomerulonephritis/micrornas-in-iga-nephropathy/2025-01-31T09:09:44+00:00weekly0.7https://www.medthority.com/journals/glomerulonephritis/complement-activation-in-iga-nephropathy/2025-01-13T09:15:59+00:00weekly0.7https://www.medthority.com/journals/glomerulonephritis/iga-vasculitis-and-iga-nephropathy-same-disease/2025-01-13T09:15:59+00:00weekly0.7https://www.medthority.com/journals/glomerulonephritis/advances-in-membranous-nephropathy/2025-01-13T09:15:59+00:00weekly0.7https://www.medthority.com/journals/glomerulonephritis/membranous-nephropathy-current-understanding-of-various-causes-in-light-of-new-target-antigens/2025-01-31T09:05:38+00:00weekly0.7https://www.medthority.com/journals/glomerulonephritis/mechanisms-of-primary-membranous-nephropathy/2025-01-13T09:15:58+00:00weekly0.7https://www.medthority.com/journals/glomerulonephritis/rituximab-or-cyclophosphamide-in-the-treatment-of-membranous-nephropathy-the-ri-cyclo-randomized-trial/2025-01-13T10:02:47+00:00weekly0.7https://www.medthority.com/journals/glomerulonephritis/transforming-growth-factor-1smad-signaling-in-glomerulonephritis-and-its-association-with-progression-to-chronic-kidney-disease/2025-01-13T09:15:58+00:00weekly0.7https://www.medthority.com/journals/glomerulonephritis/km55-monoclonal-antibody-staining-in-iga-dominant-infection-related-glomerulonephritis/2025-01-13T09:15:57+00:00weekly0.7https://www.medthority.com/journals/glomerulonephritis/efficacy-of-plasmapheresis-in-nivolumab-associated-anca-glomerulonephritis-a-case-report-and-pathophysiology-discussion/2025-01-13T09:15:57+00:00weekly0.7https://www.medthority.com/journals/glomerulonephritis/immunological-drivers-of-iga-nephropathy-exploring-the-mucosa-kidney-link/2025-01-13T12:49:22+00:00weekly0.7https://www.medthority.com/journals/glomerulonephritis/epidemiology-pathogenesis-treatment-and-outcomes-of-infection-associated-glomerulonephritis/2025-01-13T09:16:02+00:00weekly0.7https://www.medthority.com/journals/glomerulonephritis/recurrent-glomerulonephritis-after-kidney-transplantation-a-practical-approach/2025-01-31T08:44:07+00:00weekly0.7https://www.medthority.com/journals/glomerulonephritis/iga-nephropathy-an-interesting-autoimmune-kidney-disease/2025-01-31T08:45:01+00:00weekly0.7https://www.medthority.com/journals/glomerulonephritis/vitamin-d-and-glomerulonephritis/2025-01-13T09:16:01+00:00weekly0.7https://www.medthority.com/journals/glomerulonephritis/factors-affecting-the-progression-of-infection-related-glomerulonephritis-to-chronic-kidney-disease/2025-01-13T09:16:01+00:00weekly0.7https://www.medthority.com/journals/glomerulonephritis/focal-segmental-glomerulosclerosis-state-of-the-art-and-clinical-perspective/2025-01-13T09:16:01+00:00weekly0.7https://www.medthority.com/journals/glomerulonephritis/mechanisms-of-scarring-in-focal-segmental-glomerulosclerosis/2025-01-13T09:16:01+00:00weekly0.7https://www.medthority.com/journals/glomerulonephritis/pathogenesis-and-treatment-of-glomerulonephritis-an-update/2025-01-13T09:16:03+00:00weekly0.7https://www.medthority.com/journals/glomerulonephritis/global-evolutionary-trend-of-the-prevalence-of-primary-glomerulonephritis-over-the-past-three-decades/2025-01-13T09:16:04+00:00weekly0.7https://www.medthority.com/journals/chronic-kidney-disease/chronic-kidney-disease-epidemic-how-do-we-deal-with-it/2025-01-13T13:30:12+00:00weekly0.7https://www.medthority.com/journals/glomerulonephritis/glomerulonephritis/2025-01-13T09:16:03+00:00weekly0.7https://www.medthority.com/journals/glomerulonephritis/glomerular-diseases-dependent-on-complement-activation-including-atypical-hemolytic-uremic-syndrome-membranoproliferative-glomerulonephritis-and-c3-glomerulopathy-core-curriculum-2015/2025-01-13T12:04:35+00:00weekly0.7https://www.medthority.com/journals/chronic-kidney-disease/barriers-and-enablers-to-detection-and-management-of-chronic-kidney-disease-in-primary-healthcare-a-systematic-review/2025-01-13T09:15:15+00:00weekly0.7https://www.medthority.com/journals/glomerulonephritis/infections-associated-glomerulonephritis/2025-01-13T09:16:03+00:00weekly0.7https://www.medthority.com/journals/acute-coronary-syndrome/optical-coherence-tomography-based-treatment-approach-for-patients-with-acute-coronary-syndrome/2025-01-13T10:06:56+00:00weekly0.7https://www.medthority.com/journals/acute-coronary-syndrome/a-review-of-acute-coronary-syndrome-and-its-potential-impact-on-cognitive-function/2025-01-13T09:14:07+00:00weekly0.7https://www.medthority.com/journals/acute-coronary-syndrome/prognostic-value-of-left-atrial-volume-index-in-acute-coronary-syndrome-a-systematic-review-and-meta-analysis/2025-01-13T10:16:22+00:00weekly0.7https://www.medthority.com/journals/acute-coronary-syndrome/role-of-beta-blockers-following-percutaneous-coronary-intervention-for-acute-coronary-syndrome/2025-01-13T09:14:06+00:00weekly0.7https://www.medthority.com/journals/acute-coronary-syndrome/differences-in-mortality-and-causes-of-death-between-stemi-and-nstemi-in-the-early-and-late-phases-after-acute-myocardial-infarction/2025-01-13T09:14:10+00:00weekly0.7https://www.medthority.com/journals/acute-coronary-syndrome/stemi-a-transitional-fossil-in-mi-classification/2025-01-13T09:14:10+00:00weekly0.7https://www.medthority.com/journals/acute-coronary-syndrome/bridging-the-gap-current-and-future-insights-for-improving-suboptimal-platelet-inhibition-in-stemi/2025-01-30T14:55:54+00:00weekly0.7https://www.medthority.com/journals/acute-coronary-syndrome/platelet-to-lymphocyte-ratio-and-prognosis-in-stemi-a-meta-analysis/2025-01-31T09:16:25+00:00weekly0.7https://www.medthority.com/journals/acute-coronary-syndrome/updates-in-anti-anginal-and-anti-ischemic-therapies-for-acute-coronary-syndromes/2025-01-13T09:14:09+00:00weekly0.7https://www.medthority.com/journals/acute-coronary-syndrome/correlates-of-residual-thrombus-burden-in-successfully-thrombolysed-patients-of-st-elevation-myocardial-infarction-receiving-dual-anti-platelet-therapy/2025-01-13T09:14:09+00:00weekly0.7https://www.medthority.com/journals/acute-coronary-syndrome/dual-antiplatelet-therapy-after-percutaneous-coronary-intervention-and-drug-eluting-stents-a-systematic-review-and-network-meta-analysis/2025-01-31T09:13:45+00:00weekly0.7https://www.medthority.com/journals/acute-coronary-syndrome/prasugrel-based-de-escalation-of-dual-antiplatelet-therapy-after-percutaneous-coronary-intervention-in-patients-with-acute-coronary-syndrome-host-reduce-polytech-acs-an-open-label-multicentre-non-inferiority-randomised-trial/2025-01-13T10:08:06+00:00weekly0.7https://www.medthority.com/journals/acute-coronary-syndrome/meta-analysis-of-dual-antiplatelet-therapy-versus-monotherapy-with-p2y12-inhibitors-in-patients-after-percutaneous-coronary-intervention/2025-01-13T09:47:08+00:00weekly0.7https://www.medthority.com/journals/acute-coronary-syndrome/the-safety-and-efficacy-of-aspirin-discontinuation-on-a-background-of-a-p2y-12-inhibitor-in-patients-after-percutaneous-coronary-intervention-a-systematic-review-and-meta-analysis/2025-01-13T13:32:59+00:00weekly0.7https://www.medthority.com/journals/acute-coronary-syndrome/acute-coronary-syndrome-with-non-ruptured-plaques-nonrupla-novel-ideas-and-perspectives/2025-01-13T09:14:08+00:00weekly0.7https://www.medthority.com/journals/acute-coronary-syndrome/dual-antiplatelet-therapy-duration-in-acute-coronary-syndrome-patients-the-state-of-the-art-and-open-issues/2025-01-31T09:03:00+00:00weekly0.7https://www.medthority.com/journals/acute-coronary-syndrome/noncoding-rnas-as-biomarkers-for-acute-coronary-syndrome/2025-01-13T10:13:52+00:00weekly0.7https://www.medthority.com/journals/eosinophilic-esophagitis/diagnosis-and-treatment-of-eosinophilic-esophagitis/2025-01-17T09:59:58+00:00weekly0.7https://www.medthority.com/journals/eosinophilic-esophagitis/eosinophilic-esophagitis/2025-01-13T09:15:33+00:00weekly0.7https://www.medthority.com/journals/eosinophilic-esophagitis/systematic-assessment-of-adult-patients-satisfaction-with-various-eosinophilic-esophagitis-therapies/2025-01-13T09:15:26+00:00weekly0.7https://www.medthority.com/journals/eosinophilic-esophagitis/food-induced-immediate-response-of-the-esophagus-a-newly-identified-syndrome-in-patients-with-eosinophilic-esophagitis/2025-01-17T09:56:02+00:00weekly0.7https://www.medthority.com/journals/eosinophilic-esophagitis/efficacy-of-proton-pump-inhibitor-therapy-for-eosinophilic-oesophagitis-in-630-patients-results-from-the-eoe-connect-registry/2025-01-17T09:55:23+00:00weekly0.7https://www.medthority.com/journals/eosinophilic-esophagitis/incidence-and-prevalence-of-eosinophilic-oesophagitis-increase-continiously-in-adults-and-children-in-central-spain-a-12-year-population-based-study/2025-01-17T09:54:28+00:00weekly0.7https://www.medthority.com/journals/eosinophilic-esophagitis/emerging-incidence-trends-of-eosinophilic-esophagitis-over-25-years-results-of-a-nationwide-register-based-pathology-cohort/2025-01-20T14:34:09+00:00weekly0.7https://www.medthority.com/journals/eosinophilic-esophagitis/helicobacter-pylori-infection-does-not-protect-against-eosinophilic-esophagitis-results-from-a-large-multicenter-case-control-study/2025-01-17T09:53:25+00:00weekly0.7https://www.medthority.com/journals/eosinophilic-esophagitis/esophageal-perforation-in-eosinophilic-esophagitis-a-systematic-review-on-clinical-presentation-management-and-outcomes/2025-01-20T14:41:19+00:00weekly0.7https://www.medthority.com/journals/eosinophilic-esophagitis/efficacy-of-therapy-for-eosinophilic-esophagitis-in-real-world-practice/2025-01-20T15:20:55+00:00weekly0.7https://www.medthority.com/journals/eosinophilic-esophagitis/novel-therapeutic-approaches-to-eosinophilic-esophagitis/2025-01-13T09:15:29+00:00weekly0.7https://www.medthority.com/journals/eosinophilic-esophagitis/budesonide-orodispersible-tablets-maintain-remission-in-a-randomized-placebo-controlled-trial-of-patients-with-eosinophilic-esophagitis/2025-01-17T09:57:31+00:00weekly0.7https://www.medthority.com/journals/eosinophilic-esophagitis/orodispersible-budesonide-tablets-for-the-treatment-of-eosinophilic-esophagitis-a-review-of-the-latest-evidence/2025-01-20T14:33:38+00:00weekly0.7https://www.medthority.com/journals/eosinophilic-esophagitis/non-invasive-tests-for-eosinophilic-esophagitis-ready-for-use/2025-01-17T09:58:18+00:00weekly0.7https://www.medthority.com/journals/eosinophilic-esophagitis/epidemiology-and-natural-history-of-eosinophilic-esophagitis/2025-01-20T14:33:03+00:00weekly0.7https://www.medthority.com/journals/eosinophilic-esophagitis/eosinophilic-esophagitis-established-facts-and-new-horizons/2025-01-13T09:15:30+00:00weekly0.7https://www.medthority.com/journals/eosinophilic-esophagitis/documenting-the-journey-of-patients-with-eosinophilic-esophagitis-and-the-impact-of-the-disease-on-patients-and-their-caregivers-a-cross-sectional-qualitative-research-study/2025-01-13T09:15:30+00:00weekly0.7https://www.medthority.com/journals/eosinophilic-esophagitis/eosinophilic-esophagitis-current-status-and-future-directions/2025-01-13T09:15:29+00:00weekly0.7https://www.medthority.com/journals/eosinophilic-esophagitis/mechanisms-of-disease-of-eosinophilic-esophagitis/2025-01-13T09:15:29+00:00weekly0.7https://www.medthority.com/journals/eosinophilic-esophagitis/eosinophilic-esophagitis-incidence-diagnosis-management-and-future-directions/2025-01-13T09:15:31+00:00weekly0.7https://www.medthority.com/journals/eosinophilic-esophagitis/treatment-of-eosinophilic-esophagitis-diet-or-medication/2025-01-13T09:15:31+00:00weekly0.7https://www.medthority.com/journals/eosinophilic-esophagitis/eosinophilic-esophagitis-a-review-of-the-pediatric-population-and-consideration-of-upcoming-therapies/2025-01-17T09:59:14+00:00weekly0.7https://www.medthority.com/journals/eosinophilic-esophagitis/the-role-of-the-allergist-in-the-management-of-eosinophilic-esophagitis/2025-01-17T09:58:53+00:00weekly0.7https://www.medthority.com/journals/eosinophilic-esophagitis/eosinophilic-esophagitis-etiology-and-therapy/2025-01-13T09:15:33+00:00weekly0.7https://www.medthority.com/journals/eosinophilic-esophagitis/eosinophilic-esophagitis-and-igg4-is-there-a-relationship/2025-01-13T09:15:33+00:00weekly0.7https://www.medthority.com/journals/eosinophilic-esophagitis/eosinophilic-esophagitis-a-review/2025-01-13T09:15:33+00:00weekly0.7https://www.medthority.com/journals/eosinophilic-esophagitis/eosinophilic-esophagitis-for-the-general-pediatrician/2025-01-20T15:21:36+00:00weekly0.7https://www.medthority.com/journals/eosinophilic-esophagitis/eosinophilic-esophagitis-novel-concepts-regarding-pathogenesis-and-clinical-manifestations/2025-01-13T09:15:32+00:00weekly0.7https://www.medthority.com/journals/eosinophilic-esophagitis/eosinophilic-esophagitis-and-microbiota-state-of-the-art/2025-01-13T09:15:32+00:00weekly0.7https://www.medthority.com/journals/eosinophilic-esophagitis/the-role-of-the-environment-in-eosinophilic-esophagitis/2025-01-13T09:15:32+00:00weekly0.7https://www.medthority.com/journals/acute-coronary-syndrome/diagnosis-and-management-of-acute-coronary-syndrome-what-is-new-and-why-insight-from-the-2020-european-society-of-cardiology-guidelines/2025-01-13T09:14:13+00:00weekly0.7https://www.medthority.com/journals/acute-coronary-syndrome/early-rule-out-and-rule-in-strategies-for-myocardial-infarction/2025-01-13T09:14:12+00:00weekly0.7https://www.medthority.com/journals/acute-coronary-syndrome/timing-of-oral-p2y-12-inhibitor-administration-in-patients-with-non-st-segment-elevation-acute-coronary-syndrome/2025-01-13T09:14:12+00:00weekly0.7https://www.medthority.com/journals/acute-coronary-syndrome/ticagrelor-or-prasugrel-in-patients-with-non-st-segment-elevation-acute-coronary-syndromes/2025-01-13T09:14:12+00:00weekly0.7https://www.medthority.com/journals/acute-coronary-syndrome/coronary-ct-angiography-in-patients-with-non-st-segment-elevation-acute-coronary-syndrome/2025-01-13T09:14:12+00:00weekly0.7https://www.medthority.com/journals/acute-coronary-syndrome/antithrombotic-pretreatment-and-invasive-strategies-in-patients-with-non-st-segment-elevation-acute-coronary-syndrome/2025-01-13T09:14:11+00:00weekly0.7https://www.medthority.com/journals/acute-coronary-syndrome/speckle-tracking-echocardiography-in-non-st-segment-elevation-acute-coronary-syndromes/2025-01-13T09:14:11+00:00weekly0.7https://www.medthority.com/journals/acute-coronary-syndrome/value-of-territorial-work-efficiency-estimation-in-non-st-segment-elevation-acute-coronary-syndrome-a-study-with-non-invasive-left-ventricular-pressure-strain-loops/2025-01-13T09:14:11+00:00weekly0.7https://www.medthority.com/journals/acute-coronary-syndrome/safety-of-same-day-discharge-after-percutaneous-coronary-intervention-in-selected-patients-with-non-st-elevation-acute-coronary-syndrome/2025-01-13T09:14:11+00:00weekly0.7https://www.medthority.com/journals/respiratory-syncytial-virus-rsv/biomarkers-for-disease-severity-in-children-infected-with-respiratory-syncytial-virus-a-systematic-literature-review/2025-01-13T09:17:21+00:00weekly0.7https://www.medthority.com/journals/respiratory-syncytial-virus-rsv/estimating-transmission-parameters-for-respiratory-syncytial-virus-and-predicting-the-impact-of-maternal-and-pediatric-vaccination/2025-01-13T09:17:21+00:00weekly0.7https://www.medthority.com/journals/respiratory-syncytial-virus-rsv/respiratory-syncytial-virus-associated-hospital-admissions-in-children-younger-than-5-years-in-7-european-countries-using-routinely-collected-datasets/2025-01-13T09:17:20+00:00weekly0.7https://www.medthority.com/journals/respiratory-syncytial-virus-rsv/burden-of-respiratory-syncytial-virus-infection-in-community-dwelling-older-adults-in-europe-resceu-an-international-prospective-cohort-study/2025-01-13T09:17:20+00:00weekly0.7https://www.medthority.com/journals/respiratory-syncytial-virus-rsv/risk-factors-for-rsv-associated-acute-lower-respiratory-infection-poor-outcome-and-mortality-in-young-children-a-systematic-review-and-meta-analysis/2025-01-13T09:17:20+00:00weekly0.7https://www.medthority.com/journals/respiratory-syncytial-virus-rsv/nebulised-alx-0171-for-respiratory-syncytial-virus-lower-respiratory-tract-infection-in-hospitalised-children-a-double-blind-randomised-placebo-controlled-phase-2b-trial/2025-01-30T14:56:41+00:00weekly0.7https://www.medthority.com/journals/respiratory-syncytial-virus-rsv/trim22-inhibits-respiratory-syncytial-virus-replication-by-targeting-jak-stat12-signaling/2025-01-30T15:01:22+00:00weekly0.7https://www.medthority.com/journals/respiratory-syncytial-virus-rsv/neutrophils-in-respiratory-syncytial-virus-infection-from-harmful-effects-to-therapeutic-opportunities/2025-01-30T14:57:52+00:00weekly0.7https://www.medthority.com/journals/respiratory-syncytial-virus-rsv/expert-consensus-on-palivizumab-use-for-respiratory-syncytial-virus-in-developed-countries/2025-01-13T09:17:21+00:00weekly0.7https://www.medthority.com/journals/respiratory-syncytial-virus-rsv/immunological-and-inflammatory-biomarkers-of-susceptibility-and-severity-in-adult-respiratory-syncytial-virus-infections/2025-01-13T09:17:21+00:00weekly0.7https://www.medthority.com/journals/respiratory-syncytial-virus-rsv/respiratory-syncytial-virus-consortium-in-europe-resceu-birth-cohort-study-defining-the-burden-of-infant-respiratory-syncytial-virus-disease-in-europe/2025-01-13T09:17:21+00:00weekly0.7https://www.medthority.com/journals/respiratory-syncytial-virus-rsv/safety-and-immunogenicity-of-the-ad26.rsv.pref-investigational-vaccine-coadministered-with-an-influenza-vaccine-in-older-adults2025-01-13T09:17:23+00:00weekly0.7https://www.medthority.com/journals/respiratory-syncytial-virus-rsv/the-immunogenicity-and-safety-of-respiratory-syncytial-virus-vaccines-in-development-a-systematic-review/2025-01-31T08:39:46+00:00weekly0.7https://www.medthority.com/journals/respiratory-syncytial-virus-rsv/respiratory-syncytial-virus-and-airway-microbiota---a-complex-interplay-and-its-reflection-on-morbidity/2025-01-30T14:58:43+00:00weekly0.7https://www.medthority.com/journals/respiratory-syncytial-virus-rsv/functional-features-of-the-respiratory-syncytial-virus-g-protein/2025-01-13T09:17:22+00:00weekly0.7https://www.medthority.com/journals/respiratory-syncytial-virus-rsv/passive-immunoprophylaxis-against-respiratory-syncytial-virus-in-children-where-are-we-now/2025-01-13T09:17:22+00:00weekly0.7https://www.medthority.com/journals/respiratory-syncytial-virus-rsv/high-morbidity-and-mortality-in-adults-hospitalized-for-respiratory-syncytial-virus-infections/2025-01-13T09:17:24+00:00weekly0.7https://www.medthority.com/journals/respiratory-syncytial-virus-rsv/considerations-for-a-respiratory-syncytial-virus-vaccine-targeting-an-elderly-population/2025-01-13T09:17:23+00:00weekly0.7https://www.medthority.com/journals/respiratory-syncytial-virus-rsv/respiratory-syncytial-virus-associated-hospitalizations-among-adults-with-chronic-medical-conditions/2025-01-13T09:17:23+00:00weekly0.7https://www.medthority.com/journals/respiratory-syncytial-virus-rsv/current-state-of-respiratory-syncytial-virus-disease-and-management/2025-01-13T09:17:25+00:00weekly0.7https://www.medthority.com/journals/respiratory-syncytial-virus-rsv/global-disease-burden-estimates-of-respiratory-syncytial-virus-associated-acute-respiratory-infection-in-older-adults-in-2015-a-systematic-review-and-meta-analysis/2025-01-13T09:17:25+00:00weekly0.7https://www.medthority.com/journals/respiratory-syncytial-virus-rsv/the-future-of-respiratory-syncytial-virus-disease-prevention-and-treatment/2025-01-13T09:17:25+00:00weekly0.7https://www.medthority.com/journals/respiratory-syncytial-virus-rsv/social-economic-and-health-impact-of-the-respiratory-syncytial-virus-a-systematic-search/2025-01-13T09:17:24+00:00weekly0.7